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ABSTRACT
Glycans are chemically heterogeneous macromolecules that have profound
importance in a variety of biological processes. Located at the surfaces of cells, deposited
in the extracellular matrix, or attached to soluble signaling agents, these molecules are
characterized by a structural complexity that has thus far prevented their widespread
exploitation in biomedicine. Insight into the fine structure and sequence of these complex
biomolecules provides a novel niche for the development of therapeutic interventions.
Such an understanding is rapidly accumulating via the molecular cloning, recombinant
genetic expression, and protein purification of glycosaminoglycan-degrading enzymes.
To this end, enzymes from the chondroitinase family of Pedobacter heparinus and
Proteus vulgaris were developed. This library of enzymatic tools will reveal
glycoconjugate structure-function motifs, allowed for by structural elucidation of glycan
species using coupled bioinformatics/analytical chemistry techniques centered on mass
spectrometry, nuclear magnetic resonance, and capillary electrophoresis. Biochemical
characterization of these enzymes has allowed for the rational genetic manipulation of
substrate recognition and binding site amino acid residues, producing site-directed
protein engineered mutants with altered action pattern and substrate specificity. Progress
in these areas will allow for the elucidation of critical roles of glycans in the biological
regulation of growth factors, morphogens, cytokines, and cell-surface proteins. This
extension of the capabilities of glycan analytical biotechnologies will help to translate
basic science glycobiology to applied glycomedicine and drug discovery.
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Chapter 1
Glycotechnology and Biomedicine
Summary
The 2 0 th century witnessed remarkable scientific advances that opened wide the
science of life. Specifically, the study ofDNA and proteins heralded a new age of
biotechnology, where medicine would be pursued from the level of a single molecule to
whole systems. But a third class of complex biomolecules, the glycans, so long neglected
by investigators, are coming to the fore in the new millennium as complex players in
normal and disease processes. Glycans, or complex sugars, reside throughout the body
within every tissue and organ system. So structurally complex is this class of
biomolecules that few tools exist to decipher the code inherent in their chemical
components. Perhaps one of the most important efforts in establishing the fundamental
importance of glycans in biomedicine is the development of technologies to unravel their
myriad functions in biology. To this end, this work focuses on the development of these
biotechnologies.
Part 1 is reproduced from a chapter of the Elsevier series, 'Advances in
Pharmacology, ' and is included here with permission.
Part 2 is in press with Annual Reviews in Biochemistry, and is included here with
permission.

Vikas Prabhakar and Ram Sasisekharan
Division of Biological Engineering
Massachusetts Institute of Technology
Cambridge, Massachusetts 02139
The Biosynthesis and Catabolism
of Galactosaminoglycans
I. GalAG Biopolymers
A. Introduction
The glycosaminoglycan (GAG) family of structurally complex linear
polysaccharides is composed of four chemically distinct subsets: the heparin
and heparan sulfate (HS) GAGs, the chondroitin and dermatan sulfate (CS
and DS, respectively) GAGs, keratan sulfate (KS), and hyaluronic acid (Ernst
et al., 1995). The following material focuses on GAGs of the CS and DS
type, also known as galactosaminoglycans (GalAGs). Covered herein are the
most prominent details concerning GalAG structure, their roles in biology
and medicine, GalAG biosynthesis, their in vivo cellular degradation, and
analytical biotechnologies pertinent to the study of GalAGs (Fig. 1).
The study of biological phenomena, from the molecular to the tissue
level, has evolved substantially as scientists have focused on the emerging
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FIGURE I Chapter contents and organization. This work provides an overview of
chondroitin and dermatan sulfate GAGs, including their structure, roles in biology and
pathogenesis, biosynthesis, cellular degradation, and enzymatic degradation.
paradigm of extracellular regulation of cell function. GAG polysaccharides
are attached to a protein core and are impelled to the cell surface and into the
extracellular space. The cell surface machinery at the cell-extracellular
matrix (ECM) interface acts as a complex battery of regulators that dyna-
mically modulates outside cues from diverse signaling molecules. Specifical-
ly, GAGs govern signaling molecules by controlling their effective
concentration and state at the cell surface.
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B. Composition and Chemical Complexity
GalAGs are composed of a disaccharide repeat unit of uronic acid
[aO-L-iduronic acid (IdoA) or #-D-glucuronic acid (GlcA)] (1-3) linked to
N-acetyl-D-galactosamine (GalNAc). These basic disaccharide units are lin-
early associated via l(1-4) linkages to form GalAG polymers (Fig. 2). In
CS, all of the uronic acid moieties are GlcA. In DS, epimerization at the C-S
position of the uronic acid moiety during biosynthesis results in a mixture of
IdoA and GlcA epimers. Biosynthesis of CS and DS also involves chemical
modification of the sugar backbone at various positions, generating diversity
in oligosaccharide sequences. CS is commonly O-sulfated at the C-4 of the
galactosamine (chondroitin-4-sulfate, C4S, also known as CS A) or the C6
of the galactosamine (chondroitin-6-sulfate, C6S, also known as CS C). Less
common modifications in CS, such as 2-0 or 3-0 sulfation of the GlcA
moiety, have also been reported (Nadanaka and Sugahara, 1997; Sugahara
et al., 1996). DS (also known as CS B) is commonly O-sulfated at C-4 of
GalNAc; O-sulfation at C-6 of GalNAc and C-2 of IdoA also occasionally
occur.
The various backbone modifications in GAG biopolymers confer infi-
nitely more chemical complexity when compared to DNA and proteins.
Theoretically, the five different modifications possible for each disaccharide
unit give rise to 2s = 32 chemical combinations. In comparison, DNA is
composed of only four basic building blocks, and proteins are made up of 20
amino acids. This vast complexity makes these biopolymers among the most
information-rich in nature.
C. Structural Features
GAGs are distinguished from other polysaccharides as a distinct class by
their related backbone moieties. Modification of these backbone elements
confers great diversity among GAGs. The heterogeneity of GAG sequences is
notable, especially when compared to other biopolymers like DNA and
proteins. The template-based biosynthesis of these molecules has greatly
facilitated their study; in contrast, the nontemplate-driven biosynthesis of
complex polysaccharides has largely suppressed attempts at their analysis.
DS is predominantly 4-O-sulfated. Iduronic acid content of DS is variable
and has been reported as low as 7% and as high as 93%, depending on tissue
origin and the method of compositional analysis (Linhardt et al., 1991;
Maimone and Tollefsen, 1990; Poole, 1986). In CS, copolymers with both
4-0- and 6-O-sulfation in the same chain occur often (Ernst et al., 1995).
Individual CS residues sometimes are sulfated at both the 4-0- and 6-0-
positions (Linhardt et al., 1991). Two levels of organization have been
described for GalAGs. Macroscopically, clustering of residues in DS results
in regions with IdoA and a high degree of sulfation interspersed with regions
72 Prabhakar and Sasisekharan
Chondroitin sulfate A
[GIcAP(1-+3) GalNAc4S]
Chondroitin suffate B
[IdoA2S a(1->3) GalNAc4S]
Chondroitin sulfate C
[GlcA p(1 -+3) GalNAc6S]
Chondroitin sulfate D
[GIcA2S 1(1-+3) GahlAc6S]
Chondroitin sulfate E
[GIcA p(1-)3) GalNAc4S6S]
FIGURE 2 Galactosaminoglycan chemical structure. Biopolymers of the chondroitin
sulfate and dermatan sulfate type are composed of a basic building block, a disaccharide
consisting of an uronic acid P(1--3) linked to GalNAc. These disaccharide units are linearly
associated via P(1--4) linkages. In the case of CS, all of the uronic acid moieties correspond to
the glucuronic acid epimerization state. For DS, modification of the uronic acid CS position
during biosynthesis leads to a mixture of epimers within the chain. Common sulfation patterns
within the oligosaccharide backbones are indicated for each GalAG form. Additionally, CS-A
and CS-C are sometimes sulfated at the 2-0 or 3-0 positions of GlcA. The CS-B form is also
known as DS. DS occasionally incorporates O-sulfation at GalNAc C6.
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with GlcA and a lower degree of sulfation (Fransson et al., 1990). Sulfation
at the 6-O-position of CS often seems to be clustered near the chain termina
(Cheng et al., 1992). Microscopically, specific sequences of GAGs are func-
tionally relevant. Rare residues can, in fact, have critical physiological
functions. A specific DS hexasaccharide, for instance, has a specific affinity
for heparin cofactor II (Maimone and Tollefsen, 1990). These two levels of
organization, therefore, are important in modulating the physical form
of GAGs and in regulating the specific interaction between a GAG and
another biomolecule. Form is also a function of the ionic environment,
which can shield repulsive ionic forces between charged chains.
In solution, CS seems to exist in defined spatial orientations; DS has a
flexible conformation (Casu et al., 1988; Venkataraman et al., 1994). A
central issue, a controversial one, regarding the structural diversity of GAGs
is the conformational flexibility of the iduronate residue (Ferro et al., 1990;
Mitra et al., 1983; Venkataraman et al., 1994; Winter et al., 1986). The four
main conformers of IdoA are 1C4 , 4C 1, 2T0 , and OT2 . These conformers for
IdoA are stereochemically satisfactory and are consistent with the available
physico-chemical data. Interconversion between IdoA puckers may generate
chain conformational flexibility, facilitating interaction with proteins (Casu
et al., 1986).
Rotary shadowing/electron microscopy studies have revealed that C6S is
capable of forming aggregates of two or more chains (Scott et al., 1992). The
charge distribution of the twofold helix of C6S is near the periphery, creating
regions of hydrophobicity. Such hydrophobic zones from separate chains can
interact with each other. Chondroitin-4-sulfate is incapable of such network
formation, as sulfate groups are clustered close to the helical axis, minimiz-
ing aggregation behavior. Although C4S cannot self-aggregate, it is capable
of association with DS. Alternating IdoA and GlcA in DS can self-associate
in the absence of divalent cations under physiological conditions (Fransson
and Coster, 1979). Chemical modification of the sugar backbone, hydrogen
bonding, and cation chelation are critical determinants of self-aggregation
potential and solid-state structural conformation, necessary for conferring
the biological information inherent in GAG biomolecules.
D. GalAG Proteoglycans
GalAGs' chains, as with all other members of the GAG family with the
exception of hyaluronic acid, occur as constituents of proteoglycans (PGs)
(Table I) (Iozzo, 1998). As such, they are attached, via a glycosidic linkage,
to a serine residue in a core protein through a tetrasaccharide composed
of glucuronic acid-galactose-galactose-xylose. Core proteins can range in
size from 10 to 500 kDa. CS is usually found in large aggregating PGs
with 20-100 sidechains; DS occurs primarily in smaller PGs with 2-8 side-
chains (Poole, 1986). Overall PG size ranges from 80 to 3500 kDa (Ghiselli
74 Prabhakar and Sasisekharan
TABLE I Galactosaminoglycan Proteoglycans
Core protein Expression References
Bamacan
Decorin
Biglycan
Thrombomodulin
Astrochondrin
Collagen IX
Endocan
Epiphycan
Serglycin
Versican
NG2
Neurocan
CALEB
Aggrecan
Brevican
Phosphacan
Te38
Neuroglycan C
TAP-1
Testican-1, -2, -3
CD44
Perlecan
APP
Somatoglycan-S
Glypican-5
Syndecan-1
CAT301, CAT315
Basement membranes
Connective tissue, cornea
Bone, cartilage, skin
Endothelia, cornea
Glia
Cartilage
Endothelia
Cartilage
Myeloid cells, granules
Fibroblasts, connective tissue
Glia
Glia, retinal and embryonic
vasculature
Glia, neurons
Neurons, cartilage
Glia, neurons
Glia, neurons
Chick embryo brain
Cerebellum
Nervous tissue
Neurons, glia
Lymphocytes
Vasculature
Glia
Nervous tissue
Neurons
Nervous tissue
Neurons
Ghiselli and lozzo, 2000
Reed et al., 2005
Wadhwa et al., 2004;
Kinsella et al., 2004
Sadler, 1997
Streit et al., 1993
Bishop et al., 2000
Bechard et al., 2001
Knudson and Knudson, 2001
Valiyaveettil et al., 2004
Kinsella et al., 2004;
Sheng et al., 2005
Blakemore et al., 2002
Mishima and Hoffman, 2003;
Zhang et al., 2003
Schumacher et al., 1997
Johnson et al., 2005
Beggah et al., 2005
Hayashi et al., 2005;
Popp et al., 2003
Monnier et al., 2003
Oohira et aL, 2004
Iwata et al., 1991
Edgell et al., 2003;
Oohira et al., 2000
Lesley et al., 1997
Knudson and Knudson, 2001
Umehara et al., 2004
Williams et al., 1994
Saunders et al., 1997
Deepa et al., 2004;
Lee et al., 2004
Lander et al., 1997
Adapted with permission from Trowbridge
(2001).
and Gallo (2002) and Hartmann and Maurer
and lozzo, 2000; Sadler, 1997; Silbert and Sugumaran, 2002; Streit
et al., 1993).
E. GalAGs in Biology
Long thought of as inert structural components, GAGs have in recent
years come to the forefront in the thinking of bioscientists as important
modulators of biological phenomena. Polysaccharide structure governs
Chondroitin and Dermatan Sulfate Biopolymers
myriad interactions between powerful biological players, imparting effects
on cell function in both normal and aberrant pathophysiological states.
Interactions between proteins and heparin/HS GAGs, and more recently
GalAG polymers, have shed considerable light on basic biological functions.
Further, the implications of these biomolecular interactions reverberate in
importance through the entire cascade of biomedical events, from funda-
mental biological phenomena to clinical biomedicine.
II. GalAGs in the Extracellular Matrix
The ECM is a highly heterogeneous mixture of proteins, saccharides,
and other biomolecules that surrounds cells. The ECM is instrumental in
providing the physical support necessary for macromolecular organization
into tissues and organs. Traditionally, the ECM was considered to be solely
an inert scaffold providing structure. This conventional view has been over-
turned, and it has become apparent that the ECM is in fact a fundamental
player in orchestrating cellular responses, both in normal and disease states.
GAGs are among the most important constituents of the ECM, as they
interact with transient ECM molecules, such as growth factors, often resulting
in a cascade of bioregulatory events including signal transduction and nuclear
transcriptional phenomena (Kovanen and Pentikainen, 1999; Olsson et al.,
1999). These interactions impart profound implications on the type and
strength of signaling in gene expression. The specialized functions elicited by
GAG activity in vivo emphasize the importance of structural (and sequence)
diversity among GAGs. In addition to binding heparin cofactor II (Tovar et al.,
2005), GalAGs also appear to be involved in a variety of processes, including
the covalent crosslinking of the blood protein pre-a-inhibitor (Enghild et al.,
1991), infectivity mechanisms (Achur et al., 2000; Alkhalil et al., 2000;
Schmidtchen et al., 2001), and tenascin-X binding (Elefteriou et al., 2001).
GAGs are found in the ECM bound to structural proteins (including collagen,
laminin, and fibronectin), aggregated with other PGs, or as constituents of
integral membrane PGs (Hardingham and Fosang, 1992).
III. GalAG-Protein Interactions
GAGs bind a wide variety of ECM, intracellular, and plasma proteins
(Table II) (Cardin and Weintraub, 1989; Frevert et al., 2003; Garcia-Olivas
et al., 2003; Jackson et al., 1991; Marino et al., 2003; Murai et al., 2004;
Priglinger et al., 1994; Proudfoot et al., 2001; Schmidtchen et al., 2001).
Requirements for GAG-protein binding include sequence specificity within
the oligosaccharide chain and, in many cases, a region of enriched basic
amino acids for the protein (Cardin and Weintraub, 1989; Prabhakar et al.,
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2005; Schreuder et al., 1994). The spatial conformation of the GAG chain
must be geometrically complementary to the protein's binding pocket. Since
the protein is more rigid than the saccharide, it is likely that a given GAG
molecule imparts some level of conformational flexibility that facilitates the
interaction (Grootenhuis et al., 1994; Ornitz et al., 1995; Thompson et al.,
1994; Venkataraman et al., 1994).
IV. GalAGs in Biomedicine
A. Cell Signaling and Cancer
Although there has long been a dedicated exploration of HS involve-
ment in signaling, only recently have GalAGs emerged as central players.
The GalAG constituents of PGs are critical regulators of growth factor and
cytokine signaling (Table II) (Brooks et al., 2000; Hildebrand et al., 1994;
Stacey et al., 2003; Wisniewski et al., 2005). Further, GalAG chains are
central to a variety of interactions modulating ECM-mediated cell-to-cell
signaling. For example, chondroitin sulfate proteoglycans (CSPGs) on neu-
trophils specifically bind to platelet factor 4 and are responsible for cellular
activation (Petersen et al., 1998, 1999). Interactions of DS chains with
fibroblast growth factor-2 (FGF-2) and keratinocyte growth factor have
been characterized with respect to cellular proliferation and wound repair
(Trowbridge and Gallo, 2002; Trowbridge et al., 2002). DS is additionally
capable of activating the hepatocyte growth factor/scatter factor signaling
pathway through the c-met receptor (Catlow et al., 2003; Lyon et al., 1998,
2002). The same signaling cascade can promote cell proliferation through
endocan, a PG composed of both CS and DS sidechains (Bechard et al.,
2001). CS and DS chains found in the PG versican bind L-selectin, P-selectin,
and chemokines, significant in leukocyte trafficking and inflammatory dis-
ease (Kawashima et al., 2002; Kinsella et al., 2004; Lesley et al., 1997; Sheng
et al., 2005; Sugahara et al., 2003).
Dermatan sulfate proteoglycans (DSPGs) play an active role both in
modulating ECM integrity and cellular signaling processes, and it therefore
follows that DS has also been implicated in oncogenesis and angiogenesis
(Nelimarkka et al., 2001). GAG-degrading enzymes led to a decrease in
cell proliferation and invasion of melanoma or endothelial cells (Denholm
et al., 2001) and to a reduction in FGF-2 responsiveness (a known regulator
of tumor cell proliferation) in human dermal fibroblasts (Denholm
et al., 2000; Liu et al., 2002). GAG modulation of tumor growth and
dissemination has revealed a regulatory layer of tumorigenesis governed by
GAG crosstalk with various oncogenic agents (Sanderson et al., 2004; Yang
et al., 2005).
78 Prabhakar and Sasisekharan
B. Coagulation
DS selectively activates heparin cofactor II, an important member of
the serpin family of proteins, resulting in the inactivation of thrombin
without an accompanying interaction with antithrombin III (Liaw et al.,
1999, 2001; Maimone and Tollefsen, 1990, 1991; Mascellani et al., 1993;
Nenci, 2002; Tollefsen et al., 1989). An oversulfated DS hexasaccharide,
(IdoA2S-GalNAc4S) 3, binds heparin cofactor II with high affinity, produc-
ing as much as a 100-fold increase in heparin cofactor II-mediated inhibition
of thrombin (Casu et al., 2004; Maimone and Tollefsen, 1991; Mascellani
et al., 1993). Sequence specificity of the DS oligosaccharide is critical, as a
DS hexasaccharide with two repeats of the disaccharide sequence, IdoA-
GalNAc4S, 6S, can also mediate heparin cofactor II activation but a
hexasaccharide with the sequence IdoA2S-GalNAc6S cannot (Denti et al.,
1995; Ernst et al., 1995; Trowbridge and Gallo, 2002). Thus, it is
plausible that heparin cofactor II activation through a GalAG polymer
requires a specific epimerization state (IdoA) and a precise sulfation pattern
(GalNAc4S).
Heparin also activates heparin cofactor II through a chain length-
dependent mechanism (Liaw et al., 1999), resulting in a far higher in-
crease (1000-fold) in antithrombin activity when compared to DS-mediated
phenomena. The action of DS regarding coagulation is distinct from hepa-
rin, as DS behaves as a selective thrombin inhibitor. Heparin acts on the
coagulation system through a template-based mechanism, involving com-
plex formation with the simultaneous binding of heparin to thrombin
and the GAG-binding domain of heparin cofactor II. Interaction of DS
with heparin cofactor II is capable of inactivating thrombin bound to
fibrin on the surface of an injured vessel (Bendayan et al., 1994). This
outcome cannot be achieved through heparan sulfate glycosaminoglycans
(HSGAGs).
A variety of DS-based anticoagulant therapies have been developed.
These include GAG mixtures, including mesoglycan, danaparoid, and sulo-
dexide, which contain both DS and HSGAGs, and intimitan, a semisynthetic
oversulfated DS. Intimitan contains an increased content of the IdoA-
GalNAc4S,6S disaccharide and more effectively inhibits clot-bound throm-
bin than standard heparin or DS therapies (Buchanan and Brister, 2000;
Buchanan et al., 2001; Coccheri et al., 2002a,b; Harenberg, 1998; Nenci,
2002; Nenci et al., 2001; Ofosu, 1998). DS-based therapeutics are being
developed for heparin-induced thrombocytopenia, a disorder resulting from
an autoimmune response to a complex of heparin and platelet factor 4 in
which heparin treatment must be discontinued (Imberti et al., 2003; Taliani
et al., 1999). Novel anticoagulants composed of complexes of GAGs, and
heparin cofactor II are also under investigation (Fernandez et al., 1999;
Monagle et al., 1998).
Chondroitin and Dermatan Sulfate Biopolymers
C. Cartilage Function and Osteoarthritis
Degenerative joint disease or osteoarthritis is characterized by the break-
down of cartilage. Cartilage, composed of up to 90% ECM, serves to essen-
tially cushion the ends of bones. The disease affects more than 20 million
Americans and becomes more prevalent on aging. CS is the predominant
GAG present in cartilage ECM (Hardingham and Fosang, 1992; lozzo, 1997;
Tumova et al., 2000). The high overall charge of the chemical groups present
on CS chains in cartilage PGs are believed to provide the necessary electro-
static forces to promote high-water content, enabling joints to withstand
dynamic mechanical compression (Ragan et al., 2000). PG core proteins
also interact with the collagen fibrils present in cartilage, thus imparting
additional mechanical integrity. These and other biological roles are achieved
through a variety of CS-containing PGs, including aggrecan (Plaas et al.,
2001; Watanabe et al., 1998), decorin, biglycan, and perlecan (Table I)
(Kinsella et al., 2004; Knudson and Knudson, 2001; Reed et al., 2005;
Wadhwa et al., 2004). Cartilage degradation in osteoarthritis proceeds
both through mechanical forces at play in the joint and with the enzymatic
degradation of critical cartilage ECM components. Chondrocytes are largely
responsible for regulating ECM molecules, and the aberrant behavior of
these cells results in pathogenesis (Ragan et al., 2000). Arthritic tissues
have been observed to carry GAG pattern profiles, most notably a decrease
in the abundance of 6-O-sulfated disaccharides accompanying an increase in
4-O-sulfated CS disaccharides (Plaas et al., 1998). The development of
nutraceuticals (including chondroitin, glucosamine, and mannosamine) to
treat osteoarthritis has been controversial.
D. Neurobiology
The neurons and glia of the central nervous system express a wide
variety of PGs that impinge upon diverse processes, including the migration
of neural precursor cells, control of neuronal tracking, the regulation of
neuronal cell adhesion molecules, and the formation of synapses (Edgell
et al., 1996, 2004; Hartmann and Maurer, 2001; Iwata and Carlson, 1991;
Monnier et al., 2003; Oohira et al., 2000, 2004). Through these processes,
PGs of nervous system origin play an essential role during neural develop-
ment (Deepa et al., 2004; Lander et al., 1997; Lee et al., 2004; Saunders
et al., 1997; Umehara et al., 2004; Williams et al., 1994). CSPGs are
particularly abundant in brain tissue. The signal transducing receptor-type
protein tyrosine phosphatase (PTPý) and phosphacan are CSPGs involved in
neuron-glial cell interaction, gliogenesis, neuronal migration, and neurite
outgrowth (Table II) (Holland et al., 1998; Margolis and Margolis, 1993).
Maintenance of long-term potentiation is repressed in mice deficient in the
CSPGs neurocan and brevican (Beggah et al., 2005; Blakemore et al., 2002;
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Hayashi et al., 2005; Johnson et al., 2005; Mishima and Hoffman, 2003;
Popp et al., 2003; Schumacher et al., 1997; Zhang et al., 2003). The absence
of CSPGs is in some notable cases (as with PTPc, neurocan, and brevican)
compensated for by other lecticans (Brakebusch et al., 2002; Harroch et al.,
2000; Rauch et al., 2005; Zhou et al., 2001). The PTPý signaling pathway
has been examined, and several characterizations have been postulated
(Garwood et al., 2001; Margolis and Margolis, 1993; Sugahara et al.,
2003; Tanaka et al., 2003). Pleiotrophin and midkine are growth factors
that can bind PTPc on cell surfaces through CS chains. Receptor dimeriza-
tion and subsequent phosphatase inactivity could manifest, altering G pro-
tein-coupled receptor kinase interactor 1 (GIT1) tyrosine phosphorylation
levels resulting in cytoskeleton modulation. Binding by pleitrophin and mid-
kine can be thoroughly ablated by free CS-D and CS-E saccharides and
partially inhibited via DS and C6S chains (but not through C4S) (Kawachi
et al., 2001; Sugahara et al., 2003). Phosphacan is a secreted variant of PTPc
present in the ECM. Phosphacan CS chains can interact with pleitrophin
and midkine as well, and it has been proposed that this interaction results in
the presentation of these two ligands to PTPh on the cell surface (Sugahara
et al., 2003).
Perhaps the most provocative evidence for the role of GalAGs in neural
development is the findings that these sugars are critical in cytokinesis and
morphogenesis during the early embryonic stages of the nematode, Caenor-
habditis elegans (Hwang et al., 2003; Mizuguchi et al., 2003). Investigations
of GalAG biosynthesis have led to a unique human chondroitin synthase
gene family.
Although GAG chains are essential for the proper development and
functioning of the central nervous system, CS chains in particular have
also been implicated as a major deterrent to the regeneration of axons
following traumatic injury to brain and spinal cord (Fawcett and Asher,
1999; Moon et al., 2001; Morgenstern et al., 2002; Properzi et al., 2003;
Zuo et al., 1998, 2002). Such injuries result in paralysis, and the prognosis
for recovery is bleak. One strategy in development for neural regeneration
makes use of enzymes that prune away inhibitory CS chains present in the
glial scar, allowing regrowth of axons and some functional locomotor
recovery in animal models (Bradbury et al., 2002).
E. Pathogen Receptors
Various pathogens, including viruses and bacteria, use CS and DS on
cell surfaces as the point of attachment to host tissues (Menozzi et al.,
2002; Sugahara et al., 2003; Trowbridge and Gallo, 2002). The role
of glycoprotein C for the binding of herpes simplex virus type 1 to cell
surface CS has been established (Mardberg et al., 2002). By interfering
with glycoprotein C-GAG interaction, a CS chain with the sequence
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GlcA/J1-3GalNAc4S6S can inhibit herpes simplex virus' infectivity (Nyberg
et al., 2004; Sugahara et al., 2003). Undersulfated C4S dodecasaccharides
(minimum length) are required for the adhesion of malaria-infected erythro-
cytes to placenta (Achur et al., 2003; Gamain et al., 2002; Valiyaveettil et al.,
2004); 6-O-sulfation inhibits this process (Chai et al., 2002). The causative
agent of Lyme disease, Borrelia burgdorferi, has strain-specific interactions
with GAG chains, as some strains bind both HS and DS and some recognize
only DS (Parveen etal., 2003). Streptococcus pyogenes expresses a variety of
surface adhesins including M protein, an important virulence factor that
binds heparin, HS, and DS (Frick et al., 2003).
V. The Biosynthesis of GalAGs
GalAGs play such a central role in biology that it is worthwhile to
consider just how the structural diversity that governs their function actually
comes about. The chemical complexity that allows these biopolymers to
control so many essential life functions is the result of a system of intricate
molecular machines each of which put in place a particular structural
element of the polymer chain. Unlike DNA or proteins, the biosynthesis of
polysaccharides does not proceed through a template-based mechanism.
A. Overview
The extensive variation in GalAG composition based on core protein or
tissue localization is so pronounced that one must closely examine GalAG
production processes in order to further develop a context for their bior-
egulatory roles. It has become clear that cells apply exquisite control over
GalAG composition and sequence. This supervision is governed by tissue-
specific expression of only certain isoforms of GalAG biosynthetic enzymes
(Table III). Since the polymer modification reactions colocalize to a specific
area within the Golgi apparatus, it has been postulated that these enzymes
form a larger supramolecular complex that coordinates polymer modifica-
tion (Sasisekharan and Venkataraman, 2000). Such a situation may provide
for enzyme "crosstalk" to supplement further control over the GalAG's
structural milieu.
Figures 3 and 4 summarize the biosynthetic steps in the formation of CS
and DS. Following synthesis of the core protein, xylosylation of specific
serine residues sets in motion GAG formation (Esko, 1999). Addition of
two galactose residues and a GlcA residue completes the linker tetrasacchar-
ide common to both HSGAGs and GalAGs. Subsequent addition of GalNAc
to the linker commits the chain to GalAG lineage. Then, the alternate
addition of GlcA and GalNAc residues results in chain elongation. There is
also variable modification of the chain through epimerization and sulfation
TABLE III Galactosaminoglycan Biosynthetic Enzymes
Enzyme Reaction Accession
Linkage region
Xyl transferasea
Gal transferase Ib
Gal transferase IIC
GlcA transferase Id
GalNAc transferase I"e
Chain elongation
GlcA transferase IIt
GalNAc transferase II
Chondroitin synthaseh
Chondroitin synthase 2i
Chondroitin synthase 3i
Chain modification
Chondroitin 4-O-ST-1k
Chondroitin 4-0-ST-21
Chondroitin 4-0-ST-3"
Dermatan 4-O-ST-1"
Chondroitin 6-0-STo
Chondroitin 6-0-ST-2P
GalNAc4S 6-O-STV
Galactosaminyl uronyl 2-0-
STr
Epimerase
Xylosylation of specific core
protein serines
Addition of 1st Gal moiety in
linkage region
Addition of 2nd Gal moiety to
linkage region
Transfers GlcA to complete linker
tetrasaccharide
Transfer of GalNAc to linkage
oligosaccharide, 1st GalAG
specific step
Transfer of GIcA to growing
oligosaccharide chain
Transfer of GalNAc to growing
oligosaccharide chain
Polymerization: alternate addition of
GlcA & GalNAc
Polymerization: alternate addition of
GlcA & GalNAc
Polymerization: alternate addition of
GlcA & GalNAc
Sulfates GalNAc in CS at 4-0 position
Sulfates GalNAc in CS at 4-O-position
Sulfates GalNAc in CS at 4-O-position
Sulfates GalNAc in DS at 4-O-position
Sulfates GalNAc in CS at 6-O-position
Sulfates GalNAc in CS at 6-O-position
Sulfates GalNAc4S in CS
Sulfates GIcA in [GlcA-GalNAc6S] or
IdoA in [IdoA-GalNAc] or
[IdoA-GalNAc4S]
Epimerization of GlcA to IdoA
ST, sulfotransferase
aGotting et al., 2000.
bJu et al., 2000; Okajima et al., 1999; Uyama et al., 2003.
cBai et al., 2001; Kolbinger et al., 1998.
dKitagawa et al., 1998; Wei et al., 1999.
eKitagawa et al., 2001; Uyama et al., 2003.
fGotoh et al., 2002.
gGuo et al., 2001; Uyama et al., 2003.
"Kitagawa et al., 2001.
'Yada et al., 2003.
AJ277442
AB028600
AF155582
AX092340
Y15014
AB009598
AB071403
AB037823
AB024434
BC030268
AB023207
AB086063
AB086062
AF239820
AF239822
AY120869
AF401222
AB017915
U65637
AB037187
NM_015892
NM_005715
None
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FIGURE 3 GalAG Biosynthesis: precursor configuration and linkage region synthesis. (A)
The formation of the sugars necessary for the biosynthesis of CS and DS. Glucose is the main
source of all GalAG precursors. Galactose, derived predominantly from lactose, can be
processed to UDP-Gal, UDP-GlcA, and UDP-Xyl. (B) The synthesis of the linkage region.
GalAG chains are linked to specific serine residues in core proteins by the same tetrasaccharide
sequence as HSGAGs (GIcA-Gal-Gal-Xyl). The first step that commits the nascent chain to
GalAG formation rather than HSGAG formation is catalyzed by GalNAc transferase I. The
pertinent chemistry outlined in each step in the GalAG biosynthesis pathway is highlighted in
red. The nomenclature for the monosaccarides is as follows: glucose (blue circles), galactose
(yellow circles), xylose (orange stars), galactose (yellow circles), glucuronic acid (diamond in
blue), N-acetyl-D-galactosamine (yellow square), core protein with linkage serine (green),
iduronic acid (diamond in brown). Enzymes are indicated in purple.
'Yada et al., 2003.
kHiraoka et al., 2000; Yamauchi et al., 2000.
'Hiraoka et al., 2000.
"Kang et al., 2002.
"Evers et al., 2001.
"Fukuta et al., 1998; Uchimura et al., 2002.
"Kitagawa et al., 2000.
qOhtake et al., 2001.
rKobayashi et al., 1999.
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FIGURE 4 GalAG biosynthesis: chain polymerization and chain modification. (A) Chain
polymerization is mediated by a variety of enzymes (Table III) that have alternating GlcA
transferase II and GalNAc transferase II activities. (B) Modification of the polymer chain.
GalAG biosynthesis ensues with a series of modification reactions that may alter the sulfation
pattern of the oligosaccharide backbone or switch the epimerization state of uronic acid
moieties. The pertinent chemistry of each step in the GalAG biosynthesis pathway is indicated
in red. The nomenclature is as described in Fig. 3.
reactions. Following synthesis of the GalAG chain within the PG context,
the PG is transported, using specific recognition, sorting, and delivery
mechanisms, from the Golgi apparatus to the ECM, the cell surface, or
intracellular organelles (Prydz and Dalen, 2000).
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B. Core Protein Synthesis and Precursor Formation
It is unclear how a protein is committed to a particular PG lineage. No
single consensus sequence has been determined for chain initiation, although
generally a substituted serine and glycine pair (following several acidic
amino acids) is required. Biosynthesis of the core protein is initiated with
translation in the cytosol. Translocation of the nascent polypeptide into the
lumen of the endoplasmic reticulum through the translocon follows via a
signal sequence-mediated process. Then, N-linked oligosaccharides are
added to asparagine residues from dolichol phosphate intermediates. Prior
to exit from the endoplasmic reticulum, the core protein undergoes chaper-
one-mediated folding and the formation of disulfide bonds (Silbert and
Sugumaran, 2002).
Cells active in GAG synthesis contain all of the necessary enzymes for
precursor formation (Fig. 3A). This is critical as sugar nucleotides do not
normally enter cells (Silbert and Sugumaran, 2002). Glucose is the chief
source of sugar nucleotides for GalAG biosynthesis. To a lesser extent,
galactose (from lactose or other sources) and glucosamine are also capable
of contributing to precursor formation. ATP sulfurylase and APS kinase
catalyze the formation of 3'-phosphoadenosine 5'-phosphosulfate (PAPS),
important for backbone sulfation (Lyle et al., 1994). After cytosol-based
activation of the sugars and sulfation, an antiport mechanism transports the
nucleotides and PAPS into the lumen of the endoplasmic reticulum or Golgi
apparatus (Abeijon et al., 1997).
C. The Linker Tetrasaccharide
Both GalAG and heparin/heparan chains are linked to core protein
serine residues by the same tetrasaccharide sequence: GlcA-Gal-Gal-Xyl
(Fig. 3B) (Silbert and Sugumaran, 2002; Sugahara and Kitagawa, 2002).
Many of the enzymes that catalyze the addition of the linkage sugars
in GalAG biosynthesis are the same for heparin/HS formation, including Xyl
transferase and Gal transferase I (Esko and Zhang, 1996; Gotting et al.,
2000; Prydz and Dalen, 2000; Silbert and Sugumaran, 2002; Sugahara and
Kitagawa, 2002). Xylosylation is initiated in the endoplasmic reticulum
and continues in the early Golgi apparatus (Kearns et al., 1993; Vertel
et al., 1993). The interaction of the Xyl transferase first with the core protein
and subsequently with Gal transferase I likely serves a docking purpose,
delivering the xylosylated core protein to the Gal I transferase in the
early Golgi apparatus (Ju et al., 2002; Okajima et al., 1999; Silbert
and Sugumaran, 2002; Uyama et al., 2003). Gal transferase II mediates the
transfer of another galatose residue (Bai et al., 2001; Kolbinger et al., 1998).
The addition of GIcA to Gal in the linkage region proceeds in the medial/
trans Golgi, distal to the position of Gal addition (Kitagawa et al., 1998;
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Wei et al., 1999). The next step in the pathway is a point of divergence,
where addition of GalNAc to the linker tetrasaccharide commits to GalAG
(rather than HSGAG) formation. This step is catalyzed by GalNAc trans-
ferase I (Kitagawa et al., 2001; Uyama et al., 2003). A cloned and expressed
enzyme, human chondroitin N-acetylgalactosaminyltransferase, was
shown to both add the initial GalNAc residue and synthesize the polymer
chain. This suggests that there may exist several GalNAc I transferases,
each differing in their polymerization capacity (Silbert and Sugumaran,
2002; Uyama et al., 2003).
D. Polymer Biosynthesis
The GalAG chain undergoes polymerization in the Golgi (Gotoh et al.,
2002; Guo et al., 2001; Kitagawa et al., 2001; Silbert and DeLuca, 1969;
Silbert and Freilich, 1980; Yada et al., 2003a,b) with the alternate transfer
of GlcA and GalNAc residues from activated precursors (Fig. 4A). The
GalNAc and GlcA transferases add individual sugars to the nonreducing
end of the PG acceptor (Prydz and Dalen, 2000).
The addition of each unit (GlcA and GalNAc) is independent (Silbert
and Reppucci, 1976). That is, the addition of the next sugar does not
proceed until the concentration of the chain with the first sugar in place is
substantial. This suggests that the chemical machinery facilitating GlcA and
GalNAc addition occurs on discrete proteins or at least through separate sets
of catalytic machinery at distinct sites on the same protein. Several human
and bacterial chondroitin synthases (DeAngelis and Padgett-McCue, 2000;
Kitagawa et al., 2001; Ninomiya et al., 2002) have been identified that have
both GlcA and GalNAc transferase activities (the ability to influence linkage
region chemistry varies).
E. Chemical Modification
The linkage region of the GalAG chain can itself be chemically modified.
The C-2 of xylose can be phosphorylated in a variety of PGs (Oegema et al.,
1984; Sugahara et al., 1992a,b,c). Often, xylose is phosphorylated
subsequent to the addition of the two Gal linker residues and dephos-
phorylated on addition of the linker GIcA (Moses et al., 1997, 1999).
Linkage region sulfation occurs in GaIAGs but not in HSGAGs. CS
and DS can be 4-O-sulfated at the second linker Gal and 4-O-sulfated or
6-O-sulfated in the first GalNAc distal to the linkage region (Sugahara et al.,
1988, 1991). Epimerization of the final moiety of the linker tetrasaccharide
also occurs.
Studies with GAG-degrading enzymes (Ernst et al., 1995; Saito et al.,
1968) have revealed that GalAG sulfation patterns are highly heterogeneous
in vivo (Kusche-Gullberg and Kjellen, 2003). CS polymers can comprise
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only GalNAc4S; only GalNAc6S; both GalNAc4S and GalNAc6S in the
same chain; GalNAc4S,6S; 2- or 3-sulfated GlcA; or unsulfated GalNAc. DS
most commonly contains GalNAc4S, 2-sulfated IdoA, unsulfated GalNAc,
and unsulfated IdoA. GalNAc6S also has been reported (Evers et al., 2001;
Hiraoka et al., 2000; Kang et al., 2002). GalAG 6-O-sulfation occurs in
the medial/trans Golgi apparatus, and 4-O-sulfation takes place later in the
trans Golgi (Silbert and Sugumaran, 2002). Polymer sulfation seems to
occur as the chain grows (Sugumaran and Silbert, 1990) and not after
chain termination. A number of chondroitin 6-O-sulfotransferases have
been characterized (Table III) (Fukuta et al., 1998; Kitagawa et al., 2000;
Uchimura et al., 2002). These generally catalyze the sulfation of KS Gal
residues and chondroitin GalNAc (Fukuta et al., 1995; Habuchi et al.,
1993, 2000; Sugumaran et al., 1995). Another 6-O-sulfotransferase, puri-
fied from squid cartilage and related to the human B-cell recombination
activating gene-associated gene, transfers sulfate to the nonreducing ter-
minal GalNAc4S residue of CS (Ohtake et al., 2001). An additional 6-0-
sulfotransferase (Nadanaka et al., 1999) acts only on GalNAc residues
adjacent to dermatan IdoA. Sulfation at the 4-O-position of GalNAc pro-
ceeds via specific 4-O-sulfotransferases that modify either chondroitin
(Yamauchi et al., 2000) or dermatan (Evers et al., 2001), exclusively. Sulfa-
tion at the 2-O-position, prevalent in DS but relatively rare in CS, is
mediated by a 2-O-sulfotransferase (Kobayashi et al., 1999) that sulfates
IdoA adjacent to GalNAc4S. Although 3-O-sulfated GlcA chondroitin has
been observed from nonmammalian sources (Kitagawa et al., 1997), no
3-O-sulfotransferase has been characterized to date.
Chemical modification at CS of the uronic acid moiety of a GalAG
disaccharide offers two possible epimerization states, resulting in CS
(GlcA) or DS (IdoA). This process of transforming GlcA to IdoA
likely takes place in the early Golgi apparatus, during or shortly after chon-
droitin formation and concomitant with sulfation at the 4-O-position (Silbert
and Sugumaran, 2002). The C5-epimerase responsible has not been cloned.
F. Chain Termination
CS chains terminate in unsulfated GlcA or GalNAc with any of the usual
sulfation states (Silbert, 1978). Although the addition of GlcA to terminal
GalNAc6S is facile, the further addition of GlcA is blocked with GalNAc4S
at the nonreducing end (Silbert and Freilich, 1980). Further, GalNAc addi-
tion is inhibited with a GalNAc4S residue preterminal to GlcA at the
nonreducing end (Cogburn and Silbert, 1986; Silbert and Sugumaran,
2002). A process has been postulated whereby action with a 6-O-sulfotrans-
ferase specific for terminal GalNAc4S and desulfation at the 4-O-position
results in terminal GalNAc6S (Nakanishi et al., 1981; Otsu et al., 1984),
allowing further chain elongation.
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VI. The Catabolism of GalAGs
Just as polysaccharides are synthesized by intricate biological and chem-
ical processes, they must also be degraded as a part of the normal turnover
of biomolecules. The cellular degradation of polysaccharides represents a
cluster of critical biological pathways, essential for the continued proper
functioning of the organism as a whole.
A. Cellular Degradation of GalAGs
GalAG polymers are degraded in lysosomes to liberated mono-
saccharide moieties, many of which are shuffled back into biosynthetic
pathways. Aberrant degradation of GalAG polymers results in one of a
group of lysosomal storage diseases. These genetic disorders are rare, yet
their study has led to the elucidation of catabolic pathways for complex
polysaccharides.
GalAG degradation in vivo is a highly ordered process dependent upon
the action of specific hydrolases. These hydrolases are substrate specific
according to: (1) sugar stereoconfiguration, (2) glycosidic linkage, (3) sub-
stitution pattern of backbone hydroxyl groups, (4) pH of the subcellular
compartment, and (5) the sugar residues adjacent to the site of cleavage.
The first class of glycoprotein hydrolases is the exoglycosidases
(Table IV), which catalyze the release of specific monosaccharides that
terminate the nonreducing end of the oligosaccharide chain. Because they
generally recognize only one nonreducing end monosaccharide, they are
TABLE IV Enzymes of Galactosaminoglycan Cellular Degradation
Enzyme (EC number) Reaction References
Iduronate-2-sulfatase Hydrolysis of 2-sulfate groups of Bielicki et al., 1993;
(3.1.6.13) L-iduronate of DS and heparin/HS Wilson et al., 1993
a-Iduronidase (3.2.1.76) Hydrolysis of unsulfated a-L- Scott et al., 1991;
iduronosidic linkages in DS Unger et al., 1994
GalNAc-4-sulfatase Hydrolysis of 4-sulfate groups of Litjens et al., 1996
(3.1.6.12) GalNAc4S of GalAGs
GalNAc-6-sulfatase Hydrolysis of 6-sulfate groups of Masuno et al., 1993;
(3.1.6.4) GalNAc6S of CS (and D-galactose Morris et al., 1994;
of KS) Sukegawa et al.,
2000
P-N-Acetyl-hexosaminidase Removal of terminal non-reducing Keyhani and Roseman,
(3.2.1.52) GalNAc4S moiety 1996; Pennybacker
et al., 1996
P-Glucuronidase (3.2.1.31) Cleavage of i-GlcA residue Oshima et al., 1987;
Shipley et al., 1993
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often broadly specific, barely receptive to other sugar moieties in the chain.
The endoglycosidases hydrolyze specific sugar sequences within
the biopolymer (Jourdian, 1996). One should note that there are no highly
conserved glycosidase domains. Oligosaccharide chains are therefore par-
tially cleaved by enzymes at a few specific internal sites, generating frag-
ments on the order of 10 kDa. This endoglycosidase action results in
multiple terminal residues, which can be catalytically released through the
action of various sulfatases (Table IV) and exoglycosidases, obviating
the time-consuming and tedious scenario of exoglycosidase-only digestion.
Since exoglycosidases do not degrade substituted sugars, such chemical
groups must first be removed.
B. Pathological Catabolism
The loss of GAG-catabolizing lysosomal enzymes leads to the accumu-
lation of undegraded oligosaccharide in cells and tissue and the subsequent
secretion of this material. Most diseases of GAG catabolic pathways share a
variety of common symptoms (Table V). Specific diagnosis usually requires
an experienced and expert clinician to pinpoint specific symptomatic features
of the given disorder. Defects in glycan degradation generally manifest with
a range of severities. The mucopolysaccharidoses are lysosomal disorders
that share many clinical features. These involve mulitsystem involvement,
organomegaly, dysostosis multiplex, and abnormal facies. Respiration, vi-
sion, and cardiovascular function may be impaired. Joint mobility and
skeletal abnormalities are common (Neufeld and Muenzer, 2001). Onset
in youth is usually the most severe; onset during adulthood is often more
mild (Freeze, 1999; Jourdian, 1996; Michalski, 1996).
C. Catabolism of DS and CS
Figure 5 summarizes the important events in the cellular degradation of
GaIAG polymers. Following hyaluronidase-mediated slicing of an oligosac-
charide chain, DS is degraded initially with iduronate-2-sulfatase (E.C.
3.1.6.13), a hydrolase of lysosomal origin (Bielicki et al., 1993; Wilson
et al., 1993). The 24 kb gene for iduronate-2-sulfatase has been localized
to Xq27/28. The protein is synthesized as two precursor forms of 76 and 90
kDa. Subsequent modification of N-linked sugar residues follows. Posttrans-
lational processing to incorporate phosphorylated mannose-6-phosphate
allows targeting of the protein to the lysosome. In humans, an inherited
deficiency of this enzyme results in a congential storage disorder known as
mucopolysaccharidosis type II (Hunter syndrome). Afflicted individuals
accumulate undegraded DS (and HS) in the lysosome. Accumulation of
these GAG chains leads to a spectrum of clinical phenotypes, including
progressive neurological dysfunction and mental retardation. Preliminary
TABLE V Summary of Lysosomal Disorders
Life
expectancy
Disorder Enzyme deficiency Substrate (years)
Hunter syndrome Iduronate-2-sulfatase DS, HS 20-60
(MPS Type II)
Hurler syndrome a-iduronidase DS, HS 5-10
(MPS Type I H)
Morquio syndrome
MPS Type IVA GalNAc-6-sulfatase C6S, KS 20-40
MPS Type IV B Bf-galactosidase KS 20-40
Sanfilippo syndrome
MPS Type III A Heparan N-sulfatase HS 20-30
MPS Type III B a-N-acetylglucosaminidase HS 20-30
MPS Type III C Acetyl CoA:a-glucosaminide HS 20-30
N-acetyltransferase
MPS Type III D GalNAc-6-sulfatase HS 20-30
Maroteaux-Lamy GalNAc-4-sulfatase DS 10-30
(MPS Type VI)
Sly syndrome (MPS 8f-glucuronidase DS, HS, C6S, C4S 4-20
Type VII)
Gm2 gangliosidoses
Tay-Sachs disease Bf-hexosaminidase A Sphingolipid, 5
oligosaccharides
Sandhoff disease P-hexosaminidase Sphingolipid, 3
A and B oligosaccharides
MPS Type IX hyaluronidase Hyaluronan Unknown
Adapted from Neufeld and Muenzer (2001), with permission.
approaches for therapy include the delivery of recombinant iduronate-2-
sulfatase to neuronal and glial cells (Daniele et al., 2002).
a-Iduronidase (E.C. 3.2.1.76) is a hydrolase that follows the action of
iduronate-2-sulfatase in the lysosome (Scott et al., 1991; Unger et al., 1994).
It cleaves terminal nonreducing IdoA from DS (and HS). A deficiency in this
enzyme results in a failure to degrade GAGs, manifesting in mucopolysac-
charidosis type I patients present with a range of clinical phenotypes, includ-
ing Hurler and Scheie syndromes. Enzyme replacement therapy has been
shown to have some benefit (Brooks, 2002). The enzyme has been purified
from a variety of mammalian tissues (Table IV). It has been proposed that
c-iduronidase acts in concert with other GAG-degrading enzymes as a
multienzyme complex near the lysosomal membrane (Jourdian, 1996).
Terminal GalNAc4S can be removed via multiple pathways. The first
possibility is the sequential action of GalNAc-4-sulfatase (also known as
arylsulfatase B) to remove sulfate at the 4-O-position followed by P-N-
Acetyl-hexosaminidase A or B to remove the hexosamine moiety. Alterna-
tively, f-N-acetylhexosaminidase A can first clip the GalNAc4S moiety, and
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FIGURE 5 Cellular degradation of galactosaminoglycans.. The degradation in vivo of
GalAG polymers proceeds sequentially via the action of a combination of endoglycosidases,
sulfatases, and exoglycosidases. Degradation is initiated by the endolytic cleavage of the long
oligosaccharide chain into smaller fragments. Then, removal of sulfatases and exoglycosidase
action mediates further degradation. The pertinent target for degradation at each step is
indicated in red. The nomenclature is as described in Fig. 3.
then sulfatase cleavage occurs. 1f-N-acetylhexosaminidase A is one of the very
few exoglycosidases that can cleave sulfated amino sugars at low pH
(Keyhani and Roseman, 1996; Litjens etal., 1996; Pennybacker etal., 1996).
Absence of GalNAc-4-sulfatase affects DS catabolism and manifests in
mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Clinically,
growth retardation starts at the age of two or three, with coarsening of
facial features, corneal clouding, joint stiffness, and abnormalities in the
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hands and spine. Tay-Sachs disease is a disorder in glycolipid degradation
resulting from deficiency in P-N-acetylhexosaminidase A. In its most severe
form, neurodegeneration leads to death within 4 years. At its mildest, there
is a somewhat slower onset of neurological symptoms. f-N-acetylhexosa-
minidase A and B deficiencies lead to Sandhoff disease with excreted gluco-
saminyl oligosaccharides. Clinical symptoms of Sandhoff disease closely
resemble Tay-Sachs disease.
Pl-Glucuronidase cleaves the fl-GlcA residue (Oshima et al., 1987;
Shipley et al., 1993). This process is continuously cycled until the oligosac-
charides are reduced to free monosaccharide derivatives and sulfate ions.
Deficiency in /-glucuronidase activity results in mucopolysaccharidosis type
VII, affecting the catabolism of DS, HS, and CS. Clinical features of this
syndrome vary from patient to patient, but all patients have growth retarda-
tion with resultant short stature, some bone abnormalities, and mental
retardation. Osteoarthritis is also prevalent. Survival into adulthood is
common with milder forms of the pathology.
Hyaluronidase sets the stage for CS degradation at the cellular level.
Lysosomal CS catabolism proceeds in analogous fashion to DS, with-
GalNAc-4-sulfatase and GalNAc-6-sulfatase (Masuno et al., 1993; Morris
et al., 1994; Sukegawa et al., 2000) leading the way for f-N-Acetyl-hexosa-
minidase A or B and fl-glucuronidase.
No mammalian endoglycosidases specific for GalAGs have been
reported, although a variety of bacterial chondroitinases has been isolated
and characterized. Hyaluronidase deficiency (MPS Type IX) has been
reported in only one case in which it clinically manifested in periarticular
soft tissue masses, episodic painful swelling, and short stature (Natowicz
et al., 1996).
VII. The Enzymatic Degradation of GalAGs
A. Mechanisms of GAG Depolymerization
We have seen that in vivo, GAGs are degraded by a variety of enzymes of
predominantly lysosomal origin-the hydrolases and various exoglycosi-
dases. Another class of GAG-degrading enzymes includes the bacterial lyases
(Table VI). These come in three categories, classified according to substrate:
hyaluronidases, heparinases, and chondroitinases. Many lyases have been
purified and employed in a variety of analytical and industrial applications.
The following describes the depolymerizing action of lyases that act on
GalAGs, the chondroitinases, and the hyaluronidases.
There are two chemical mechanisms whereby GAGs undergo cleavage.
With eliminative cleavage, the proton off of C5 of the uronic acid moiety is
first abstracted. This results in an unsaturated bond between C4 and CS of
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TABLE VI Overview of GalAG-Depolymerizing Lyases
Mode of Cleavable MW
Enzyme Organism action linkage (kDa)
Chondroitinase Proteus (Type I) Endolytic -GalNAc 4 x6 x(fl1,4)U2X- >100
ABC Proteus (Type II) Exolytic GalNAc4x 6x(p1,4)U2x- >100
Pedobacter Exolytic GalNAc4 x6 x(fl1,4)U2x- >70
Bacillus 53
Beta (Type I) 104
Beta (Type II) 108
Chondroitinase Arthrobacter Exolytic GalNAc4 x6 x(fl1,4)- 76
AC GlcA2 x-
Aurebacterium >80
Aeromonas X
Pedobacter Endolytic GalNAc4x 6x(fll,4)- 75
GlcA2 x-
Serritia 70
Chondroitinase B Pedobacter Endolytic -GalNAc 4x 6x(fl1,4)- 54
IdoA2x-
Chondroitinase C Pedobacter -GalNAc 6s(f31,4)GlcA2 x- <70
Hyaluronate Lyase Staphylococcus Endolytic -GalNAc(fl1,4)GlcA 2 x- 84
Streptococcus Endolytic 120
Apis Endolytic 40
X, sulfated or unsubstituted. U, uronic acid of either CS epimerization state.
the uronic acid. Protonation of the anomeric oxygen completes the reaction
with the breaking of the glycosidic bond. At its simplest, it can be visualized
as a proton acceptance and donation mechanism (Jedrzejas, 2000). Hydro-
lytic cleavage proceeds slightly differently, first with proton donation to the
glycosidic bond. This breaks away the glycosidic oxygen, creating an 05
oxonium ion. Water addition neutralizes the oxonium ion and saturates all
carbons (Linhardt et al., 1986). One should note that although lyases can
only cleave linkages on the nonreducing side of uronic acid, the hydrolases
have no such limitation and can cleave either bond.
B. GalAG Lyase-Mediated Degradation of GAGs
Chondroitinases (Table VI) are produced in soil and intestinal bacteria.
Polysaccharides trafficked to the intestinal lumen with epithelial cells pro-
vide these bacteria with their nutrient source. Chondroitin lyases have been
isolated and characterized from a variety genera, most notably Pedobacter
(Fethiere et al., 1999; Huang et al., 1999; Michelacci et al., 1987; Pojasek
et al., 2001, 2002; Yamagata et al., 1968) and Proteus (Hamai et al., 1997;
Huang et al., 2003; Michel et al., 2004; Ryan et al., 1994; Sato et al., 1994;
Yamagata et al., 1968). Chondroitinases have also been isolated from
Arthrobacter (Lunin et al., 2004), Aeromonas (Kitamikado and Lee,
1975), Bacillus (Ernst et al., 1995), and Bacteroides (Guthrie et al., 1985;
Hwa and Salyers, 1992a,b; Linn et al., 1983).
C. Chondroitinases from Pedobacter heparinus
Chondroitinase ABC from P. heparinus is a broad substrate specificity
lyase that acts on a variety of GAGs, including C4S, C6S, DS, chondroitin,
chondroitin D and E. The enzyme is unable to catalyze the depolymerization
of hyaluronate, heparin and HS, or KS. It has a molecular weight in excess of
70,000 kDa and an optimal activity temperature of 300C. The enzyme is
fully active against DS, which is unusual for cABC lyases generally. Other
cABC lyases have DS activities under 40% of their C4S activity (Ernst et al.,
1995). Chondroitinase ABC causes the weight average molecular weight of a
GalAG substrate to decrease slowly. The enzyme acts exclusively on the
reducing end of the oligosaccharide chain, suggesting a wholly exolytic
activity (Michelacci et al., 1987). The enzyme does not seem amenable to
modeling by Michaelis-Menten kinetics, and thus some other mechanism
may be in force. The reaction is inhibited by its product (UA-GalNAc4S), by
excess substrate (Michelacci et al., 1987), Ca 2 , PO3-, Fe3+ , and Mn2+
Chondroitinase AC (E.C. 4.2.2.5) from P. heparinus is a 75-kDa enzyme
that acts on C4S, C6S, chondroitin, and hyaluronate (Fig. 6) (Huang et al.,
2001). It is completely incapable of DS cleavage. At the onset of reaction, the
substrate's molecular weight drops dramatically, producing intermediate
hexasaccharide and tetrasaccharide, with further degradation over time
(Rye and Withers, 2002). This suggests a predominantly endolytic mode of
action. Heparin and DS are notable inhibitors of enzyme activity (Pojasek
et al., 2001; Rye and Withers, 2002a,b,c).
Chondroitinase B from P. heparinus has been characterized extensively
(Fig. 7) (Huang et al., 1999; Michel et al., 2004; Pojasek et al., 2001, 2002).
It is the only known lyase that cleaves DS as its sole substrate. Chondro-
itinase B can cleave DS /(1,4) bonds that contain the commonly occurring
4-O-sulfate but also linkages with sulfation at the 2-O-position, 6-0-
position, or both. X-ray crystallography (Huang et al., 1999), site-directed
mutagenesis (Michel et al., 2004; Pojasek et al., 2002), and modeling studies
(Pojasek et al., 2002) have identified critical amino acids involved in sub-
strate binding and catalytic activity. Chondroitinase B's activity is nonran-
dom, nonprocessive, and endolytic, preferring longer substrate to shorter
ones. It works primarily by cutting internal bonds proximal to the reducing
end, although other cleavage sites are also susceptible. An Arg364Ala mu-
tant has been shown to have an altered mode of action yielding an altered
product profile. This phenomenon is most likely explained through the
differentiated binding between this mutant and DS. Additionally, a complex
between Ca2+, chondroitinase B, and DS is required for substrate cleavage.
It has been proposed that the Ca'+ ion neutralizes the IdoA carboxylate in
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FIGURE 6 Structural comparision of cAC and cABC I. (A) Structure of chondroitinase AC
from Pedobacter heparinus based on the crystal structure of Fethiere et al. (1999) and Huang
et al. (2001). (B) Structure of chondroitinase ABC I from Proteus vulgaris based on the crystal
structure by Huang et al. (2003). The similarities in the domains of both enzymes are evident.
On a closer inspection, the middle domain of cABC I has very little sequence identity with the
catalytic domain of cAC (and bacterial hyaluronidases). However, the residues that are
implicated to play important roles in catalysis are conserved in both enzymes (Prabhakar et al.,
2005). These catalytic residues are shown in full (purple). The more open cleft of cABC I is
possibly suggestive of this enzyme's ability to accommodate a variety of oligosaccharide
geometries and thus its wider substrate specificity. (See Color Insert.)
the catalytic groove, and two residues, Lys250 and Arg271, act as Bronsted
base and acid, respectively (Michel et al., 2004). This strategy makes use of
the flexibility of the IdoA moiety.
Very little is known about chondroitinase C from P. heparinus, an
enzyme specific for 6-O-sulfated CS linkages. Cross-reactivity with C4S is
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FIGURE 7 Chondroitinase B from Pedobacter heparinus. Structure of chondroitinase B
based on the crystal structure of Huang etal. (1999) and Michel et al. (2004). Chondroitinase B is
the only known enzyme that cleaves dermatan sulfate as its sole substrate. The structure shows the
right-handed parallel #-helix fold representative in chondroitinase B and pectate lyases. The
authors thank Dr Rahul Raman for support in preparing this schematic. (See Color Insert.)
the result of the general heterogeneity of GAG polymers in which oligosac-
charides that may contain predominantly C6S actually exist as copolymers
with C4S.
D. Chondroitinases from Proteus vulgaris
The conventional broad substrate specificity enzyme from P. vulgaris
(Ernst etal., 1995; Sato etal., 1994; Yamagata etal., 1968) has actually been
found to comprise two distinct lyases, chondroitinases ABC I and II. Both
enzymes cleave a wide variety of GalAGs and hyaluronan. Chondroitinase
ABC I has been recombinantly expressed and characterized (Hamai et al.,
1997; Michel et al., 2004), and its structure has been elucidated (Fig. 7)
(Huang et al., 2003). It has a molecular weight of 105 kDa and optimally
processes CS and DS substrates at 37 0 C. CS substrates are processed at
greater rates than DS: 40% greater activity with C6S and more than a
twofold increase with C4S. Activity is maximal for CS substrates at a pH
of 7.9; for hyaluronan, the optimal pH is 6.1. Chondroitinase ABC I activity
is inhibited by Zn2 + and heparin. The products of an exhaustive digestion
~
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of CS or DS comprise a mixture of unsaturated tetrasaccarides and
disaccharides (Prabhakar et al., 2005). Putative catalytic residues of cABC
I include His501, Tyr508, Arg560, and Glu653 (Prabhakar et al., 2005).
Arginine-500 may also be involved in substrate catalysis (Huang et al.,
2003). The lyase acts using the proton acceptance and donation mechanism
described earlier. Chondroitinase ABC I is commercially available.
The cABC II lyase from P. vulgaris has been scrutinized far less thor-
oughly (Hamai et al., 1997; Ryan et al., 1994). Chondroitinase ABC II is
100 kDa in size and optimally processes GalAG substrates at pH 7.9 at
400C. Although cABC II is just as broad as cABC I in terms of substrate
profile, it is a far less efficient enzyme regarding catalytic activity. In fact,
cABC II processes C4S 16 fold less effectively than cABC I and DS 8 fold less
(Hamai et al., 1997; Ryan et al., 1994). The product profile for cABC II is
similar to that of cABC I.
E. Chondroitinase AC from Arthrobacter aurescens
Chondroitinase AC from A. aurescens (Hiyama and Okada, 1976,
1977) is a 76-kDa enzyme that processes C4S, C6S, chondroitin, and
hyaluronan. It is inhibited by DS. The enzyme processes these substrates
exolytically, producing almost exclusively disaccharide products (Jandik
et al., 1994). Chondroitinase AC will cleave CS/DS copolymers but only at
linkages containing glucuronic acid (Gu et al., 1993; Linhardt et al., 1991).
F. Bacterial Hyaluronidases
Hyaluronidases have been purified from the bacterial genera Propioni-
bacterium, Peptostreptococcus, Staphylococcus, Streptococcus, and Strep-
tomyces (Linhardt et al., 1986). Specific activities of hyaluronidases vary
widely. The lyase from Peptostreptococcus has a remarkably high turnover
number, with an activity of 600,000 IU/mg (Tam and Chan, 1985). Hyal-
uronidase from Staphylococcus has a specific activity of 15 IU/mg (Rautela
and Abramson, 1973; Vesterberg, 1968). Through hyaluronate is the major
substrate, C4S and C6S can also be cleaved by many hyaluronidases, albeit
at lower rates. Because of the great variation in catalytic rates among
hyaluronidases and the relative inconsequentiality of pH for activity, it has
been suggested that these enzymes may employ a mechanism fundamentally
distinct from other GAG lyases.
VIII. Perspectives
The limited availability and vast heterogeneity of tissue-derived GalAGs
(and other GAGs) has hampered efforts to characterize their sequence-
specific influences on proteins and other signaling molecules. Their complex
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nontemplate-driven biosynthesis precludes the possibility of amplification,
unlike DNA and proteins, further complicating glycobiological study. Novel
synthetic strategies for the fabrication of complex polysaccharides are still
in their infancy. These limitations have forced investigators to cultivate
sensitive analytical systems to examine GAG properties.
Biological sample Many possible
Tissue source sequences
Isolation of polysaccharide
I~ ~~ I TisesucN
Mass signature Linkage information
GaAG 4X6X 2X 4X6X 2X 4X6X
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FIGURE 8 Techniques for GalAG sequencing analysis. Three major developments have
propelled techniques to characterize the fine structural elements of complex polysaccharides:
(1) the development of enzymatic tools to specifically degrade functional groups on an
oligosaccharide chain, (2) analytical chemical approaches, including mass spectrometry,
capillary electrophoresis, and nuclear magnetic resonance to establish complementary,
orthogonal sets of structural data, and (3) a bioinformatics platform to integrate disparate
data elements into a numerical strategy for sequencing. These techniques allow for the rapid
and bias-free sequencing of complex polysaccharides by considering all possible compositions
and converging at a single solution.
r
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TABLE VII Biotechnological Applications of Chondroitinases
Enzyme Application Organization
cABC Promoting neural plasticity in the central
nervous system
cB Mutants Rationally-designed polysaccharide lyases
for compositional analysis and
inhibiting anticoagulant activity and
angiogenesis
cAC and cB Attenuation of tumor growth, metastasis,
and angiogenesis
cGP Human chondroitinase glycoprotein
cABC Treatment targeting mucus resulting from
cystic fibrosis
cABC Treatment of chemonucleolysis
cB
cABC
cB and cAC
cABC
cABC
Treatment of surface tissue diseases
Clearance of hemorrhagic blood from the
vitreous humor of the eye
Treatment of fibroproliferative diseases
Treatment for disc herniation
Cleaning and detergent compositions
cABC I and II Method for disinserting vitreous body
from the neural retina
cAC, cB, Compositional analysis of GAG mixtures;
cABC I and treatment of pathologies resultant from
II, mutants the presence of GAGs; the use of defined
thereof GAGs and GAG mixtures to treat cancer
Cambridge University Kings
College London
Massachusetts Institute of
Technology
IBEX Technologies
Deliatroph Pharmaceuticals
Beth Israel Deaconess Hospital
Rush Presbyterian/St. Luke's
Hospital
Seikagaku Corporation
Advanced Corneal Systems
IBEX Technologies
Seikagaku Corporation
Procter & Gamble
Corporation
American Cynamid Company
Massachusetts Institute of
Technology
The cloning and characterization of heparinase I allowed the first determi-
nation of a heparin-binding site (Sasisekharan et al., 1993). Since then, there
has been a surge of activity regarding the development of biopolymer-degrad-
ing enzymes, including various chondroitinases and exoenzymes. Structural
investigations of these enzymes, including crystallographic, spatial modeling,
and nuclear magnetic resonance studies, have shed considerable light on
enzyme interaction with substrate. Further, the study of GAG biosynthetic
and catabolic enzymes in vivo has revealed a wealth of insight regarding
structural and chemical properties of GAG populations. GAG detection on a
variety of platforms has been sensitized by introducing UV chromophores and
covalent derivitization with fluorescence or radioactive tags. Mass spectromet-
ric methods have enabled detection of pico- to femtogram quantities of
material. Matrix-assisted laser desorption ionization MS of sulfated oligosac-
charides is now accurate to within 1 Da. Capillary electrophoresis and liquid
chromatography are now being used in tandem with MS to directly identify
disaccharides based on mass. These approaches have been coupled with bioin-
formatics methodologies, including property-encoded nomenclature, to form
sequencing strategies (Fig. 8) to elucidate the fine structural elements of com-
plex polysaccharides (Sasisekharan and Venkataraman, 2000; Tumbull et al.,
1999; Venkataraman et al., 1999). These tactics rely on the integration of
disparate experimentally derived data sets, each of which reinforce each other
to provide a solution set of possible polysaccharide sequences. Numerical
constraints, including established rules for linkage susceptibility to cleavage,
further allow convergence to a single sequence. These attempts at sequence
elucidation will be crucial in extending our understanding of the emerging
paradigm of sequence-specific binding and modulation of proteins by
polysaccharides.
The sweeping involvement of complex polysaccharides like GalAGs
within critical biochemical pathways and disease processes heralds a coming
age in which glycan biotechnologies will be central elements in diagnostic
strategies and therapeutic interventions (Table VII). Such biomedical tech-
nologies will include glycan-based approaches for multicellular diseases
(Shriver et al., 2004), glycan-based drug improvement strategies, enzyme
replacement therapies, and glycome profiling both to screen disease severity
in patients and to develop novel medical interventions.
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1.2.1 Glycomics Approach to Biology
Extracellular modulation of phenotype is an emerging paradigm in this current
post-genomics age of molecular and cell biology. Glycosaminoglycans [GAGs] are
primary components of the cell surface and the cell-extracellular matrix [ECM] interface.
Advances in development of technology to analyze GAGs and in whole organism
genetics have led to a dramatic increase in the known important biological role of these
complex polysaccharides. Due to their ubiquitous distribution at the cell-ECM interface,
GAGs interact with numerous proteins and modulate their activity, thus impinging on
fundamental biological processes such as cell growth and development. Many recent
reviews have captured important aspects of GAG structure and biosynthesis, GAG-
protein interactions and GAG biology. The area of GAG research is currently at a stage
where there is a need for an integrated systems or glycomics approach that involves an
integration of all of the above concepts to truly define their structure-function
relationships. Focusing on heparin/heparan [HSGAGs] and chondroitin/dermatan sulfate
[CSGAGs], this annual review highlights the important aspects of GAGs and summarizes
these aspects in the context of taking a glycomics approach that integrates the different
technologies to define structure-function relationships of GAGs.
In this present 'omics' age of cell and molecular biology, there has been a
dramatic transformation in the role of post-translational modification and protein-protein
interactions in governing how genotype influences cellular phenotype. This age has
witnessed advances in technologies such as DNA microarrays, 2-D gel electrophoresis,
mass spectrometry, and micro-scale fluidics. These technologies have led to high
throughput measurements of expression of several thousand genes and hundreds of
protein-protein interactions to construct comprehensive biochemical pathways and
interaction networks within a single cell. More recently, there has been an increasing
appreciation for the role of extracellular events in understanding phenotype, going
beyond a single cell to tissues, organs, and entire organisms.
The central components of these extracellular interactions are complex
polysaccharides, present at the cell-extracellular matrix [ECM] interface of virtually all
eukaryotic cells. The most extensively studied complex polysaccharides are the
glycosaminoglycans [GAGs]. Recent advances, specifically in developmental biology
and cancer biology, have resulted in a dramatic increase in the number of important
implicated roles for extracellular GAGs in critical biological processes. These include
regulatory functions in development [1-3], angiogenesis [4], axonal growth [5-11], cancer
progression [11-17], microbial pathogenesis [18], and anticoagulation [19, 20]. An
emerging paradigm in the extracellular modulation of biological function is the specific
interactions between GAGs and numerous proteins at the cell-ECM interface. These
interactions modulate protein function and thus impinge on fundamental biological
processes (Figure 1.2.1).
Despite the numerous known biological roles of GAGs, it has been challenging to
decode their structure function relationships. The biosynthesis of GAGs is non-template
driven involving several enzymes and their tissue specific isoforms [21-23]. The complex
biosynthesis and lack of proof reading machinery leads to inherent heterogeneity and
large diversity of GAG structures. The chemical heterogeneity and diversity of GAGs
have challenged the development of analytical techniques to accurately define their
chemical structures. Also, due to their mode of biosynthesis, ubiquitous sub-cellular
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Figure 1.2.1. Biological interactions of GAGs.
Shown in A is a schematic of the location and distribution of GAGs and their interactions
with numerous proteins such as growth factors, morphogens, proteases and pathogens.
The chemical and structural diversity of GAGs enables their specific interactions with
these proteins thus impinging on their biological roles. B, schematic to show glycomics as
an emerging paradigm in the post- genomics dogma of molecular and cell biology. The
dynamic GAG-protein interactions at the cell-ECM interface provide a new perspective
to understanding how genotype influences phenotype at the cellular and higher levels.
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cell surface also complicates the understanding of the specificity of GAG-protein
interactions in the context of a biological process.
Given the complexity and the challenges involved in truly decoding the structure-
function relationships of GAGs in their physiological context, it is important to take an
integrated or glycomics approach. Such an approach would combine three main aspects:
1) structural characterization of GAGs, 2) detailed understanding of GAG-protein
interactions and 3) rigorous in vitro and in vivo model systems that provide defined
functional readouts for correlation with structural attributes.
Focusing mainly on heparin/heparan sulfate [HSGAGs] and chondroitin/dermatan
sulfate [CSGAGs], this review provides detailed insight into the structure-function
relationships of GAGs by highlighting the unique challenges that necessitate a glycomics
approach to GAGs. The main aspects summarized in this work include structure and
biosynthesis of GAGs, structural characterization of GAGs and GAG-protein
interactions. The final part of this review highlights the integration of the above aspects
in a glycomics approach to GAGs in anticoagulation and cancer. While each of these
aspects has been discussed in recent reviews, they are summarized here in the context of
taking an integrated approach to GAG structure function relationships for the first time.
GAGs: Morphology, biosynthesis and chemical structure
GAGs are linear polysaccharides comprising of a disaccharide repeat unit of a
hexuronic acid linked to a hexosamine (see Table 1.2.1 for monosaccharide abbreviations
used in this review). Based on the backbone chemical structure, there are four classes of
GAGs. HSGAGs and CSGAGs are synthesized in the Golgi, where the individual GAG
chains are linked to a core protein, forming a large polysaccharide-protein conjugate
called a proteoglycan [PG]. Keratan sulfate, on the other hand, can be either N-linked or
O-linked to the core protein of the PG. Hyaluronic acid is not synthesized in the Golgi
from the core protein but rather by an integral plasma membrane synthase, which secretes
the nascent chain immediately.
Table 1.2.1. Different classes of GAGs and their disaccharide building blocks
Category Disaccharide U H Modifications
Heparin/Heparan U2X (o/pl,4) HNY,3X,6X (al1,4 IdoA/GlcA Glucosamine X - sulfated
[HSGAG] Y - acetylated/ sulfated
Chondroitin[CS]/ U2X (a/pl,3) HNAc,4X,6X (pI,4 IdoA/GlcA Galactosamine X - sulfated
Dermatan[DS][CSGAG]
Keratan Gal6x (01.4) HNAc,6X (pl.3 Gal Glucosamine X - sulfated
Hyaluronic Acid GIcA (1.3) HNA (•1.4 GlcA Glucosamine None
The abbreviations used in the manuscript are as follows - a-L-iduronic acid, IdoA or I;
P-D-glucuronic acid, GlcA or G; H is either a/P-D-glucosamine [GlcNAc] or P-D-
galactosamine [GalNAc] depending on the GAG class; 3-D-Galactose, Gal. Acetylation
[COCH 3] is indicated using Ac and sulfation [S03-] using S. Example: The disaccharide
2-0 sulfated oc-L-iduronic acid linked to 4-0 of an N-, 6-0 sulfated glucosamine is
represented either as IdoA2S-GlcNS,6S or I2s-HNS,6s.
The biosynthesis of GAGs has been discussed in great detail in recent reviews and
is summarized in the following [22-24]. It is a complex non-template driven process
involving several enzymes that assemble the GAG polymer and sulfate them at specific
positions. The GAG attachment sites on the core protein of the PG have a consensus Ser-
Gly/Ala-X-Gly motif, where chain initiation begins from the Oy atom of the serine. The
initial steps in the chain-building process involve the attachment of a tetrasaccharide
linker - GlcAfl -3Galfl -3Galfll -4Xylfll-O-(Ser), where four different enzymes,
including xylosyl transferase, 34-galactosyl transferase [GaIT-I], 33-galactosyl
transferase [GalT-II] and P3-GlcA transferase [GlcAT-I] transfer the four
monosaccharides, respectively. After the attachment of the linker, the first modification
to the chain determines whether the chain matures into a CSGAG or HSGAG chain. This
modification involves the transfer of a GIcNAc [HSGAG] or a GaiNAc [CSGAG]
monosaccharide.
The enzyme GlcNAcT-I transfers GlcNAc to the tetrasaccharide linker, initiating
HSGAG biosynthesis. This enzyme is distinct from the glycosyltransferase GlcNAcT-II
involved in the elongation of the HSGAG chain. Two genes in the EXT family, EXTL2
and EXTL3 of tumor suppressors, have been shown to have the GIcNAcT-I activity. In
the case of CSGAGs, the GalNAc is transferred to the linker region by a GalNAcT. It is
not fully clear if the activity of this enzyme is different from the GalNAc transferase
activity of chondroitin synthase which is involved in the chain elongation process.
The actual chain-building ensues after the transfer of GIcNAc [HSGAG] or
GalNAc [CSGAG] to the linker. In the case of HSGAGs, a multidomain
glycosyltransferase successively transfers GlcNAc and GlcA initiating the chain
elongation process. This multidomain enzyme is encoded by EXT1 and EXT2 of the
EXT family of genes. Although each of EXT1 and EXT2 possess the ability to transfer
both GlcNAc and GlcA, it has been established that these enzymes form a single
oligomeric unit which is required for complete in vivo chain elongation activity.
Similarly, in the case of CSGAGs, chondroitin synthase, also a multidomain enzyme,
transfers GalNAc and GlcA successively for chain elongation. After the elongating chain
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Figure 1.2.2. Biosynthesis of GAGs. The biosynthesis of HSGAGs and CSGAGs
starting from the core protein is illustrated using the symbol nomenclature for glycans.
The anomeric configuration of the monosaccharide and the position of the oxygen atom
involved in the glycosidic linkages are shown. The different glycosyltransferases and
sulfotransferases involved in the biosynthesis [as described in the text] are also shown.
matures to a particular stage, it is modified by the action of C-5 uronyl epimerase and
sulfotransferases.
The nascent HSGAG chain is first modified by N-deacetylase, N-sulfotransferase
[NDST], which is a multidomain enzyme that cleaves the N-acetyl group from the
GlcNAc monosaccharides and transfers a sulfate group to the N-position. This is
followed by the action of the C-5 uronyl epimerase that converts D-GlcA to L-IdoA
(Figure 1.2.2). 2-0 sulfation of the uronic acid by the 2-0 sulfotransferase [2-OST]
follows the epimerization process. The 2-0 sulfotransferase acts on both IdoA- as well as
HSGAGs
CSGAGs
GlcA-containing HSGAG chains; however, the IdoA-containing chains are the
catalytically preferred substrates [25, 26]. The final set of modification enzymes are the
6-0 [6-OST] and 3-0 [3-OST] sulfotransferases, which sulfate the 6-0 and 3-0 positions
of the GlcNAc moiety, respectively. Many of the above biosynthetic enzymes have
distinct isoforms that are selectively expressed in different tissues. Four different
isoforms of NDST, three different 6-OSTs and six different 3-OSTs and have been
characterized in the human and the mouse.
The biosynthesis of CSGAGs can be broadly divided into that of chondroitin and
dermatan sulfate. Chondroitin sulfate predominantly comprises the GlcA epimer, whereas
dermatan predominantly comprises IdoA. Thus, the CSGAG C-5 uronyl epimerase is
more prominent in the biosynthesis of dermatan sulfate. The three main sulfation events
of the CSGAG chains are 4-0 and/or 6-0 sulfation of GalNAc and 2-0 sulfation of
uronic acid. There are four different isoforms of the CSGAG GalNAc 4-0
sulfotransferase [C4ST-1, C4ST-2, C4ST-3 and D4ST-1] and three different isoforms of
the CSGAG GalNAc 6-0 sulfotransferase [C6ST, C6ST-2, GalNAc4S-6ST].
The biosynthesis of GAGs generates significant diversity in the primary sequence
of GAGs as defined by the chemical structure of the polysaccharide backbone and the
sulfation patterns. A clustered organization of specific sulfation patterns has been
proposed [27]. For example, in the case of HSGAGs, the overall sulfation is divided into
N-sulfated domains, NS/NAc mixed domains, and NAc domains (based on sulfation of
the glucosamine) that are interspersed amongst each other. In the literature, a general
distinction is made between heparin and heparan sulfate. Heparin is synthesized
exclusively on the serglycin core protein, and is stored in intracellular granules of mast
cells where it acts as a reservoir for proteases. Heparin chains are highly sulfated and are
comprised of a predominant disaccharide repeat unit, -[I2s-HNs,6S]n-. Heparan sulfate, on
the other hand, is more ubiquitously found on cell surfaces and displays tissue-specific
variability with respect to sulfation pattern. The overall sulfation of heparan sulfate is
generally lower than that of heparin. Heparan sulfate also comprises a larger abundance
of unsulfated glucuronic acid. A similar clustering of specific chemical modifications has
also been proposed for CSGAGs.
Understanding the sequence diversity of GAGs as a consequence of their
biosynthesis has been complicated by the characterization of the substrate specificities
and mode of action of the biosynthetic enzymes. Central to these challenges has been the
lack of defined substrates of suitable chain length [higher than octasaccharides]. Two
different models have been proposed for the action pattern of GAG biosynthesis. The first
model involves independent action of these enzymes in a sequence that starts with chain-
building. Each enzyme recognizes and binds to a part of the chain that forms the
precursor for the modification event. The second model involves the formation of a
multidomain enzyme complex, where the action of one enzyme is coupled with that of
the other. Despite these challenges, there has been significant progress in the
characterization of these biosynthetic enzymes in terms of their substrate-product
relationships and tissue specific expression of their isoforms.
The inherent heterogeneity in the chain length and the sulfation pattern of GAGs
has complicated their isolation and structural characterization. The non-template driven
nature of the biosynthesis has also made it challenging to develop techniques to amplify
biological GAGs. As a result, there is a practical requirement for the analytical tools to be
able to handle minute sample amounts of GAGs isolated from various biological sources.
These issues pose important challenges to the characterization of biologically active
GAG species, which are typically found in low abundance within a heterogeneous
mixture. From a functional perspective, the involvement of several enzymes and their
isoforms in GAG biosynthesis complicates genetic studies founded on knock-in or
knock-out strategies of specific oligosaccharide sequences. Moreover, due to the
physiological heterogeneity of GAGs in the cellular environment, comprehending the
biological roles of GAGs often goes beyond a single sequence to an ensemble of chains
that are involved in a specific biological process.
The following section highlights some of the well established and recent studies
highlighting the important biological roles of HSGAGs and CSGAGs. These biological
functions raise fundamental questions on how the sequence diversity of GAGs translates
into their structure-function relationships with various physiological players.
Biological roles of HSGAGs and CSGAGs
The earliest known biological role of GAGs is that of heparin, which has been
used as a clinical anticoagulant for several decades. Following years of dedicated study
focused on the molecular aspects of the coagulation cascade, a specific pentasaccharide
sequence in heparin was identified and characterized [28-30]. This motif interacts with
AT-III and plays a critical role in the inhibition of the coagulation cascade. Over the past
decade, rapid progress in the development of technology for GAG structural
characterization has complemented whole organism genetics, leading to a dramatic
increase in the known important roles of GAGs in fundamental aspects of cell growth,
cell-cell interactions, and developmental processes. Given that GAGs are present at the
interface of the cell surface and the ECM, they are at the heart of numerous extracellular
signaling events that trigger cell growth in response to cues from growth factors and
morphogens. Thus, GAGs are critically involved in growth factor-based signaling events
such as angiogenesis and also during the various stages of development.
The early-stage GAG biosynthetic enzymes involved in the formation of the
linker and chain initiation have been the target of numerous genetic studies in D.
melanogaster and C. elegans. The first genetic evidence for the role of HSGAGs in
Wingless signaling of D. melanogaster was provided by mutating the kiwi gene which
encoded the UDP-glucose dehydrogenase. This enzyme converts UDP-Glc to UDP-
GlcA, which is incorporated as GlcA into HSGAG chains. Several genetic studies have
identified and implicated genes in D. melanogaster which are orthologous to mammalian
HSGAG biosynthetic enzymes in Hedgehog, Wingless, TGF3 and FGF signaling
pathways that are critical to patterning and other aspects of embryonic development.
RNAi mediated inhibition of the D. melanogaster homologue of the 6-0 sulfotransferase
has been shown to disrupt tracheal development, which requires FGF signaling. Also,
mutation of the 2-0 sulfotransferase using a gene trap method was demonstrated to be
lethal to the development of mouse kidney [31]. The phenotypic linkage between
HSGAGs and growth factors was also identified by null mutation of the EXTI gene in
mice, which affected morphogenesis and midline axon guidance during development of
the brain.
The squashed vulva (sqv) family of genes in C. elegans is involved in vulval
epithelial cells and in normal oocyte formation and embryogenesis. This family includes
orthologs of mammalian enzymes involved in the biosynthesis of CSGAGs. Mutations in
eight of these genes were shown to cause defects in vulval morphogenesis during post-
embryonic development [32]. More recently, the RNA-mediated interference and
deletion mutagenesis of sqv-5 [orthologous to mammalian chondroitin synthase, involved
in the biosynthesis of chondroitin sulfate] causes defects in cytokinesis and vulval
morphogenesis events that occur during C. elegans development [2].
In addition to examining enzymes involved in GAG biosynthesis, extracellular
GAG-degrading enzymes have also been the focus of many studies. Through cloning and
characterization of the human heparanase enzyme [depolymerizes cell surface HSGAGs]
which is secreted by tumor cells during metastasis, HSGAGs have been implicated as
important barriers to tumor metastasis [33, 34]. Following this study there have been
various efforts directed at understanding the role of the heparanases in the metastasis of
other tumors, such as myeloma and breast tumors. Recently, a novel extracellular
sulfatase, Qsulfl, was discovered and was implicated to play a key role in embryogenesis
through the Wnt signaling pathways. Qsulfl and Qsulf2 from quail have been
characterized as endosulfatases that can cleave the 6-0 sulfate groups of internal GlcNAc
residues on cell surface HSGAGs. These enzymes are novel in their action, since they
modify the mature HSGAG chain displayed on the cell surface. HSULF1 and HSULF2
are human orthologs of the quail endosulfatases, which have been implicated to inhibit
progression of the myeloma tumors in vivo.
The studies summarized thus far provide direct evidence of the biological roles of
GAGs. However, it is important to understand these roles from the perspective of GAG
structure-function relationships in the context of GAG interactions with the different
proteins. A central element allowing progress along these lines has been the development
of recombinant GAG-degrading enzymes as tools both for the structural characterization
of GAGs as well as for their direct application in in vitro and in vivo models. By using
recombinant heparinase I and heparinase III from P. heparinus to depolymerize cell
surface HSGAGs in a mouse model for cancer, it was shown that distinct HSGAG
fragments either promoted or inhibited tumor growth and metastasis. Beyond the cancer
arena, the recombinant heparinases have also been used to investigate in great detail the
role of HSGAGs in governing changes in lung endothelial cell permeability upon
induction by polycationic peptides secreted by leukocytes during inflammation and
endothelial cell apoptosis.
Chondroitinase ABC [cABC], which depolymerizes CSGAGs, has been shown to
promote functional recovery following central nervous system injury in adult rats [8]. A
similar set of GAG-mediated neuronal path finding is evident in the visual system during
development [35]. Retinal axons avoid CS chains in vitro. CS chains guide axons in the
optic pathway. Outer regions of the retina contain rich CS regions, which are inhibitory
and thus prevent axons from generating outwards. They are instead directed toward the
optic nerve. Chondroitinase application obliterates this control and axons grow non-
specifically. Studies in zebrafish suggest that re-growing retinal axons are excluded from
some midbrain nuclei via CS barrier. Retinal axons grow through the optic tecta, but are
prevented from crossing the midline to the contralateral tectum by a CSPG barrier.
Interestingly, there exists a discernable distinction in sulfation content in CS within the
barrier and the surrounding tecta, which has lower sulfate incorporation.
CSGAGs also play an important role in providing mechanical stiffness to
cartilage tissue. Mechanically, PG core proteins interact with collagen fibrils, and CS
sidechains provide electrostatic forces, enabling joints to function amid dynamic
compressive, shear, and tensile forces. Cartilage degradation manifests in osteoarthritis, a
prevalent degenerative joint disease. In osteoarthritis, there is an increased catabolism
and increased synthesis of ECM components. Differences in CSGAG sulfation profiles
have been observed in arthritic tissues. Particularly striking is a decrease in the
abundance of 6-O-sulfated disaccharides accompanying an increase in 4-O-sulfated CS
disaccharides [36-39].
1.2.2 Structural Characterization of GAGs
Although the centrality of GAGs to fundamental biological phenomena has been
recognized for quite some time, it has been difficult to investigate their structure-function
relationships. The prototypic example that highlights this fact is the characterization of the AT-III
binding pentasaccharide motif in heparin, which required many years of serious effort by many
investigators. The non-template-based biosynthesis of GAGs has complicated the development of
techniques, such as PCR for DNA or recombinant expression for proteins, to amplify specific
GAG sequences. Thus, the starting material available for analysis was highly limited, posing
significant challenges to the development of analytical tools. Due to the heterogeneity of GAGs,
the relative abundance of rare species with biological activity [such as the AT-III binding motif]
is very low, making it difficult to isolate and characterize these species.
The high charge density and labile sulfate groups have also posed significant challenges
in the extension of conventional analytical techniques, based on chromatography and
electrophoresis, to characterize GAGs. Based on the different sulfation sites in the disaccharide
repeat unit and the epimeric state of the uronic acid, GAGs are theoretically far more information-
dense compared to DNA and proteins. Specifically, the four potential sites of sulfation in
HSGAGs, along with the epimeric state of the uronic acid, gives rise to 48 different building
blocks. Thus the use of alphabetic codes (similar to A, T, G or C in DNA) for representing a
GAG sequence is difficult and cumbersome. Representation of the information content inherent
in GAG sequences is important for correlating specific sequences to their associated biological
activity.
Despite these challenges, there has been remarkable progress in the development of tools
for the isolation and structural characterization of GAGs. The two major areas of progress on this
front are: 1) the development of recombinant enzymes for orchestrated depolymerization and
modification of GAGs, and 2) the development of sensitive analytical techniques to accurately
define attributes, such as mass and composition, of GAG oligosaccharides.
Enzymatic tools for depolymerizing and modifying GAGs
Both bacterial and mammalian cells produce enzymes that degrade GAGs. Catabolism of
GAGs such as hyaluronic acid and the cartilage proteoglycans has been outlined in reviews [40].
However, the last review that focused on the degradation of GAGs by bacterial enzymes was in
1995 [41]. This section summarizes the progress in enzymatic degradation of GAGs and
highlights the development of bacterial enzymes as tools for structural characterization of GAGs.
In microbes, GAG degradation processes are utilized by some soil bacteria, like Pedobacter
heparinus, for metabolizing GAGs, while in others, like Streptococcus pneumonia, the
degradation of GAGs in the ECM enhances the virulence of the microbe.
The bacterial depolymerizing enzymes are lyases that cleave the glycosidic linkage
between a hexosamine and an uronic acid through the j3-elimination mechanism. The lyase action
leaves a A4,5 unsaturated linkage on the non-reducing end uronic acid, which has a characteristic
absorbance at 232 nm. The overall sequence of GAG degradation in bacteria involves the
depolymerization of GAG chains by the heparinases and chondroitinases down to di- and
tetrasaccharide fragments. These small fragments are then acted upon by the exolytic sulfatases,
such as AU 2-0 sulfatase, A4,5 glycuronidase, N-sulfamidase [HSGAG], GlcNAc 3-0 sulfatase,
GlcNAc 6-0 sulfatase, GalNAc 4-0 sulfatase, and GalNAc 6-0 sulfatase (Figure 1.2.3).
The mammalian GAG degrading enzymes including heparanases and hyaluronidases are
glycosidases which hydrolyze the glycosidic linkage and retain the epimeric state of the uronic
acid in the products formed. The human heparanase I enzyme has been demonstrated to cleave
the GlcA-GlcNS,3S,6S linkage within the oligosaccharide motif -GlcNAc,6S-GlcA-
GlcNS,3S,6S-IdoA2S-GlcNS,6S-, where the 2-0 sulfation on the adjacent IdoA has been shown
to play a key role in the activity of the enzyme. The GAG catabolic pathway involves
depolymerization of the endocytosed GAG chains by heparanases and hyaluronidases and
desulfation of the smaller fragments by lysosomal sulfatases, which are exolytic enzymes
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Figure 1.2.3. Enzymatic degradation of HSGAGs by Pedobacter heparinus.
Shown in the figure is a schematic of the sequence of steps involved in the enzymatic
degradation of HSGAG chains by the heparinases and exolytic enzymes. The arrows
indicate the potential sites of cleavage by the different heparinases based on their
substrate specificities. AU represents the A4,5 uronic acid resulting from lyase action of
the heparinases.
analogous to the bacterial sulfatases. In addition to the lysosomal exolytic sulfatases, the
endolytic sulfatases appear to cleave the 6-0 sulfate group from GlcNAc and GlcNS
monosaccharides in mature HSGAGs at the cell-ECM interface. These endosulfatases represent a
novel family of enzymes that modify extracellular GAG chains.
The bacterial and mammalian GAG-degrading enzymes are valuable tools for the
isolation and structural characterization of GAGs, which includes decoding their primary
sequence. The native forms of the heparinases and chondroitinases purified from soil bacteria
have been used in the past for the isolation and characterization of GAGs [42]. However, the
utility of these native enzymes has been impeded by contaminating activities of other enzymes
that co-purify with the target enzyme. Cross-contamination of enzyme activities limits the
accurate assignment of sequence information obtained from depolymerization of the parent GAG
chain. To circumvent these issues, our group and others have cloned, recombinantly expressed,
and biochemically characterized heparinases and chondroitinases to enhance their utility as tools
for the structural characterization of GAGs.
Cloning, recombinant expression and biochemical characterization of the heparinases:
Heparinases I, II, and III [hep I, II, and III] have been cloned from P. heparinus and have been
recombinantly expressed in E. coli [43, 44]. These enzymes have been characterized extensively
in terms of the critical amino acids involved in substrate binding and catalysis, involvement of
divalent cations in enzymatic activity, substrate specificities, and action pattern towards defined
HSGAG substrates. It was shown that hep I prefers to cleave substrates starting from the non-
reducing end [exolytic], and continues to depolymerize [processive] at successive cleavable
linkages towards the reducing end. Hep I was shown to cleave -GlcNS,6X-I2S- linkages in highly
sulfated regions of HSGAG chain.
Heparinase II [hep II] from P. heparinus has the broadest substrate specificity among the
heparinases. Biochemical investigation of this enzyme has revealed two distinct active sites
involved in the processing of regions of high sulfation and low sulfation, respectively. The action
pattern of hep II is distinct from that of hep I. Specifically, studies indicate that hep II processing
proceeds through an endolytic and non-random mechanism. In addition, hep II releases
intermediates, unlike hep I, which processively cleaves its substrate. Heparinase III [hep III] has
an orthogonal substrate specificity compared to that of hep I, in that, it cleaves GlcNAc,6X-G or
GlcNS,6X-G linkages in regions of low sulfation in HSGAGs.
Crystal structures of heparinase enzymes have heretofore been elusive, and thus the
above-mentioned studies represent the most significant efforts to date in understanding the
structure-function relationships of the activity of these enzymes. Efforts have been made to
crystallize the heparinases for over four years, with little success. However, after testing
extensively several crystallization conditions and improving the purification protocol, crystals of
hep II diffracting at 2.0 A resolution have recently been obtained. These promising results
indicate that the crystal structures of heparinases will be solved in the near future. The availability
of the crystal structures will enable the further development of these enzymes by elucidating the
interactive nature of enzyme-oligosaccharide complexes.
Cloning, expression, & characterization of exolyvtic HSGAG-degrading enzymes:
Building on the efforts to develop enzymatic tools for HSGAGs, additional exolytic HSGAG-
degrading enzymes (Figure 1.2.3) were cloned from P. heparinus and recombinantly expressed.
The first of these enzymes was the A4,5 glycuronidase, which cleaves an unsulfated A4,5
unsaturated uronic acid at the non-reducing end of heparinase-depolymerized oligosaccharides.
Using the AU-HNS, 6s disaccharide substrate, the conditions for optimal activity of this enzyme
were determined. The second enzyme, the 2-0 sulfatase, cleaves the 2-0 sulfate group of AU.
Using a homology modeled structure of P. heparinus 2-0 sulfatase, the structural basis for
exolytic activity and substrate specificity of this enzyme was determined. The unsaturated A4,5
linkage was shown to be critical for the activity of the enzyme. Furthermore, it was shown that
the 2-0 sulfatase generated the substrates for the A4,5 glycuronidase, since the 2-0 sulfate group
inhibited glycuronidase activity. These enzymes were used in tandem with the heparinases for the
compositional analysis of heparin [45, 46].
More recently the 6-0 sulfatase [cleaves 6-0 sulfate of glucosamine] and N-sulfamidase
[cleaves N-sulfate of the glucosamine] were cloned. These enzymes were shown to be
downstream of the 2-0 sulfatase and the A4,5 glycuronidase [unpublished data] since they
required the glucosamine to be at the non-reducing end [i.e. after the AU or AU2s has been
cleaved]. Furthermore, the presence of 6-0 sulfate in N-,6-0 disulfated glucosamine completely
inhibited the activity of N-sulfamidase on these substrates, whereas 6-0 sulfate has a broader
substrate specificity, including N-acetylated and N-sulfated glucosamines. On the other hand, 3-0
sulfate completely inhibits both 6-0 sulfatase and N-sulfamidase.
Cloning, Recombinant Expression, & Biochemical Characterization of the
Chondroitinases: The chondroitinases represent another important family of bacterial GAG lyases
that cleave CSGAG chains. Analogous to the efforts involved in developing HSGAGs as
enzymatic tools, there have been numerous studies to produce recombinant chondroitinases and
characterize their activity and substrate specificity. Chondroitinase AC [cAC] and chondroitinase
B [cB] from P. heparinus have been cloned and expressed in E. coli as N-terminal hexahistidine
fusion proteins [47, 48]. Chondroitinase AC cleaves C4S and C6S as its primary substrates.
Chondroitinase B cleaves DS as its sole substrate. Chondroitinase ABC has the broadest substrate
specificity in that it cleaves both CS and DS substrates. The orthogonal specificities of these
enzymes [cAC and cB] offer important experimental constraints for the structural characterization
of CSGAGs. Unlike heparinases, the availability of several crystal structures of the different
chondroitinases has facilitated detailed investigations into their substrate binding and catalysis.
Crystallography studies on cAC have revealed a tetrad of residues important in catalysis.
Biochemical characterization of these residues sites has resulted in three possible scenarios for
the roles of these amino acids in the 3-elimination mechanism of lyase action. Similarly, the
crystal structures of cB combined with molecular docking studies to construct enzyme-substrate
structural complexes have provided a comprehensive picture of the cB active site. Based on these
modeled enzyme-substrate complexes of cB, novel mutants with altered substrate specificities
have been generated recombinantly. Furthermore, the role of Ca2+ ions in enhancing the activity
of cB was also demonstrated in recent structural studies. These structural studies also provided
insights into the specificity of cB towards IdoA-containing DS substrates compared to the GlcA-
containing CS substrates [49-54].
Two different cABC enzymes from Proteus vulgaris, cABC I and cABC II, have been
identified. More recently, cABC I was cloned, recombinantly expressed, and biochemically
characterized [51, 55-57]. Similar to cB, theoretical models of the enzyme substrate structural
complexes have been constructed for cABC I, using its crystal structure. These theoretical models
provided a framework to identify important active site amino acids, which were validated using
site directed mutagenesis. The role of CaZ+ in the activity of cABC I is being investigated. cABC I
mutants with preference for specific substrates have also been generated and characterized
[unpublished data]. Similar to the HSGAG-degrading exoenzymes, there are sulfatases that
cleave specific sulfate groups of CSGAGs. Chondro-4-sulfatase acts at the 4-0 position of the
GalNAc moiety; chondro-6-sulfatase cleaves sulfate from the 6-O-position of the GalNAc
moiety. These enzymes have been isolated from Proteus vulgaris and they need to be developed
further as enzymatic tools similar to the heparinases and chondroitinases.
The recombinant expression and biochemical characterization of the enzymes discussed
above has enabled their utility as tools for the characterization of GAGs as well as for
investigating GAG structure-function relationships. The application of these enzymes for the
isolation and sequencing of GAGs is discussed in the following section.
Analytical techniques to determine different attributes of GAGs
There has been tremendous progress in the development of technology to analyze GAGs.
Covering all the aspects of GAG analysis would be beyond the scope of a single review given the
diversity in the techniques that have been developed. This section covers some of the major
methodologies highlighting their strengths and weaknesses. Most methods of analyzing the
purified oligosaccharides involve degradation of these species using the GAG-degrading enzymes
or other chemical methods. The accurate sequence assignment relies on the highly pure activity of
GAG-degrading enzymes as well as a detailed understanding of their action towards specific
linkages. The substrate specificity and action pattern of the enzymes provide important
constraints to reconstruct the GAG sequence. Several techniques have been developed to analyze
GAG oligosaccharides. Each technique provides a distinct attribute [i.e. mass, charge,
composition] that pertains to a single GAG oligosaccharide or a set of attributes that characterize
mixtures of GAG oligosaccharides.
Chromatographic techniques involve charge-based separation of GAG fragments using
an amine-based or a strong anion exchange [SAX] column coupled to a high performance liquid
chromatography [HPLC] instrument. For detection, GAGs are end-labeled, using either a
radiolabel [3H] or a fluorescent marker. Various GAG oligosaccharides have been sequenced
using HPLC methods. SAX-HPLC has also been used to quantify CSGAG content in biological
samples and medicinal preparations. In another approach, HSGAGs have been sequenced by
chemical depolymerization and sequential application of the exolytic enzymes. The GAG
fragments formed after each degradation step have been separated on polyacrylamide gel using
electrophoresis [PAGE]. This separation results in a ladder of fragments formed after each
successive degradation step and the sequence of the parent oligosaccharide is reconstructed from
this ladder [58-62].
Chromatographic and electrophoretic approaches share several limitations. The
enzymatic cleavage is characterized based purely on gel mobility or HPLC elution, which are not
completely predictable. Elution of GAGs from SAX or amine columns using salt could
potentially bias the analysis towards species that have relatively higher sulfation and may not be
sensitive to the separation of species with low sulfation. Both methodologies rely on end-labeling
of saccharides requiring the introduction of excess labeling reagent. The ladder of peaks or gel
shifts caused by treatment with exolytic enzymes is not fully comprehensible, as these substrate
specificities have not been thoroughly characterized.
Sensitive methodologies based on capillary electrophoresis [CE] and mass spectrometry
have been developed to detect the femto/picomolar amounts of GAG oligosaccharides that are
typical of the starting material isolated from different tissues. CE is a powerful tool that offers
high sensitivity. The unsaturated A4,5 bond resulting from lyase cleavage [with heparinases or
chondroitinases] of a parent oligosaccharide provides a detectable chromophore [at 232 nm]. The
migration times of enzymatically-derived oligosaccharides through the capillary are compared
with known standards. Specifically, CE based approaches have been developed to accurately
quantify the disaccharide composition of HSGAGs upon exhaustive depolymerization by the
heparinases. CE also enables the resolution of structural isomers which include disaccharides
having the same number of sulfates, but at different modification sites. Therefore, distinguishing
unusual sulfation patterns is facilitated using CE-based methodologies.
While the A4,5 unsaturated bond on the uronic acid facilitates detection and
quantification of the oligosaccharides, the information on the epimeric state of this uronic acid is
lost during the lyase-based depolymerization of GAGs. Chemical depolymerization methods
often result in modification of the non-reducing or reducing end monosaccharides which could
potentially co-migrate with other species in the CE. The co-migration issue has been addressed by
the application of exo-enzymes such as AU, 2-0 sulfatase, and A4,5 glycuronidase. Alternate
methods for labeling GAG oligosaccharides with fluorescent tags have also been employed. The
oligosaccharides are reducing end-labeled with a fluorophore through acid catalyzed nucleophilic
attack at the ester group of the reducing end glucosamine. Coupling CE with UV and laser
induced fluorescence detection has been successful for the analysis of heparinase-digested (I, II,
and III) HSGAGs [63].
Various mass spectrometry techniques have been applied to GAGs, including liquid
secondary ion MS, matrix-assisted laser desorption/ionization [MALDI-MS], and electrospray
ionization [ESI-MS] [63-66]. MS analysis has been complicated due to inefficient complexation
of oligosaccharides with metal ions (Na) during separation and labile sulfate groups that
dissociate during ionization. These factors result in complex spectra for longer oligosaccharides
that are difficult to interpret. To address these issues, a rapid MALDI-MS procedure has been
developed wherein the GAG chain is complexed with a basic peptide of the form [Arg-Gly]n-Arg
[n = 15, 17, or 19]. The formation of a non-covalent complex with the basic peptide protects the
sulfate groups of the oligosaccharides from dissociation during ionization, allowing mass
determination up to tetradecasaccharide length.
Further, a technique that couples separation by liquid chromatography using an ion-
pairing agent to analysis by ESI-MS minimizes adduct formation with metal ions and improves
spectra quality. This technique is more accurate than MALDI-MS (sensitivity of 0.1 Da versus
1.0 Da for MALDI), allows quantification with a UV detector, iterative fragmentation, and more
facile resolution of disaccharide species. However, conditions to optimize separation are
cumbersome and time-consuming and must be determined for each experiment. This procedure
also requires more material than MALDI-MS (only 100 femtomoles are required for MALDI).
Nonetheless, mass spectrometry is a highly powerful technique that allows for an assignment of
fragment length, and the number and type of substituents (sulfates and acetates). ESI-MS and
tandem MS have also been developed for the rapid, accurate compositional analysis of HSGAG
disaccharides.
Nuclear magnetic resonance [NMR] spectroscopy has also been successfully developed,
particularly for the characterization of heterogeneous mixtures of GAGs [67-70]. The
characteristic anomeric signals [proton and '3C] for the commonly-occurring monosaccharide
species have been identified. NMR provides the most accurate quantitative estimate for IdoA vs.
GlcA in a GAG preparation. The l-D proton NMR spectrum along with the 2D COSY, HSQC,
and TOCSY spectra afford information on the chemical shifts and coupling constants of most of
the ring protons of the constituent monosaccharides. This data is used to identify and quantify the
uronic acid and hexosamine constituents of a given oligosaccharide, as well as provide direct
linkage information for adjacent monosaccharides [H-U linkage]. The 2D NOESY spectrum
gives H1-H4 coupling constants between adjacent monosaccharides and enables walking through
the various linkages in the sequence from a known starting point.
Despite these clear advantages of NMR, there are some important limitations in applying
NMR to characterize tissue-derived GAGs. NMR requires milligram quantities of material
[particularly for the '3C and NOESY spectra], which is not easily procured from tissue samples.
The sensitivity of this technique is lower than that based on detection of chromatographic
effluents and MS. Specifically, NOESY and ROESY spectra usually require more sample and
high field instruments for reasonable sensitivity and signal resolution.
Informatics-based approach to characterize GAGs
Despite the limitations of each of the techniques discussed above, it is clear that the
different analytical methods provide complimentary information on a GAG sequence. For
example, while CE provides information on disaccharide composition, MALDI-MS provides
information on the masses of longer oligosaccharides, which in turn are related to their
composition in terms of chain length, number of sulfates, and acetate groups. To fully utilize the
value of these complimentary analytical methods, an informatics framework has been developed
for HSGAGs (Figure 1.2.4) [65]. This framework enables the application of the attributes
obtained from different enzymatic tools [such as specificity and action pattern] and analytical
methods [mass, composition, etc.] as constraints to provide the best solution that satisfies all
constraints. The solution could either be the complete assignment of a single GAG
oligosaccharide sequence or the best characterization of a mixture of GAG oligosaccharides.
The primary component of this framework was the property-encoded nomenclature
[PEN], a binary coded hexadecimal notation designed to capture all possible modifications in an
HSGAG disaccharide unit (Figure 1.2.4). PEN accounts for both the mass as well as the charge
distribution of the different disaccharides that compose an HSGAG polymer. The numerical basis
of the PEN system enabled the use of mathematical and binary operations on the PEN
representation to simultaneously incorporate rules for the breaking down of HSGAG
oligosaccharides into smaller fragments as well as relate different physical properties of an
oligosaccharide (i.e. mass and charge) to its composition and chain length. Two PEN-based
approaches that coupled distinct analytical platforms to sequence HSGAG oligosaccharides were
recently developed [68].
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Figure 1.2.4. Informatics-based approach to characterize GAGs.
Shown in figure is the schematic of the logic behind the PEN based sequencing approach
for HSGAGs. The best set of attributes obtained from each methodology viz. disaccharide
composition from CE, monosaccharide composition and linkage information from NMR,
and chain length from MALDI-MS are incorporated as constraints into a computational
framework which iteratively reduces the large solution space to the final set of solutions
that satisfy all the experimental constraints. The use of binary digits in the PEN
framework to capture sulfation state of a disaccharide facilitates mathematical operations
to rapidly apply experimental constraints.
PEN-MALDI: The theoretical limit distinguishing the composition of unique HSGAG
oligosaccharides based on their mass was determined by constructing a mass line using the PEN
framework [65]. Based on this simulated theoretical mass line, it was determined that given the
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accuracy of MALDI-MS (< 1 Da), the length and the composition (number of sulfates and
acetates) of any oligosaccharide up to a tetradecasaccharide could be determined solely by mass.
This mass-to-length/composition relationship enabled the application of MALDI-MS data to
assist in the sequence assignment of HSGAGs using PEN-MALDI. In this sequencing approach,
the mass of an HSGAG oligosaccharide as determined by MALDI-MS is used to determine its
overall length and its total number of sulfates and acetates. In addition, the disaccharide
composition of the sample is determined using CE-based techniques. A master list of all possible
oligosaccharide sequences with the observed mass and disaccharide composition is assembled
using the PEN framework. The sequence of the unknown oligosaccharide is then determined by
applying different MALDI-MS profiles of enzymatic/chemical degradation of the sample to
eliminate sequences from the master list that do not meet the experimental constraints. This
iterative approach converges on the unique sequence of the unknown HSGAG oligosaccharide
from the initial master list while using a minimal amount of sample material.
The PEN-MALDI methodology has been successfully applied to sequence several
biologically important HSGAG oligosaccharides. This methodology was the first to point out that
a heparin derived decasaccharide [AT-10] with high affinity to antithrombin III (AT-III) actually
contained only a part of the well-established AT-III binding pentasaccharide motif. This
observation led to further investigations on the implications of enzymatic generation of low
molecular weight heparins as clinical anticoagulants.
PEN-NMR: Analogous to incorporating mass information from MALDI-MS and
disaccharide composition from CE, the PEN framework was utilized to incorporate data from
NMR spectroscopy to sequence HSGAG oligosaccharides [68]. This NMR data is used to
identify and quantify the uronic acid and hexosamine constituents of a given oligosaccharide, as
well as provide direct linkage information for adjacent monosaccharides [H-U linkage] (Figure
1.2.4), thereby generating a master list of all possible sequences that match the data. CE-based
disaccharide compositional analysis provides information on the U-H linkages and is used to
reduce the NMR master list down to a single sequence. Incorporating the CE data into the PEN-
NMR technique reduced the reliance on the 2D NOESY/ROESY experiments that are often noisy
and require significantly more sample as well as advanced instrumentation.
The PEN-NMR methodology was applied to successfully sequence AT-10, thereby
further confirming the correct sequence of this decasaccharide. NMR data sets provide valuable
constraints on the sequence parameters that significantly reduce the sample space even before the
application of enzymatic constraints. This methodology highlighted the utility of NMR as a
powerful technique for the sequence analysis of HSGAGs.
The informatics-based approaches outlined above have clear advantages. First, through
examination of all possible sequences for an oligosaccharide chain, it is possible to design further
experimental constraints that will result in convergence to a single sequence in the fewest number
of steps, thus making the sequencing approach rapid. Second, because these approaches begin
with a list of all possible sequences and eliminate those that do not conform to the experimental
constraints, it ensures that unusual sequences are not eliminated with bias. Third, these
methodologies are flexible and allow for portability for analyses of GAG mixtures.
1.2.3 GAG-Protein Interactions
As mentioned earlier, GAGs are present in an environment comprising of a
variety of proteins such as growth factors, cytokines, morphogens, and enzymes
[proteases, protease inhibitors]. GAGs play a critical role in assembling protein-protein
complexes such as growth factor-receptor or enzyme-inhibitor aggregates on the cell
surface and in the extracellular matrix which are directly involved in initiating cell
signaling events or inhibiting biochemical pathways. Furthermore, extracellular GAGs
can potentially sequester proteins and enzymes and present them to the appropriate site
for activation. Thus, for a given high affinity GAG-protein interaction, the positioning of
the protein-binding oligosaccharide motifs along the GAG chain determines if an active
signaling complex is assembled at the cell surface or an inactive complex is sequestered
in the matrix.
It should be noted that high affinity GAG-protein interactions are not the only
biologically significant ones. GAGs have been shown to play important roles in
maintaining morphogen gradients across a cell or tissue which have been implicated in
developmental processes. Maintaining a gradient in the concentration of growth factors or
morphogens would involve graded affinities between different GAG sequences with the
given protein. Thus, the nature of GAG-protein interactions coupled with their sequence
diversity enables GAGs to "fine- tune" [analog modulation] the activity of the protein.
This can be contrasted with DNA-protein interactions, which block the expression of a
protein or protein-protein interactions, completely activating or inhibiting [digital
regulation] protein function.
The ability to obtain GAG oligosaccharides or oligosaccharide mimics with
defined primary sequence has enabled detailed investigations into the biochemical and
structural basis of GAG-protein interactions. Specific GAG oligosaccharides are obtained
by isolation from biological sources using chemical/enzymatic depolymerization coupled
with chromatographic separation techniques. Important advances in chemical and
chemoenzymatic synthesis starting from K5 polysaccharide has also resulted in valuable
model compounds that are GAG mimetics. These compounds have been valuable for
understanding the requirements of specificity of FGF-HSGAG and AT-III heparin
interactions.
The different aspects of GAG-protein interactions have been discussed in many
articles [24, 71, 72]. A list of established GAG-protein interactions based on the reviews
is presented in Table 1.2.2 [73]. This section recaptures these important aspects that
govern the specificity of GAG-protein interactions to provide a context for applying the
tools outlined in Section 2 to decode GAG structure function relationships.
Biochemical characterization of GAG-protein interactions
Growth factors
Based on their important roles in cell growth and development, the most
extensively studied interactions are those of HSGAGs and CSGAGs with growth factors
and chemokines. Among these interactions, HSGAG-fibroblast growth factor [FGF]
interactions are the most extensively characterized.
Fibroblast Growth Factor [FGF]: The best studied GAG-protein interactions are
that of HSGAGs with basic FGF [FGF-2] and acidic FGF [FGF-1]. FGF signaling
involves the following steps- FGF binding to its cell surface tyrosine kinase receptors
Table 1.2.2. Known GAG-Protein Interactions in Fundamental Biological Processes
GAG Binding Proteins and their Biological Roles GAG oligosaccharide specificity
Cell Growth and Development
FGF-1 - HSGAG: -[12s-HNs,6s]n- n>2 for
binding > 5 for FGF-mediated cell
signalling
FGF-HSGAG: FGF-oligomerization, assembling FGF- FGFR
complexes leading to receptor oligomerization and cell FGF-2 - HSGAG: -[I2s-HNs,6x]n- n>2 for
signaling. Cell growth and development, angiogenesis. binding > 5 for FGF-mediated cell
signalling. Sulfation at 6-0 position is
not required for binding but may be
required for cell signalling
HGF/SF-Dermatan: Hepatocyte regeneration,
morphogenesis, cell motility, tumorigenesis and
metastasis.
Midkine, Pleotrophin - Chondroitin: Neuronal adhesion, -[G-HNA,4s,6s]n- or -[G2sHac,6s]n
migration and neurite outgrowth.
Other Growth factors/ Morphogens: FGFs (1-21), TGFP,
VEGF, PDGF, EGF Amphiregulin, Betacellutin, Neuregulin,
IGF II, Activin, Sonic Hedgehog, Sprouty peptides, Wnts
(1-13), BMP-2, 4.
Anticoagulation and Antithrombosis
AT-Ill - heparin: Enhances factor Xa and Ila inhibition. -[HNA,6s-G-HN,3s,6s-H6s]
Annexin V-heparin: Enhances protein oligomerization. -[I2s-HNS,6s]n-
HCF II - DS: Inhibition of factor Ila and factor Ila-fibrin I2s-HNAc,4s- 125s-HNAc,4s-12s-HNAc,4S
complex.
Other factors/proteases: factor Xa, Ila, Thrombomodulin
Microbial Pathogenesis
kU-HNS-12S-HNACI 125(orG2S)-HNS- 12S-HNH2,3S,6S
[I2S-HNS,6S]n-
[I2S-HNS,6S]n-
Inflammation/lmmune Response
Cytokines/Adhesion: Interleukins, GM-CSF, Interferony, Inflammation/ Immune Response
TNF-cc, Angiostatin, Endostatin, L-selectin, N-CAM, MAC-1,
PECAM-1, CXC, Bac-5,7, PR-39.
[FGFRs], oligomerization of FGF leading to receptor oligomerization, phosphorylation of
other signaling molecules, and initiation of the signaling cascade. HSGAGs play a critical
role in FGF signaling by facilitating the formation of FGF-FGFR complexes [and/or
stabilizing these complexes] and enhancing [and/or stabilizing] FGF oligomerization. The
numerous crystal and co-crystal structures of FGF, FGF-HSGAG and FGF-FGFR-
HSGAG complexes provide important structural insights into the molecular complexity
of FGF-FGFR-HSGAG interactions in FGF signaling.
The oligomerization of FGF in the presence and absence of HSGAGs has been
studied quite extensively [74]. The co-crystal structure of FGF-1 with its receptor and a
HSGAG oligosaccharide revealed that a single oligosaccharide chain bridges two FGF-
1:FGFR complexes in 2:2:1 stoichiometry. On the other hand, the co-crystal structure of
FGF-2 with its receptor and HSGAG oligosaccharides indicated that two oligosaccharide
chains bridge two FGF-2:FGFR complexes is a 2:2:2 stoichiometry. Both these co-crystal
structures indicated that there are no protein-protein contacts between the FGFs in their
respective oligomeric states. This notion was challenged in another study, where a novel
dimeric FGF-2 construct with protein-protein contact was engineered and shown to have
significantly enhanced HSGAG mediated signaling in vitro and in vivo. Taken together,
these studies reemphasize the complexity of molecular interactions in assembling an
active ternary FGF-FGFR-HSGAG signaling complex at the cell surface.
The specificity of FGF-HSGAG interactions has also been investigated in great
detail and summarized in many of the reviews mentioned above. The heparin derived
oligosaccharides in the co-crystal structures contain predominant repeat units of -[12s-
HNS,6S]n-, where n = 2, 3, 4, 5, 6. The 2-0 sulfate of the iduronate and the N-sulfate of the
glucosamine are critical modifications that are required for both FGF-1 and FGF-2
signaling. The 6-0 sulfation has been shown to be critical for FGF-1 signaling but is not
completely necessary for FGF-2 signaling. Typically, tetra- to hexasaccharides are
sufficient to bind with high affinity to FGF-1 or FGF-2. However, octasaccharides or
longer are required for bridging a dimeric FGF-2 along with the receptor to form a
ternary signaling complex.
Other GAG-growth factor interactions: The biological functions modulated by the
interactions of CS and DS with growth factors and cytokines have been summarized in
recent reviews. Similar to HSGAGs, highly sulfated DS chains have been shown to bind
FGF-2 and FGF-7 [with lower affinity compared to HSGAGs], impacting cell growth and
wound repair. DS has also been shown to bind and activate Hepatocyte Growth Factor
[HGF] signaling pathway through the c-met receptor. Comparison of HSGAG and DS
interactions with two truncated C-terminal variants [NK1 and NK2] of HGF revealed that
the minimal length that binds with high affinity is a tetrasaccharide for HSGAGs and a
hexasaccharide for DS [75]. Oversulfated CS with specific sulfation patterns in the brain
CS PGs have been implicated in neuronal adhesion, migration, and neuritogenesis via
their interactions with pleiotrophin and midkine. Similar to the growth factor model,
assembling of the pleiotrophin complexes on cell surfaces by CS imparts pressure in
signaling, while CS in the extracellular environment has been implicated in sequestering
this cytokine.
Inhibitors of the coagulation cascade
The coagulation cascade is controlled by a group of serine protease inhibitors
including AT-III, heparin co-factor II, tissue factor pathway inhibitor, and other factors.
AT-III is the most prominent since all of the coagulation proteases [except factor VIIa]
are inhibited by AT-III, which forms equimolar covalent complexes with these enzymes.
Heparin-AT-III: Heparin forms a ternary complex with thrombin and AT-III,
accelerating by 2000-fold the rate of thrombin inhibition by AT-III, thereby preventing
coagulation [76]. AT-III recognizes a specific pentasaccharide sequence motif [HNAc,6S-
G-HNs,3s,6s-12s-HNs,6s] within heparin. This pentasaccharide motif, which makes up only
3% of all chains in commercially- prepared heparin, binds to AT-III with a Kd R 0.6 nM .
The X-ray co-crystal structure of a synthetic mimic of this pentasaccharide motif with
AT-III shows that the 3-0 sulfate group on the glucosamine [HNs,3s,6s] is absolutely
necessary for the specific heparin-AT-III interactions. This co-crystal structure also
reveals that pentasaccharide binding and subsequent conformational changes activate
AT-III for rapid inhibition of Factor Xa.
Chemical synthesis of heparin mimetics have implicated that AT-III inhibition of
thrombin [factor IIa] requires a much longer heparin chain of at least 16-18
monosaccharides, in addition to requiring the presence of the pentasaccharide sequence.
More recently, the co-crystal structure of a ternary complex of AT-III:thrombi:heparin
mimetic was solved. This crystal structure demonstrated the bridging of AT-III and
thrombin by a 16-mer synthetic mimic of a heparin containing a highly sulfated poly-f3-
D-glucose tetrasaccharide at the non-reducing end followed by a stretch of neutral poly-
3-D-glucose heptasaccharide and the pentasaccharide motif at the reducing end. Thus, it
is apparent that sequence and chain length is important for anticoagulant activity of
heparin. In a recent study, the chain length was also shown to be an important
determinant for heparin-mediated inhibition of thrombin by binding to heparin co-factor
II. It was shown that heparin binding to heparin co-factor II required a minimal chain
length of 13 monosaccharides and the complete allosteric inhibition of thrombin [2000-
fold higher than without heparin] required a chain length of 26 monosaccharides.
Heparin-Annexin V: Exposure of phosphatidylserine [PS] on the outer
membranes of activated cells is a physiological signal for the onset of processes such as
coagulation and apoptosis. Extracellular annexin V [a Ca2+ dependent membrane
phospholipid binding protein] recognizes this signal, binds to PS components of the
membrane, and self-assembles laterally into an organized array. This annexin array forms
a shield that prevents excessive clot formation. A recent X-ray co-crystal structure of
annexin V with a heparin derived tetrasaccharide, AU2s-HNs,6s-I2s-HNs,6s, suggested that
Ca2+-mediated annexin V-heparin interactions via these sequence motifs may facilitate
the annexin self assembly process and/or stabilize the oligomeric annexin layer [77].
DS - Heparin cofactor II: A specific DS hexasaccharide [I2s-HNAc,4s]3 has been
shown to bind with high affinity to heparin cofactor II and inhibit thrombin. This
hexasaccharide has been reported to constitute only 2% of hexasaccharides in DS -
another example of a rare modification providing a critical functional role. It has been
proposed that unlike heparin that inhibits thrombin by bridging it with heparin co-factor
II, DS inhibits the thrombin-fibrin complex via heparin co-factor II [78, 79].
Microbial Pathogens
A growing number of pathogens, including bacteria, viruses, and parasites, have
been shown to utilize cell surface GAGs as receptors to target their host cells. A heparan
sulfate octasaccharide, AU-HNs-12s-HNAc-I2s[or G2s]-HNs-I2s-HNH2,3S,6S, containing a rare
3-0 sulfated free amine bound to the gD glycoprotein of herpes simplex virus [18].
Another HSGAG-virus interaction is that of an HSGAG oligosaccharide involved in
binding to the virus shell protein of the foot and mouth disease virus [FMDV]. In fact, the
co-crystal structure of this oligosaccharide with the FMDV shell protein has been solved.
More recently the co-crystal structure of the vaccinia virus complement control protein
[VCP] with a heparin-derived decasaccharide, [I2S-HNS,6s]5, provided valuable insights
into the regulation of the complement pathway by pathogens interacting with cell surface
polysaccharides on host cells. The adhesion of erythrocytes infected by the malarial
parasite to placenta requires a low-sulfated CS [G-HNAc,4S repeat unit] with a minimum
length of a dodecasaccharide.
The above examples summarize some important aspects of the biological roles of
GAG-protein interactions in terms of specific GAG sequences. The oligosaccharide motif
that is recognized by a protein is often found in low abundance. Most of these
interactions involve formation of multimeric complexes [self oligomers, protein-receptor,
enzyme-inhibitor, etc.] that are facilitated by GAGs. The structural aspects of the
interactions between the GAG binding proteins and specific GAG oligosaccharides are
discussed in the following.
Structural basis for the specificity of GAG-protein interactions
From the examples of GAG-protein interactions described above, it is clear that
the specificity ofbiomolecular interactions goes beyond the GAG primary sequence. In
the heparin:AT-III complex, the specificity is precisely defined at the level of the
pentasaccharide sequence. Any modifications to this sequence are detrimental to the
binding and activation of AT-III. On the other hand, in the case of growth factor binding,
it is more challenging to define specificity at the level of a single oligosaccharide motif
like the pentasaccharide. Recently, the preferences of different FGFs for defined HSGAG
sequences were studied using a library of octasaccharides [80]. The authors concluded
that they were unable to determine a highly specific motif for each FGF similar to the
pentasaccharide sequence that binds to AT-III. Further, they concluded that there is a
significant overlap in the specificities of different FGFs to different HSGAG sequences
and challenged the notion of specificity in these interactions.
Intuitively, these differences can be rationalized in the context of the biological
pathways involving these interactions. The coagulation cascade requires a tight regulation
in a short time-span, which involves activation or inhibition of enzymes [digital
regulation]. On the other hand, interactions involving cell growth and development
require some level of degeneracy in the GAG sequence space to accommodate longer
time frames for the signaling events as well as maintaining graded affinities for
generating morphogen gradients.
Going beyond the sequence space into the three-dimensional structure space, it is
possible to define specificity of GAG-protein interactions as the optimal 'fit' of a GAG
structure into the GAG-binding site of the protein. This 'fit' is governed by the ionic
interactions of the sulfate and carboxylate groups of GAGs with the basic amino acids on
the protein as well as the van der Waals contacts made by the GAG chain with the
binding site of the protein. The topology and distribution of the basic amino acids of the
GAG binding site on the protein influences its specificity in the molecular recognition of
GAG sequences. Thus, specificity as defined by structural fit or molecular recognition
can be viewed in the three- dimensional space for GAGs in terms of conformation of the
polysaccharide backbone and the orientation of the sulfate groups.
It is possible for more than one GAG sequence to satisfy the constraints imposed
by the structural fit of the GAG chain to the protein. Thus it is important to understand
how the primary GAG sequence translates into a specific GAG conformation and
topology [i.e. sulfate and carboxylate groups]. Since GAGs are typically known to adopt
a linear extended conformation with helical symmetry [see below], it is more manageable
to relate their primary sequence to three-dimensional structure [unlike the challenging
problem of protein structure prediction]. The following discusses important aspects of
GAG conformation, and its role in governing the structural specificity of GAG-protein
interactions.
Table 1.2.3. Helical structure of GAGs
Category Helical Axial rise per disaccharide
symmetry unit (nm)
Heparin 21 0.82 - 0.84 (Na÷ or Cal )
0.87 (Na')
Heparan 21 0.93 (Na')
0.84 (Ca2+)
21 0.94-0.97 (Na')
Dermatan 32 0.95 (Na')
83 0.92-0.93 (Na')
21 0.98 (Ca 2+)
Chond roitin-4suLfate 32 0.94-0.96 (Na')
21 0.93 (low pH)
Chondroitin-6-sulfate 32 0.95-0.96 (Ca2+)
83 0.98 (Na')
Keratan sulfate 21 0.95 (Na')
21 0.98 (Na' or low pH)
Hyaluronic acid 32 0.94-0.95 (Ca2+)
43 0.84, 0.93-0.97 (Na')
43 double helix 0.82 (K' or low pH)
GAG Conformation
X-ray fiber diffraction [81] and solution NMR analysis of GAGs [82] have
pointed to an extended conformation with different helical symmetries for different
GAGs (Table 1.2.3). The GAG polysaccharide backbone comprises of the glycosidic
oxygens and ring atoms [C4, C3, C2 and C1] of the U - H disaccharide repeat unit
(Figure 1.2.5). The parameters associated with the different helical structures of GAGs
include bond lengths, bond angles, and torsion angles of the GAG backbone. Given that
bond lengths and bond angles are mostly constant, the main parameters that determine the
topology of the GAG chain are the glycosidic torsion angles ( 1, Igl) and (ý2, Xy2) and
the hexapyranose ring conformation of the monosaccharides.
Several structural studies have determined the preferred pyranose pucker
conformations of the monosaccharides in GAGs. The glucosamine in HSGAGs and
galactosamine in CSGAGs adopt a 4C1 [C-chair] conformation. For the glucuronic acid,
the 4C1 pyranose pucker is highly favored over the 1C4 conformation. After GlcA is
epimerized to IdoA during GAG biosynthesis, the carboxylate group will be equatorial in
the 1C4 conformation, and both chair conformations are equienergetic. Typically, rotation
about the glycosidic bonds is considered the only significant conformational flexibility of
polysaccharides. However, in the case of GAGs, the IdoA ring has the ability to adopt
multiple conformations that are essentially equienergetic. X-ray co-crystal structures of
HSGAG and CSGAG oligosaccharides with different proteins and enzymes, NMR, and
molecular modeling studies have pointed to four different conformers of IdoA - 4C1, 1C4
and 2So [S-skew boat] and OS2 (Figure 1.2.5). Further, by mapping NMR coupling
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Figure 1.2.5. Parameters governing the conformation of GAGs.
Shown in A is the chair conformation of expanded disaccharide unit -[HNS,6s-12s]- where
the backbone atoms [colored red ] are labeled and along with the glycosidic torsion
angles [41, wl] and [42, xy2]. Shown in B, are the commonly observed low energy ring
conformations of iduronic acid [carbon atoms colored grey and oxygen atoms colored
red]. Hydrogen atoms are not shown for clarity. The glycosidic torsion angles along with
the conformation of the pyranose ring govern the overall helical structure of GAGs.
constants on a continuous conformational space of iduronate in DS, "2So-like" and "aC4-
like" conformations have been posited to best satisfy the coupling constants.
The orientation and topological arrangement of specific sulfate groups, governed
by the rotation about glycosidic torsion angles and the ring conformation of the
monosaccharides, play a key role in the specificity of GAG-protein interactions. The
ability of the iduronate ring to adopt multiple conformations provides additional freedom
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for IdoA containing GAG chains to form specific structural motifs that optimally
compliment the binding surfaces on different proteins.
Structural implications of GAG-protein interactions
As mentioned earlier, the structural aspects of specificity in GAG-protein
interactions have been investigated by analysis of all the protein-HSGAG co-crystal
structures and have also been summarized in a recent review [73, 83]. These studies
revealed local conformational changes causing a kink in the oligosaccharide helical
structure which directly interacted with the protein. These deviations were captured by
measuring localized helical parameters, nL [number of disaccharide units per turn] and hL
[axial rise per disaccharide unit]. The localized helical parameters were obtained by
repeating each successive disaccharide unit with the experimentally observed glycosidic
torsion angles. Thus, any local deviation from the helical structure would be reflected as a
significant change in these parameter values when compared to those of a uniform helical
structure. The salient features of these studies are described in the following to emphasize
the importance of understanding GAG protein interactions in a glycomics approach to
GAG structure-function relationships.
FGF-HSGAG complexes: In all the co-crystal structures of HSGAG
oligosaccharides with FGF-1 and FGF-2 and their receptors, the kink in the FGF binding
oligosaccharide spanned a trisaccharide [HNs,6s-I2s-HNs,6s] where the iduronate is flanked
by two glucosamines (Figure 1.2.6). This trisaccharide comprises of the critical NS and
6-0 sulfate groups on the hexosamine and 2-0 sulfate groups on IdoA, which have been
implicated in high affinity FGF interactions. The sharp curvature of the kink in the
oligosaccharide was reflected in the deviation of the hL value from around 8.4 A
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10 H1 12 H3 14 H5
FGF-1 bound FGF-2 bound
Repeat
unit Pi4 S P4p i S L hL Pil n Pij s "j pL hL
HI-12 -171 99 166 136 -2,1 8.4 -147 119 172 141 -2.5 7.8
-157 99 166 136 -2.2 8.3 -158 119 172 141 -2.3 7.6
12-H3 -157 121 166 136 -2.4 7.9 -158 80 172 141 2.1 8.3
H3-14 1-157 121 162 136 -2.2 7.7 -158 80 166 141 2.5 8.7
Figure 1.2.6. Kink in HSGAG oligosaccharides bound to FGF.
Shown in A is the representation of the oligosaccharide observed in all FGF-HSGAG co-
crystal structures along with numbered monosaccharide units (starting from 0 on non-
reducing end) and glycosidic torsion angles. Shown in B the stepwise formation [top to
bottom] of the kink caused by changes in plj and slj of the FGF bound oligosaccharide
[blue] relative to the unbound oligosaccharide [red]. Shown in C is the local helical
parameters as a function of glycosidic torsion angles of successive disaccharide units
repeated in space. Only the regions where hL deviates significantly from 8.4 to 7.7 in
FGF-1-bound and 8.7 to.7.6 in FGF-2-bound motifs are shown for clarity.
[unbound region] to around 7.6 A [kink region], whereas the nL value was -2.0
throughout the structure. The formation of the kink was associated with changes in two
specific glycosidic torsion angles (Figure 1.2.6), where change in one caused the helical
axis to bend below and change in the other caused the helical axis to bend above the
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reference axis of the unbound oligosaccharide structure, thus forming a kink.
Furthermore, the ring conformation of the IdoA in the trisaccharide spanning kink was in
1C4 . Thus, the axial positioning of the glycosidic bonds due to the 'C4 IdoA conformation
enhanced the degree of the kink.
Together, these results indicated that the kink in the oligosaccharide and the
proper orientation of the sulfate groups together provided the appropriate electrostatic
and surface [van der Waals] complimentarity to the HSGAG binding site on FGF.
Binding of HSGAGs to FGFs does not induce any conformational changes on the protein.
In fact, the topology of the HSGAG binding loop regions on FGF-1, -2, -4, -7, and -9
[whose crystal structures have been solved] almost coincide with each other. On the other
hand, the distribution of the basic amino acids in the binding loops is different for each of
the FGFs. Thus, the narrow binding pocket formed by the HSGAG binding loops on each
FGF imposes structural constraints on the HSGAG oligosaccharide which induce a kink
for optimal surface contact with the protein. The distribution of the basic residues within
the HSGAG binding loops imposes unique constraints on the orientation and spatial
arrangement of the sulfate groups.
AT-III - pentasaccharide complex: In contrast with FGF, binding of the
pentasaccharide motif to AT-III induces conformational change that causes widening of
the heparin binding groove of AT-III. These conformational changes around the heparin
binding groove also leads to allosteric conformational changes, leading to the expulsion
of the reactive site loop of AT-III [that is distant from the heparin binding site] which
enhances the binding of this loop to Factor Xa. The recently solved AT-
III:thrombin:synthetic heparin mimetic co-crystal structure demonstrated that the
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bridging of thrombin and AT-III by heparin is relatively insensitive to the expulsion of
the reactive site loop.
The kink in the AT-III-bound pentasaccharide motif [HNAc,6s-G-HNs,3s,6s-I2s-
HNS,3S,6S] spanned a trisaccharide [HNs,3s,6s-12s-HNs,3S,6s] which contains the critical 3-0
sulfate group [of non-reducing end glucosamine] required for AT-III binding.
Interestingly, the kink in the pentasaccharide is reflected by a transition in nL value from
2 [unbound region] to 3 [bound region]. This transition in the nL value causes helical
overwind compared to the sharp bend in the FGF-bound oligosaccharide. Thus, in the
case of the AT-III:pentasaccharide complex, the optimal ionic and van der Waals
contacts with the protein requires the overwinding of the helical axis of the
pentasaccharide, resulting in a kink. Chemical synthesis of heparin mimics containing
IdoA conformation locked into either the 1C4 or 2So form and NMR studies have shown
that the 2So conformation of the IdoA is important for high affinity binding to AT-III.
NMR analysis of the free pentasaccharide in solution further indicates that
conformational equilibrium of the IdoA is shifted towards 1C4. Thus the transition of the
IdoA conformation to 2So in the bound pentasaccharide enhances the helical overwind to
provide optimal interactions with AT-III.
Other protein-HSGAG structural complexes: In the other protein-HSGAG co-
crystal structures viz. FMDV [84], annexin V, NK1 domain of HGF [85] and the most
recently solved vaccinia virus complement protein [VCP] [86], the heparin-derived
oligosaccharides predominantly contained the trisulfated disaccharide repeat unit, -[I2s-
HNS,6S]-. The oligosaccharide kink in the FMDV co-crystal structure was similar to that
of the AT-III-bound pentasaccharide, in that there was a helical overwind the nL value
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going from 2[unbound] to 3[protein bound]. This region spans three monosaccharides
[HNs,6s-I2s-HNS,6S] with the iduronate in the 2So conformation. On the other hand, the
oligosaccharide kink in the NK1 domain co-crystal structure was similar to that of the
FGF-1- and FGF-2-bound oligosaccharides. Since annexin V was co-crystallized with
only tetrasaccharides, it was difficult to make a meaningful interpretation of the nL and hL
values for quantifying the deviations from the overall uniform helical structure.
In the case of the VCP co-crystal structure, the kink spans a hexasaccharide
showing two distinct transitions in hL values [nL was around 2], one from 8.0 to 7.3 and
the other from 7.3 to 6.3. There were two structural VCP-oligosaccharide complexes in
the asymmetric unit related by an approximate two-fold symmetry. The region on the
oligosaccharide which showed a transition in hL from 8.0 to 7.3 interacted with the other
VCP molecule in the asymmetric unit and the sharper bend [hL transition from 7.3 to 6.3]
interacted with the VCP in the structural complex. All IdoAs in the region spanning the
kink were observed to adopt the 2So conformation. The co-crystal structure studies also
indicated that there was a conformational change manifested as a hinge movement in the
protein, which is stabilized by heparin binding. The hinge movement exposes the binding
site of VCP for proteins in the complement pathway and enhances the deceleration of
complement pathway activation.
Chondroitinase B - dermatan sulfate complex: More recently, the
oligosaccharide kink was also implicated in an enzyme-substrate complex viz.
chondroitinase B and its substrate, DS. Chondroitinase B [cB] cleaves DS
oligosaccharides at the [-HNAc,4s -- I-HNAc,4S -- I-HNAc,4S-] linkages [cleavage sites marked
with --] via 3-elimination to give AU-HNAc,4s-containing reaction products, where AU is
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an uronic acid with a A4,5 unsaturated linkage. The co-crystal structure of cB with three
disaccharide reaction products of DS depolymerization was solved recently, and two of
the products were in the catalytic site of cleavage. In addition, the co-crystal structure
also contained a Ca 2+ ion which was coordinated by the oxygen atoms on the enzyme as
well as the carboxylate of the AU of the reaction product in the catalytic site. Based on
the interactions between the active site amino acids and the Ca 2+ coordination, the
conformation of the intact substrate in the active site was modeled based on the two
disaccharide reaction products. Analysis of the final substrate conformation indicated that
there was almost a perpendicular local bending of the DS helical structure to position the
substrate in an optimal fashion for catalysis. In fact, the co-crystal structures of cB with
GlcA-containing CS oligosaccharides indicated that the substrate did not occupy the
catalytic site completely. This was due to the inability of the rigid chair conformation of
GlcA to accommodate the bending of the oligosaccharide. Thus, the topology and
distribution of basic amino acids in the cB active site and the Ca2+ ion coordination
impose unique structural constraints in terms of sulfation pattern and conformation of the
substrate that was satisfied only by an IdoA-containing DS substrate.
The co-crystal structures of HSGAGs with their biosynthetic enzymes specifically
3-0 sulfotransferases provide additional insights into the structural specificity of GAG-
enzyme interactions. From the examples discussed above, it is becoming increasingly
evident that the propensity of GAG oligosaccharides to form distinct kinks in their
otherwise uniform helical conformation provides a structural signature or molecular
recognition motiffor sequence specific protein binding. This kink in the GAG
oligosaccharide is reminiscent of DNA kink upon binding to proteins [such as
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transcription factors, restriction endonucleases, etc.] - a hallmark for regulating the
specificity of DNA-protein interactions. Protein binding induces distinct conformational
changes to the sugar phosphate backbone of DNA, leading to the kink formation.
Although more restrictive compared to the multiple ring conformations sampled by IdoA
in GAGs, the ribose sugar pucker can also adopt different ring conformations such as 2'-
endo and 3'-endo.
It should be noted that the kink in the helical axis can be induced by changes in
glycosidic torsion angles of GlcA-containing GAG backbones in the case of heparan and
chondroitin sulfate. Nevertheless, the IdoA in HSGAGs and DS would provide additional
conformational flexibility to the GAG backbone and thus influence the degree of the
kink. It is important to note that the motif that spans the kink is a high energy structure,
since it is a sharp bend or overwind of the otherwise low energy helical structure. Thus,
from an energetics standpoint, unbound GAG oligosaccharides would not favor the
formation of a kink. The higher internal steric energy of the kink-spanning motif is
compensated by the favorable van der Waals and ionic contact energy with the binding
site of the protein. The kinks in oligosaccharide chains have also been observed in other
polysaccharides. The co-crystal structure study of pectate lyase with its pectate substrate
indicates a local deviation in the helical symmetry of the substrate from 3 1 to 21
conformation at the catalytic site of the enzyme.
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1.2.4 Applications of Glycotechnology
The structure-function relationship of GAGs in modulation of numerous
biological processes is a complex area that requires a "systems" or "glycomics"
approach. Such an approach integrates the applications of technology development such
as enzymatic and analytical tools in the context of understanding GAG-protein
interactions to define and correlate structural and functional attributes pertaining to GAG
biology (Figure 1.2.7). The advances in the GAG field are heading towards the
systematic development of the glycomics approach to GAGs. These advances are leading
to a paradigm shift of understanding how cell-ECM interactions influence phenotype at
the cellular and the higher order tissue and organ levels. Among the numerous well
characterized biological roles of GAGs, perhaps the best understood structure-function
relationships of GAGs are in anticoagulation and cancer. The role of HSGAGs in
anticoagulation and the development of clinical anticoagulants/antithrombotics have been
the subject of recent interest. The role of HSGAGs in cancer has also been an important
topic discussed in many reviews as described earlier. Important relationships between
anticoagulation and tumor growth and metastasis have also been discussed in recent
reviews. Thus using these prototypic examples, the evolution of the glycomics approach
to GAGs is discussed in the following.
Rational design of low molecular weight heparins [LMWHs].
Heparins and low molecular weight heparins (LMWHs) are the choice
anticoagulant and antithrombotic drugs that have been widely used clinically in surgery,
interventional cardiology, hematology and prevention of post-operative thrombosis. The
pharmaceutical grade heparin known as unfractionated heparin [UFH] is prepared from
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Figure 1.2.7. Glycomics Approach to GAGs.
Glycomics is a multidimensional approach that involves measurement and manipulation
of structure and function attributes of GAGs to eventually correlate these attributes to
truly define their structure-function relationships.
porcine intestinal mucosa. UFH is a heterogeneous and polydisperse mixture of heparin
oligosaccharides varying both in chain length and composition having an average
molecular weight of 15 kDa. The high polydispersity of UFH has caused unwanted side
effects such as bleeding and thrombocytopenia due to non-specific interactions with other
proteins endothelial cell surfaces. Given the potential therapeutic opportunity of UFH and
motivated by the need to minimize its side effects, LMWHs were developed by chemical
and enzymatic degradation of UFH. LMWHs are less polydisperse compared to UFH and
comprise of a mixture of shorter oligosaccharides with average molecular weights of 4-6
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kDa. LMWHs have largely replaced UFH in many thrombosis related clinical
applications due to their ideal clinical pharmacokinetic attributes associated with their
anticoagulant activity and potentially less pronounced side effects [87].
Despite the lower polydispersity and minimized side effects, LMWHs had many
issues that challenged the development of optimal dosing regimens also hindered their
interchangeability for appropriate treatment of a given clinical indication. These issues
arise from the methodologies used to generate LMWHs from UFH. The initial
development of LMWHs largely focused on depolymerizing UFH using different
methods in an attempt to reduce their polydispersity. Depending on the methodology
used to depolymerize UFH, modifications to the natural HSGAG disaccharide repeat
units were introduced. Furthermore, the different depolymerization methods also led to
differences in the distribution and positioning of important oligosaccharide motifs such as
the AT-III binding pentasaccharide motif among the different oligosaccharide chains.
Addressing the above issues necessitates a framework for the rational design and
development of LMWHs. As mentioned earlier, the identification of the pentasaccharide
motif that binds to AT-III was one of the major achievements towards understanding the
structure-function relationships of heparin in anticoagulation. Furthermore, crystal
structures of AT-III-pentasaccharide, AT-III-thrombin-oligosaccharide structural
complexes have provided detailed insights into the molecular principles that govern these
interactions that are critical for anticoagulant activity of heparin. Advances in chemical
synthesis of oligosaccharide mimics containing the pentasaccharide motif has provided
important insights into the role of chain length and positioning of this motif in AT-III
mediated inhibition of factor IIa. Finally, the development of technology to characterize
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different attributes of heparins and LMWHs such as monosaccharide/disaccharide
composition and oligosaccharide mapping has enabled identification of the structural
differences between different LMWHs.
These advances has enabled the formulation of a framework that combines
technology to characterize heparins and LMWHs, a detailed molecular understanding of
interactions between heparin oligosaccharides, AT-III and other factors such as factor Xa
and IIa and standardized measurement of functional endpoints of anticoagulation.
Building on these developments, our approach to rational design of LMWHs is discussed
in the following.
The PEN-based sequencing of AT-10 revealed that this AT-III binding
decasaccharide derived by heparinase I cleavage of heparin contained only a part of the
pentasaccharide motif. This finding motivated further investigation into the cleavage of
the AT-III binding motif by the recombinant heparinases. Based on these studies it was
demonstrated that while hep I and II cleave oligosaccharides with partial or complete AT-
III binding sites, hep III does not cleave any of the linkages in the AT-III binding motif
(Figure 1.2.8). Furthermore, it was shown that none of the heparinases cleaved before the
non-sulfated glucuronic acid linked to the 3-0 sulfated glucosamine in the AT-III binding
motif (Figure 1.2.8).
The resistance of heparinases to cleave the linkage prior to -G-GlcNS,3S,6S of
the AT-III binding pentasaccharide enabled the identification of a tetrasaccharide I-
HNAc,6s-G-HNS,3S,66S [4-7 based on its PEN code] that would not be cleaved by any of the
heparinases (Figure 1.2.8). The 4-7 tetrasaccharide provided a structural correlate whose
mol percentage identified based on the disaccharide compositional analysis using CE
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Figure 1.2.8. Enzymatic cleavage of AT-III binding motif.
The arrows indicate the sites that are potentially cleaved by hep I, II and III. The red
cross indicates that the linkage cannot be cleaved by any of the heparinases. The 4-7
tetrasaccharide formed after cleavage by hep I, II and III is shown in the bottom.
correlated very well [R2 = 0.98] with the in vitro anti-Xa activity of different heparins and
LMWHs. This observation indicated that 4-7 is always present in heparin or LMWHs as
a part of the AT-III binding pentasaccharide motif. The understanding of the action of
heparinases on the AT-III binding pentasaccharide and the identification of the 4-7
structural correlate represent important practical steps towards the rational design of
LMWHs. As mentioned earlier, the factor Xa inhibition of AT-III involves binding of the
pentasaccharide to AT-III which induces a conformational change in the protein that
increases its affinity for factor Xa. While the pentasaccharide is sufficient for factor Xa
activity, inhibition of factor IIa requires longer oligosaccharide [16-18 mer].
The requirement of longer oligosaccharide chains for factor IIa inhibition explains
the typically observed low anti-IIa activity of LMWHs compared to that of UFH.
Furthermore, this also explains the weak correlation between the mol percent of 4-7 with
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IdoA GlcNAc,6S
that of the anti-IIa activity. Given that heparinase III is resistant to highly sulfated regions
and the pentasaccharide motif, this enzyme is likely to be a better tool to generate
LMWHs that heparinase I which cuts at highly sulfated regions. The integration of
developing enzymatic [heparinases] and analytical tools with the molecular basis of
heparin mediated anti-Xa and anti-IIa activity via AT-III has culminated in the
development of two rationally designed LMWHs. These LMWHs have a much higher
anti-Xa and anti-IIa activity compared to that of the other LMWHs.
The important missing piece in the above developments is the definition of
additional attributes that characterize structural properties and functional end points of
LMWHs. These attributes are required to comprehensively define structure-function
relationships of LMWHs for therapeutic applications. It is clear that the abundance of 4-7
and its positioning within a desired chain length in a mixture of oligosaccharide chains
provide the right set of parameters for rationally designing the next generation of heparin
based therapeutics. Thus it is important to extend the development of enzymatic and
analytical tools to define these parameters and correlate them with both in vitro
anticoagulant activities as well as in vivo pharmacological parameters.
Understanding the role of HSGAGs in cancer
Among the biological roles of HSGAGs described in Section 1, their involvement
in tumor growth and progression is one of the highly complex and dynamic processes.
The HSGAG proteoglycans are present on the tumor cell surface, in the environment of
the tumor cell and the neighboring cells [such as endothelial cells and platelets] and on
the cell surface of the neighboring cells. This ubiquitous presence of HSGAGs in the
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environment of tumor cells enables their multifaceted role in promoting or inhibiting
tumor growth and metastasis.
The known anchor points for biological role of HSGAGs in cancer are cellular
growth and adhesion, angiogenesis, anticoagulation and immune modulation [88]. The
HSGAGs on tumor cell surface bind to different growth factors that are involved in
autocrine and paracrine signaling loops during tumor growth and progression. On the
other hand HSGAGs in the neighboring endothelial cells bind to angiogenic factors such
as VEGF and FGF2 and induce angiogenesis. The HSGAGs in the ECM of the tumor
cells influence both tumor growth as well as growth of endothelial cells by sequestering
the growth factors and angiogenic factors. The HSGAGs in the ECM also sequester
potential antiangiogenic factors such as endostatin to maintain the balance in the growth
of normal blood vessels. The HSGAGs in on tumor cell surface and ECM also regulate
cell-cell adhesion processes between tumor cells and platelets as well as between
endothelial cells and host organ cells thus playing a key role in tumor metastasis.
In addition to the above mentioned modulation of tumor growth, HSGAGs in the
ECM along with structural proteins such as collagen and laminin make up a physical
barrier to tumor metastasis. Heparanases [which are mammalian HSGAG depolymerizing
enzymes] which could potentially be secreted by tumor cells have been implicated in the
degradation of the ECM barrier and promote metastasis. In fact, the increased expression
of heparanases has correlated with the progression of colorectal, pancreatic and osteolytic
carcinomas.
Many studies have also demonstrated antitumor effects of heparins and LMWHs
through anticoagulation which facilitates targeting of the tumor cells by immune
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modulation. Coagulation and fibrinolytic systems are closely associated with tumor
growth and progression. It has been demonstrated that tumor cells express high levels of
procoagulation factors such as thrombin which leads to the formation of a protective
fibrin clot around the tumor cell surface. This fibrin "coat" is implicated to shield the
tumor from immune response. Thus the anticoagulant activity of heparins and LMWHs
prevents the fibrin coat formation making the tumor cells more vulnerable to the immune
response. Heparins have also shown to block P-selectin mediated adhesion of tumor cells
to platlets and thus inhibiting the metastasis formation.
The above aspects provide different systems to specifically target the promotion
or inhibition of tumor growth and metastasis. The advances in technology coupled with a
detailed understanding of the processes that involve HSGAGs in promoting or inhibiting
tumor progression has enabled progress towards decoding the structure-function
relationships of HSGAGs in cancer. Specifically, the orthogonal substrate specificities of
heparinases I and III have been employed to understand the potential promontory and
inhibitory roles of HSGAGs in tumor growth and metastasis using a mouse model for
lung cancer. Treatment of tumor-bearing mice [after injection of these cancer cell lines]
with hep I activated tumor growth, while treatment with hep III inhibited tumor growth.
Furthermore, hep III-treated cells were significantly less able to colonize to the lungs
compared to hep I treated cells. The treatment of the tumor cell lines with either hep I or
hep III, releases distinct HSGAG oligosaccharide fragments from the tumor cell surfaces
due to their orthogonal substrate specificities. Treatment of mice with hep I-generated
HSGAG fragments promoted primary tumor growth. On the other hand, hep III-derived
fragments showed significant inhibition of primary tumor growth.
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The structural differences between the hep I and hep III generated HSGAG
fragments were compared by applying the CE-based disaccharide compositional analysis
and oligosaccharide mapping studies. The saccharide fragments derived from hep III
treatment had more of tri- and di- sulfated disaccharides, whereas the hep I-treated
HSGAGs had more mono- and un-sulfated disaccharides. MALDI-MS analysis of hep I-
and III- derived HSGAGs yielded an oligosaccharide "fingerprint" proving that the
saccharide fragments generated from the different treatments are structurally distinct.
Detailed investigations into the downstream events such as growth factor signaling
pathways indicated that the fragments generated by hep I and hep III influenced tumor
growth via the FGF2 signaling pathway.
Recent studies have also extensively utilized the HSGAG glucosamine 6-0
endosulfatases [HSULF1 and HSULF2] to investigate the role of HSGAGs in cancer
[89]. The low expression of HSULF1 has been correlated with up-regulation of HSGAG
mediated growth factor signaling in ovarian cancer. More recently it was shown that
HSULF1 and HSULF2 are potent inhibitors of myeloma tumor growth.
Clearly the above mentioned approaches have shown promising leads for the
formulation of an integrated framework to understand the complex biological roles of
HSGAGs. There have been many advances in developing sophisticated animal models to
investigate the role of HSGAGs in other tumors such as myeloma. These model systems
are in search for enzymatic and analytical techniques to truly bridge their application in
understanding structure-function relationships of GAGs.
Significance and Future Directions
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Understanding the structure-function relationships of GAGs is a fundamental area
of research envisioned to contribute to the missing parts of the overall paradigm of how
genotype governs phenotype. Furthermore, this approach also offers intriguing
perspectives into physiological and pathological processes, thus providing novel
therapeutic targets for unmet diseases such as cancer. The chemical heterogeneity and
polydispersity of GAGs arise from their non-template driven complex biosynthetic
machinery. Moreover, physiologically-relevant GAG protein interactions are quite
complex from the standpoint of specificity and affinity [need to go beyond a single GAG
sequence binding with high affinity to a protein] and multivalency [assembling
multimeric protein complexes]. These unique challenges have confounded attempts to
characterize GAG structure-function relationships.
There have been rapid advances in technology ranging from whole organism
genetics to evaluate functional effects of knocking-out enzymes involved in GAG
biosynthesis to development of enzymatic and analytical tools for structural
characterization of GAGs. These advances have resulted in a paradigm shift of the GAG
field into an integrated glycomics approach [similar to genomics and proteomics] to GAG
structure-function relationships. The underlying theme behind this approach is to
simultaneously capture the summary properties of an ensemble of GAG chains isolated
from different cells and tissues and correlate them with functional end points in the
context of a biochemical pathway or a biological process. The significance of this
approach has already been widely appreciated in the glycobiology community studying
branched N-linked and O-linked glycosylation. The National Institute of General Medical
Sciences has funded a $35 million dollar large scale collaborative initiative called the
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Consortium for Functional Glycomics [www.functionalglycomics.orql to enable such
an approach.
An important component that is needed for this integrated approach is a
bioinformatics platform comprising of a relational database that captures the analytical
and functional data-sets pertaining to GAG structure-function relationships [90]. Such a
platform would rapidly disseminate information to the broader scientific community and
facilitate the uncovering of novel paradigms underlying the biological roles of HSGAGs.
The primary types of information that could be captured in such a database include 1)
information on GAG sequence or parameters such as composition, oligosaccharide maps
that define a GAG mixture, 2) biochemical and structural aspects of GAG protein
interactions including literature citations and entries in structural databases such as
protein databank [PDB}, 3) biosynthetic pathways of GAGs including the known
substrate specificities of enzymes, 4) enzymatic and chemical tools for degrading GAGs
along with their substrate specificities and action patterns and 5) functional endpoints of
known GAG biological roles such as anti-Xa and anti-IIa activities for anticoagulation,
cell proliferation indexes for tumor growth, etc. Capturing the relationships between the
kinds of information described above is critical and it would enable scientists to pose
completely novel questions based on the sheer diversity of information that will be
available to them.
The second important aspect is addressing the emerging need to continue the
expansion of enzymatic and analytical tools. The identification of the extracellular
HSGAG degrading endo 6-0 sulfatase has truly opened the doors for development of
novel tools. Given that these enzymes can selectively modify a HSGAG chain as opposed
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to breaking it down, they provide a new kind of enzymatic tools for finer tuning of the
biological responses of HSGAGs.
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Conclusions
Glycans, including chondroitin sulfate and dermatan sulfate, have emerged as important
regulators of a wide variety of biological events. However, adequate tools to probe the
importance of these biomolecules are lacking. The development of chondroitinase enzymes will
greatly advance efforts at characterizing bioactive glycans in a fashion analogous to the use of
restriction enzymes for genes, proteases for proteins, and heparinases for heparan sulfate
glycosaminoglycans.
The overarching goal of this program is to create a complementary library of enzymatic
tools to study chondroitin sulfate and dermatan sulfate glycosaminoglycans. This collection will
ultimately comprise recombinant chondroitinase ABC I, chondroitinase ABC II, chondroitinase
AC II, chondroitinase B, and mutants with altered substrate specificity and action pattern. These
mutants will include engineered chondroitinase enzymes that process only chondroitin sulfate;
only dermatan sulfate; and process GalAGs with altered action pattern and end-product profile.
These tools will be used in conjunction with analytical biotechnologies currently
undergoing development to study the structure of GalAG polymers. These technologies couple
capillary electrophoresis, nuclear magnetic resonance, and mass spectrometry with a
bioinformatics platform. This system will lay the foundation for the fine sequencing and
structural characterization of biologically relevant GalAGs. The proposal spans several areas of
glycotechnology: the recombinant expression and purification of the enzymatic tools,
biochemical studies to characterize the processing of GalAG substrates, and analytical chemistry
techniques to elucidate GalAG chemical structures. A comprehensive understanding of GalAG
chemical structure in a biological setting is central to unraveling function with regard to human
pathology in a variety of organ systems. Future work will make use of these enzymatic tools to
craft novel diagnostic and therapeutic strategies for human disease.
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Chapter 2
Recombinant Expression and Purification of
Chondroitinase ABC I from Proteus vulgaris
Summary
An important lyase that degrades both chondroitin sulfate and dermatan sulfate,
chondroitinase ABC I, has been isolated and cloned from Proteus vulgaris. The focus of
this chapter is the development of a rigorous methodology for the recombinant
expression and purification of this enzyme, and an investigation of the substrate
specificity, optimal reaction conditions, and stability of the enzyme. Utilizing an N-
terminal hexa-histidine tag, the recombinant chondroitinase ABC I was produced,
purified to homogeneity in a single chromatographic step. The products of exhaustive
digestion of various chondroitin and dermatan polysaccharides were analyzed using
capillary electrophoresis. Further, the Michaelis-Menten parameters were determined
for these enzymes. With chondroitin-6-sulfate as a substrate, the recombinant
chondroitinase ABC I had a Km of 1.2 4uM and a kca, of 37000 min1'. With chondroitin-4-
sulfate as the substrate, chondroitinase ABC I had a Km of 1.5 ,UM and a kcat of52000
min-'. With dermatan sulfate as the substrate, chondroitinase ABC I had a Km of 2.5 pM
and a kcat of 27000 min-1 . Sodium acetate was found to promote the chondroitinase ABC
I-mediated depolymerization ofglycosaminoglycan substrates in a concentration-
dependent manner. The efficient recombinant expression of chondroitinase ABC I has
facilitated the structure-function characterization ofglycosaminoglycan lyases and will
help to advance the development of enzyme-enabled strategies for the sequencing and
manipulation of biologically relevant chondroitin and dermatan polymers. This work was
published in the Biochemical Journal and is reproduced here with permission.
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2.1.1 Chondroitinase ABC I from Proteus Vulgaris
Here, we report the sub-cloning of chondroitinase ABC I from Proteus vulgaris,
the recombinant expression of the enzyme in Escherichia coli, and a one-step preparation
of the pure protein. An activity assessment and a product profile determination of the
recombinant enzyme against a spectrum of GAG substrates are described. Mutagenesis
studies provide the first conclusive proof of residues that are critical for catalytic activity,
paving the way for a more rigorous comprehension of the catalytic topology and mode of
action of cABC I [1].
2.1.2 Cloning of the Chondroitinase ABC I Gene from the Proteus vulgaris Genome
The gene for cABC I was cloned from P. vulgaris genomic DNA as a full-length
version and the mature enzyme, without its putative leader sequence. The PCR product of
approximately 3 kb was subcloned into pET-28a, via an intermediate TOPO cloning step,
to facilitate its incorporation and expression in E. coli. Chondroitinase ABC I was
expressed in E. coli as previously described, with an N-terminal 6x histidine tag [1-3].
The histidine tag enabled quick purification of the enzyme over a charged Ni+2 column.
Expression of the initial clone resulted in an enzyme with very low activity against
GalAG substrates.
2.1.3 Recombinant Expression and Purification of Chondroitinase ABC I
To establish the functionality of our "fixed" cABC I clone [1], we set out to
recombinantly express the protein in E. coli. Expression of the original full-length clone
generated an enzyme almost wholly present in the insoluble fraction. The yield of soluble
recombinant enzyme was greatly improved by the engineered removal of the
hydrophobic N-terminal signal sequence. This result is
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Table 2.1. Purification of Recombinant Chondroitinase ABC I.
Specific activityFraction Protein yield Specific activity x-fold Purificationa(1 mg/ml C6S)
(mg) (Units / mg)
Crude lysate 195 92.1
Elution from Ni+2  35 197.9 2.1
column
Thrombin cleavage b 35 230.6 2.5
a The x-fold purification was determined relative to the specific activity measured for
crude lysate.
b Cleavage of the 6x His tag from the recombinant protein was confirmed by Western blot
analysis using an anti-His tag antibody (Amersham Biosciences). No detectable
difference in activity against GalAG substrates was observed between the recombinant
cABC I and its His tag-cleaved counterpart.
consistent with most GAG-degrading enzymes we have studied [3]. This sequence tag is
most likely responsible for targeting to a specific location in the periplasm [4].
Chondroitinase ABC I purification generally yielded upwards of 35 mg of protein from
500 ml of culture (Table 2.1). SDS-PAGE analysis (Figure 2.1) revealed a highly pure
band at -1 10 kDa, in close agreement with previously reported masses of cABC I [5, 6]
and its theoretical mass 112,614 Da based solely on amino acid composition.
A check for the absorbance at 232 nm, suggestive of the double bond formed in
the degradation reaction, was performed spectrophotometrically with 5.0 gg of each
recombinant enzyme (the original and the clone that underwent mutagenesis repair) and 1
mg/ml C6S or DS. Expression and purification of the "fixed" truncated clone restored
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Figure 2.1. SDS-PAGE Analysis of the purification of recombinant cABC I.
Summary of protein expression and purification following expression in BL21(DE3) as
6x N-terminal fusion proteins. Lanes: 1, cell pellet; 2, crude lysate; 3, Invitrogen SeeBlue
Plus2 Pre-Stained Standard; 4, inactive recombinant chondroitinase ABC I; 5, active
recombinant chondroitinase ABC I (altered via site-directed mutagenesis).
robust processing activity against a variety of GAG substrates. The original enzyme
showed negligible activity against both of the GalAG substrates, whereas the "fixed"
version acted on both C6S and DS at healthy rates [1].
2.1.4 Biochemical Conditions for Optimal in vitro Activity
Having established the broad substrate specificity of the recombinant cABC I [7],
we next sought to optimize the reaction conditions so as to achieve maximal enzyme
activity. These parameters included temperature, pH, ionic strength, and dependence on
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Figure 2.2. Chondroitinase ABC I biochemical reaction conditions.
(A) pH profile. Inset (A) effect of buffer system on enzyme activity: (1) 50 mM Tris
buffer pH 8.0; (2) 50 mM sodium phosphate buffer pH 8.0; white indicates dermatan
sulfate; black indicates chondroitin-6-sulfate. (B) Effect of reaction temperature. (C)
NaCl titration. (D) Sodium acetate titration. Open white circles indicate dermatan sulfate;
filled black circles indicate chondroitin-6-sulfate.
sodium acetate. A Tris buffer system was chosen, as it resulted in a greater relative
activity than phosphate buffer. The enzyme displayed maximal activity at pH 8.0 and was
essentially inactive for both C6S and DS at pH 9.0 (Figure 2.2).
We also examined the recombinant enzyme's activity against C6S and DS with
regard to ionic strength. Recombinant cABC I was optimally active at 62.5 mM NaC1 for
C6S and 125 mM for DS. For C6S, 50% inhibition occurred at slightly more than 125
mM NaC1, with activity virtually ablated at -400 mM NaCl. For DS, 50% inhibition
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Table 2.2. Specific Activity of Recombinant cABC I on GAG Substrates. a
Substrate Specific activity
(Units/mg protein)
Chondroitin-4-sulfate 290.8
Chondroitin-6-sulfate 174.6
Dermatan sulfate 122.3
Chondroitin 69.8
Chondroitin sulfate D 54.2
Chondroitin sulfate E 34.8
Hyaluronan 14.8
Heparin/Heparan sulfate n.d.
a Specific activity was determined by monitoring the increase in absorbance at 232 nm for
5 minutes. The initial rate of increase in A232 was determined for each substrate. The
enzyme activity in units (1 U = 1 C[mole product formed / min.) was calculated from the
initial rate using a = 3800 M-1 for reaction products at pH 8.0.
occurred at under 250 mM NaCl, and activity was essentially negligible over 500 mM
NaC1.
In terms of temperature optima, with C6S as the substrate, the recombinant
enzyme demonstrated maximal activity at 37"C. At slightly over 40°C, enzyme activity
was 50% inhibited, and activity fell dramatically at 45"C. For DS, a greater level of
enzyme activity was evident over the range from 25"C to 40°C, with an optima between
300C and 370C. At 450C, processing of DS by the recombinant cABC I was inhibited by
over 60%. For both GalAG substrates, 370C was chosen as the optimal temperature for
biochemical experiments.
It has previously been reported that acetate promotes cABC I activity [6]. Our
investigation found that 50 mM sodium acetate provided optimal activity with C6S as the
substrate, and 100 mM sodium acetate with DS as the substrate. An
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Figure 2.3. Kinetic analysis of Chondroitinase ABC I on GalAG Substrates.
Hanes representations of recombinant chondroitinase ABC I on chondroitin-4-sulfate (e),
chondroitin-6-sulfate (o), and dermatan sulfate (V). Inset, a comparison of enzyme
activity on 1 mg/ml chondroitin-6-sulfate substrate in 50 mM Tris pH 8.0 with 50 mM
sodium acetate. Expression of the original clone (A) results in a protein with negligible
activity; expression of the clone manipulated to conform to the desired sequence (A)
results in robust enzyme activity.
absence of sodium acetate in the reaction buffer inhibited enzyme activity against C6S by
-50%, and resulted in an almost complete decline in activity against DS.
2.1.5 Chondroitinase ABC I Activity Analysis
The specific activity of recombinant cABC I acting on a variety of substrates was
assessed (Table 2.2). These experiments are consistent with previously reported data for
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Table 2.3. Kinetic Analysis of Chondroitinase ABC I with Various Substrates. a
Substrate Km Kcat Kcat/ Km
RM min"' gM-' min-'
Chondroitin-6-Sulfate 1.2 ± 0.6 37000 ± 6500 31000
Dermatan Sulfate 2.5 ± 0.5 27000 ± 2500 11000
Chondroitin-4-Sulfate 1.5 ± 0.1 52000 ± 1300 35000
a Values are the mean of at least three experiments ± standard deviation.
the cABC I enzyme purified from P. vulgaris and available commercially as "protease-
free chondroitinase ABC" from Seikagaku [6]. Kinetic parameters were determined for
recombinant cABC I against C6S, DS, and C4S substrates and are summarized in Table
2.3. Our kinetic analysis corroborates our specific activity results, wherein cABC I seems
to prefer C4S and C6S over DS (Figure 2.3).
We also compared the specific activity of our recombinant active chondroitinase
ABC I with the commercially available purified "protease-free" cABC I from Seikagaku.
Rate of product formation (AA232 / min) was measured for 2 - 4 min. at 37 °C using a 1
mg / mL C6S solution in 50 mM Tris buffer (pH 8.0) containing 50 mM sodium acetate.
The Bradford assay was used to calculate the amount of protein present in each sample.
Based on the results our recombinant enzyme gave us a specific activity value of 164.2
mU / jig, whereas the Seikagaku enzyme had a specific activity of 20.2 mU / jg. The
difference in specific activity could be the result of enzyme stability or storage
conditions.
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Figure 2.4. Capillary electrophoretic analysis of recombinant active cABC I.
Product profiles for chondroitinase ABC I acting on (A) chondroitin-4-sulfate (B)
chondroitin-6-sulfate and (C) dermatan sulfate (ADi4S = AUA-GalNAc4S, ADi6S =
AUA-GalNAc6S, ADi2S6S = AUA2S-GalNAc6S, ADi4S6S = AUA-GalNAc4S6S).
Impurities in commercial substrate preparations result in the ADi6S peak in
electrophoretogram (A) and the ADi4S peak in electrophoretogram (B).
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The activity of cABC I on these three substrates was also analyzed by CE [8-11].
This study represented an end-point assay for activity and allowed for a characterization
of the final products of cABC I digestion on all of the substrates after an 18-hour 37 *C.
For C4S and C6S, the product profile shows predominantly disaccharide products with
minor tetrasaccharide products also detected (Figure 2.4). In both of these cases the
respective monosulfated disaccharide (i.e. AUA-GalNAc4S or AUA-GalNAc6S)
represents the major product. In the case of DS we also observe a mixture of
disaccharides and tetrasaccharides as the final products of digestion. However, one of the
tetrasaccharide peaks is much larger than those observed for the C4S and C6S substrates.
This suggests that there may be some resistance by tetrasaccharide fragments within DS
to cleavage by cABC I. The structure of the resistant tetrasaccharide was determined to
be AUA-GalNAc4S-IdoA-GalNAc4S based on co-elution (on CE) with a previously
isolated pure dermatan tetrasaccharide having the same structure. In order to confirm that
this tetrasaccharide is indeed resistant to cABC I action, we incubated the pure
tetrasaccharide with enzyme at 37 'C and analyzed the resulting products by CE. The CE
trace showed that there is no breakdown of the tetrasaccharide, thereby confirming that
cABC I cannot degrade this tetrasaccharide fraction in DS. The diminished ability of the
recombinant cABC I to cleave DS tetrasaccharides is consistent with previous reports on
cABC I action pattern [6].
2.1.6 Mutagenesis Studies
A comparison between the crystal structures of F. heparinum (P.heparinus) cAC and P.
vulgaris cABC I revealed a similar linear arrangement of domains that are superficially
similar in terms of overall structure [12-16]. On a closer inspection of the catalytic
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Table 2.4. Activity Analysis of Chondroitinase ABC I Mutants. a
cABC I Mutant C6S Kinetics DS Kinetics Activity on C.E. b
C6S C4S DS
Km kcat Km kcat
H501A n.d. n.d. n.d. n.d. - - -
H561A 15.2 39100 6.90 3970 + + +
H712A 8.60 1140 5.10 613 + + +
Y508A n.d. n.d. n.d. n.d. - - -
R560A n.d. n.d. n.d. n.d. - - -
R500A 19.9 419 35.7 162 + + +
E653A n.d. n.d. n.d. n.d. - - -
aKinetic parameters are reported in pM (Km) and min-' (kcat). n.d., activity was too low to
be detected.
b (+) refers to an exhaustive digestion of the substrate; (-) indicates that no products were
detected.
C The R537A mutant did display some residual activity on DS.
domain of cAC with the middle domain of cABC I, one can observe a paucity of
sequence identity. This is consistent with the exception of the several amino acid residues
incubation at that have previously been implicated as active site players in cAC [13] and
that seem to have counterparts in cABC I. Using this framework of potential conserved
catalytic active site residues, we undertook site-directed mutagenesis studies to probe the
importance of several residues in enzyme activity (Table 2.4). His501, Tyr508, Glu653,
and Arg560 were all mutated to alanine and characterized in activity experiments. These
residues were previously suggested by Huang et al [12] and could constitute the active
site, whereby the proton acceptance and donation mechanism could take place [17]. Since
a general base, like histidine, is believed to be a key component for this catalysis, we also
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Figure 2.5. Representative capillary electrophoresis profiles of cABC I mutants.
Products of chondroitin-6-sulfate degradation following digestion by (A) His501Ala and
(B) His561Ala. Tables 2.3 and 2.4 provide further information regarding the substrate
specificity of recombinant chondroitinase ABC I and its mutants.
mutated histidine residues (His561 and His712). These residues are not conserved
between the two enzymes but are in close proximity to the proposed active site.
Examination of the mutant enzymes in an end-point assay by CE demonstrated a
number of residues which seem to be absolutely critical to catalysis. His501Ala produced
no products on overnight digestion with C6S, DS, or C4S as the substrate (Figure 2.5).
This is in sharp contrast with His561Ala and His712Ala, which both produced a product
profile comparable to recombinant active cABC I against all three of these GalAGs after
an overnight digestion. Tyr508Ala, Glu653Ala, and Arg560Ala all were unable to yield
products in an exhaustive digestion with any of these substrates. These observations
provide direct evidence that His5O 1, Tyr508, Glu653, and Arg560 are crucial for the
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activity of our recombinant cABC I. The relative positions between these critical residues
within the active site cleft of cABC I lends further credence to the notion of this amino
acid grouping as the enzyme active site.
2.1.7 Perspectives
Here, we report the sub-cloning of the cABC I gene from P. vulgaris, and its
recombinant expression in E. coli. We also examine this recombinant cABC I
biochemically, providing the first conclusive evidence of the residues that constitute the
enzyme active site. The establishment of a well characterized enzyme with defined
GalAG substrate specificity provides insight into important structure-function
relationships in biology.
Purification of cABC I directly from cultures of P. vulgaris resulted in
preparations with low yields and considerable protease contamination [18, 19]. These
conditions spurred investigators toward recombinant production approaches. Early
attempts to recombinantly express cABC I in E. coli were laden with difficulty.
Expression of a soluble protein was hampered by both the size of the gene and the signal
sequence. Random proteolysis also proved to be a nuisance to achieving the recombinant
protein, and this complication has been observed previously [5]. Our one-step
purification process allowed for the preparation of an abundance of soluble protein. It
was, however, discovered that this protein lacked the ability to effectively degrade
GalAG substrates. Sequence anomalies in the original clone suggest that there may have
been underlying structural changes responsible for this eradication of enzyme activity.
The sequential repair via site-directed mutagenesis of the original truncated clone
was accompanied by a restoration of enzyme activity. Indeed, the "repaired" recombinant
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enzyme was able to process C4S, DS, and C6S at robust rates. It was also able to degrade
a variety of other GalAG substrates and hyaluronan at lesser rates. It is clear that our
recombinant active cABC I possessed a specific activity that far exceeded that of the
commercially-available enzyme. Therefore it is evident that our cloning, expression, and
purification system does not at all compromise the activity of our cloned enzyme. It is
possible that the disparity in specific activities between our recombinant enzyme and the
commercially-available cABC I is the result of different purification and storage practices
rather than intrinsic enzymatic properties. It is also feasible that an overestimation of
active protein content for the commercial enzyme led to a dramatically diminished
observed rate, as some portion of quantified protein may have been distorted in the
isolation process.
The optimal conditions for activity of our recombinant cABC I are similar to
those obtained for the purified enzyme. However, we also observed that different buffer
systems affect the processing activity on different substrates. For enzyme activity on C6S
in 50 mM sodium phosphate, the optimal pH was determined to be pH 7.0; however, in
50 mM Tris buffer optimal activity was observed at pH 8.0. This discrepancy was not
observed with DS as substrate, where the activity maximum was at pH 8.0 regardless of
the buffer system. In both cases, however, the enzyme showed more activity in Tris
buffer than sodium phosphate. It was also observed that there was a slight inconsistency
in the concentration of NaCl and sodium acetate required for maximum activity on C6S
as compared to DS. For DS, a higher concentration (approximately double) of both NaCl
and sodium acetate in the buffer showed the highest activity in terms of product
formation. Another interesting observation is the absolute importance of the presence of
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salt i.e. either NaCI or sodium acetate in the buffer system for activity of recombinant
cABC I on DS. From Figure 2.2 (panels C and D) we can see that in the absence of any
salt in the buffer the enzyme activity on DS is about 5% of the observed maximum
activity. However, with C6S as substrate, even when there is no salt in the buffer, we
observe around 50 - 60% of the maximum activity.
We hypothesize that the salt requirement for DS is important in abolishing non-
specific interactions of this substrate with the enzyme. Dermatan sulfate has considerable
intrinsic flexibility due to the presence of iduronic acid in its structure. Therefore it can
potentially display a wider range of interactions than C6S and may bind to positively
charged patches on the surface of the enzyme, rather than in the active site. In the
presence of salt these non-specific interactions would be markedly reduced.
Our results with CE indicated that cABC I was unable to cleave a tetrasaccharide
fragment within DS and we identified this fragment to be AUA-GalNAc4S-IdoA-
GalNAc4S. This is in contrast to the product profile obtained on treating DS with cB,
where the major products are predominantly disaccharides [20]. This is not surprising
since cABC I and cB have totally different structures and therefore may bind to and
process DS very differently.
The crystal structure of cABC I [12] revealed a three domain protein. The middle
domain contains the catalytic site in a wide-open cleft. Despite very limited sequence
homology with the catalytic domain ofF. heparinum cAC, this middle domain of cABC I
did contain a conserved grouping of residues that were implicated in catalysis in cAC
[13]. These cABC I residues were His501, Tyr508, Arg560, and Glu653. Manipulation of
these residues via mutagenesis to alanine resulted in knockout proteins- enzymes with a
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Figure 2.6. Active Site Tetrad of Chondroitinase ABC I.
Chondroitinase ABC I structural representation. Inset, the active site residues of
chondroitinase ABC I are shown in full.
complete inability to degrade GAG substrates. Thus this tetrad of residues is crucial for
enzyme activity (Figure 2.6). With regard to the f3-elimination mechanism previously
suggested for GAG lyases, it seems that this group of residues is potentially capable of
performing the stabilization and proton shuffling responsibilities required for GAG
degradation. This study provides the first experimental evidence that this grouping of
amino acids comprises the cABC I active site.
It was demonstrated that His501 was in fact the histidine critical in catalysis. Two
other histidines were examined, His561 and His712. Alanine mutants of these residues
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demonstrated that these histidines were not critical for GAG degradation. In fact, on an
exhaustive digestion with GalAG substrate, these mutants both provided a full product
profile.
Previously, it was suggested that Arg500 was essential for cABC I's ability to
process both CS and DS [12]. Arg500's sidechain was predicted to be positioned toward
the uronate carboxylate group of either substrate, serving some role in charge
neutralization. However, our product profile analysis and specific activity determinations
with the mutant Arg500Ala suggest that this residue is not actually critical for catalysis.
In fact, with C6S, C4S, and DS, an exhaustive digestion with Arg500Ala resulted in a
product profile virtually indistinguishable from those generated with our recombinant
cABC I.
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GalAGs (galactosaminoglycans) are one subset of the GAG (gly-
cosaminoglycan) family of chemically heterogeneous polysac-
charides that are involved in a wide range of biological processes.
These complex biomacromolecules are believed to be responsible
for the inhibition of nerve regeneration following injury to the
central nervous system. The enzymic degradation of GAG chains
in damaged nervous tissue by cABC I (chondroitinase ABC I),
a broad-specificity lyase that degrades GalAGs, promotes neural
recovery. In the present paper, we report the subcloning of cABC I
from Proteus vulgaris, and discuss a simple methodology for the
recombinant expression and purification of this enzyme. The ori-
ginally expressed cABC I clone resulted in an enzyme with neg-
ligible activity against a variety of GalAG substrates. Sequencing
of the cABC I clone revealed four point mutations at issue with the
electron-density data of the cABC I crystal structure. Site-directed
INTRODUCTION
GAGs (glycosaminoglycans) are linear acidic polysaccharides
consisting of a disaccharide repeat unit of a hexosamine linked
to an uronic acid. GAGs reside both in the ECM (extracellular
matrix) and at the cell surface as constituents of proteoglycans.
These sugars, apart from having important structural roles in the
ECM, are also fundamental modulators of many biological pro-
cesses, such as development, cell proliferation, signalling and
inflammation [1-3]. The great chemical heterogeneity of these
GAGs [4] is responsible for their wide-ranging biological in-
fluence. Each GAG disaccharide repeat unit can be customized
through a variety of biosynthetic modifications that include epi-
merization of the uronic acid and variable sulphation. The estab-
lishment of a means to elucidate the fine structure of these complex
polysaccharides is an essential biotechnological pursuit [5-8].
Two related enzymes with broad substrate specificity are
produced by the bacterium Proteus vulgaris: cABC I (chondro-
itinase ABC I) and cABC II (chondroitinase ABC II) (EC 4.2.2.4)
[9]. These enzymes depolymerize a variety of GAG substrates,
including C4S (chondroitin 4-sulphate), DS (dermatan sulphate),
C6S (chondroitin 6-sulphate) and hyaluronic acid. These enzymes
have been purified and studied previously [9]. cABC I is a 997-
amino-acid-residue endolytic enzyme that cleaves GAG sub-
strates to tetrasaccharides and disaccharides. It degrades GalAGs
(galactosaminoglycans) regardless of the C5 epimerization state
of the uronic acid. This is particularly notable, as cABC I
processes DS despite having little sequence or structural identity
when compared with cB (chondroitinase B) (EC 4.2.2.4) [10].
The crystal structure of cABC I [11] reveals that it has three major
mutagenesis produced a clone with restored GalAG-degrading
function. We have characterized this enzyme biochemically,
including an analysis of its substrate specificity. By coupling struc-
tural inspections of cABC I and an evaluation of sequence homol-
ogy against other GAG-degrading lyases, a set of amino acids was
chosen for further study. Mutagenesis studies of these residues
resulted in the first experimental evidence of cABC I's active site.
This work will facilitate the structure-function characterization
of biomedically relevant GalAGs and further the development of
therapeutics for nerve regeneration.
Key words: active site, chondroitinase ABC, chondroitin sulphate,
dermatan sulphate, glycosaminoglycan, recombinant protein ex-
pression.
domains and indicates that this enzyme shares considerable struc-
tural homology with Flavobacterium heparinum cAC (chondro-
itinase AC) (EC 4.2.2.5) [12], although there is little sequence
identity between the enzymes.
Discrepancies in past cloned sequences of cABC I have
augmented confusion in studying this enzyme [13,14]. Moreover,
the cloning and expression of cABC I is challenging because of
its size, stability and solubility. In addition to the difficulty of ob-
taining a pure recombinant protein, the broad substrate specificity
complicates the elucidation of the mechanism of action. It is
unclear how this GAG lyase is able to process such a broad range
of substrates [4,9,11,15,16].
In the present study, we report the subcloning of cABC I
from P. vulgaris, the recombinant expression of the enzyme in
Escherichia coli and a one-step preparation of the pure protein.
We offer both an activity assessment and a product profile deter-
mination of the recombinant enzyme against a spectrum of GAG
substrates. Mutagenesis studies provide the first conclusive proof
of residues that are critical for catalytic activity, paving the way
for a more rigorous comprehension of the mode of action of
cABC I.
EXPERIMENTAL
Subcloning of cABC I from P. vulgaris
Genomic DNA was isolated from cultures of P. vulgaris (ATCC
number 6896) using a DNeasy purification kit from Qiagen. Pri-
mers were designed based on the previously published sequence
of the gene (GenBank® accession number E08025) [13]. It has
© 2005 Biochemical Society
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chondroitinase AC; cB, chondroitinase B; CE, capillary electrophoresis; DS, dermatan sulphate; ECM, extracellular matrix; GAG, glycosaminoglycan;
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been reported previously that the active form of cABC I isolated
from P. vulgaris is missing the N-terminal signal sequence [9].
Therefore two 5' end primers were designed so as to generate a
full-length clone and a truncated version of the gene by omitting
72 bases encoding the signal sequence. In order to facilitate
cloning into a pET-28a vector (Novagen), the forward primer
was constructed so as to incorporate an NdeI restriction site, and
the reverse primer had a BamHI and a XhoI restriction site built
in. The primers for cloning cABC I have the sequences: 5'-CATA-
TGCCGATATTTCGTTTTACTGCA-3' (forward primer for full-
length gene), 5'-CATATGCCCACCAGCAATCCTGCATTTG-3'
(forward primer for truncated gene) and 5'-GGATCCTCGA-
GTCAAGGGAGTGGCGAGAGTTTG-3' (reverse primer). PCR
was run using P. vulgaris genomic DNA as the template, and a
slightly longer extension time (3 min) was used to account for the
length of the gene (2994 bp) being amplified.
The PCR product was initially ligated into the pCR® 4-TOPO
vector using the TOPO TA Cloning Kit (Invitrogen) and trans-
formed into TOP10 E. coli cells. Plasmid DNA was isolated from
positive colonies, and the cABC I gene was excised from the
TOPO vector using the previously engineered NdeI and XhoI re-
striction sites. The excised gene was ligated into pET-28a that had
been digested with the same restriction enzymes. The ligation
products were then transformed into DH5ca E. coli cells, and
plasmid DNA that was isolated from the colonies was screened by
restriction digestion for incorporation of the cABC I gene. Plasmid
DNA isolated from the positive colonies was also sequenced to
confirm incorporation of the gene.
Site-directed mutagenesis studies
The QuikChange Site-Directed Mutagenesis Kit (Stratagene) was
used with plasmid DNA template to produce mutants of cABC I.
Briefly, mutants were produced by plasmid denaturation and an-
nealing of complementary oligonucleotide primers containing the
desired mutation. This was followed by extension of the primers
with a temperature cycler and PfuTurbo DNA polymerase, result-
ing in a mutated plasmid with staggered nicks. Digestion of hemi-
methylated DNA of the parental template with DpnI endonuclease
selects for the mutation-containing synthesized DNA. Primer
sequences for mutagenesis studies are presented in Table 1. The
mutated plasmids were transformed into XL1-Blue supercom-
petent cells. The plasmids were prepared using a miniprep kit
(Qiagen). Each clone was sequenced to confirm the presence of
the desired mutation. Plasmid DNA was used to transform BL21
(DE3) E. coli.
Recombinant expression and protein purification of cABC I
and mutants
Recombinant cABC I and the site-directed mutants were ex-
pressed in E. coli and purified essentially as described previously
[8]. Cultures for expression contained 40 gg/ml kanamycin. The
presence and purity of the proteins were assessed by SDS/PAGE
analysis using pre-cast NuPAGE 12% Bistris gels, the XCell
SureLock Mini-Cell and Simply Blue SafeStain (Invitrogen).
Relative protein concentration was calculated using the Bradford
assay (Bio-Rad protein assay kit) with BSA (Sigma) as a stan-
dard. The His6 tag was cleaved using the Thrombin Capture Kit(Novagen) as described previously [17].
Structural characterization
CD spectra were recorded at 25 °C on an Aviv 202 CD spectro-
photometer using quartz cuvettes with optical path length of
1 mm. Scans were collected between 300 and 195 nm with
Table 1 Summary of primer sequences for site-directed mutagenesis
studies
Mutation codons are indicated in bold; bases modified in order to create the desired point
mutations are underlined. Forward primers for each mutant are listed first.
Mutant Primer pair sequences
Thr' 4 - Ala 5'-ACTGGCTGGCGTGCTGTGGGAGTCTCT-3'
5'-AGAGACTCCCACAGCACGCCAGCCAGT-3'
Val309  lie 5-GGMCGCAAGGCAGACATCTGATCACTGATAAACAAATC-3'
5'-GATTTGTTTATCAGTGAITCAGATGTCTGCCTTGCGTTCC-3'
Pro322  Leu 5'-CAACCAGAGAATCTTAACTCTCAAGATAAACAACTATTTG-3'
5'-CAAATAGTTGTTTATCTTGAGAGTTAAGATTCTCTGGTTG-3'
Prom - Gin 5'-GGTTGGGATTGGAATAGAATGCAAGGGGCAACCACT-3'
5'-AGTGGTTGCCCCTTGCATTCTATTCCAATCCCAACC-3'
His5' -- Ala 5'-TGATGGTACAGCATGGCGAGCTGAAGGCAACTATCCGGGCTA-3'
5'-TAGCCCGGATAGTTGCCTTCAGCTCGCCATGCTGTACCATCA-3'
Typo8 - Ala 5'-GGCAACTATCCGGGCGCCTCTTTCCCAGCC-3'
5'-GGCTGGGAAAGAGGCGCCCGGATAGTG CC-3'
Arg5 m- Ala 5'-CCGCTTGCAGGAGCACACCCTTTTAACTCACCTTCG-3'
5'-CGAAGGTGAGTTAAAAGGGTGTGCTCCTGCAAGCGG-3'
Glun P Ala 5'-CACCAATGTTTGGTCATCTGCAATTTATAACAAAGATAACCGT-3'
5'-ACGGTTATCTTTGTTATAAATTGCAGATGACCAAACATTrGGTG-3'
His" --+ Ala 5'-CCGCTTGCAGGAAGAGCCCCTTTTAACTCACCTTCG-3'
5' -CGAAGGTGAGTTAAAAGGGGCTCTTCCTGCAAGCGG-3'
His712 -. Ala 5'-GACAGTCCTAAACCTGCTACCTTAATGCAACGTGGAGAG-3'
5'-CTCTCCACGTTGCATTAAGGTAGCAGGTTTAGGACTGTC-3'
Args4 - Ala 5'-CCTGATGGTACAGCATGGGCACATGAAGGCAACTATCCGGGC-3'
5'-G CCCGGATAGTTG CCTTCA GTGCCCATG CTGTACCATCAGG-3'
a 1.0 nm bandwidth and a scan rate of 1 nm/min. Three scans were
averaged for each protein. For melting experiments, spectra
were collected at 5 'C intervals from 5 to 80 'C. Recombinant pro-
teins were concentrated and buffer-exchanged into 50 mM sodium
phosphate, pH 7.5, using Centricon 10 filters (Millipore). Protein
content was quantified by standard methods using the Bio-Rad
protein assay kit. All spectra were collected using a protein con-
centration of 0.2 mg/ml. The buffer contribution was accounted
for in all spectra. The signal was normalized to molar ellipticity,
[0]M, in degrees -cm2 -dmol- '.
Determination of optimal biochemical conditions for recombinant
cABC I activity
For these studies, C6S and DS were dissolved at a 1 mg/ml con-
centration in various buffers in an attempt to determine the relative
effects of pH, temperature, ionic strength and sodium acetate con-
centration on enzyme activity (characterization with C4S was
cost-prohibitive). The activity of a fixed amount of recombinant
active cABC I (0.2 /g) was assessed based on the change in
absorbance at 232 nm per min (AA 232/min) as reaction con-
ditions were varied. The effect of pH was investigated by using
two different buffer systems: (1) 50 mM sodium phosphate buffer,
pH 6.5, 7.0, 7.5, 8.0, 8.5 or 9.0, and (2) 50 mM Tris buffer, pH 7.5,
8.0, 8.5 or 9.0. Activity at various temperatures (25-45 oC) was
also investigated. To determine the relative effect of ionic strength,
the NaCl concentration was varied from 0 to 1.0 M in 50 mM Tris
buffer (pH 8.0). Previous studies have suggested that addition of
sodium acetate to the buffer enhances the activity of cABC I [9].
To confirm this, we varied the sodium acetate concentration from
0 to 0.5 M in 50 mM Tris buffer (pH 8.0).
The temperature study was carried out using a temperature-
controlled UV spectrophotometer (DU 800, Beckman-Coulter)
in a quartz cuvette at a 1 ml final reaction volume. The other opti-
mization experiments were carried out on a SpectraMax 190 (Mol-
ecular Devices) using a 96-well quartz plate. Eight enzyme
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reactions (i.e. one column of the plate) could be initiated and moni-
tored simultaneously using our set-up. This semi-high-throughput
approach enabled us to sample multiple reaction conditions in an
easily repeatable manner. The temperature on the SpectraMax
was set to 37 'C for these experiments. Absorbance at 232 nm
was monitored for 2-4 min, and activity was calculated based on
the initial rate of product formation.
cABC I product profile and activity analysis
For product profile analysis, CE (capillary electrophoresis) was
performed using similar conditions to those developed for the sep-
aration of heparan sulphate GAG disaccharides [18]. Substrates
used included C6S from shark cartilage (Sigma), DS from porcine
intestinal mucosa (Sigma) and C4S from sturgeon notochord
(Seikagaku). For activity experiments, 2 pl of enzyme was placed
in 248 01 of 50 mM Tris/HCI and 50 mM sodium acetate, pH 8.0,
with 1 mg/ml substrate (0.25 mg/ml for hyaluronan) at 37 0 C.
Product formation was monitored as an increase in absorbance at
232 nm as a function of time in our semi-high-throughput format.
Initial rates represent < 10 % substrate turnover. cABC (protease-
free) was purchased from Seikagaku. Substrates used in these
studies are described above and additionally include chondroitin
from shark cartilage (Seikagaku), hyaluronan from human um-
bilical cord (Sigma), heparin (Celsus) and heparan sulphate
(Celsus). The quantity of enzyme used in each reaction was meas-
ured using the Bio-Rad protein assay kit. A kinetic analysis of
cABC I employed our semi-high-throughput spectrophotometric
approach, and is essentially as described previously [19]. A
volume of 1 .l of 0.2 jig/pl cABC I was added to 249 /l of a solu-
tion containing different concentrations of GalAG substrates
(C4S, C6S and DS) in 50 mM Tris/HCI and 50mM sodium
acetate, pH 8.0. Each well contained different substrate concen-
trations ranging from 0.1 to 5 mg/ml. Product formation was
monitored by measuring the absorbance at 232 nm every 2 s.
To evaluate the kinetic data, the initial reaction rate (vo) was first
determined from the value of the slope from the plot of product
formation as a function of time. The values of Vm,, and K. were ex-
tracted from the slope and y-intercept of the Hanes plot generated
by monitoring the product formation and using eqn (1):
[substrate] 1 ) [substrate] + (1)
where [substrate] represents the substrate concentration. The
kca, was calculated by dividing Vm,, by the concentration of
enzyme in the reaction. A molar absorption coefficient (e) for
the product of the enzymic reaction of 3800 M- ' cm- ' was used
[8]. The calculated value for the path length of the well using a
250 ttl volume for the reaction was 0.904 cm. The analyses were
performed in triplicate.
RESULTS
Cloning of the cABC I gene from the P. vulgaris genome
The gene for cABC I was cloned from P. vulgaris genomic DNA
as a full-length version and as the mature enzyme, without its
putative leader sequence. The PCR product of approx. 3 kb was
subcloned into pET-28a, via an intermediate TOPO cloning step,
to facilitate its incorporation and expression in E. coli. cABC I
was expressed in E. coli as described above, with an N-terminal
His6 tag. The histidine tag enabled quick purification of the
enzyme over a charged Ni2+ column. Expression of the initial
clone resulted in an enzyme with very low activity against GalAG
substrates.
Table 2 Purification of recombinant cABC I
Specific activity
(1 mg/ml C6S)
Fraction Protein yield (mg) (units/mg) x-Fold purification*
Crude lysate
Elution from Ni2+ column
Thrombin cleavaget
92.1
197.9
230.6
*The x-fold purification was determined relative to the specific activity measured for crude
lysate.
t Cleavage of the His6 tag from the recombinant protein was confirmed by Western blot
analysis using an anti-(His tag) antibody (Amersham Biosciences). No detectable difference
in activity against GalAG substrates was observed between the recombinant cABC I and its
His-tag-cleaved counterpart.
DNA sequencing analysis revealed a number of differences
between our sequence and the previously published sequence
of the gene (GenBank® accession number E08025). The major
irregularity was observed in the resulting amino acid sequence
between residues 494-530, which can be attributed to a pair
of frame-shift errors in the published DNA sequence [13].
After position 1771, there should be an additional cytosine base
(underlined) in the published sequence (CGC CCT G instead
of CGC CTG), that would result in a proline residue instead of
leucine at position 494. At position 1870, there is an additional
thymidine base (underlined) which should be removed (TCA
GTG GGT instead of CAG TTG GGT), thereby resulting in a
better alignment between the published sequence and our cloned
sequence. Other errors in the sequence of Sato et al. [13] produce
differences in amino acids at positions 125 (proline instead of
leucine), 369 (valine instead of methionine), 670 (glycine instead
of alanine) and 865 (arginine instead of serine). These errors in
the previously published sequence have also been observed by
Huang et al. [11].
At the protein level, the sequence reported by Ryan et al. [14]
is identical with the sequence by Huang et al. [11]. Therefore our
clone is in close agreement to the sequence of Ryan et al. [14].
However, there were four point mutations present in our clone at
variance with the sequence suggested by Ryan et al. [14]. Since
expression of our initial clone resulted in a low-activity enzyme,
we decided to 'repair' these point mutations using site-directed
mutagenesis techniques. All four point mutations were corrected
so as to conform precisely with the protein sequences reported in
the crystal structure [11] and by Ryan et al. [14].
Recombinant expression and purification of cABC I
To establish the functionality of our 'fixed' cABC I clone, we set
out to recombinantly express the protein in E. coli. Expression of
the original full-length clone generated an enzyme almost wholly
present in the insoluble fraction. The yield of soluble recombinant
enzyme was greatly improved by the engineered removal of the
hydrophobic N-terminal signal sequence. This result is consistent
with most GAG-degrading enzymes that we have studied [8]. This
sequence tag is most likely responsible for targeting to a specific
location in the periplasm. cABC I purification generally yielded
upwards of 35 mg of protein from 500 ml of culture (Table 2).
SDS/PAGE analysis (Figure 1) revealed a highly pure band at
approx. 110 kDa, in close agreement with previously reported
masses of cABC I [9,13] and its theoretical mass of 112614 Da
based solely on amino acid composition.
A check for the absorbance at 232 nm, suggestive of the
double bond formed in the degradation reaction, was performed
spectrophotometrically with 5.0 1Lg of each recombinant enzyme
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Figure 1 SDS/PAGE analysis of the purification of recombinant cABC I
Summary of protein expression and purification following expression in BL21(DE3) as His6N-terminal fusion proteins. Lane 1, cell pellet; lane 2, crude lysate; lane 3, Invitrogen SeeBlue
Plus2 pre-stained standard; lane 4, inactive recombinant cABC I; lane 5, active recombinant
cABC I (altered via site-directed mutagenesis). Sizes are indicated in kDa to the right of
the gel.
(the original and the clone that underwent mutagenesis repair)
and 1 mg/ml C6S or DS. Expression and purification of the
'fixed' truncated clone restored robust processing activity against
a variety of GAG substrates. The original enzyme showed
negligible activity against both of the GalAG substrates, whereas
the 'fixed' version acted on both C6S and DS at healthy rates.
Biochemical conditions for optimal in vitro activity
Having established the broad substrate specificity of the recom-
binant cABC I, we next sought to optimize the reaction conditions
so as to achieve maximal enzyme activity. These parameters in-
cluded temperature, pH, ionic strength and dependence on sodium
acetate. A Tris buffer system was chosen, as it resulted in a greater
relative activity than phosphate buffer. The enzyme displayed
maximal activity at pH 8.0 and was essentially inactive for both
C6S and DS at pH 9.0 (Figure 2).
We also examined the recombinant enzyme's activity against
C6S and DS with regard to ionic strength. Recombinant cABC I
was optimally active at 62.5 mM NaCl for C6S and 125 mM
for DS. For C6S, 50 % inhibition occurred at slightly more than
125 mM NaCl, with activity virtually ablated at approx. 400 mM
NaCl. For DS, 50 % inhibition occurred at - 250 mM NaCl, and
activity was essentially negligible at > 500 mM NaC1.
In terms of temperature optima, with C6S as the substrate,
the recombinant enzyme demonstrated maximal activity at 37 °C.
At slightly over 40 C, enzyme activity was 50 % inhibited, and
activity fell dramatically at 450 C. For DS, a greater level of
enzyme activity was evident over the range from 25 to 400 C, with
an optimum between 30 and 37 oC. At 45 °C, processing of DS
by the recombinant cABC I was inhibited by over 60 %. For both
GalAG substrates, 37'C was chosen as the optimal temperature
for biochemical experiments.
It has been reported previously that acetate promotes cABC I
activity [9]. Our investigation found that 50 mM sodium acetate
provided optimal activity with C6S as the substrate, and 100 mM
sodium acetate with DS as the substrate. An absence of sodium
acetate in the reaction buffer inhibited enzyme activity against
C6S by approx. 50 %, and resulted in an almost complete decline
in activity against DS.
cABC I activity analysis
The specific activity of recombinant cABC I acting on a vari-
ety of substrates was assessed (Table 3). These experiments are
consistent with previously reported data for the cABC I enzyme
purified from P. vulgaris and available commercially as "protease-
free chondroitinase ABC I" from Seikagaku [9]. Kinetic para-
meters were determined for recombinant cABC I against C6S,
DS and C4S substrates, and are summarized in Table 4. Our
kinetic analysis corroborates our specific activity results, wherein
cABC I seems to prefer C4S and C6S over DS (Figure 3).
We also compared the specific activity of our recombinant
active cABC I with the commercially available purified "protease-
free chondroitinase ABC I" from Seikagaku. Rate of product
formation (AA 232/min) was measured for 2-4 min at 37 oC using
a 1 mg/ml C6S solution in 50 mM Tris buffer (pH 8.0) containing
50 mM sodium acetate. The Bradford assay was used to calculate
the amount of protein present in each sample. Based on the results,
our recombinant enzyme gave us a specific activity value of
164.2 m-units//hg, whereas the Seikagaku enzyme had a specific
activity of 20.2 m-units//g. The difference in specific activity
could be the result of enzyme stability or storage conditions.
The activity of cABC I on these three substrates was also
analysed by CE. This study represented an end-point assay for
activity, and allowed for a characterization of the final products
of cABC I digestion on all of the substrates after an 18 h
incubation at 37'C. For C4S and C6S, the product profile shows
predominantly disaccharide products, with minor tetrasaccharide
products also detected (Figure 4). In both of these cases, the
respective monosulphated disaccharide [i.e. AUA-GalNAc4S or
AUA-GalNAc6S, where AUA is A4,5 unsaturated uronic acid
and GalNAc is N-acetylgalactosamine either 4-O-sulphated (4S)
or 6-O-sulphated (6S)] represents the major product. In the
case of DS, we also observed a mixture of disaccharides and
tetrasaccharides as the final products of digestion. However, one
of the tetrasaccharide peaks is much larger than those observed
for the C4S and C6S substrates. This suggests that there may
be some resistance by tetrasaccharide fragments within DS to
cleavage by cABC I. The structure of the resistant tetrasaccharide
was determined to be AUA-GalNAc4S-IdoA-GaINAc4S (IdoA
is iduronic acid) based on co-elution (on CE) with a previously
isolated pure dermatan tetrasaccharide having the same structure.
In order to confirm that this tetrasaccharide is indeed resistant to
cABC I action, we incubated the pure tetrasaccharide with enzyme
at 37 'C and analysed the resulting products by CE. The CE trace
showed that there is no breakdown of the tetrasaccharide, thereby
confirming that cABC I cannot degrade this tetrasaccharide
fraction in DS. The diminished ability of the recombinant cABC I
to cleave DS tetrasaccharides is consistent with previous reports
on cABC I action pattern [9].
Mutagenesis studies
A comparison between the crystal structures of F. heparinum cAC
and P. vulgaris cABC I revealed a similar linear arrangement
of domains that are superficially similar in terms of overall
structure. On a closer inspection of the catalytic domain of cAC
with the middle domain of cABC I, one can observe a paucity
of sequence identity. On comparison of these domains between
the two enzymes, the lack of sequence identity persists throughout,
except for this group of amino acids, which have been implicated
previously as active-site players in cAC [20] and that seem to
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Figure 2 cABC I biochemical reaction conditions
(A) pH profile. Inset, effect of buffer system on enzyme activity: (1) 50 mM Tris buffer, pH 8.0; (2) 50 mM sodium phosphate buffer, pH 8.0; open bars are DS; closed bars are C6S. (B) Effect of
reaction temperature. (C) NaCI titration. (D) Sodium acetate titration. For all panels: 0, DS; *, C6S.
Table 3 Specific activity of recombinant cABC I on GAG substrates
Specific activity was determined by monitoring the increase in A232 for 5 min. The initial rate of
increase in A232 was determined for each substrate. The enzyme activity in units (1 unit= 1 1mol
of product formed/min) was calculated from the initial rate using e = 3800 M-' -cm- 1 for
reaction products at pH 8.0. n.d., not detected.
Specific activity
Substrate (units/mg of protein)
Table 4 Kinetic analysis of cABC I with various substrates
Results are the means + S.D. for at least three experiments.
Substrate K. (pM) kcat (min-') kcat/Km (/M- 1' min - ' )
1.2+0.6
2.5 + 0.5
1.5+0.1
37000+ 6500
27000 + 2500
52000+1300
31000
11000
35000
C4S
C6S
DS
Chondroitin
Chondroitin sulphate D
Chondroitin sulphate E
Hyaluronan
Heparin/heparan sulphate
290.8
174.6
122.3
69.8
54.2
34.8
have counterparts in cABC I. Using this framework of potential
conserved catalytic active site residues, we undertook site-
directed mutagenesis studies to probe the importance of several
residues in enzyme activity (Table 5). His 5 1O, TyOs', Glu6' and
Arg560 were all mutated to alanine and characterized in activity
experiments. These residues were suggested previously by Huang
et al. [11], and could constitute the active site, whereby the
proton acceptance and donation mechanism could take place [21].
Since a general base, such as histidine, is believed to be a key
component for this catalysis, we also mutated histidine residues(His561 and His712). These residues are not conserved between the
two enzymes, but are in close proximity to the proposed active
site.
Examination of the mutant enzymes in an end-point assay
by CE demonstrated a number of residues that seem to be
absolutely critical to catalysis. His5O1 -+ Ala produced no products
on overnight digestion with C6S, DS or C4S as the substrate(Figure 5). This is in sharp contrast with His 56 -- Ala and
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Figure 3 Kinetic analysis of cABC I on GalAG substrates
Hanes representations of recombinant cABC I on C4S (0), C6S (0) and DS (7). Inset, a comparison of enzyme activity on 1 mg/ml C6S substrate in 50 mM Tris buffer, pH 8.0, with 50 mM sodium
acetate. Expression of the original clone (A) results in a protein with negligible activity; expression of the clone manipulated to conform to the desired sequence (A) results in robust enzyme
activity.
His712 -+ Ala, which both produced a product profile comparable
with recombinant active cABC I against all three of these GalAGs
after an overnight digestion. Tyr°oS -> Ala, Glu653 • Ala and
Arg 56 - Ala were all unable to yield products in an exhaustive
digestion with any of these substrates. These observations provide
direct evidence that His50 1, Tyr5so, Glu653 and Args60 are crucial for
the activity of our recombinant cABC I. The relative positions
between these critical residues within the active-site cleft of
cABC I lends further credence to the notion of this amino acid
synergy as the enzyme active site.
CD spectroscopy was used to analyse the overall secondary
structure of the proteins. The resulting spectra displayed a high
ct-helix and fl-sheet content (Figure 6). These results are in
agreement with the crystal structure of cABC I [11]. CD analysis
was also used to confirm that the loss of activity displayed by
the inactive mutants (His501 -+ Ala, Tyrs0 -+ Ala, Glu653 - Ala
and Arg56° -* Ala) was not due to an alteration of the overall
secondary structure of the protein. As shown in Figure 6, no
significant differences on the CD spectra between the mutants and
the recombinant cABC I were observed. To address further the
effect of mutations on protein stability, heat-denaturation studies
were used to compare the recombinant enzyme with its mutants.
All proteins displayed melting transitions of 45 ± 5 C (Figure 6,
inset). Although these results do not exclude the possibility of
minor structural perturbations in the local environment, they do
suggest that the overall structure and stability of the protein are
not compromised when these particular residues are mutated to
alanine.
DISCUSSION
In the present paper, we report the subcloning of the cABC I gene
from P. vulgaris, and its recombinant expression in E. coli. We also
examine this recombinant cABC I biochemically, providing the
first conclusive evidence of the residues that constitute the en-
zyme active site. The establishment of a well-characterized
enzyme with defined GalAG substrate specificity provides insight
into important structure-function relationships in biology.
Purification of cABC I directly from cultures of P. vulgaris
resulted in preparations with low yields and considerable protease
contamination [22,23]. These conditions spurred investigators
toward recombinant production approaches. Early attempts to
recombinantly express cABC I in E. coli were laden with
difficulty. Expression of a soluble protein was hampered by both
the size of the gene and the signal sequence. Random proteolysis
also proved to be a nuisance to achieving the recombinant protein,
and this complication has been observed previously [13]. Our
one-step purification process allowed for the preparation of an
abundance of soluble protein. It was, however, discovered that
this protein lacked the ability to effectively degrade GalAG
substrates. Sequence anomalies in the original clone suggest that
there may have been underlying structural changes responsible
for this eradication of enzyme activity.
The sequential repair via site-directed mutagenesis of the
original truncated clone was accompanied by a restoration of
enzyme activity. Indeed, the 'repaired' recombinant enzyme
was able to process C4S, DS and C6S at robust rates. It was
also able to degrade a variety of other GalAG substrates and
hyaluronan at lesser rates. It is clear that our recombinant active
cABC I possessed a specific activity that far exceeded that of
the commercially available enzyme. Therefore it is evident that
our cloning, expression and purification system does not at all
compromise the activity of our cloned enzyme. It is possible
that the disparity in specific activities between our recombinant
enzyme and the commercially available cABC I is the result of
different purification and storage practices rather than intrinsic
enzymic properties. It is also feasible that an overestimation
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Figure 4 CE analysis of recombinant active cABC I
Product profiles for cABC I acting on (A) C4S, (B) C6S and (C) DS. ADi4S, AUA-GaINAc4S;
ADi6S, AUA-GalNAc6S; ADi2S6S, AUA2S-GalNAc6S; ADi4S6S, AUA-GalNAc4S6S; Tetra,
tetrasaccharide. Impurities in commercial substrate preparations result in the ADi6S peak in
electrophoretogram (A) and the ADi4S peak in electrophoretogram (B). mAU, milli-absorbance
units.
of active protein content for the commercial enzyme led to a
dramatically diminished observed rate, as some portion of quanti-
fied protein may have been distorted in the isolation process.
The optimal conditions for activity of our recombinant cABC I
are similar to those obtained for the purified enzyme. However, we
also observed that different buffer systems affect the processing
activity on different substrates. For enzyme activity on C6S in
50 mM sodium phosphate buffer, the optimal pH was determined
to be pH 7.0; however, in 50 mM Tris buffer, optimal activity was
observed at pH 8.0. This discrepancy was not observed with DS as
substrate, where the activity maximum was at pH 8.0 regardless
of the buffer system. In both cases, however, the enzyme showed
Table 5 Activity analysis of cABC I mutants
Kinetic parameters are reported in jtM (Km) and min - 1 (kt). n.d., activity was too low to be
detected. + refers to an exhaustive digestion of the substrate; - indicates that no products were
detected.
C6S kinetics DS kinetics Activity on CE
cABC I mutant Km knt Km kcat C6S C4S DS
HisSO' - Ala n.d. n.d. n.d. n.d. - - -
His561 - Ala 15.2 39100 6.90 3970 + + +
His712 - Ala 8.60 1140 5.10 613 + + +
Tyr50- Ala n.d. n.d. n.d. n.d. -
Arg50 -+ Ala n.d. n.d. n.d. n.d. - - -
ArgOO Ala 19.9 419 35.7 162 + + +
Glum - Ala n.d. n.d. n.d. n.d. - - -
* The ArgsB - Ala mutant did display some residual activity on DS.
more activity in Tris buffer than in phosphate buffer. It was also
observed that there was a slight difference in the concentration
of NaCl and sodium acetate required for maximum activity on
C6S as compared with DS. For DS, a higher concentration
(approximately double) of both NaCl and sodium acetate in the
buffer showed the highest activity in terms of product formation.
Another interesting observation is the absolute importance of
the presence of salt, i.e. either NaCl or sodium acetate, in the
buffer system for activity of recombinant cABC I on DS. From
Figures 2(C) and 2(D), we can see that, in the absence of any
salt in the buffer, the enzyme activity on DS is approx. 5 % of the
observed maximum activity. However, with C6S as substrate, even
when there is no salt in the buffer, we observe approx. 50-60 %
of the maximum activity.
We hypothesize that the salt requirement for DS is important
in abolishing non-specific interactions of this substrate with the
enzyme. DS has considerable intrinsic flexibility due to the pre-
sence of IdoA in its structure. Therefore it can potentially display
a wider range of interactions than C6S, and may bind to positively
charged patches on the surface of the enzyme, rather than in the
active site. In the presence of salt, these non-specific interactions
would be reduced markedly.
Our results with CE indicated that cABC I was unable to
cleave a tetrasaccharide fragment within DS, and we identified
this fragment to be AUA-GalNAc4S-IdoA-GalNAc4S. This is in
contrast with the product profile obtained on treating DS with
cB, where the major products are predominantly disaccharides
[19]. This is not surprising since cABC I and cB have totally
different structures and therefore may bind to and process DS
very differently.
The crystal structure of cABC I [11] revealed a three-domain
protein. The middle domain contains the catalytic site in a
wide-open cleft. Despite very limited sequence identity with the
catalytic domain of F. heparinum cAC, this middle domain of
cABC I did contain a conserved grouping of residues that were im-
plicated in catalysis in cAC [20]. These cABC I residues were
His501, ITyr5 s, Arg56W and Glu"3 . Manipulation of these residues via
mutagenesis to alanine resulted in knockout proteins: enzymes
with a complete inability to degrade GAG substrates. Thus this
tetrad of residues is crucial for enzyme activity (Figure 7). With
regard to the fl-elimination mechanism suggested previously for
GAG lyases, it seems that this group of residues is potentially
capable of performing the stabilization and proton shuffling
responsibilities required for GAG degradation. The present study
provides the first experimental evidence that this grouping of
amino acids comprises the cABC I active site.
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Figure 5 Representative CE profiles of cABC I mutants
Products of C6S degradation following digestion by (A) HisS01 - Ala and (B) His 561 - Ala cABC I mutants. Tables 4 and 5 provide further information regarding the substrate specificity of
recombinant cABC I and its mutants. ADi4S, AUA-GalNAc4S; ADi6S, AUA-GalNAc6S; ADi2S6S, AUA2S-GalNAc6S. mAU, milliabsorbance units.
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Figure 6 CD spectra of cABC I and the Inactive mutants
The recombinant cABC I (- ) and the mutants His501 - Ala (....), Tyr08 -+ Ala (- -), Glu63 - Ala (-..-) and Arg560 - Ala (- -) were concentrated and buffer-exchanged into 50 mM
sodium phosphate buffer, pH 8.0. Proteins were analysed in a quartz cell with a 1 mm path length. All spectra were collected using a protein concentration of 0.2 mg/ml in sodium phosphate, pH 7.0.
For melting experiments (inset), spectra were collected in 500C intervals from 5 to 8000C. The slight deviations in spectra intensity can be attributed to errors inherent in protein quantification.
It was demonstrated that His5°' was in fact the histidine residue
critical for catalysis. Two other histidine residues were examined,
His 61' and His712. Alanine mutants of these residues demonstrated
that these histidine residues were not critical for GAG degradation.
In fact, on an exhaustive digestion with GalAG substrate, both of
these mutants provided a full product profile.
Previously, it was suggested that ArgS"O was essential for
cABC I's ability to process both CS and DS [11]. ArgSO"'s
side chain was predicted to be positioned toward the uronate
carboxy group of either substrate, serving some role in charge
neutralization. However, our product profile analysis and specific
activity determinations with the ArgS'O --* Ala mutant suggest that
this residue is not actually critical for catalysis. In fact, with
C6S, C4S and DS, an exhaustive digestion with ArgSo° -- Ala
resulted in a product profile virtually indistinguishable from those
generated with our recombinant cABC I.
cABC I's broad substrate specificity complicates fine under-
standing of its GalAG-degradation mechanism. The present
study outlines the cloning and expression of cABC I, provides
a biochemical characterization of this enzyme and offers the
first conclusive proof of the active site. This will allow for
the further biochemical characterization of the enzyme, an
essential element in advancing GAG sequencing biotechnology
[16,17].
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Figure 7 Active-site tetrad of cABC I
Structural representation of cABC I. Inset, the active site residues of cABC I are shown in full.
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Conclusions
The research discussed in this chapter outlines the recombinant expression and
purification of multi-milligram quantities of chondroitinase ABC I from Proteus vulgaris,
without any contaminating activities. The gene for chondroitinase ABC I was sub-cloned
into an Escherichia coli-based expression plasmid and expressed as an N-terminal hexa-
histidine tag fusion protein. This allowed one-step purification of the enzyme using a Ni2+
affinity column. The identity and purity of the enzyme was confirmed by SDS-PAGE and
circular dichroism studies. The optimal conditions for enzyme activity, including pH,
temperature, and salt concentration were assessed. The kinetic parameters of the enzyme
were established against a full spectrum of glycosaminoglycan substrates. The product
profile generated by the exhaustive digestion of chondroitin sulfate and dermatan sulfate
substrates was analyzed using capillary electrophoresis. These results form the
biochemical foundation for the further characterization of chondroitinase ABC I.
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Chapter 3
Biochemical Characterization of the
Chondroitinase ABC I Active Site
Summary
The present chapter examines in detail the active site of recombinant
chondroitinase ABC I from Proteus vulgaris. By coupling site-directed mutagenesis of the
recombinant chondroitinase ABC I with a structural model of the enzyme-substrate
complex, the roles of active site amino acids in the catalytic action of the enzyme were
investigated. The putative catalytic residues HisSO1, Tyr508, Arg560, Glu653, and
Arg5OO were probed systematically via mutagenesis. Assessment of these mutants in
kinetic and end-point assays provided direct evidence on the catalytic roles of these
active-site residues. The inactivity of all His501 mutants implicated this residue as a
central player in catalysis, with the role of abstracting the proton from position C-5 of
the hexosamine moiety of the substrate. The kinetic data for Glu653 mutants suggests that
it is involved in a hydrogen bonding network within the active site. The proximity of
Tyr508 to the glycosidic oxygen of the substrate at the site of cleavage suggested its
potential role in protonating the leaving group. The rigorous biochemical
characterization of chondroitinase ABC I and other glycosaminoglycan-degrading
enzymes will allow for their more intelligent application, opening up the vast store of
information inherent in biologically relevant glycan species. This work was published in
the Biochemical Journal, and is reproduced here with permission.
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3.1.1 Introduction
Galactosaminoglycans (GalAGs) are one of four classes of structurally complex
linear polysaccharides called glycosaminoglycans (GAGs) [1]. Due to their ubiquitous
presence on the cell surface and in the extracellular matrix, GalAGs interact with a wide
variety of proteins such as growth factors, chemokines, lipoproteins, and enzymes in the
extracellular environment. These interactions play critical roles in modulating the
function of the protein [2, 3]. Dermatan sulfate is known to bind with thrombin [4] and
activated protein C [5] to influence anticoagulation; collagen [6], fibronectin [7-9], and
tenascin-X [10] to stabilize the extracellular matrix; transforming growth factor-3 [11,
12] to regulate growth; and hepatocyte growth factor/scatter factor [13, 14] to spur
cellular proliferation and organogenesis. It is becoming increasingly evident that there is
sequence-specificity in GalAG-protein interactions in terms of the precise modifications
in the chemical structure of GalAGs that bind with high affinity to a given protein [15,
16]. Manipulation of GAG chemical structure has been shown to promote anti-tumor
activities, inhibiting angiogenesis and tumor metastasis [17]. Modification of CS-
containing proteoglycans has been observed in a variety of human cancers including
those of the colon [18, 19], blood [19], and larynx [20]. Defined GalAG oligosaccharides
are also being developed as therapeutics for blood coagulation disorders [21, 22]. Thus,
the characterization of structure-function relationships of GalAGs is important for
understanding their biological roles.
The structural characterization of complex acidic polysaccharides, like GAGs, is a
challenging task. Due to their complex non-template based biosynthesis, it has been
difficult to develop methodologies to obtain sufficient material containing pure GAG
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oligosaccharides. Further, the chemical heterogeneity and highly acidic nature of GAGs
have complicated their analysis. Despite these challenges, significant advances have been
made in the development of methodologies for sequencing biologically important GAGs
[23]. These techniques involve the precise depolymerization of GAGs at specific linkages
and analysis of the resulting fragments using sensitive analytical methods such as mass
spectrometry and capillary electrophoresis (CE) [24].
Various microorganisms express GAG-depolymerizing polysaccharide lyases.
Mechanistically, these lyases degrade their substrates via a p-elimination reaction that
generates products with an unsaturated 4, 5 bond on the uronic acid at the site of
cleavage. Extensive biochemical characterization of the activity and substrate specificity
of some of these enzymes, such as the heparinases from Flavobacterium heparinum (now
known as Pedobacter heparinus), have successfully enabled their utilization as tools for
the structural characterization of heparin and heparan sulfate GAGs (HSGAGs) [23, 25].
Having extensively characterized the heparinases, we focused our efforts on the
cloning, expression and characterization of the GalAG-depolymerizing enzymes. The
GalAG lyases include chondroitinase AC (cAC, EC 4.2.2.5) and chondroitinase B (cB)
from P. heparinus, and chondroitinase ABC I (cABC I) and ABC II (cABC II, EC
4.2.2.4) from Proteus vulgaris. Chondroitinase AC shows activity against C4S and C6S.
Chondroitinase B cleaves DS as its sole substrate. Chondroitinase ABC I and cABC II
process a variety of substrates including C4S, C6S, DS, and hyaluronan. Particularly
striking is the ability of these broad substrate specificity enzymes (cABC I and cABC II)
to process GalAGs containing either uronic acid epimer. We have already cloned and
recombinantly expressed cB and cAC from P. heparinus [26]. Unlike the heparinases,
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there is abundant structural information available on the chondroitinases. Co-crystal
structures of cB with the disaccharide reaction products and cAC with different CS and
DS substrates have been solved [27, 28]. These co-crystal structures provided a
framework to design site-directed mutagenesis experiments to obtain a detailed
understanding of the role of the active site residues and divalent ions (such as Ca2+ in the
case of cB) in the catalytic mechanism and substrate specificity of these enzymes [29].
The biological significance of cABC has been demonstrated in studies that have
utilized this enzyme for functional recovery through nerve regeneration following spinal
cord injury, thus offering a potential treatment strategy for an unmet medical condition
[30]. We recently cloned and recombinantly expressed cABC I from Proteus vulgaris.
We also completed a preliminary biochemical characterization of this enzyme which
involved mutating to alanine the four structurally conserved amino acid residues (His501,
Tyr508, Arg560 and Glu653) that were identified in the cABC I crystal structure studies
[31]. Our observation that all four mutants were inactive towards both CS and DS
substrates suggested that these residues could potentially be part of the enzyme's catalytic
machinery. In this study, we systematically engineered conservative and non-
conservative site-directed mutants of the putative catalytic amino acids and analyzed the
activity of these mutants using both short-term kinetic assays and overnight end-point
product formation assays. Additionally, we modeled structural complexes of cABC I with
CS and DS substrates, providing a framework to guide our mutagenesis studies and to
further develop a chemical context for enzyme activity. These structural complexes were
constructed by molecular docking of substrates into the proposed active site of the
enzyme, modeled using the cABC I crystal structure [31].
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Table 3.1. Kinetic Analysis of cABC I & mutants with C6S as substrate. a
Enzyme Km Kcat Keat/ Km
AM min1' M-' min-'
Chondroitinase ABC Ib 1.2 + 0.6 37000 ± 6500 31000
His501Ala or Lys or Arg nac na na
Tyr508Ala na na na
Tyr508Phe 36.4 + 0.8 31 0.85
Arg560Ala na na na
Glu653Ala or Asp na na na
Glu653Gln 6.1 + 0.4 1600 + 300 260
Arg500Ala 19.9 ± 1.0 410 ± 50 21
a Values are the mean of at least three experiments ± standard deviation.
b Values are consistent with previously reported data.
C na, not available.
3.1.2 Chondroitinase ABC I Action
The gene for cABC I was cloned from Proteus vulgaris genomic DNA without its
putative leader sequence. The PCR product was subcloned into pET28a and expressed in
Escherichia coli with an N-terminal 6x histidine tag. As reported in our previous study,
there were sequence discrepancies between our clone and the reported protein sequence
of the enzyme [31-33]. Thus it was necessary to perform site-directed mutagenesis to
make our protein sequence consistent with the published sequence [31]. The catalytic
activity of our cloned cABC I was previously characterized with various GalAG
substrates (including C4S, C6S and DS) using a semi-high throughput procedure. This
procedure enabled us to obtain multiple initial velocity measurements between one
substrate-enzyme pair within one minute. Multiple runs for each enzyme-substrate pair
could also be performed in a short period of time to establish a better confidence in the
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data generated. Km and Vmax information could be generated from this data almost
immediately. The data suggests robust activity on all three substrates; however there is a
clear preference for the chondroitin substrates. (Tables 3.1 and 3.2). The catalytic
efficiency is about 3-fold higher for CS compared to DS.
Table 3.2. Kinetic Analysis of cABC I & mutants with DS as substrate. a
Enzyme Km Kat Keat/ Km
AM min"1  plM1 min-1
Chondroitinase ABC I b 2.5 ± 0.5 27000 + 2500 11000
His501Ala or Lys or Arg nac na na
Tyr508Ala na na na
Tyr508Phe 48.9 ± 0.6 110 ± 40 2.2
Arg560Ala na na na
Glu653Ala or Asp na na na
Glu653Gln 4.2 ± 0.5 5200 ± 400 1200
Arg500Ala 35.7 ± 0.5 160 ± 40 4.5
a Values are the mean of at least three experiments ± standard deviation.
b Values are consistent with previously reported data.
C na, not available.
3.1.3 Biochemical Characterization: Site-Directed Mutagenesis Studies
Building on our preliminary biochemical characterization, we sought to establish
unambiguously the roles of the four putative catalytic amino acids His501, Tyr508,
Arg560 and Glu653. Our model of the enzyme-substrate structural complex (see below)
was used as a framework to systematically design additional conservative mutants. In
order to evaluate the role of His501 in cABC I's activity (substrate binding vs. direct
contribution to catalysis), histidine was conservatively mutated to lysine and then to
arginine, retaining this position's basic character. Tyr508Phe was constructed to evaluate
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the importance of the hydrophobic group in positioning the substrate, compared to the
hydroxyl group that could potentially protonate the glycosidic bond after cleavage. Based
on our enzyme-substrate structural complex, Glu653 was proposed to be involved in a
hydrogen bonding network with neighboring His501 and arginine. Thus two different
Glu653 mutants were designed - Glu653Asp to study the effect of side chain length and
Glu653Gln to study the effect of acidic versus amide group on the hydrogen bonding
network in the active site.
These mutants were analyzed for their activity against GalAG substrates by
scanning for product formation (as measured via OD 232 detection) against C6S and DS
(Tables 3.1 and 3.2). Mutants with detectable activities were further characterized
through kinetics assays. Capillary electrophoretic studies allowed for an inspection of an
end-point product profile analysis following an exhaustive 14-18 hour digestion with
C6S, DS, or C4S as substrate.
All His501 mutations (His501Ala, His501Lys, and His501 Arg) showed no
activity against C6S and DS substrates while scanning for product formation.
Additionally, the His501 mutants did not produce any products in capillary
electrophoretic assays, suggesting that His501 is absolutely critical for cABC I activity.
Though Tyr508Ala proved inactive against C6S and DS while scanning for product
formation and was unable to degrade C6S, DS, and C4S in exhaustive digestions,
Tyr508Phe was able to process GalAG substrates. In an exhaustive digestion, product
profile analysis revealed electropheretograms virtually indistinguishable from those
produced with recombinant cABC I. Tyr508Phe processes C6S (Figure 3.1) with both
diminished binding (Km of 36.4 pgM compared with 1.2 pM for wild-type recombinant
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Figure 3.1. Capillary Electrophoretic Analysis of cABC I Tyr508 Mutants.
Product profiles for (A) Tyr508Ala acting on chondroitin-6-sulfate, (B) Tyr508Phe acting
on chondroitin-6-sulfate, (C) Tyr508Ala acting on dermatan sulfate, and (D) Tyr508Phe
acting on dermatan sulfate. Depicted below are the relevant amino acids, which illustrate
the nature of the chemical groups involved and the relative protrusion of each sidechain
into the catalytic pocket.
cABC I) and markedly reduced turnover number (kat of 31 min 1 compared with 37000
min' for recombinant cABC I). Tyr508Phe acts on DS in similar fashion (Figure 3.1),
with a Km of 48.9 jM and a kcat of 110 min' (compared with a Km of 2.5 jiM and a kat of
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Figure 3.2. Capillary Electrophoretic Analysis of cABC I Glu653 Mutants.
Products of dermatan sulfate degradation following digestion by (A) Glu653Ala, (B)
Glu653Asp, and (C) Glu653Gln. Depicted below are the relevant amino acids. For each
sidechain, the relative length of protrusion into the catalytic pocket and the potential to
participate in hydrogen bonding determine end-product profiles.
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27000 min1 for recombinant cABC I). Therefore, the tyrosine to phenylalanine mutation
results in an enzyme with a much higher Km and a greatly reduced kcat, suggesting that
this residue possibly plays an important role in substrate positioning and turnover. Unlike
His501, the Tyr508Phe mutant does not seem to affect a critical step in GalAG
degradation since it still produces products in an end-point analysis.
The other mutants were active against both C6S and DS, though with far less
processing efficiency than recombinant cABC I (Table 3.1 and 3.2). Although the
Glu653Asp mutant proved to be catalytically inactive against both C6S and DS in
kinetics assays, on overnight digestion this mutant was able to produce products on these
substrates as well as on C4S. Glu653Gln maintained some level of activity against both
C6S and DS, with a slight increase in Km for both substrates, and a greater than 20-fold
reduction in kat for C6S and a 5-fold reduction in kcat for DS (Figure 3.2). The data
suggests that while this residue does not play a major role in substrate positioning, its
major role is probably in affecting the catalytic turnover of the enzyme. Against C6S,
Arg500Ala remained active, but with a 17-fold increase in Km and a 1500-fold reduction
in catalytic efficiency. With DS, Arg500Ala showed similar losses, with a 14-fold
increase in Km and a greater than 2000-fold decrease in catalytic efficiency. The results of
the kinetic analysis of the mutants were interpreted using the modeled enzyme-substrate
structural complexes to understand the role of the amino acid in the catalytic mechanism
of cABC I.
3.1.4 Enzyme-Substrate Structural Complex
The structure of cABC I contains three domains viz. an N-terminal 1-domain with
a jellyroll fold, the catalytic a-helix domain (incomplete toroid (a/a)5 fold) and a C-
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terminal antiparallel 1-sheet domain. The structural fold of cABC I, comprising the
catalytic a-helix domain and the C-terminal P-sheet domain, is very similar to that of
cAC and bacterial hyaluronate lyases [34]. To obtain a clearer picture of the active site
and positioning of the substrate within cABC I, its structure was superimposed on the
enzyme-substrate co-crystal structures of the structurally related cAC [28] and
hyaluronate lyase (HAL) [34]. This superimposition aligned most of the C-terminal 3-
sheet domains. However, the a-helix domain did not align very well, since the cleft
formed by the N-terminal and C-terminal regions of this domain was more open in cABC
I as compared to the closed grooves found in cAC and HAL. Consistent with the earlier
structural alignment [31], the four structurally conserved amino acids His501, Tyr508,
Arg560 and Glu653 appear to be involved in the catalytic activity of cABC I.
The superimposition of the cAC co-crystal structures with their CS and DS
substrates [28, 35] and cABC I provided a guiding framework for modeling the cABC I-
substrate structural complexes. Using the information from the co-crystal structures as a
starting point, the representative low-energy enzyme-substrate complexes were obtained
by systematic energy minimization methods where the active site amino acids and the
substrates were allowed to move freely. First, unfavorable steric contacts were removed
by an initial energy minimization to obtain good starting structures for the enzyme-
substrate complexes. These structures were further subject to total energy minimization to
obtain local minimum energy structural complexes.
In the case of cABC I, the active site groove is more open, and there are no ring
tryptophan residues to provide the necessary constraints on the orientation by means of
ring stacking interactions. These differences in the topology of the active site cAC and
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BFigure 3.3. Structural Comparison of Chondroitinases AC and ABC I.
Grasp rendering of (A) cAC (pink) and (B) cABC I (blue) structural complexes with
dermatan sulfate. Note that the active site groove of cAC is more closed compared to that
of cABC I. This narrower groove and the presence of Trp127 and Trp427 (both orange)
in cAC locks the dermatan substrate in an orientation that allows binding to the active site
but does not allow cleavage. On the other hand, the wider active site of cABC I provides
room for the dermatan substrate to re-orient during catalysis.
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Figure 3.4. Chondroitinase ABC I and the Chondroitin-4-Sulfate Substrate.
Shown above is a stereoview of C4S substrate in the active site. The oligosaccharide is
colored in orange. The basic amino acids (His, Arg and Lys in dark blue), acidic amino
acids (Asp and Glu in red), and Tyr (in pink) are also shown. Shown below is a detailed
schematic of the different amino acids in the active site (numbered according to the
crystal structure) and their proximity to the oligosaccharide. The cleavable bond is
between the -1 and +1 sites, and the monosaccharides on the non-reducing side of the
cleavable bond are numbered -2, -3, etc and those on the reducing side are number +1,
+2, etc.
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cABC I could perhaps account for the broader substrate specificity of cABC I (Figure
3.3). These differences in the topology of the active site cAC and cABC I could perhaps
account for the broader substrate specificity of cABC I (Figure 3.3). These differences
are outlined in further details in the following which discusses the interactions of the
active site amino acids of cABC I with C4S and DS substrates.
3.1.5 Interactions with C4S substrate
The position and orientation of C4S relative to the active site of cABC I was
obtained using the cAC co-crystal structure with the C4S substrate as a starting point
(Figure 3.4). From the proximity of the amino acids towards the C5 proton of GlcA in the
+1 subsite, His501 is positioned more favorably to abstract this proton compared to
Tyr508. The close proximity between the glycosidic oxygen of the -1, +1 glycosidic bond
and Tyr508 suggests that it is more likely to play a role in protonating the leaving group.
Arg560 is also proximal to the glycosidic oxygen of the scissile bond and its equivalent
cAC Arg288 has been implicated to play a role in protonation of the leaving group [28].
However, the Arg288Ala mutant in cAC did not completely abolish its activity [28].
Glu653 does not seem to be involved directly in catalysis, but it is at hydrogen bonding
distance with His501 and Arg560 and thus likely plays a critical role in positioning these
residues for catalysis. The hydrogen bonding interaction of the analogous cAC Glu371
with the corresponding histidine and arginine residues has been observed in cAC and a
similar role for Glu371 has been proposed [30]. Another important step in the 13-
eliminative cleavage of lyases is the neutralization of the charge on the carboxyl group of
the uronic acid to facilitate the abstraction of the proton. Based on our structural complex,
Arg500 is positioned to interact with the carboxylate group of the uronic acid at the +1
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Figure 3.5. Chondroitinase ABC I and the Dermatan Sulfate Substrate.
Shown above is a stereoview of DS in the active site. The color scheme is analogous to
Figure 3.4. Shown below is a detailed schematic of the interaction between various active
site amino acids and the dermatan substrate oriented optimally for proton abstraction
(left) and proton donation (right). The numbering of monosaccharides (-2, -1, +1 and +2)
is described in Figure 3.4. Note that the two schematics are shown for clarity. It is
possible that there is a re-orientation of the substrate during catalysis. However, this
cannot be determined conclusively.
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subsite. This role for Arg500 has also been implicated in the earlier cABC I crystal
structure study [31]. The stabilization of the carbanion intermediate could be achieved by
potential interactions of either the protonated base His501 or Arg500 or Arg560, since all
of these groups are positioned to interact with the C5 carbanion on the uronic acid formed
after abstraction of the ca-proton.
3.1.6 Interactions with DS substrate
The initial positioning of the DS substrate based on its relative orientation in the
cAC active site was such that the C5 proton of the IdoA in the +1 subsite was facing
away from the putative catalytic amino acids. In the cAC active site, the DS substrate is
locked in this orientation due to the structural constraints imposed by the more closed
active site groove and the two tryptophan amino acids. These observations are consistent
with the inability of cAC to cleave DS. Rather, it has been observed that DS binds to the
active site of cAC and inhibits its activity toward chondroitin substrates.
The chemical differences between IdoA in DS and GlcA in C4S provide further
insights into differences in the positioning of these substrates within the active site. While
in GlcA the C5 proton and the glycosidic oxygen of the cleavable bond are in the cis
orientation, in IdoA these two atoms are in the trans orientation. Since the active site
amino acids involved in the proton abstraction (from C5 of uronic acid) and donation (to
the glycosidic oxygen of the cleaved bond) are on the same face of the active site groove,
the DS substrate would need to re-orient in order for these amino acids to cleave it. Thus,
there are salient differences between the mechanism governing DS cleavage and the
mechanism cABC I employs for C4S degradation.
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Based on our model of the cABC I-DS structural complex, His501 is still the best
candidate to serve as the general base that abstracts the C5 proton from the IdoA in the
+1 subsite (Figure 3.5). The positioning of the C5 proton such that it would be abstracted
by His501 results in the carboxylate group of the IdoA being proximal to Arg560. Thus,
Arg560 could potentially play a role in neutralizing the charge on this group to make the
C5 proton more labile (Figure 3.5). It is possible that the dermatan substrate reorients
itself after proton abstraction for the lone pairs of the glycosidic oxygen to face the active
site Tyr508 or Arg560. The fact that Arg560 and Arg500 are on opposing sides of the
substrate provide further flexibility for interaction with substrate during the proton
abstraction and donation processes (Figure 3.5).
3.1.7 The Mode of Action of cABC I
The results from the site-directed mutagenesis of the active site amino acids are
consistent with the interactions observed in the theoretical enzyme-substrate structural
complexes. Coupled analysis of both the kinetics experiments and the investigations of
product profiles by capillary electrophoresis strongly support the notion that His501 is
absolutely critical for the activity of cABC I on C6S, DS, and C4S. From this, we suggest
that His501 plays a central role in catalysis-- the abstraction of the C5 proton from the
uronic acid moiety. The proximity of Tyr508 to the C5 proton and the glycosidic oxygen
in the cABC I-chondroitin structural complex suggested its potential role in protonating
the leaving group. However, the Tyr508Phe mutant did produce products against both
C6S and DS in the overnight digestion. This mutant retains the hydrophobic group of
tyrosine but abolishes the proton donating hydroxyl group. Thus the role of Tyr508 in
proton donation is less conclusive and it can potentially be compensated for by water
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molecules in the active site, albeit at reduced catalytic efficiency consistent with the
kinetics data. This also suggests that the aromatic ring of Tyr508 is likely to play a role in
the positioning of substrate.
The role of Glu653 in forming the hydrogen bonding network with His501 and
Arg560 is confirmed by the kinetic data and overnight product formation of Glu653Asp
and Glu653Gln mutants. Indeed, the relatively unchanged Km between cABC I and
Glu653Gln for both C6S (Table 3.1) and DS (Table 3.2) suggests that this residue is not
important for directly binding substrate. Further, the diminished protrusion of the aspartic
acid hydrogen bonding sidechain as compared with the glutamic acid and glutamine
sidechains is consistent with the relative order of activities (Figure 3.2).
The proximity of Arg560 to the C5 atom and the glycosidic oxygen suggests that
it may play a role in proton donation and/or stabilization of the carbanion intermediate
following proton abstraction. It is more likely to play the latter role since proton donation
can be compensated via neighboring water molecules, and further, the Tyr508 is better
positioned to protonate the leaving group based on our model. Arg560 could potentially
play an additional role in neutralizing the carboxylate of the IdoA in DS based on its
proximity to this group in the modeled cABC I-dermatan structural complex. Our
structural model of the cABC I-CS complex and the earlier crystal structure studies [28,
31] suggest that Arg500 is likely to neutralize the charge on the carboxylate group of
GlcA in CS. However, the Arg500Ala mutant does not conclusively justify this role since
this mutant retains its activity towards chondroitin and dermatan substrates.
In addition to the catalytic amino acids already described, the cABC I active site
contains several other basic residues. While some of these have structural analogs in the
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cAC and HAL co-crystal structures, there are many others which are unique to cABC I.
The highly basic nature of the active site could potentially be involved in accommodating
a wide variety of substrates including C4S, C6S, DS and HA which have different charge
distributions due to their differences in sulfation pattern. His561 and Asn564 are
positioned to interact with the 4-0 sulfate group of the GalNAc4S at the -1 subsite
(present in both C4S and DS). Furthermore, several additional basic amino acids,
including His388, Arg395, Argl05, Lys312, are located on the upper side of the active
site cleft towards the N-terminal n-sheet domain (Figure 3.3). These basic amino acids
could play a potential role in governing the specificity of cABC I towards different
substrates.
3.1.8 The Catalytic Topology of the Enzyme Active Site
The present study provides a first step towards identifying and defining the roles
of the active site amino acids in substrate recognition, positioning, and processing
functions of cABC I. Chondroitinase ABC I, like other GalAG lyases, cleaves its
substrate at the glycosidic linkage between the hexosamine and uronic acid via a p-
elimination mechanism. The fundamental steps involved in this mechanism are proton
acceptance and donation [36]: (1) the abstraction of the C-5 proton on the uronic acid
moiety, causing the formation of a double bond between C-4 and C-5, (2) the
stabilization of the carbanion intermediate, and (3) the protonation of the anomeric
oxygen, breaking the glycosidic bond. By coupling kinetic analysis of site-directed
mutants of the active site amino acids with the construction of theoretical enzyme-
substrate structural complexes to interpret the effects of the mutants, the detailed roles of
the four active site amino acids have been outlined.
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His501 is an absolutely critical residue, as its mutants (Ala, Lys, Arg) proved null
against all GalAG substrates. This residue is likely involved in proton abstraction from
the uronic acid moiety of the GalAG. Though our initial studies with Tyr508Ala proved
consistent with its acting as a general base, our Tyr508Phe mutant eliminated the
likelihood of this function. Tyr508Phe generated products on overnight digestion with all
GalAG substrates, making it unlikely that this residue modulates such a central role in
catalysis. Our results suggest that Tyr508 plays a role in the positioning of substrate via
hydrogen bonding with the glycosidic bond of the GalAG. Similarly the role of Glu653
with other catalytic residues via hydrogen bonding is confirmed by our mutagenesis
studies. Arg560 seems to play an important part in cABC I's activity, perhaps in
stabilizing the enolate intermediate through its positive charge. It also may act as the
general acid in the reaction.
We also performed mutagenesis on Arg500, since it was previously suggested that
Arg500 would be able to interact with the carboxylate group of either epimer of uronic
acid, thus enabling cABC I's most remarkable ability to process both CS and DS [31].
Through its sidechain flexibility, Arg500's guanidinium group was thought to aid in
charge neutralization of either uronic acid configuration. However, our results indicate
that Arg500 is not crucial for the processing of GalAG substrates, since the Arg500Ala
mutant did generate products in both product profile studies and kinetics assays. It may
be that a number of residues are important in this charge neutralization process.
Based on the enzyme-substrate structural complexes, we obtained insights into the
differences in processing of chondroitin and dermatan sulfate by cABC I. Our structural
models suggest that the catalytic residues in cABC I are positioned to cleave chondroitin
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substrates more favorably than dermatan substrates. This is consistent with the kinetics of
the wild-type enzyme which shows increased catalytic efficiency towards chondroitin
versus dermatan substrates. The enzyme-substrate structural models also revealed several
other amino acids in the active site that are likely to play a role in substrate positioning
and specificity. We are currently studying the roles of these amino acids in the substrate
specificity and processing of cABC I. In summary, engineering cABC enzymes via site-
directed mutagenesis would provide a repertoire of mutants with fine-tuned substrate
specificities. These mutants not only facilitate the structural characterization of GalAGs,
but they can also be directly utilized in physiological scenarios such as nerve
regeneration after spinal cord injury, thus expanding the scope of treatment strategies.
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Biochemical characterization of the chondroitinase ABC I active site
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cABC I (chondroitinase ABC I) from Proteus vulgaris is a GalAG presentative CS and DS substrates. This enabled us to con-
(galactosaminoglycan) depolymerizing lyase that cleaves its sub- struct recombinant enzyme-substrate structural complexes. These
strates at the glycosidic bond via f-elimination. cABC I cleaves studies together provided structural insights into the effects of the
a particularly broad range of GalAG substrates, including CS mutations on the catalytic mechanism of cABC I and the differ-
(chondroitin sulphate), DS (dermatan sulphate) and hyaluronic ences in its processing of CS and DS substrates. All His-501
acid. We recently cloned and recombinantly expressed cABC I in mutants were essentially inactive and thereby implicating this
Escherichia coli, and completed a preliminary biochemical amino acid to play the critical role of proton abstraction during
characterization of the enzyme. In the present study, we have catalysis. The kinetic data for Glu-653 mutants indicated that it
coupled site-directed mutagenesis of the recombinant cABC I is involved in a hydrogen bonding network in the active site. The
with a structural model of the enzyme-substrate complex in order proximity of Tyr-508 to the glycosidic oxygen of the substrate
to investigate in detail the roles of active site amino acids in the at the site of cleavage suggested its potential role in protonating
catalytic action of the enzyme. The putative catalytic residues the leaving group. Arg-560 was proximal to the uronic acid C-5
His-501, Tyr-508, Arg-560 and Glu-653 were probed system- proton, suggesting its possible role in the stabilization of the
atically via mutagenesis. Assessment of these mutants in kinetic carbanion intermediate formed during catalysis.
and end-point assays provided direct evidence on the cata-
lytic roles of these active-site residues. The crystal structure of the Key words: active site, chondroitin sulphate (CS), chondroitinase
native enzyme provided a framework for molecular docking of re- ABC (cABC), dermatan sulphate, mode of action, mutagenesis.
INTRODUCTION tenascin-X [12] to stabilize the extracellular matrix; transforming
growth factor-f [13,14] to regulate growth; and hepatocyte growth
GalAGs (galactosaminoglycans) are one of the four classes of factor/scatter factor [15,16] to spur cellular proliferation and
structurally complex linear polysaccharides called GAGs (glyco- organogenesis. It is becoming increasingly evident that there is se-
saminoglycans) [1]. GalAGs are composed of disaccharide repeat quence-specificity in GalAG-protein interactions in terms of the
units of uronic acid [IdoA (ot-L-iduronic acid) or GlcA (f-D- precise modifications in the chemical structure of GalAGs that
glucuronic acid)] (1 -+ 3) linked to GalNAc (N-acetyl-D-galacto- bind with high affinity to a given protein [17,18]. Manipulation of
samine). These basic disaccharide units (Figure 1) are linearly GAG chemical structure has been shown to promote anti-tumour
associated via P-(1 -* 4) linkages to form polymers of CS (chon- activities, inhibiting angiogenesis and tumour metastasis [19].
droitin sulphate) or DS (dermatan sulphate). The uronic acids Modification of CS-containing proteoglycans has been observed
in CS are exclusively GlcA; with DS, epimerization at the C-5 in a variety of human cancers including those of the colon [20,21],position of the uronic acid moiety during biosynthesis results in blood [21] and larynx [22]. Defined GalAG oligosaccharides
a mixture of IdoA and GlcA epimers. Biosynthesis of CS and are also being developed as therapeutics for blood coagulation
DS also involves sulphation of the sugar backbone at various disorders [23,24]. Thus the characterization of structure-function
positions, which generates diversity in their oligosaccharide se- relationships of GalAGs is important for understanding their
quences. CS is commonly O-sulphated at the C-4 of the galacto- biological roles.
samine [C4S (chondroitin-4-sulphate) or CSA] or the C-6 of The structural characterization of complex acidic polysacchar-
the galactosamine [C6S (chondroitin-6-sulphate) or CSC]. Other ides, like GAGs, is a challenging task. Due to their complex
rare modifications in CS, such as 2-0-or 3-O-sulphation of the non-template-based biosynthesis, it has been difficult to develop
GlcA moiety, have also been reported [2,3]. In the case of DS, methodologies to obtain sufficient material containing pure GAGO-sulphation at C-4 of GaINAc is a common modification; 0- oligosaccharides. Furthermore, the chemical heterogeneity and
sulphation at C-6 of GalNAc and C-2 of the IdoA also occur, but highly acidic nature of GAGs have complicated their analysis.
with less frequency. Despite these challenges, significant advances have been madeDue to their ubiquitous presence on the cell surface and in the in the development of methodologies for sequencing biologically
extracellular matrix, GalAGs interact with a wide variety of pro- important GAGs [25]. These techniques involve the precise de-
teins such as growth factors, chemokines, lipoproteins and en- polymerization of GAGs at specific linkages and analysis of the
zymes in the extracellular environment. These interactions play resulting fragments using sensitive analytical methods such as
critical roles in modulating the function of the protein [4,5]. DS MS and CE (capillary electrophoresis) [26].
is known to bind with thrombin [6] and activated protein C [7] Various microorganisms express GAG-depolymerizing poly-
to influence anticoagulation; collagen [8], fibronectin [9-11] and saccharide lyases. Mechanistically, these lyases degrade their
Abbreviations used: C4S, chondroitin-4-sulphate; C6S, chondroitin-6-sulphate; cABC, chondroitinase ABC; cAC, chondroitinase AC; cB, chondroitinaseB; CE, capillary electrophoresis; CS, chondroitin sulphate; DS, dermatan sulphate; GAG, glycosaminoglycan; GalAG, galactosaminoglycan; GalNAc, N-acetyl-D-galactosamine; GIcA, i-D-glucuronic acid; HAL, hyaluronate lyase; IdoA, a-L-iduronic acid.
1 To whom correspondence should be addressed (email rams@mit.edu).
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Figure 1 GalAG disaccharide chemical structures
GAGs are polymers of repeated disaccharide units consisting of an uronicacidand a hexosamine.
In the case of GalAGs, the hexosamine moiety is an N-acetyl-D-galactosamine (R = S03-
or H).
substrates via a P-elimination reaction that generates products
with an unsaturated 4,5-bond on the uronic acid at the site of cleav-
age. Extensive biochemical characterization of the activity and
substrate specificity of some of these enzymes, such as the hep-
arinases from Flavobacterium heparinum (now known as Pedo-
bacter heparinus) have successfully enabled their utilization as
tools for the structural characterization of HSGAGs (heparin and
heparan sulphate GAGs) [25,27].
Having extensively characterized the heparinases, we focused
our efforts on the cloning, expression and characterization of
the GalAG-depolymerizing enzymes. The GalAG lyases include
cAC (chondroitinase AC) (EC 4.2.2.5) and cB (chondroitinase B)
from P. heparinus, and cABC I (chondroitinase ABC I) and cABC
II (EC 4.2.2.4) from Proteus vulgaris. cAC shows activity against
C4S and C6S. cB cleaves DS as its sole substrate. cABC I and
cABC II process a variety of substrates including C4S, C6S, DS
and hyaluronan. Particularly striking is the ability of these broad
substrate specificity enzymes (cABC I and II) to process GalAGs
containing either of the uronic acid epimers. We have already
cloned and recombinantly expressed cB and cAC from P. hep-
arinus [28]. Unlike the heparinases, there is abundant structural
information available on the chondroitinases. Co-crystal struc-
tures of cB with the disaccharide reaction products and cAC with
different CS and DS substrates have been solved [29,30]. These
co-crystal structures provided a framework to design site-directed
mutagenesis experiments to obtain a detailed understanding of the
role of the active site residues and bivalent ions (such as Ca2+ in
the case of cB) in the catalytic mechanism and substrate specificity
of these enzymes [30,31,35].
The biological significance of cABC has been demonstrated
in studies that have utilized this enzyme for functional recovery
through nerve regeneration following spinal cord injury, thus of-
fering a potential treatment strategy for an unmet medical con-
dition [32]. We recently cloned and recombinantly expressed
cABC I from P. vulgaris [33]. We also completed a preliminary
biochemical characterization of this enzyme [33], which involved
mutating to alanine the four structurally conserved amino acid
residues (His-501, Tyr-508, Arg-560 and Glu-653) that were
identified in the cABC I crystal structure studies [34]. Our observ-
ation that all four mutants were inactive towards both CS and
DS substrates suggested that these residues could potentially be
part of the enzyme's catalytic machinery. In the present study, we
systematically engineered conservative and non-conservative site-
directed mutants of the putative catalytic amino acids and analysed
the activity of these mutants using both short-term kinetic assays
and overnight end-point product formation assays. Additionally,
we modelled structural complexes of cABC I with CS and DS sub-
strates, providing a framework to guide our mutagenesis studies
and to further develop a chemical context for enzyme activity.
These structural complexes were constructed by molecular dock-
ing of substrates into the proposed active site of the enzyme,
modelled using the cABC I crystal structure [34].
EXPERIMENTAL
Materials
Porcine intestinal mucosa DS (average molecular mass 35 000 Da)
and shark cartilage C6S (average molecular mass 50 000 Da) were
purchased from Sigma. C4S (super special grade, average molecu-
lar mass 50 000 Da) was purchased from Seikagaku/Associates of
Cape Cod (Falmouth, MA, U.S.A.). Oligonucleotides were pur-
chased from Invitrogen (Carlsbad, CA, U.S.A.). The QuikChange
site-directed mutagenesis kit was purchased from Stratagene (La
Jolla, CA, U.S.A.). All other materials are from common sources
or are as given below.
Subcloning and site-directed mutagenesis of cABC I
Genomic DNA was isolated from cultures of P. vulgaris
(A.T.C.C. 6896) using a Qiagen DNeasy purification kit. Sub-
cloning procedures were as previously described [28,33]. The
QuikChange site-directed mutagenesis kit was used to produce
mutants of cABC I, as previously described [33]. Primer se-
quences for all studies are presented in Table 1. The plasmids
were prepared using a miniprep kit (Qiagen, Chatsworth, CA,
U.S.A.). Each clone was sequenced to confirm the presence of
the desired mutation. Plasmid DNA was used to transform BL21
(DE3) E. coli.
Recombinant expression and protein purification of cABC I
and mutants
Recombinant cABC I and the site-directed mutants were ex-
pressed and purified as previously described [28,33]. The purity
of the enzymes was assessed by SDS/PAGE using a precast
Invitrogen NuPAGE 12% (w/v) Bis/Tris gel and Simply Blue
SafeStain. Protein concentration was measured using the Bio-Rad
Laboratories (Hercules, CA, U.S.A.) Bradford assay kit.
CE
To study the activities and product profiles of the proteins on each
substrate (C6S, DS and C4S), digests of 100 /g/ml substrate,
50 mM Tris/HC1, 50 mM sodium acetate (pH 8.0) with 1 pg of
recombinant cABC I or the site-directed mutants were placed at
37 oC for 14 h. The digests were analysed using CE as previously
described [28,35].
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Table 1 Summary of primer sequences for site-directed mutagenesis
studies
Mutation codons are indicated in bold; bases modified in order to create the desired point
mutations are underlined.
Mutant Primer pair sequences
T154A 5'-ACTGGCTGGCGTGCTGTGGGAGTCTCT-3'
5'-AGAGACTCCCACAGCACGCCAGCCAGT-3'
V3091 5'-GGAACG CAAG CAGACATCTGATCACTGATAAACAAATC-3'
5'-GATTTGTTTATCAGTGATCAGATGTCTGCCTTGCGTTCC-3'
P322L 5'-CAAC CAGAGAATCTTAACTCTCAAGATAAACAACTATTTG-3'
5'-CAAATAGTTGTTTATCTTGAGAGTTAAGATTCTCTGGTTG-3'
P694Q 5-GGTTGGGATGGAATAGAATGCAAGGGG CAACCACT-3'
5'-AGTGGTTGCCC CIrGCATTCTATTCCAATCCCAACC-3'
H501A 5'-TGATGGTACAGCATGGCGAGCTGAAGGCAACTATCCGGGGCTA-3'
5'-TAGCCCGGATAGTG CCTTCAGCTCGCCATGCTGTACCATCA-3'
Y508A 5'-GGCAACTATCCGGGCGCCTCTTTCCCAGCC-3'
5'-GG CTGGGAAAGAGGCGCCCGGATAGTTGCC-3'
R560A 5'-CCGCTG CAGGAGCACACCCTTTTMCTCACCTTCG-3'
5'-CGAAGGTGAGTTAAAAGGGTGTGCTCCTGCAAGCGG-3'
E653A 5-CAC CAATGTTrGGTCATCTGCAATATAACAAAGATAAC CGT-3'
5'-ACGGTrATCTTTGTTATAAATTGCAGATGACCAAACATTGGTG-3'
R500A 5'-CCTGATGGTACAGCATGGGCACATGAAGGCAACTATCCGGG C-3'
5'-GCCCGGATAGTTGCCTTCATGTGC CATGCTGTACCATCAGG-3'
H501K 5'-GGTACAGCATGGCGAAAGGAAGGCAACTATCCGGGGC-3'
5'-GCCCGGATAGTTGCCTTCC.TTCGCCATGCTGTACC-3'
H501R 5'-ACAGCATGGCGACGTGAAGGCAACTATCCGGGC-3'
5'-GCCCGGATAGTrGcCTTCACGTCGCCATGCTGT-3'
Y508F 5'-AACTATCCGGGCTTCTCTTTCCCAGCC-3'
5'-GGCTGGGAAAGAGAAGCCCGGATAGTT-3'
E653D 5'-CAATGTTTGGTCATCTGATATTTATAACAAAGATAACCGTTATGG-3'
5'-CCATAACGGTTATCTTTGTTATAAATATCAGATGACCAAACATTG-3'
E6530 5'-CAATGTTTGGTCATCTCAAATTTATAACAAAGATAACCGTTATGG-3'
5'-CCATAACGGTTATCTGTrTATAAATTTGAGATGAC CAAACATTG-3'
CD
CD spectra were recorded at 25 'C on an Aviv 202 CD spectro-
photometer using Quartz cuvettes with an optical path length of
0.1 cm. Scans were collected between 300 and 195 nm with a
1.0 nm bandwidth and a scan rate of 1 nm/min. Three scans were
averaged for each protein. For melting experiments, spectra
were collected at 5 'C intervals from 5 to 75 °C. Recombinantly
expressed proteins were concentrated and buffer-exchanged
into 50 mM sodium phosphate (pH 7.5) using Centricon 10 fil-
ters (Millipore, Watertown, MA, U.S.A.). All spectra were col-
lected using a protein concentration of 0.2 mg/ml. The buffer
contribution was subtracted for all spectra. The signal was
normalized to molar ellipticity, [O],, in degrees -cm2 -dmol- ' .
Kinetic analysis
Recombinant proteins were concentrated and buffer-exchanged
into 50 mM Tris/HCl and 50 mM sodium acetate (pH 8.0). In
order to evaluate the activity of cABC I and mutants in a semi-high
throughput manner, the kinetic analysis was adapted to a 96-well
plate format. The studies were performed in a quartz 96-
well plate at 37 C using a Molecular Devices Spectramax
190. The assay was initiated by adding 0.2-6 /.g of enzyme
to 249 /l of a solution containing different concentrations of
GalAG substrates (C4S, C6S and DS) in 50 mM Tris/HCl and
50 mM sodium acetate (pH 8.0), total reaction volume of 250 Jdl.
Each well contained different substrate concentrations (0.1-
5 mg/ml). Product formation was monitored by measuring the
absorbance A at 232 nm every 2-3 s. Evaluation of the kinetic data
was based on the initial reaction rate and was performed as pre-
viously described [33].
Docking of CS and DS substrates in the active site of cABC I
The SARF2 program [36] was used to determine the CA (Ca)
atoms in the cABC I and cAC structures that gave an optimal rmsd
(root mean-squared deviation) upon superimposition. Superpos-
ition of the 452 CA atoms identified by the SARF2 program in
the cAC co-crystal structures (with C4S and DS) and the cABC
I crystal structure [rmsd of 2.2 A (1 A = 10-'` m or 0.1 nm)] pro-
vided the initial location and orientation of the CS and DS
substrates relative to the putative active site of cABC I. The co-
ordinates of C4S (GlcA-GalNAc4S) 2 and DS (IdoA-GalNAc4S) 2
tetrasaccharides were available from the two cAC co-crystal
structures [30]. In the case of the DS tetrasaccharide, the C-5 pro-
ton was facing away from the putative active site residues (His-
501, Tyr-508 and Arg-560). Thus this substrate was further
reorientated to ensure that the C-5 proton was accessible for
abstraction by the active site amino acids.
The starting structural models of the enzyme-substrate com-
plexes were subject to energy minimization. The AMBER force
field modified for carbohydrates was further modified to include
O-sulphate and sulphamate groups [37,38]. This modified
AMBER force field was used to assign the potentials for both the
enzyme as well as the tetrasaccharide substrates. A subset of
the enzyme co-ordinates around the active site groove was defined
to include all of the putative active site amino acids and several
additional amino acids that could potentially be involved in the
catalytic activity. The enzyme-substrate complex was subject to
minimization first without charges and then with charges using
500 steps of steepest descent and 500 steps of conjugate-gradient
methods. Most of the protein was fixed and only the amino acids
that were a part of the active site subset were allowed to move
during the minimization. The final rms derivatives of the energies
were below 0.1. The ring conformation of the monosaccharides
was not distorted by the minimization procedure. The Viewer and
Discover modules of InsightII (Release 2000.1; Accelrys, San
Diego, CA, U.S.A.) were used for the orientation of the substrate
and energy minimization respectively.
RESULTS AND DISCUSSION
cABC I characterization
The gene for cABC I was cloned from P. vulgaris genomic DNA
without its putative leader sequence. The PCR product was sub-
cloned into pET28a and expressed in E. coli with an N-terminal
His6 tag. As reported in our previous study [33], there were se-
quence discrepancies between our clone and the reported protein
sequence of the enzyme [34,39,40]. Thus it was necessary to
perform site-directed mutagenesis to make our protein sequence
consistent with the published sequence [34]. The catalytic activity
of our cloned cABC I was previously characterized with various
GalAG substrates (including C4S, C6S and DS) using a semi-high
throughput procedure [33]. This procedure enabled us to obtain
multiple initial velocity measurements between one substrate-
enzyme pair within 1 min. Multiple runs for each enzyme-sub-
strate pair could also be performed in a short period of time
to establish a better confidence in the data generated. K, and
V,, information could be generated from these data almost im-
mediately. The data suggest robust activity on all three substrates;
however, there is a clear preference for the chondroitin sub-
strates (Tables 2 and 3) [33]. The catalytic efficiency is about
3-fold higher for CS compared with DS.
Site-directed mutagenesis studies
Building on our preliminary biochemical characterization [33],
we sought to establish unambiguously the roles of the four putative
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Table 2 Kinetic analysis of cABC I and mutants with C6S as substrate
Values are the means + S.D. for at least three experiments. NA, not available.
Enzyme Km (ApM) Keat (min - 1) Kcat/Km (uM - 1 -min - 1)
cABC I* 1.2+0.6 37000+ 6500 31000
H501A or K or R NAt NA NA
Y508A NA NA NA
Y508F 36.4 + 0.8 31 0.85
R560A NA NA NA
E653A or D NA NA NA
E653Q 6.1+0.4 1600+300 260
R500A 19.9+1.0 410+50 21
* Values are consistent with previously reported data [33].
Table 3 Kinetic analysis of cABC I and mutants with DS as substrate
Values are the means + S.D. for at least three experiments. NA, not available.
Enzyme Km (AIM) Kcat (min - 1) Kcat/Km (AM- 1 min- 1)
cABC 1* 2.5+0.5 27000 +2500 11000
H501A or K or R NA* NA NA
Y508A NA NA NA
Y508F 48.9+0.6 110+40 2.2
R560A NA NA NA
E653A or D NA NA NA
E653Q 4.2+0.5 5200+ 400 1200
R500A 35.7+0.5 160+40 4.5
* Values are consistent with previously reported data [33].
catalytic amino acids His-501, Tyr-508, Arg-560 and Glu-653.
Our model of the enzyme-substrate structural complex (see
below) was used as a framework to systematically design ad-
ditional conservative mutants. In order to evaluate the role of
His-501 in cABC I's activity (substrate binding versus direct
contribution to catalysis), the histidine residue was conservatively
mutated to lysine and then to an arginine residue, retaining this
position's basic character. Y508F (Tyr"08 -- Phe) was constructed
to evaluate the importance of the hydrophobic group in positioning
the substrate, compared with the hydroxy group that could
potentially protonate the glycosidic bond after cleavage. Based on
our enzyme-substrate structural complex, Glu-653 was proposed
to be involved in a hydrogen bonding network with neighbouring
His-501 and arginine. Thus two different Glu-653 mutants were
designed: E653D to study the effect of side-chain length and
E653Q to study the effect of acidic versus amide group on the
hydrogen bonding network in the active site.
These mutants were analysed for their activity against GalAG
substrates by scanning for product formation (as measured using
A2 32 detection) against C6S and DS (Tables 2 and 3). Mutants with
detectable activities were further characterized through kinetics
assays. CE studies allowed for an inspection of an end-point
product profile analysis following an exhaustive 14-18 h digestion
with C6S, DS or C4S as substrate. CD data on all mutants was also
collected and heat-denaturing experiments performed to ensure
that mutagenesis did not compromise the enzyme structure (Fig-
ure 2). All mutants displayed melting transitions of approx. 450 C.
All His-501 mutations (H501A, H501K and H501R) showed no
activity against C6S and DS substrates while scanning for product
formation. Additionally, the His-501 mutants did not produce any
products in CE assays, suggesting that His-501 is absolutely criti-
cal for cABC I activity. Though Y508A proved inactive against
C6S and DS while scanning for product formation and was unable
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Figure 2 CD spectra of recombinant enzymes
The recombinant cABC I (--) and the mutants H501K (...-), H501R (- - -) and E653D
(-. --) were concentrated and buffer-exchanged into50 mM sodium phosphate buffer (pH 8.0).
Proteins wereanalysed in al 1 mm path length quartz cell. Theslight deviations in spectral intensity
can be attributed to errors inherent in protein quantification.
to degrade C6S, DS and C4S in exhaustive digestions, Y508F
was able to process GalAG substrates. In an exhaustive digestion,
product profile analysis revealed electrophoretograms virtually
indistinguishable from those produced with recombinant cABC I.
Y508F processes C6S (Figure 3) with both diminished binding
(Km of 36.4 /LM compared with 1.2 gM for wild-type recom-
binant cABC I) and markedly reduced catalytic-centre activity
(kca,, of 31 min-' compared with 37000 min-' for recombinant
cABC I). Y508F acts on DS in similar fashion (Figure 3), with a
Km of 48.9 p/M and a kcat of 110 min-' (compared with a Km of
2.5 tM and a kcat of 27000 min-' for recombinant cABC I).
Therefore the tyrosine to phenylalanine mutation results in an
enzyme with a much higher Km and a greatly reduced kcat, sug-
gesting that this residue possibly plays an important role in
substrate positioning and turnover. Unlike His-501, the Y508F
mutant does not seem to affect a critical step in GalAG degradation
since it still produces products in an end-point analysis.
The other mutants were active against both C6S and DS, though
with far less processing efficiency than recombinant cABC I
(Tables 2 and 3). Although the E653D mutant proved to be
catalytically inactive against both C6S and DS in kinetics assays,
on overnight digestion this mutant was able to produce pro-
ducts on these substrates as well as on C4S. E653Q maintained
some level of activity against both C6S and DS, with a slight
increase in Km for both substrates, and a greater than 20-fold re-
duction in kca, for C6S and a 5-fold reduction in kcat for DS
(Figure 4). The results suggest that while this residue does not play
a major role in substrate positioning, its major role is probably
in affecting the catalytic turnover of the enzyme. Against C6S,
R500A remained active, but with a 17-fold increase in Km and
a 1500-fold reduction in catalytic efficiency. With DS, R500A
showed similar losses, with a 14-fold increase in Km and a greater
than 2000-fold decrease in catalytic efficiency. The results of
the kinetic analysis of the mutants were interpreted using the
modelled enzyme-substrate structural complexes to understand
the roles of the amino acid in the catalytic mechanism of cABC I.
Enzyme-substrate structural complex: putative roles for active site
amino acids
The structure of cABC I contains three domains, namely an N-ter-
minal j6-domain with ajellyroll fold, the catalytic ca-helix domain
@ 2005 Biochemical Society
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Figure 3 CE analysis of cABC I Tyr-508 mutants
Product profiles for (A) Tyr508Ala acting on C6S, (B) Tyr508Phe acting on C6S, (C) Tyr508Ala acting on DS and (0) Tyr508Phe acting on DS. Depicted below are the relevant amino acids,
which illustrate the nature of the chemical groups involved and the relative protrusion of each side chain into the catalytic pocket. Abbreviations: ADi2S,6S, AU2s-GalNAcss (where AU2s is
2-0-sulphated uronic acid with a A 4' unsaturated bond); ADi4S, AU-GalNAc 4s (where AU is uronic acid with a A4.5 unsaturated bond and GalNAc4s is 4-0-sulphated N-acetylgalactosamine);
ADi6S, AU-GalNAcas (where GalNAces is 6-0-sulphated N-acetylgalactosamine; mAU, milli-absorbance units; Tetra, tetrasaccharide.
[incomplete toroid (ac/a)-fold] and a C-terminal antiparallel 6-
sheet domain. The structural fold of cABC I, comprising the cata-
lytic a-helix domain and the C-terminal fl-sheet domain, is
very similar to that of cAC and bacterial HALs (hyaluronate
lyases) [41]. To obtain a clearer picture of the active site and
positioning of the substrate within cABC I, its structure was
superimposed on the enzyme-substrate co-crystal structures of the
structurally related cAC [30] and HAL [41]. This superimposition
aligned most of the C-terminal fl-sheet domains. However, the ta-
helix domain did not align very well, since the cleft formed by
the N- and C-terminal regions of this domain was more open in
cABC I when compared with the closed grooves found in cAC and
HAL. Consistent with the earlier structural alignment [34], the four
structurally conserved amino acids His-501, Tyr-508, Arg-560 and
Glu-653 appear to be involved in the catalytic activity of cABC I.
The superimposition of the cAC co-crystal structures with
their CS and DS substrates [30,42] and cABC I provided a
guiding framework for modelling the cABC I-substrate structural
complexes. Using the information from the co-crystal structures as
a starting point, the representative low-energy enzyme-substrate
complexes were obtained by systematic energy minimization
methods where the active site amino acids and the substrates were
allowed to move freely. First, unfavourable steric contacts
were removed by an initial energy minimization to obtain good
starting structures for the enzyme-substrate complexes. These
structures were further subjected to total energy minimization to
obtain local minimum energy structural complexes.
In the case of cABC I, the active site groove is more open,
and there are no tryptophan residues to provide the necess-
ary constraints on the orientation by means of ring-stacking inter-
actions. These differences in the topology of the active sites of
cAC and cABC I could perhaps account for the broader substrate
specificity of cABC I (Figure 5). These differences are outlined
in further detail in the following sections, which discuss the
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Figure 4 CE analysis of cABC I Glu-653 mutants
Products of DS degradation following digestion by (A) E653A, (B) E653D and (C) E653Q. Depicted below are the relevant amino acids. For each side chain, the relative length of protrusion into the
catalytic pocket and the potential to participate in hydrogen bonding determine the end-product profiles. mAU, milli-absorbance units.
interactions of the active site amino acids of cABC I with C4S
and DS substrates.
Interactions with C4S substrate
The position and orientation of C4S relative to the active site of
cABC I was obtained using the cAC co-crystal structure with the
C4S substrate as a starting point (Figure 6). From the proximity
of the amino acids towards the C-5 proton of GlcA in the + 1 sub-
site, His-501 is positioned more favourably to abstract this
proton compared with Tyr-508. The close proximity between the
glycosidic oxygen of the - 1, + 1 glycosidic bond and Tyr-508
suggests that it is more liable to play a role in protonating the
leaving group. Arg-560 is also proximal to the glycosidic oxygen
of the scissile bond and its equivalent cAC Arg-288 has been
implicated to play a role in protonation of the leaving group [30].
However, the R288A mutant in cAC did not completely abolish
its activity [30]. Glu-653 does not seem to be involved directly in
catalysis, but it is at a hydrogen bonding distance with His-501
and Arg-560 and thus probably plays a critical role in positioning
these residues for catalysis. The hydrogen bonding interaction of
the analogous cAC Glu-371 with the corresponding histidine and
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Figure 5 Structural comparison of cAC and cABC I
Grasp rendering of (A) cAC (pink) and (B) cABC I (blue) structural complexes with DS. Note that the active site groove of cAC is more closed compared with that of cABC I. This narrower groove and
the presence of Trp-127 and Trp-427 (both orange) in cAC locks the dermatan substrate in an orientation that allows binding to the active site but does not allow cleavage. On the other hand, the
wider active site of cABC I provides room for the dermatan substrate to reorient during catalysis.
arginine residues has been observed in cAC and a similar role
for Glu-371 has been proposed [30]. Another important step in
the f-eliminative cleavage of lyases is the neutralization of the
charge on the carboxy group of the uronic acid to facilitate the ab-
straction of the proton. Based on our structural complex, Arg-
500 is positioned to interact with the carboxylate group of the
uronic acid at the + 1 subsite. This role for Arg-500 has also been
implicated in the earlier cABC I crystal structure study [34]. The
stabilization of the carbanion intermediate could be achieved by
potential interactions of either the protonated base His-501 or
Arg-500 or Arg-560, since all of these groups are positioned to
interact with the C-5 carbanion on the uronic acid formed after
abstraction of the a-proton.
Interactions with DS substrate
The initial positioning of the DS substrate based on its relative
orientation in the cAC active site was such that the C-5 proton
of the IdoA in the + 1 subsite was facing away from the putative
catalytic amino acids. In the cAC active site, the DS substrate is
locked in this orientation due to the structural constraints imposed
by the more closed active site groove and the two tryptophan
amino acids. These observations are consistent with the inability
of cAC to cleave DS. Rather, it has been observed that DS binds to
the active site of cAC and inhibits its activity towards chondroitin
substrates [30].
The chemical differences between IdoA in DS and GlcA in C4S
provide further insights into differences in the positioning of these
substrates within the active site. Whereas in GlcA the C-5 proton
and the glycosidic oxygen of the cleavable bond are in the cis-
orientation, in IdoA these two atoms are in the trans-orientation.
Since the active site amino acids involved in the proton abstraction
(from C-5 of uronic acid) and donation (to the glycosidic oxygen
of the cleaved bond) are on the same face of the active site groove,
the DS substrate would need to reorient in order for these amino
acids to cleave it. Thus there are salient differences between the
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Figure 6 cABC I and the C4S substrate
Shown above is a stereoview of C4S substrate in the active site. The oligosaccharide is coloured in orange. The basic amino acids (histidine, arginine and lysine in dark blue), acidic amino acids(aspartic and glutamine in red), and tyrosine (in pink) are also shown. Shown below is a detailed schematic of the different amino acids in the active site (numbered according to the crystal structure)
and their proximity to the oligosaccharide. The cleavable bond is between the -1 and + 1 sites, and the monosaccharides on the non-reducing side of the cleavable bond are numbered -2, - 3,
etc. and those on the reducing side are numbered +2, +3, etc.
mechanism governing DS cleavage and the mechanism cABC I
employs for C4S degradation.
Based on our model of the cABC I-DS structural complex,
His-501 is still the best candidate to serve as the general base
that abstracts the C-5 proton from the IdoA in the + 1 subsite
(Figure 7). The positioning of the C-5 proton such that it would
be abstracted by His-501 results in the carboxylate group of the
IdoA being proximal to Arg-560. Thus Arg-560 could potentially
play a role in neutralizing the charge on this group to make the
C-5 proton more labile (Figure 7). It is possible that the dermatan
substrate reorients itself after proton abstraction for the lone pair
of glycosidic oxygen to face the active site Tyr-508 or Arg-560.
The fact that Arg-560 and Arg-500 are on the opposite sides of the
substrate provide further flexibility for interaction with substrate
during the proton abstraction and donation processes (Figure 7).
Implications for the mode of action of cABC I
The results from the site-directed mutagenesis of the active site
amino acids are consistent with the interactions observed in the
theoretical enzyme-substrate structural complexes. Coupled ana-
lysis of both the kinetics experiments and the investigations of
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Figure 7 cABC I and the DS substrate
Shown above is a stereoview of DS in the active site. The colour scheme is analogous to Figure 6. Shown below is a detailed schematic of the interaction between various active site amino acids
and the dermatan substrate orientated optimally for proton abstraction (left) and proton donation (right). The numbering of monosaccharides (- 2, -1, +1 and +2) is described in Figure 6.
Note that the two schematics are shown for clarity. It is possible that there is a reorientation of the substrate during catalysis. However, this cannot be determined conclusively.
product profiles by CE strongly support the notion that His-501
is absolutely critical for the activity of cABC I on C6S, DS and
C4S. From this we suggest that His-501 plays a central role in
catalysis, the abstraction of the C-5 proton from the uronic acid
moiety. The proximity of Tyr-508 to the C-5 proton and the
glycosidic oxygen in the cABC I-chondroitin structural complex
suggested its potential role in protonating the leaving group.
However, the Y508F mutant did produce products against both
C6S and DS in the overnight digestion. This mutant retains the
hydrophobic group of tyrosine but abolishes the proton donat-
ing hydroxy group. Thus the role of Tyr-508 in proton donation
is less conclusive and it can potentially be compensated by water
molecules in the active site, albeit at reduced catalytic efficiency
consistent with the kinetics data. This also suggests that the
aromatic ring of Tyr-508 is likely to play a role in the positioning
of the substrate.
The role of Glu-653 in forming the hydrogen bonding network
with His-501 and Arg-560 is confirmed by the kinetic data and
overnight product formation of E653D and E653Q mutants.
Indeed, the relatively unchanged Km between cABC I and E653Q
for both C6S (Table 2) and DS (Table 3) suggests that this residue
is not important for directly binding the substrate. Furthermore,
the diminished protrusion of the aspartic acid hydrogen bonding
side chain as compared with the glutamic acid and glutamine side
chains is consistent with the relative order of activities (Figure 4).
The proximity of Arg-560 to the C-5 atom and the glycosidic
oxygen suggests that it may play a role in proton donation and/or
stabilization of the carbanion intermediate following proton ab-
straction. It is more likely to play the latter role since proton
donation can be compensated via neighbouring water molecules,
and further, the Tyr-508 is better positioned to protonate the
leaving group based on our model. Arg-560 could potentially play
an additional role in neutralizing the carboxylate of the IdoA in
DS based on its proximity to this group in the modelled cABC I-
dermatan structural complex. Our structural model of the cABC
I-CS complex and the earlier crystal structure studies [30,34]
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suggest that Arg-500 is likely to neutralize the charge on the
carboxylate group of GlcA in CS. However, the R500A mutant
does not conclusively justify this role since this mutant retains its
activity towards chondroitin and dermatan substrates.
In addition to the catalytic amino acids already described, the
cABC I active site contains several other basic residues. While
some of these have structural analogues in the cAC and HAL co-
crystal structures, there are many others that are unique to cABC I.
The highly basic nature of the active site could potentially be
involved in accommodating a wide variety of substrates including
C4S, C6S, DS and HA, which have different charge distributions
due to their differences in sulphation pattern. His-561 and Asn-
564 are positioned to interact with the 4-O-sulphate group of
the GalNAc4S at the - 1 subsite (present in both C4S and DS).
Furthermore, several additional basic amino acids, including His-
388, Arg-395, Arg-105 and Lys-312 are located on the upper side
of the active site cleft towards the N-terminal P-sheet domain
(Figure 5). These basic amino acids could play a potential role in
governing the specificity of cABC I towards different substrates.
The catalytic machinery of cABC I
The present study provides a first step towards identifying and
defining the roles of the active site amino acids in substrate
recognition, positioning and processing functions of cABC I.
cABC I, like other GalAG lyases, cleaves its substrate at the glyco-
sidic linkage between the hexosamine and uronic acid via a
fl-elimination mechanism. The fundamental steps involved in
this mechanism are proton acceptance and donation [43]: (i) the
abstraction of the C-5 proton on the uronic acid moiety, causing
the formation of a double bond between C-4 and C-5, (ii) the sta-
bilization of the carbanion intermediate, and (iii) the protonation
of the anomeric oxygen, breaking the glycosidic bond. By coupl-
ing kinetic analysis of site-directed mutants of the active site
amino acids with the construction of theoretical enzyme-substrate
structural complexes to interpret the effects of the mutants, the
detailed roles of the four active site amino acids have been
outlined.
His-501 is an absolutely critical residue, as its mutants (Ala,
Lys and Arg) proved null against all GalAG substrates. This
residue is probably involved in proton abstraction from the uronic
acid moiety of the GalAG. Although our initial studies with
Y508A proved consistent with its acting as a general base,
our Y508F mutant eliminated the likelihood of this function.
Y508F generated products on overnight digestion with all GalAG
substrates, making it unlikely that this residue modulates such a
central role in catalysis. Our results suggest that Tyr-508 plays
a role in the positioning of substrate via hydrogen bonding with the
glycosidic bond of the GalAG. Similarly, the role of Glu-653 with
other catalytic residues via hydrogen bonding is confirmed by our
mutagenesis studies. Arg-560 seems to play an important part in
cABC I's activity, perhaps in stabilizing the enolate intermediate
through its positive charge. It also may act as the general acid in
the reaction.
We also performed mutagenesis on Arg-500, since it was pre-
viously suggested that Arg-500 would be able to interact with
the carboxylate group of either of the epimers of uronic acid, thus
enabling cABC I's most remarkable ability to process both CS and
DS [34]. Through its side chain flexibility, Arg-500's guanidinium
group was thought to aid in charge neutralization of either of the
uronic acid configurations. However, our results indicate that Arg-
500 is not crucial for the processing of GalAG substrates, since
the R500A mutant did generate products in both product profile
studies and kinetics assays. It may be that a number of residues
are important in this charge neutralization process.
Based on the enzyme-substrate structural complexes, we ob-
tained insights into the differences in processing of CS and DS by
cABC I. Our structural models suggest that the catalytic residues
in cABC I are positioned to cleave chondroitin substrates more
favourably than dermatan substrates. This is consistent with the
kinetics of the wild-type enzyme, which shows increased catalytic
efficiency towards chondroitin versus dermatan substrates. The
enzyme-substrate structural models also revealed several other
amino acids in the active site that are likely to play a role in sub-
strate positioning and specificity. We are currently studying the
roles of these amino acids in the substrate specificity and pro-
cessing of cABC I. In summary, engineering cABC enzymes via
site-directed mutagenesis would provide a repertoire of mutants
with fine-tuned substrate specificities. These mutants not only
facilitate the structural characterization of GalAGs, but they can
also be directly utilized in physiological scenarios such as nerve
regeneration after spinal cord injury, thus expanding the scope of
treatment strategies.
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Conclusions
The research described here provides the critical steps toward characterizing the
catalytic machinery of chondroitinase ABC I. Chondroitinase ABC I, like other related
lyases, cleaves its substrate at the glycosidic linkage between the hexosamine and the
uronic acid via the 13-elimination mechanism. The fundamental steps involved in this
mechanism include the abstraction of the C-5 proton from the uronic acid moiety,
stabilization of the carbanion intermediate, and the protonation of the anomeric oxygen,
breaking the glycosidic bond. An understanding of the roles of specific amino acids along
these mechanistic lines will reveal the intricate details of the substrate recognition,
positioning, and processing functions of chondroitinase ABC I. This will further advance
the possibility of engineering chondroitinase ABC I mutants with altered properties, thus
heralding the potential for a library of enzymatic tools with which to manipulate
chondroitin sulfate and dermatan sulfate structure and function.
192
References
1 Ernst, S., Langer, R., Cooney, C. L. and Sasisekharan, R. (1995) Enzymatic
degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol 30, 387-444.
2 Trowbridge, J. M. and Gallo, R. L. (2002) Dermatan sulfate: new functions from
an old glycosaminoglycan. Glycobiology 12, 117R-125R.
3 Sugahara, K., Mikami, T., Uyama, T., Mizuguchi, S., Nomura, K. and Kitagawa,
H. (2003) Recent advances in the structural biology of chondroitin sulfate and
dermatan sulfate. Curr Opin Struct Biol 13, 612-620.
4 Liaw, P. C., Austin, R. C., Fredenburgh, J. C., Stafford, A. R. and Weitz, J. I.
(1999) Comparison of heparin- and dermatan sulfate-mediated catalysis of
thrombin inactivation by heparin cofactor II. JBiol Chem 274, 27597-27604.
5 Fernandez, J. A., Petaja, J. and Griffin, J. H. (1999) Dermatan sulfate and LMW
heparin enhance the anticoagulant action of activated protein C. Thromb Haemost
82, 1462-1468.
6 Iozzo, R. V. (1997) The family of the small leucine-rich proteoglycans: key
regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32,
141-174.
7 Tumova, S., Woods, A. and Couchman, J. R. (2000) Heparan sulfate chains from
glypican and syndecans bind the Hep II domain of fibronectin similarly despite
minor structural differences. JBiol Chem 275, 9410-9417.
8 Schmidt, G., Robenek, H., Harrach, B., Glossl, J., Nolte, V., Hormann, H.,
Richter, H. and Kresse, H. (1987) Interaction of small dermatan sulfate
proteoglycan from fibroblasts with fibronectin. J Cell Biol 104, 1683-1691.
9 Walker, A. and Gallagher, J. T. (1996) Structural domains of heparan sulphate for
specific recognition of the C-terminal heparin-binding domain of human plasma
fibronectin (HEPII). Biochem J 317 ( Pt 3), 871-877.
10 Elefteriou, F., Exposito, J. Y., Garrone, R. and Lethias, C. (2001) Binding of
tenascin-X to decorin. FEBS Lett 495, 44-47.
11 Yamaguchi, Y., Mann, D. M. and Ruoslahti, E. (1990) Negative regulation of
transforming growth factor-beta by the proteoglycan decorin. Nature 346, 281-
284.
12 Hildebrand, A., Romaris, M., Rasmussen, L. M., Heinegard, D., Twardzik, D. R.,
Border, W. A. and Ruoslahti, E. (1994) Interaction of the small interstitial
proteoglycans biglycan, decorin and fibromodulin with transforming growth
factor beta. Biochem J 302 (Pt 2), 527-534.
13 Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T. and Gallagher, J. T. (1994)
Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the
major heparan sulfate structural determinants. JBiol Chem 269, 11216-11223.
14 Lyon, M., Deakin, J. A., Rahmoune, H., Fernig, D. G., Nakamura, T. and
Gallagher, J. T. (1998) Hepatocyte growth factor/scatter factor binds with high
affinity to dermatan sulfate. JBiol Chem 273, 271-278.
15 Mascellani, G., Liverani, L., Bianchini, P., Parma, B., Torri, G., Bisio, A.,
Guerrini, M. and Casu, B. (1993) Structure and contribution to the heparin
cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences
of dermatan sulphate. Biochem J296 ( Pt 3), 639-648.
193
16 Maimone, M. M. and Tollefsen, D. M. (1991) Structure of a dermatan sulfate
hexasaccharide that binds to heparin cofactor II with high affinity. JBiol Chem
266, 14830.
17 Denholm, E. M., Lin, Y. Q. and Silver, P. J. (2001) Anti-tumor activities of
chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation
and invasion. Eur JPharmacol 416, 213-221.
18 Iozzo, R. V. and Cohen, I. (1993) Altered proteoglycan gene expression and the
tumor stroma. Experientia 49, 447-455.
19 Makatsori, E., Lamari, F. N., Theocharis, A. D., Anagnostides, S., Hjerpe, A.,
Tsegenidis, T. and Karamanos, N. K. (2003) Large matrix proteoglycans, versican
and perlecan, are expressed and secreted by human leukemic monocytes.
Anticancer Res 23, 3303-3309.
20 Papadas, T. A., Stylianou, M., Mastronikolis, N. S., Papageorgakopoulou, N.,
Skandalis, S., Goumas, P., Theocharis, D. A. and Vynios, D. H. (2002)
Alterations in the content and composition of glycosaminoglycans in human
laryngeal carcinoma. Acta Otolaryngol 122, 330-337.
21 Vicente, C. P., Zancan, P., Peixoto, L. L., Alves-Sa, R., Araujo, F. S., Mourao, P.
A. and Pavao, M. S. (2001) Unbalanced effects of dermatan sulfates with different
sulfation patterns on coagulation, thrombosis and bleeding. Thromb Haemost 86,
1215-1220.
22 Gandra, M., Cavalcante, M. and Pavao, M. (2000) Anticoagulant sulfated
glycosaminoglycans in the tissues of the primitive chordate Styela plicata
(Tunicata). Glycobiology 10, 1333-1340.
23 Venkataraman, G., Shriver, Z., Raman, R. and Sasisekharan, R. (1999)
Sequencing complex polysaccharides. Science 286, 537-542.
24 Rhomberg, A. J., Ernst, S., Sasisekharan, R. and Biemann, K. (1998) Mass
spectrometric and capillary electrophoretic investigation of the enzymatic
degradation of heparin-like glycosaminoglycans. Proc Natl Acad Sci USA 95,
4176-4181.
25 Ernst, S., Rhomberg, A. J., Biemann, K. and Sasisekharan, R. (1998) Direct
evidence for a predominantly exolytic processive mechanism for
depolymerization of heparin-like glycosaminoglycans by heparinase I. Proc Natl
AcadSci USA 95, 4182-4187.
26 Pojasek, K., Shriver, Z., Kiley, P., Venkataraman, G. and Sasisekharan, R. (2001)
Recombinant expression, purification, and kinetic characterization of
chondroitinase AC and chondroitinase B from Flavobacterium heparinum.
Biochem Biophys Res Commun 286, 343-351.
27 Huang, W., Matte, A., Li, Y., Kim, Y. S., Linhardt, R. J., Su, H. and Cygler, M.
(1999) Crystal structure of chondroitinase B from Flavobacterium heparinum and
its complex with a disaccharide product at 1.7 A resolution. JMol Biol 294, 1257-
1269.
28 Huang, W., Boju, L., Tkalec, L., Su, H., Yang, H. O., Gunay, N. S., Linhardt, R.
J., Kim, Y. S., Matte, A. and Cygler, M. (2001) Active site of chondroitin AC
lyase revealed by the structure of enzyme-oligosaccharide complexes and
mutagenesis. Biochemistry 40, 2359-2372.
194
29 Michel, G., Pojasek, K., Li, Y., Sulea, T., Linhardt, R. J., Raman, R., Prabhakar,
V., Sasisekharan, R. and Cygler, M. (2004) The structure of chondroitin B lyase
complexed with glycosaminoglycan oligosaccharides unravels a calcium-
dependent catalytic machinery. JBiol Chem 279, 32882-32896.
30 Bradbury, E. J., Moon, L. D., Popat, R. J., King, V. R., Bennett, G. S., Patel, P.
N., Fawcett, J. W. and McMahon, S. B. (2002) Chondroitinase ABC promotes
functional recovery after spinal cord injury. Nature 416, 636-640.
31 Huang, W., Lunin, V. V., Li, Y., Suzuki, S., Sugiura, N., Miyazono, H. and
Cygler, M. (2003) Crystal structure of Proteus vulgaris chondroitin sulfate ABC
lyase I at 1.9A resolution. JMol Biol 328, 623-634.
32 Hamai, A., Hashimoto, N., Mochizuki, H., Kato, F., Makiguchi, Y., Horie, K. and
Suzuki, S. (1997) Two distinct chondroitin sulfate ABC lyases. An endoeliminase
yielding tetrasaccharides and an exoeliminase preferentially acting on
oligosaccharides. JBiol Chem 272, 9123-9130.
33 Sato, N., Shimada, M., Nakajima, H., Oda, H. and Kimura, S. (1994) Cloning and
expression in Escherichia coli of the gene encoding the Proteus vulgaris
chondroitin ABC lyase. Appl Microbiol Biotechnol 41, 39-46.
34 Jedrzejas, M. J., Mello, L. V., de Groot, B. L. and Li, S. (2002) Mechanism of
hyaluronan degradation by Streptococcus pneumoniae hyaluronate lyase.
Structures of complexes with the substrate. JBiol Chem 277, 28287-28297.
35 Lunin, V. V., Li, Y., Linhardt, R. J., Miyazono, H., Kyogashima, M., Kaneko, T.,
Bell, A. W. and Cygler, M. (2004) High-resolution crystal structure of
Arthrobacter aurescens chondroitin AC lyase: an enzyme-substrate complex
defines the catalytic mechanism. JMol Biol 337, 367-386.
36 Jedrzejas, M. J. (2000) Structural and functional comparison of polysaccharide-
degrading enzymes. Crit Rev Biochem Mol Biol 35, 221-251.
195

Chapter 4
Role of Calcium in Glycosaminoglycan-
Degrading Enzyme Activity
Summary
The strategy by which chondroitinase ABC I differentially processes chondroitin
versus dermatan substrates has not been established. This ability to process GalAG
polymers irrespective of the epimerization state of the uronic acid moiety is significant,
as the mechanism involved has been heretofore elusive. The current chapter provides
novel and meaningful biochemical, biophysical, and modeling analysis of the
chondroitinase ABC I enzyme from Proteus vulgaris. We implicate for the first time a
glycosaminoglycan-degrading enzyme that employs a dual-mechanism scaffold, where
catalysis ensues differentially depending on the class of substrate. Specifically, we
suggest that a selective strategy including the incorporation ofdivalent calcium is at play
during dermatan sulfate processing, but not chondroitin depolymerization. Calcium
increases the cABC I-mediated depolymerization ofdermatan, but not chondroitin
substrates, in a concentration-dependent manner. We have established that
chondroitinase ABC I does bind calcium. Experiments using terbium, a fluorescent
calcium analog, confirm the specificity of this interaction. Molecular docking models of
the enzyme-substrate complex further reveal several residues that could potentially play
a role in calcium coordination. These residues were investigated through site-directed
mutagenesis studies and kinetic assays to expose a site involved in the calcium-mediated
introduction of a cleavable dermatan substrate into the enzyme's catalytic cleft.
Part I describes the role of calcium in the catalytic action of chondroitinase B.
This work was published in the Journal ofBiological Chemistry, and is reproduced here
with permission.
Part II describes the role of calcium in the catalytic action of chondroitinase ABC
I, has been submitted to Biochemistry, and is included here with permission.
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Chondroitinase B from Pedobacter heparinus is the only
known enzyme strictly specific for dermatan sulfate and is
a widely used enzymatic tool for the structural character-
ization of glycosaminoglycans. This P-helical polysaccha-
ride lyase belongs to family PL-6 and cleaves the P(1,4)
linkage of dermatan sulfate in a random manner, yielding
4,5-unsaturated dermatan sulfate disaccharides as the
product. The previously reported structure of its complex
with a dermatan sulfate disaccharide product identified
the -1 and -2 subsites of the catalytic groove. We present
here the structure of chondroitinase B complexed with sev-
eral dermatan sulfate and chondroitin sulfate oligosaccha-
rides. In particular, the soaking of chondroitinase B crys-
tals with a dermatan sulfate hexasaccharide results in a
complex with two dermatan sulfate disaccharide reaction
products, enabling the identification of the +2 and +1 sub-
sites. Unexpectedly, this structure revealed the presence of
a calcium ion coordinated by sequence-conserved acidic
residues and by the carboxyl group of the L-iduronic acid at
the +1 subsite. Kinetic and site-directed mutagenesis ex-
periments have subsequently demonstrated that chon-
droitinase B absolutely requires calcium for its activity,
indicating that the protein-Ca2 +-oligosaccharide complex
is functionally relevant. Modeling of an intact tetrasaccha-
ride in the active site of chondroitinase B provided a better
understanding of substrate specificity and the role of Ca2+
in enzymatic activity. Given these results, we propose that
the Ca2 + ion neutralizes the carboxyl moiety of the L-idu-
ronic acid at the cleavage site, whereas the conserved res-
idues Lys-250 and Arg-271 act as Bronsted base and acid,
respectively, in the lytic degradation of dermatan sulfate by
chondroitinase B.
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All metazoans synthesize highly sulfated, unbranched
polysaccharides known as glycosaminoglycans (GAGs),i com-
posed of alternating hexosamine (gluco- or galactosamine) and
uronic acid (D-glucuronic or L-iduronic acid) moieties. These
polysaccharides are found mainly in the extracellular matrix
and on the cell surface, but are also present in secretory gran-
ules (1, 2). The numerous biological functions of GAGs, includ-
ing a structural role as matrix polysaccharides and an active
role in the modulation of cell signals, are derived from the
heterogeneous sulfation patterns and different D-glucuronic/L-
iduronic acid ratios found in the polymers (1-4).
Dermatan sulfate (DS) and chondroitin sulfate (CS) are
structurally related GAGs, consisting of alternating 1,4 -p-D-
galactosamine (GalNac) and 1,3-a-L-iduronic acid (DS) or 1,3-
P-D-glucuronic acid (CS) (5). The L-iduronic acid (IdoUA) pres-
ent in DS results from a C5-epimerization of D-glucuronic acid
(GlcUA) at the polymer level, leading to a mixture of IdoUA and
GlcUA in the mature polysaccharide (6). Chondroitin sulfate is
characterized by primary O-sulfation at either the C4 position
(chondroitin 4-sulfate) or the C6 position (chondroitin 6-sul-
fate) of GalNac, whereas DS is primarily sulfated at the C4
position. Additional O-sulfation is also found at the C2 position
of IdoUA and the C6 position of GalNac in DS creating disul-
fated disaccharide units that have been implicated in the reg-
ulating biological functions of this polymer (7).
Bacterial GAG degrading lyases from Pedobacter heparinus
(formerly Flavobacterium heparinum (Ref. 8)) and other sources
have been useful tools in dissecting how the complex structure of
GAG polysaccharides dictate their various biological roles (4, 9).
The concerted p-elimination mechanism proposed for bacterial
GAG lyases is initiated by the abstraction of the C5 proton on the
hexosamine moiety forming a carbanion that is stabilized by
the enzyme. Importantly, stabilization of the negative charge on
the carboxylate moiety is required to reduce the pKa of the C5
proton prior to abstraction. The final step of reaction mechanism
involves protonation of the anomeric oxygen by an acidic residue
with concomitant 3-elimination of the uronic acid resulting in an
unsaturated 6As' bond in the product (10). Importantly, this dou-
ble bond has LUV absorbance with a Am,, at 232 nm, thereby
providing an internal chromophore for measuring the formation
of the reaction products.
-The abbreviations used are: GAG, glycosaminoglycan; ChonB, chon-
droitinase B; DS, dermatan sulfate; CS, chondroitin sulfate; IdoUA,
L-iduronic acid; GlcUA, D-glucuronic acid; DSP te", dermatan sulfate
pentasaccharide; DSh"", dermatan sulfate hexasaccharide; C4Stet',
chondroitin-4-sulfate tetrasaccharide; DS'", reduced dermatan sulfate
tetrasaccharide; PDB, Protein Data Bank.
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Chondroitin B Lyase Comp
Chondroitinase B (ChonB), a member of the chondroitinases
family of GAG lyases, is the only known enzyme to cleave DS as
its sole substrate (11-14). The crystal structure of chondroiti-
nase B was determined at high resolution, in the native state
and as a complex with an unsaturated DS disaccharide reac-
tion product (15) (PDB codes 1DBO and 1DBG). The enzyme
adopts a right-handed, parallel 0-helix fold, an unusual fold
observed primarily in enzymes that degrade polyanionic poly-
saccharides (15-19). This co-crystal structure also revealed the
active site of the enzyme and the location of the disaccharide
relative to the active site. Recently, a site-directed mutagenesis
study identified Lys-250, His-272, Glu-333, and Arg-364 as
residues potentially involved in substrate binding and catalysis
(20).
Several enzymes that specifically degrade polysaccharides
have been shown to require calcium for their enzymatic activ-
ity. In particular, pectate lyase C was shown to have several
bound calcium ions (21, 22) that participate in substrate bind-
ing (23). In addition, heparinase I from P. heparinus contains
two unique calcium binding sites, one of which is directly
involved in enzymatic activity (24, 25). However, previous
structural and kinetic studies of chondroitinase B have never
suggested a role for calcium in enzyme activity (11, 12).
Herein, we present novel co-crystal structures of chondroiti-
nase B complexed with several DS and CS oligosaccharides. In
particular, soaking chondroitinase B crystals with a DS hexa-
saccharide revealed two DS disaccharide reaction products
bound in the active site, suggesting that the crystallized en-
zyme retains its activity. Unexpectedly, this structure also
uncovered the presence of a Ca 2+ ion coordinated by conserved
acidic residues in the enzyme active site and by the carboxyl
group of the IdoUA in the complexed DS reaction product.
Through kinetic and site-directed mutagenesis studies, we
have subsequently shown that chondroitinase B demonstrates
an absolute requirement of calcium for its activity and that
Asn-213, Glu-243, and Glu-245, which coordinate the calcium
ion in the co-crystal structure, are important for the enzymatic
activity. Furthermore, modeling studies of an intact DS tet-
rasaccharide into the chondroitinase B active site suggest that
calcium is essential for the proper positioning of the substrate
in the active site and plays an important role in specificity of
chondroitinase B toward IdoUA-containing DS substrates.
Therefore, we conclude that the Ca 2+ ion contributes to deter-
mining the substrate specificity of the enzyme as well as plays
a direct role in neutralizing the carboxyl moiety of the IdoUA.
The results of the current study demonstrate for the first time
the structural basis for the role of calcium in chondroitinase B
activity and further elucidate the role of specific amino acids in
the degradation of DS.
MATERIALS AND METHODS
Porcine intestinal mucosa dermatan sulfate, chondroitin 4-sulfate,
and chondroitin 6-sulfate were purchased from Sigma. Disaccharide
standards were from Seikagaku/Associates of Cape Cod (Falmouth,
MA). Oligonucleotide primers for PCR mutagenesis were from Invitro-
gen. The sources of all other reagents used are from common sources or
are as noted below.
Preparation of the Dermatan and Chondroitin Sulfate Oligosaccha-
rides-The dermatan sulfate pentasaccharide (DS p"'") and hexasac-
charide (DShexa) and chondroitin-4-sulfate tetrasaccharide (C4Ste tra )
were prepared and purified as previously described (26). The reduced
dermatan sulfate tetrasaccharide (DSred) was prepared by an adapta-
tion of a method shown in the literature (27). Briefly, DS hex (5 mg) in
0.5 ml of water was reacted with 1-ethyl-3-dimethyl(aminopropyl)car-
bodiimide hydrochloride (30 mg) at room temperature while maintain-
ing the pH at 4.75 with 0.1 N hydrochloric acid. The reaction was
considered complete when the pH remained stable (-- 1 h). The product
was recovered by gel permeation chromatography on a Bio-Gel P4
column (1.25 X 25 cm) at 4 'C and freeze-dried. The carbodiimide
derivative was dissolved in 50 p• of water containing sodium borohy-
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dride (4 mg), heated at 50 'C for 2 h, cooled to room temperature, and
neutralized with acetic acid, and the product was purified by gel per-
meation chromatography on a Bio-Gel P4 column (1.25 x 25 cm) at 4 'C
and freeze-dried. The product showed the correct mass by electrospray
ionization-mass spectrometry, and its NMR spectrum was consistent
with structure (28).
X-ray Data Collection and Processing-Wild type chondroitinase B
was expressed, purified, and crystallized as described previously (15,
29). Prior to the data collection, crystals were soaked for 18 h in drops
of cryoprotectant solution (22.5% (w/v) polyethylene glycol 8000, 0.1 M
Tris-HC1, pH 8.7, 15% (v/v) 2-methyl-2,4-pentadiol, 0.25 M ammonium
acetate) to which 10 mM DSpe"", DS h - a , DS'Od, or C4 Stetra oligosaccha-
rides were added. The crystals were picked up in a rayon loop, trans-
ferred to the goniometer head, and flash-frozen in a stream of nitrogen
gas at 100 K. Diffraction data were collected on a Quantum-4 CCD
detector (ADSC, San Diego, CA) at beamline X8C, National Synchro-
tron Light Source, Brookhaven National Laboratory. Data indexing,
merging, and scaling were performed using the HKL2000 package (30).
Data collection and processing statistics for the DSh',a and CS tet' a
complexes are listed in Table I. The crystals belongs to space group P21,
with one molecule in the asymmetric unit and cell parameters a = 50.6
(50.5) A, b = 74.0 (74.1) A, c = 59.1 (59.0) A, a = y = 90.00 °, and g =
93.9 (93.8)' for the ChonB-DS he a and ChonB-CSt'et  complexes,
respectively.
Crystal Structure Determination and Refinement-The structures of
ChonB complexed to DS h • and CStet'a oligosaccharides were deter-
mined and refined at 1.7 and 1.8 A, respectively. Because the crystals of
these complexes are isomorphous to the native crystals, the structures
were determined by Fourier synthesis with CNS (31) using the model of
the native ChonB (PDB code 1DBG; Ref. 15) with water molecules
removed. Clear electron densities corresponding to oligosaccharides
were observed in both complexes. In the F, - F,, electron density map of
the DS he complex, a strong spherical electron density feature was
observed in the catalytic groove and identified as a calcium ion (see
below). The missing parts of the models were built using O (32). The
structure of the DS and CS oligosaccharides bound to the chondroitin
AC lyase (PDB codes 1HM2, 1HMU, and 1HMW; Ref. 26) were initially
used to model the oligosaccharides bound to ChonB. Refinement was
done with CNS (31) using the maximum likelihood target function.
Corrections for a bulk solvent and for anisotropy in the data were also
applied. The iTA-weighted maps obtained from the subsequent refine-
ment models were used for further model building. The water molecules
were initially placed in peaks of 2F,, - F, density > 2.T that made at
least one hydrogen bond with a protein atom or another water molecule.
In the final stages, the electron density cut-off was decreased to I(T;
however, water molecules with a B-factor over 60 A2 were removed. The
last few water molecules were added manually to peaks of F, - F,
density greater than 4o. Final refinement statistics are presented in
Table I. The final models were analyzed using the program PRO-
CHECK (33) and have been deposited in the Protein Data Bank (PDB
codes 10FL and 1OFM).
The protein sequence for chondroitin B lyase (GenBank'M accession
no. AAC83384; Ref. 34) was used to search for homologous proteins
against the nonredundant sequence data base with the programs
Blastp (35). The initial sequence alignment was obtained using the
MAFFT program (36). In the most divergent regions, this sequence
alignment was manually improved on the basis of the conservation of
structural features specific to the parallel P-helix fold, such as aspara-
gine ladders and aromatic stacks (37).
PCR Site-directed Mutagenesis of Chondroitinase B-Asn-213 was
mutated to glutamine, Glu-243 and Glu-245 were mutated to alanine,
and the E243A/E245A mutant was created using E243A as the DNA
template for E245A PCR mutagenesis. In addition, the putative active
site residue Arg-271 was mutated to lysine and glutamic acid. The
site-directed mutants were created using overlap extension PCR for 15
cycles as previously described for chondroitinase B (20). The primer
sequences for each of the mutants are listed below. The N213Q mutant
primers have the sequences 5'-CAA AAA CCG GGT CAG GCC GGA
GGG GGA-3' and 5'-TCC CCC TCC GGC CTG ACC CGG TTT TTG-3'.
The E243A mutant primers have the sequences 5'-GCG TCA GGA TTC
GGC AGC AGA GAT CAT CAC C-3' and 5'-GGT GAT GAT CTC TGC
TGCC GAA TCC TGA CGC-3'. The E245A mutant primers have the
sequences 5'-TCG GAA GCA GCG ATC ATC ACC-3' and 5'-GGT GAT
GAT CGC TGC TTC CGA-3'. The R271E mutant primers have the
sequences 5'-ATG AAC TTT GAA CAC GGT GAT-3' and 5'-ATC ACC
GTG TTC AAA GTT CAT-3'. The R271K mutant primers have the
sequences 5'-ATG AAC TTT AAA CAC GGT GAT-3' and 5'-ATC AAC
GTG TTT AAA GTT CAT-3'. The N- and C-terminal primer sequences
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TABLE I
Data reduction and refinement statistics
DS~""
Data collection
Space group
Unit cell (A)
Resolution (A)
Total data
Unique data
Redundancy
Completeness (%)
R.ym ()b
Mean (I/o(I))
Refinement (CNS)
Resolution range (A)
No. of unique reflections
Rtrk (R 0 )Y
r.m.s.d. bonds (A)
r.m.s.d. angles (")
Quality of Ramachandran plot
Residues in most favored regions (%)
Residues in additional allowed regions (%)
Residues in generously allowed regions (%)
Residues in disallowed regions (%)
P21
a = 50.6, b = 74.09, c = 59.1, P = 93.9*
1.7
126,405
44,254
2.85
92.5 (65.3)"
4.1 (14.9)"
16.5 (5.5)
35.0-1.7
44,226
14.2 (17.9)
0.010
1.8
86.6
12.5
0.7
0.2 (Asp-174)
" Values in parentheses correspond to the highest resolution shell (DSh"a: 1.76-1.7 A, CSteta: 1.86-1.8 A).
bR = (I - Iav)I, where the summation is over all symmetry equivalent reflections.
cR calculated on 5% of data excluded from refinement.
d r.m.s.d., root mean square deviation.
are as previously described (38). The PCR reaction products were sep-
arated on an agarose gel, and the band corresponding to the proper
length was excised. The DNA was extracted from the gel using a Gel
Purification Kit (Qiagen, Valencia, CA), the insert was subcloned into
pCR4-TOPO (Invitrogen), and the plasmid was prepared using a Mini-
prep kit (Qiagen). Each of the clones was sequenced to verify the
presence of the individual point mutations. Each chondroitinase B
mutant was excised from pCR4-TOPO using NdeI and BamHI (New
England Biolabs, Beverly, MA) enzyme mixture and subcloned into a
pET28a expression vector (Novagen, Madison, WI) that had been di-
gested previously with these same enzymes. Recombinant chondroiti-
nase B that had been cloned in a similar fashion was also expressed and
compared with each of the alanine mutants. Expression and purifica-
tion of each of the site-directed mutants and the recombinant chon-
droitinase B were performed as previously described (20).
Kinetic Analysis-The activity of chondroitinase B and the various
site-directed mutants was determined by adding 5-10 gp of the sample
to a 1-ml cuvette containing 1 mg/ml DS in 50 mM Tris-HC1, pH 8.0, at
30 "C with or without the addition of exogenous calcium as noted.
Product formation was monitored as an increase in absorbance at 232
nm as a function of time (20, 38). The kinetic parameters, K, and k,.t,
were calculated for chondroitinase B and the site-directed mutants by
obtaining the initial reaction rate (v) as a function of substrate con-
centration at various calcium concentrations. Approximately 1 pg (13
pmol) of enzyme was added to 1 ml of DS at concentrations ranging from
0.010 pg/ml to 2 mg/ml. The initial rate was measured for 4-10 s at
30 *C in the same Tris-HC1 buffer used for the activity assay. The
kinetics of chondroitinase B were tested in Tris-HCl buffer to which
calcium chloride was added to the final concentrations of 0.01, 0.1, and
5.0 mM. The slope of the resulting line, assuming zero order kinetics,
was plotted versus the substrate concentration using SigmaPlot (SSPS,
Inc., Chicago, IL). The K. (piM) and Vm,, (piM/s) were calculated using
the Michaelis-Menten equation: Vo = (Vm. X [S])/(K,,, + [S]). The kc0 t(s- 1) was calculated by dividing the V,, by the concentration of en-
zyme in the reaction. Kinetic reactions were repeated in triplicate and
reported as an average ± standard error.
Dermatan Sulfate Digestion and Capillary Electrophoresis-To ex-
amine changes in product profile of each site-directed mutant (20 pg)
when compared with recombinant chondroitinase B (20 iAg), digests of 1
mg/ml DS in 50 mM Tris-HCI, pH 8.0, with 5 mM calcium chloride were
performed for 12-14 h at 30 *C. The digests were analyzed using cap-
illary electrophoresis as previously described (20). Briefly, the chon-
droitinase B and site-directed mutant digests were diluted 2-fold and
analyzed with an extended path-length cell and a voltage of 30 kV
applied using reverse polarity. The running buffer consisted of 50 mM
Tris, 10 AC dextran sulfate that had been brought to a pH of 2.5 using
phosphoric acid, and the reaction products were detected by monitoring
at 232 nm. The total peak areas for the recombinant chondroitinase B
P21
a = 50.5, b = 74.1, c = 58.99, P = 93.80
1.8
150,037
40,172
3.75
99.9 (100)
4.0 (8.5)
19.5 (9.2)
33.2-1.8
40,151
14.2 (18.3)
0.010
1.7
86.6
12.5
0.7
0.2 (Asp-174)
and mutant digest profiles were calculated by totaling the areas of the
oligosaccharide peaks and the AUA-GalNAc4S peak. The ratio of the
AUA-GalNAc4S peak area to the total peak area was then calculated for
the recombinant chondroitinase B and each mutant as a metric for
comparing overall enzymatic activity.
Modeling of a DS Tetrasaccharide Substrate at the Cleavage Sub-
site-The crystal structure of ChonB complexed with GalNac-4S-AUA
disaccharides determined in this work was used as a starting point for
the molecular modeling of a DS tetrasaccharide substrate occupying
subsites -2 through +2 of ChonB. Two different modeling techniques
were utilized to investigate the interactions between the enzyme
and substrate.
The first approach was energetics-driven, where the strain created
by directly forming a 3.0-A bond between the 01 atom of GalNac-4S in
the -1 subsite to the C4 atom of IdoUA in the + 1 subsite of the
co-crystal structure was relaxed by molecular mechanics calculations.
The 04 atom was added to AUA at the -2 subsite, and the C4 and C5
atoms of both AUA residues were assigned the spa hybridization. Hy-
drogen atoms were added to the protein, substrate, and retained buried
water molecules, and oriented to favor hydrogen-bonding networks. The
protonation state at physiological pH was adopted, except for the active
site putative general base Lys-250 that was treated neutral. The AM-
BER all-atom force field with the PARM94 parameter set for proteins
(39) augmented with the GLYCAM50 parameter set for glycosides and
glycoproteins (40) and the General AMBER Force Field parameter set
for organic compounds (41) were used for molecular mechanics energy
calculations. Partial atomic charges for the DS tetrasaccharide were
obtained by a two-stage restrained fitting procedure to the single-point
HF 6-31G* electrostatic potential (42).
Conjugate gradient energy minimizations were carried out with an
8-A nonbonded cutoff and a distance-dependent dielectric function (4r,,).
In the final stage of a stepwise energy minimization protocol, the
substrate and water molecules, as well as protein residues within 10 A
from the ligand, were free to relax up to a root-mean-square gradient of
0.01 kcal/(mol-A), whereas the Ca 2+ ion and its 7 coordinating oxygen
atoms were kept close to their crystallographic positions with harmonic
constraints of 20 and 5 kcal/(mol-.A), respectively. Quantitative char-
acterization of the six-membered ring conformations adopted by the
modeled tetrasaccharide was performed by expressing each ring con-
formation as a linear combination of the most suitable set of chair, boat,
and skew-boat ideal basic conformations (43).
The second approach was geometric and stereochemical, in which the
conformation of GalNac-4S-IdoUA disaccharide in the -1 and +1 was
allowed to sample the stereochemically accessible domain for discrete
low energy conformations of the IdoUA ('C4, 2So, and 4 C,). The coordi-
nates of a dermatan sulfate tetrasaccharide with sequence (IdoUA-
GalNac-4S) 2 were obtained from the recently solved chondroitinase AC
co-crystal structures (15) and were used to generate the model derma-
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FIG. 1. Chondroitinase B. A, ribbon representation of the ChonB-DSh x a complex with the secondary structures colored according to a blue-red
gradient from the N to the C terminus. B, view of the molecular surface of ChonB. The three dermatan sulfate oligosaccharides near the active site
are shown in a stick representation. The calcium ion is shown as a yellow sphere. This and subsequent figures was prepared using the program
PyMOL (DeLano Scientific, pymol.sourceforge.net/).
tan sulfate substrates. The ring conformation of the iduronic acid close
to the reducing end of the tetrasaccharide (involved in catalysis) was
modified to 2S, and 1C4 to generate different model substrates. For each
model substrate, the location of the nonreducing IdoUA was fixed to the
location of AUAB2 in the -2 subsite. The reducing end GalNac-4S was
fixed to that of GalNac-4S c:l in the +2 subsite. The glycosidic torsion
angles 41 (H1-C1-O-C4), frd (C1-O-C4-H4), 02 (H1-C1-O-C3), and (P2
(C1-O-C3-H3) of the internal GalNac-4S-IdoUA unit were allowed to
sample different values in the stereochemically accessible domains for
different IdoUA ring conformations (44, 45). For each set of(41, qil, 4P2,
@2) torsion angles, the distances between the critical sulfate groups and
the basic amino acids in the active site, the carboxylate group of the
IdoUA in the + 1 subsite and the Ca 2 + ion, and the C5 atom of the
IdoUA in the + 1 subsite and Lys-250 were all calculated. From the final
matrix of distance and bond angle values, representative substrates
that satisfied the constraints obtained from the interactions in the
DS h "ao co-crystal structure were chosen for each ring conformation of
the IdoUA. These representative substrates were docked into the active
site to obtain the theoretical enzyme-substrate complex.
RESULTS
The Overall Structure of the Complexes-Protein-carbohy-
drate complexes of ChonB with DS or CS oligosaccharides were
obtained by soaking protein crystals in a cryoprotectant solu-
tion containing 10 mM amounts of a specific oligosaccharide.
Four oligosaccharides were used: dermatan sulfate pentasac-
charide (DS pe n ta) and hexasaccharide (DShxa), reduced derma-
tan sulfate tetrasaccharide (DSr'"), and chondroitin-4-sulfate
tetrasaccharide (C4Stetra). DS r d corresponds to an oligosaccha-
ride with the carboxyl moiety of the uronic acid replaced by a
hydroxymethylene group. This substitution was expected to
prevent the substrate cleavage, because the neutralization of
the carboxylate moiety was proposed to be a critical step in the
3-elimination mechanism (10).
The electron density corresponding to these oligosaccharides
was found in the previously identified substrate binding site in
the C-terminal portion of the enzyme (Figs. 1 and 2) (15). For the
ChonB-C4Stetra complex, all four-sugar units are well defined in
the electron density map. The tetrasaccharide adopts a fully
extended conformation and occupies subsites -1 to -4, the sites
on the nonreducing side of the cleavage site (between subsites -1
and + 1). The 4-O-sulfo-N-acetylgalactosamine residue at the re-
ducing end, GalNac-4SB1, occupies the -1 subsite and superim-
poses very well with the equivalent residue of the DS disaccha-
ride product from the previous structure (15). In the -2 subsite,
GlcUAB2 is shifted slightly in comparison with the unsaturated
IdoUA in the previous structure. The next disaccharide-repeat-
ing unit, GalNac-4SB3-GlcUAB4, extends toward the solvent, al-
most perpendicularly to the P-helix axis and defines subsites -3
and -4 of the enzyme. In the crystal, the last sugar makes
contacts with a symmetry-related molecule.
In the ChonB crystal soaked with DShex a , the electron den-
sity showed the presence of three disaccharide units in the
active site (Fig. 2A). None of the disaccharides have electron
density corresponding to the C4 hydroxyl group of IdoUA,
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FIG. 2. Fo-Fc electron density map
of the dermatan sulfate disacchar-
ides bound to the active site of
ChonB and the Ca"+-binding site (A)
and the dermatan sulfate disaccha-
ride bound on the outer surface of
ChonB (B). The oligosaccharides and the
Ca2 + ion were excluded from the calcula-
tions of phases.
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indicating that the IdoUA residues are all unsaturated. We
conclude that ChonB retains activity in the crystalline form
and that the DShexa was completely cleaved into disaccharide
units. The -1 and -2 subsites are occupied by a DS disaccha-
ride, GalNac-4SBl-AUAB2 , as observed previously (PDB code
1DBO) (15). However, the conformation of AUAB2 is different of
that of the unsaturated IdoUA in 1DBO; the 02 and 03 hy-
droxyl groups are axial in that structure and equatorial
in AUAB2 .
A second disaccharide, GalNac-4SCl-AUAC2 , is deeply buried
in the groove, parallel to the 3-helix axis (Fig. 2A). The confor-
mation of AUAC2 is similar to that of AUAB2, with the hydroxyl
groups 02 and 03 nearly equatorial. Like GalNac-4SB1-AUAB 2,
this DS disaccharide exposes the B-face of the N-acetylgalac-
tosamine residue toward the solvent, whereas its A-face and its
sulfo group are located in a basic pocket within the cleft. This
disaccharide is located between GalNac-4SB1-AUAB 2 and a
cluster of polar amino acids separating the N- and C-terminal
cavities of the active site. Both DS disaccharides are similarly
oriented, with the reducing end positioned toward the N ter-
minus of the protein. Moreover, the 01 hydroxyl of GalNac-
4SB1 (the -1 subsite) is at a distance of 3.0 A from the C4 of
AUAC2 , which enable the accommodation a 13(1,4) linkage in
the context of an intact DS substrate. The binding of a DS
reaction product in this area together with the proximity of
GalNac-4SB1 and AUAC2 strengthens the previous prediction
(15) that this region corresponds to the subsites +1 (AUAC2)
and +2 (GalNac-4SCl).
The third DS disaccharide, GalNac-4SD1-AUAD 2, binds near
the end of the active site (Fig. 2A), in the general region of +3
and +4 subsites, contacting the fourth T3 loop and the C-
terminal a-helix, as well as the last 3-helical turn of a symme-
try related molecule. It makes only two direct hydrogen bonds
to the protein backbone atoms of Pro-211 and Asn-213, as well
-i
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TABLE II
Protein-carbohydrate interactions
Distance
Sugar Atom Protein
DShe"H CSte'ta
A
GalNAc-4S"1 01 Arg-271NH2  2.7 2.8
05 Arg-271NE 3.2 3.3
OSA Arg-364NH2  2.7 2.7
OS, Arg-318NH1 2.7 2.9
Arg-363NH1 3.1 3.3
OSc Arg-363NHM  3.3 2.9
Arg-364NHM  3.0 3.0
07 His-3 3 4NE
2  3.0 3.0
06, Arg-318NH2  2.9 2.9
IdoUA B 2 or GlcUAB 2  Arg-363NHM  3.3 2.8
Arg-363NH2  3.4 2.8
GalNAc-4S" 3  06 Arg-363NE 3.2
Glu-1520El (Sym)r 2.8
GlcUAB4  0 6 A Wat-688/ Lys-316Nz 3.0
06, Wat-650/Asp-153 0 (Sym)" 3.0/2.9
GalNAc-4S 1c  01 Arg-184NH2  2.6
05 His-116 NE2  3.1
06 Asn-2130 2.8
07 Arg-184NH2  2.6
OSA Gln-175 NE2  2.9
Arg-219NE 3.3
OS, Lys-250Nz 2.8
OS c  Lys-250Nz 3.00
IdoUAC2  03 His-27 2NE2 2.9
Glu-3330E2  2.6
05 Asn-213 ND2  2.9
06A  Ca
2 +  2.4
Asn-213ND2  3.0
06, Glu-2450 E1  2.5
GalNAcD1 01 Pro-2110  2.6
N2 Asn-5030DI 3.0
05 Asn-213N 2.9
07 Wat-598/Ser-1150c' 2.8/2.7
IdoUAD 2  Pyranose ring Pro-424 (Sym)"
02 Wat-142/Asn-503 0  2.6/2.8
06 A  Wat-327/Gly-422N (Sym), 2.6/2.9
GalNAcE 1  01 Tyr-197 0  2.6
N2 His-159 0  2.8
06 Wat-174/Ala-449N 2.7/2.9
07 Watl92/Arg-161NH1 2.8/2.9
OSA Arg-199NH 1  2.7
IdoUAE 2  03 GalNAcE 1 OS c  2.8
Sym, symmetry-related molecule.
as several others through bridging water molecules. The orien-
tation of this disaccharide is approximately perpendicular to
the disaccharide located at the +1 and +2 subsites, with the
distance from its C4 atom to the anomeric 01 of the sugar in
the +2 subsite greater than 6 A. Although this third disaccha-
ride does not bind in exactly the same way as would a longer
oligosaccharide extending from +1 and +2 subsites, neverthe-
less it identifies the approximate location of the +3 and
+4 subsites.
We found electron density on the concave surface of the
p-helix, on the opposite side to where the active site is located
that was interpreted as a fourth DS disaccharide, GalNac-
4SE1_-UAE2 (Fig. 2B). This disaccharide is partially buried in a
depression lined with basic residues formed by the first T2 loop,
the long C-terminal loop, and the O-linked heptasaccharide
attached to the protein at Ser-234 (15). The GalNac-4S residue
is in the vicinity of the arginine stack consisting of Arg-129-
Arg-161-Arg-199, whereas the AUA residue is oriented toward
the solvent. In contrast to the DS disaccharides bound in the
active site, the 02 and 03 hydroxyl groups of AUAD2 and
AUAE 2 are axial. Finally, the 01 hydroxyl group of GalNac-
4SE1 has an ca anomeric conformation, whereas only the 36
anomer is observed in the other CS and DS oligosaccharides
described here or in the previous studies (15, 26). This a ano-
mer may have been produced by mutarotation of the
pyranose ring.
The soaking of DSpenta resulted in the binding of an oligo-
saccharide to the C-terminal cavity with only the reducing end
disaccharide occupying the -2 and -1 subsites visible in the
2F, - F, electron density map. No other sites were occupied.
Because the well defined sugars overlap the DS disaccharide
product previously characterized (15), this complex will not be
further described.
No electron density corresponding to an oligosaccharide was
found in the structure of chondroitin B lyase soaked with DSred,
indicating that the carboxyl-reduced DS oligosaccharide does
not bind to the enzyme with high affinity.
Protein-DShex/CStet"" Oligosaccharide Interactions-All the
interactions between ChonB and the DS/CS oligosaccharides
are summarized in Table II and Fig. 3. Most of the interactions
for DSh~a and C4 Stetra sugars in subsites (-2, -1) are as
previously described (15). For both types of GAGs, the Gal-
NAc-4S residue at -1 subsite is anchored by numerous hydro-
gen bonds and ionic interactions with basic residues. The gua-
nidinium group of Arg-271 forms hydrogen bonds with the
anomeric hydroxyl group 01 and the cyclic oxygen atom 05,
whereas the neighboring His-272 contacts the oxygen atom 07
of the N-acetyl group. The sulfate substituent forms salt
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FIG. 3. Stereo view of the active site
of ChonB (subsites +1, +2, and -1,
-2). A, the close-up of the Ca 2 + coordina-
tion. The DS disaccharide in subsites + 1
and +2 is colored by atom colors, the one
in subsites -1 and -2 is shown in red,
and the disaccharide in subsites +3 and
+4 is shown in thin lines. B, the disposi-
tion of the putative catalytic residues
relative to the disaccharide reaction
products.
bridges with Arg-318 and Arg-364. In the previously described
complex, Arg-318 had a different conformation and formed
indirect interaction with the sulfo group via a water molecule
(15). In contrast, the uronic acid at subsite -2 (AUAB2 or
GlcUAB2 ) makes few contacts with the protein, mainly with
Arg-318 and Arg-363. However, the strength of the interaction
involving Arg-363 differs according to the nature of the sugar
unit in this subsite. This arginine interacts only weakly with
the carboxyl group of the unsaturated L-iduronic acid ( -3.3 A)
but makes a stronger salt bridge with the carboxyl group of
GlcUAB2 of C4St e tra (--2.8 A). There are very few contacts
between the sugars in the -4 and -3 subsites and the protein.
Only one direct hydrogen bond is observed, between the hy-
droxyl group 06 of GalNac-4SB3 and Arg-363NE. The carboxyl
group of GlcUAB4 is hydrogen-bonded to Lys-316 through a
water molecule.
Like the GalNac-4S at subsite -1, the DS disaccharide at + 1
and +2 subsites is strongly bound through numerous polar
interactions. In the +2 subsite, all the oxygens of GalNac-4SC1
are involved in hydrogen bonds. The hydroxyl group 01 and the
oxygen 07 of the N-acetyl group are both hydrogen-bonded to
Arg-184NH 2. A weaker interaction is established between the
cyclic oxygen 05 and His-11ll6NE 2 , whereas the hydroxyl group
06 is hydrogen-bonded to the main chain carbonyl group of
Asn-213. The sulfo group forms hydrogen bonds with Gln-
175 NE2 and Lys-250. The unsaturated L-iduronic acid at subsite
+ 1 forms fewer hydrogen bonds with the protein. The hydroxyl
group 03 interacts with His-272NE2 and Glu-3330E 2 , whereas
the oxygen atoms 05 and 0 6 A are hydrogen-bonded to Asn-
2 1 3 ND2
. This hydrogen bond network is supplemented by the
ionic interaction between the carboxyl group of AUAB2 and the
calcium ion. The third DS disaccharide makes contacts with
two protein molecules. The oxygen atoms 01 and 05 of GalNac-
4SD1 are hydrogen-bonded to the main chain of Pro-211 and
Asn-213, whereas the L-iduronic acid stacks against Pro-424 of
a symmetry-related ChonB. These limited carbohydrate-pro-
tein interactions involving two molecules suggest that this
binding site is aided by the environment in the crystal.
Although located far from the active site, the fourth DS
disaccharide forms specific interactions with the enzyme, no-
tably with the arginine stack distinctive of ChonB (15). The
sulfo group of GalNac-4SEl establishes a salt bridge with Arg-
199 and a hydrogen bond with Arg-161 through a water mole-
cule. The hydroxyl group 01 and the N-acetyl group are hydro-
gen-bonded to the main chain carbonyl group of Tyr-197 and
His-159, respectively. The L-iduronic acid does not interact
with the enzyme, but is stabilized by an intramolecular hydro-
gen bond between its hydroxyl group 03 and the sulfo group
of GalNac-4SE.
The Active Site of Chondroitin B Lyase Contains a Calcium
Ion-In the DShexa complex, an additional spherical electron
density was identified within the active site located between
the IdoUA at subsite + 1 (AUAC2) and the sixth and seventh T3
loops (Fig. 2A). Its intensity in the 2Fo - F, map is 11r, a value
B
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FIG. 4. Effect of Ca2" on the activity of chondroitinase B. The
activity of ChonB toward dermatan sulfate (1 mg/ml) was measured in
the presence of increasing calcium concentrations. The enzyme demon-
strated maximal activity in the presence of ~--5 mM Ca 2+ .
greater than for the sulfur atoms, the heaviest atom found in
either the protein or the DS oligosaccharides. Based on the
strong electron density and the coordination geometry, we have
modeled this electron density feature as a Ca 2+ ion with full
occupancy. In the refined structure, its thermal factor (6.9 A2)
is close to that of the surrounding protein atoms (Baverage = 6.1
A2) and there are no positive or negative peaks nearby in the
final Fo - F, map. This ion has seven oxygen ligands arranged
in pentagonal bipyramidal coordination with distances in the
range of 2.32-2.45 A (Fig. 3A). The five equatorial ligands are
carboxyl oxygens OE1 and OE2 of Glu-243, carboxyl oxygen
OE1 of Glu-245, the carbonyl oxygen OE2 of Asn-243, as well as
the carboxyl oxygen 0 6 A of AUAC2 in the disaccharide (+ 1
subsite). The two axial ligands are water molecules. The com-
parison of this ChonB-DS complex with the native ChonB
(1DBG; Ref. 15) shows that the Ca2' binding site is only par-
tially preformed; the Glu-243 and Glu-245 side chains main-
tain the same conformation in the native and Ca 2+-bound
forms, whereas Asn-213 changes the orientation of its side
chain (AX1 = -- 120', AX2 = -.60') upon binding.
Effect of Calcium on the Activity of Chondroitinase B-Al-
though the activities of pectate lyases show an absolute re-
quirement for calcium (46), previous reports suggested that
ChonB does not require Ca 2' ions for activity (11, 12). This
assertion remained undisputed in the most recent work on this
enzyme. However, the presence of this unexpected Ca 2+ ion in
the active site led us to reconsider the potential influence of
this ion on ChonB activity.
The enzyme was incubated with 1 mg/ml DS at 30 'C, and
the appearance of product was monitored as an increase in
absorbance at 232 nm, the Am. of the A4'' bond formed in the
product (38). Increasing the calcium concentration led to a
significant increase in the activity of the enzyme, with maximal
observed activity at -5 mM calcium (Fig. 4). In addition, the
presence of 5 mM EGTA, a specific chelator of calcium, led to a
complete ablation of chondroitinase B activity. In accordance
with earlier studies (11, 12), the addition of increasing amounts
of other divalent ions such as magnesium, manganese, and zinc
had no significant enhancing effect on the activity of enzyme
(data not shown). Therefore, chondroitinase B appears to dem-
onstrate an absolute and specific requirement for calcium for
maximal activity.
The kinetic parameters Km and kcat were determined for
chondroitinase B at three different calcium concentrations (Ta-
ble III). Increasing the calcium concentration produced a 3.5-
0
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TABLE III
Effect of calcium on chondroitinase B kinetics
[Ca 2 + ] K m  kcat katgK,
mM ss' -1 S-1 1
0.01 4.3 - 0.5 210 ± 50 49
0.1 2.0 + 0.3 350 - 30 175
5.0 1.2 _ 0.1 410 - 25 342
fold decrease in the Km and a 2-fold increase in the kat, thereby
dramatically increasing the catalytic efficiency (kajK,,) of
chondroitinase B (Table III). These results are consistent with
the observation that both the substrate and the enzyme chelate
the Ca 2" ion within the active site in the co-crystal structure.
Therefore, calcium likely plays a significant role both in sub-
strate binding, as well as a direct role in catalysis, likely
through the stabilization of the negative charge on the C5
carboxylate moiety.
Site-directed Mutagenesis of the Calcium Binding Site-To
further examine the role of calcium in the active site of chon-
droitinase B, the three major residues responsible for chelating
the divalent cation were mutated using site-directed mutagen-
esis. Glu-243 and Glu-245 were mutated to alanine, and Asn-
213 was mutated to glutamine. The double mutant E243A/
E245A was also created. Each of the site-directed mutants
demonstrated no detectable change in the absorbance at 232
nm as a function of time in the presence of 5 mM calcium in the
kinetic assay, suggesting that the mutant enzymes were func-
tionally inactive (data not shown). However, when each of the
mutants was incubated with 1 mg/ml DS for 14 h and analyzed
by capillary electrophoresis, detectable peaks were observed,
suggesting that each mutant retained partial enzymatic activ-
ity (Table IV). Each of the single calcium-binding residue mu-
tants produced comparable levels of DS turnover as measured
by the ratio of ADi4S:total peak area. Interestingly, the E243A/
E245A double mutant produced a turnover of DS that was
comparable with the E243A single mutant, not significantly
lower than the single glutamic acid mutants (Table IV). This
may suggest that each of the calcium-binding amino acids
contributes to differing extents to the chelation of the active
site calcium. Importantly, when chondroitinase B was incu-
bated with DS in the presence of 5 mM EGTA, no peaks were
detected, confirming that calcium is required for enzymatic
activity (Table IV).
Modeling of DS Tetrasaccharide in Active Site-To better
understand conformation and topology of an intact DS sub-
strate in the active site of ChonB and to further investigate the
structural basis for the role of calcium in substrate binding and
catalysis, we constructed different theoretical models of the
enzyme-substrate complexes. Two different modeling ap-
proaches were adopted to build structural models of the DS
tetrasaccharide substrate in the active site using the disaccha-
ride reaction products in the co-crystal structure as the starting
point.
In the first approach, the conformations of the IdoUA in the
+1 and -2 subsites were not fixed. The perturbation induced
by reducing the bond distance from approximately 3.0 A to 1.4
A between GalNac-4S in the -1 subsite and IdoUA in the + 1
subsite was distributed to the remaining structure using force
field-based energy minimization. The modeled tetrasaccharide
substrate, which preserves closely the interactions with the
active site amino acids and the calcium ion, displayed a highly
constrained structure compared with the uniform extended
helical conformation of free DS (Fig. 5, Table V). In addition,
the model shows a strained endocyclic conformation for the
iduronic acid that binds at the + 1 subsite. It is known that the
pyranose ring of the L-a-iduronic acid is characterized by con-
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TABLE IV
Ratio of Adi4S to total peak area for chondroitinase B and mutants
Enzyme Ddi4S: total peak area
Chondroitinase B 0.95
R271E NID
R271K 0.09
Chondroitinase B + 5 nmi EGTA ND"
E243A 0.26
E245A 0.15
E243A/E245A 0.24
N213Q 0.16
a No peaks were detected.
formational equilibrium between three almost equi-energetic
conformers: 1C4, 4C, chair, and the 2So skew-boat (see Ref. 47
and references therein). As listed in Table VI, the pyranose ring
of this iduronate adopts a distorted conformation with the
major contribution from the less stable 2' 5B boat conformer. We
note that the other three residues of the modeled ChonB-bound
DS tetrasaccharide adopt their respective preferred ring con-
formations, 4C, for GalNac-4S and 2So for the terminal IdoUA.
A second modeling approach was employed next to assess the
extent to which accommodation of the DS tetrasaccharide at
the ChonB active site is possible without the distortion of the
internal iduronate ring conformation. Thus, the conformation
of the IdoUA in the + 1 subsite was fixed to each of its low
energy states, i.e. 1C4, 4C,, and 
2So, and the glycosidic torsion
angles of the GalNac-4S-IdoUA disaccharide in the -1 and +1
subsites were allowed to sample stereochemically accessible
domains for each IdoUA ring conformation. We found that the
4C, chair conformation was clearly incompatible with the con-
straints that were imposed during the search for preserving the
interactions of the substrate with the active site amino acids
and the calcium ion. In contrast, the selected models having the
inner IdoUA in either the C,4 or 2S o conformations preserved
the overall topology of the substrate binding mode similarly
with the model from the first approach, and displaying the
same highly constrained compact structures characterized by a
sharp bend in the helical axis of the substrate. However, the
intermolecular contacts between the active site and the mod-
eled structures with the C,4 and 2So iduronate conformation
were less optimal compared with those observed in the co-
crystal structure. Specifically, the coordination of the Ca 2"
sphere was deformed and the distance between the Lys-250 NZ
atom and C5 atom of the IdoUA in the + 1 subsite was higher
in the modeled structures compared with these interactions in
the co-crystal structure. These deviations in the interactions
were minimized in the energetics-based model structure (ob-
tained using the first approach) where the iduronate conforma-
tion (at the +1 subsite) was allowed to deviate from its low
energy states. Taken together, the results obtained from these
modeling studies indicate first that the ability of the iduronic
acid to adopt several low energy conformations enhances the
curvature of the DS substrate and thus nucleates its contacts
with critical active site amino acids and the calcium ion. Sec-
ond, the distortion of the pyranose ring of the IdoUA at the +1
subsite into a higher energy conformation is critical to establish
the final, correct intermolecular contacts and substrate docking
in the productive binding mode.
Sequence Conservation in Family 6 Polysaccharide Lyases--
To aid in the identification of functionally important residues,
we have analyzed the pattern of amino acid conservation in
chondroitinase B. This enzyme was classified to family 6 of
polysaccharide lyases in CAZy data base (afmb.cnrs-mrs.fr/
--cazy/CAZY/index.html), which was composed until recently of
only two other enzymes, a bacterial alginate lyase and a puta-
tive polysaccharide lyase from Streptomyces coelicolor (48). In
the draft genome of the marine bacterium Microbulbifer de-
gradans (49), we have identified four open reading frames of
unknown specificity, which display clear sequence similarities
to ChonB. An updated sequence alignment of the PL-6 family is
shown in Fig. 6.
DISCUSSION
A previous crystallographic study using an unsaturated DS
disaccharide facilitated the mapping of the -2 and -1 subsites
in the ChonB active site (15). In addition, site-directed mu-
tagenesis identified specific residues within the ChonB active
site involved in substrate binding and catalysis (20). The pres-
ent study relies on the crystallization of ChonB with longer CS
and DS oligosaccharides to further refine our understanding of
the role of specific residues within the active site. The soaking
of ChonB crystals with DSh'a resulted in a novel enzyme-GAG
complex, where both the -2 and -1 subsites as well as the + 1
and +2 subsites were occupied by DS disaccharide reaction
products (Fig. 2A). Additionally, the ChonB-DSh 'a revealed
the presence in the active site of a Ca2 + ion, chelated by three
amino acids as well as by the iduronic acid at the + 1 subsite
(Fig. 3A). Enzyme kinetics and site-directed mutagenesis ex-
periments revealed for the first time an absolute requirement
of calcium for the activity of chondroitinase B (Fig. 4). In
addition, the structure of the ChonB complexed with the
C4St tra led to the localization of the putative -4 and -3
subsites within the substrate-binding site of the enzyme (data
not shown). Finally, modeling studies explored the likely struc-
ture of an intact substrate within the active site of chondroiti-
nase B shedding further light on the role of individual amino
acids and the calcium ion in the substrate binding and catalysis
of ChonB (Fig. 5).
GAG-Protein Interactions in the Active Site-Based on anal-
ysis of the present co-crystal structures, ChonB binds DS es-
sentially through ionic interactions involving its anionic
groups. These interactions are either direct, with basic residues
of the protein (Arg-219, Lys-250, Arg-318, Arg-363, and Arg-
364), or indirect, with a Ca2 + ion coordinated by acidic residues
(Glu-243 and Glu-245). ChonB also establishes numerous spe-
cific hydrogen bonds with the hydroxyl groups of the sugars,
but does not utilize aromatic staking with the pyranose rings
of DS.
Thus, ChonB displays a mechanism of GAG recognition,
which significantly differs from that of chondroitin AC lyases,
which degrade chondroitin, chondroitin-4-S, chondroitin-6-S,
and also hyaluronic acid (13, 14). These enzymes adopt a fold
radically different from the right-handed P-helix fold and rec-
ognize its various substrates mainly through the stacking of
aromatic rings against the pyranose rings, with only some
contribution from ionic interactions (26, 50, 51). This interac-
tion mode is rather typical of enzymes acting on neutral poly-
saccharides (52) and probably facilitates the binding of GAGs
with various patterns of sulfation. In contrast, the strong elec-
trostatic binding of the sulfate groups by Arg-318/Arg-264 in
the -1 subsite and Gln-175/Lys-250 in the +2 subsite is likely
responsible for the specificity of ChonB for the O-sulfation at
the C4 position of the GalNac residues, one of the hallmark
modifications of DS.
The chondroitinase B resembles other p-helical polysaccha-
ride lyases, rather than the chondroitin AC lyases, not only in
its fold but also in the nature of its interactions with the
oligosaccharide substrate. This unusual fold has been proposed
to be well adapted for the recognition of highly polyanionic
polysaccharides (19). ChonB displays a recognition mechanism
in between those of family GH-28 endopolygalacturonases (53),
family GH-82 i-carrageenases (54), and family PL-1 pectate
lyases (23). The first two enzymes, glycosyl hydrolases, recog-
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FIG. 5. Model of the DS tetrasaccharide substrate at the active
site of ChonB. A, the electrostatic complementarity between the neg-
atively charged sulfate and carboxylate groups of the substrate and the
positive electrostatic potential at the molecular surface of the binding
site. The electrostatic potential is calculated using the AMBER charge
set (39) with a protein interior dielectric constant of 4 and an ionic
strength of 0.150 M and is displayed between -15 kT/e (deep red) to + 15
kT/e (deep blue) using the program GRASP (67). All hydrogen and
non-hydrogen atoms of the protein, the Ca
2 + ion, and its two coordinat-
ing water molecules are included for the construction of the molecular
surface and calculation of the electrostatic potential. B, zoom of the
active site region displaying the proximity of the putative catalytic
residues Lys-250 and Arg-271 to the cleavage site of the substrate. The
molecular surface patches associated with the NH2 group of the puta-
tive general base Lys-250 are colored in green, and those belonging to
the guanidinium group of putative general acid Arg-271 are colored
in magenta.
TABLE V
Glycosidic dihedral angles of the modeled ChonB-bound DS
tetrasaccharide substrate
Dihedral angles
Glycosidic linkage'
degree degree
C2C1-OC3 163.3 C10-C3C4 116.3
05C1-OC3 -71.0 C10-C3C2 -120.8
C2C1-OC4 172.3 C10-C4C3 -157.3G(-1)-I(+1) 05C1-OC4 -68.3 C10-C4C5 -35.8
C2C1-OC3 173.4 C10-C3C4 111.7
I(+1)-G(+2) 05C1-OC3 -62.0 C10-C3C2 -125.4
a I, IdoUA; G, GlcUA.
TABLE VI
Characterization of pyranose ring conformations in the modeled
ChonB-bound DS tetrasaccharide substrate as linear combinations of
the most representative ideal basic conformations (43)
Residue" Chair-boat-skew-boat linear combinations
I (-2) 0.10 C 0.15B, 4  0.992So
G (-1) 0.97 C, 0.012,4B 0.14'S,
I (+1) 0.33 1C4  0.762"•B 0.06"S,
G (+2) 0.954C1  0.02B],4  0.09
0S2
"I, IdoUA; G, GlcUA.
nize the anionic groups of their respective substrate (carboxyl
groups for polygalacturonic acids, sulfo groups for t-carrag-
eenan) through direct ionic interactions with conserved basic
amino acids (53, 54). In contrast, PL-1 pectate lyases bind
polygalacturonic acids mainly through indirect ionic interac-
tions involving the coordination of calcium ions (23). The pres-
ence of both modes of interaction in ChonB may suggest an
evolutionary adaptation of the 3-helix fold to the hybrid nature
of dermatan sulfate composed of alternating sulfohexamine
and uronic acid moieties.
Structural Basis for Substrate Recognition-Understanding
the structural basis for specificity of chondroitinase B involved
determining the role of the C5 epimerization and 4-0 sulfation
modifications in recognition and binding of dermatan sulfate in
the active site of the enzyme. The role of the 4-sulfation was
attributed to the specific ionic contacts made by the 4-0 sulfate
groups of the substrate in the -1 and +2 subsites with the
basic amino acids in the active site, and which act as anchor
points that support bending of the substrate oligosaccharide as
it binds to the enzyme. The next step was to understand how
chondroitinase B distinguishes glucuronic acid containing
4-sulfated CS substrates from iduronic acid containing DS
substrates.
The binding of C4 St
etra in the "-" subsites demonstrates that
the discrimination by ChonB between the L-iduronic and D-
glucuronic acid occurs not in the - subsites but in the +
subsites of the binding site. Given that the carboxyl group of
the L-iduronate at the +1 subsite coordinates the Ca
2+ ion, a
productive binding of a DS substrate seems to require its in-
teraction with this Ca 2+ and the formation of a proper Ca2+ -
binding site. This conclusion is strongly supported by the in-
ability of the reduced DS tetrasaccharide to bind the active site
as well as by the lack of ChonB activity in the presence of the
calcium chelator, EGTA (Table IV). Because DS and chon-
droitin-4-sulfate only differ by the epimerization of their uronic
acid residues, the carboxyl group of a D-glucuronic acid is likely
not correctly oriented to coordinate the Ca
2+ ion, precluding CS
to simultaneously bind the - and + subsites. The Ca
2 + ion has
been observed neither in the native ChonB structure nor in the
complexes with oligosaccharides occupying only the - subsites.
To better understand the structural basis for substrate rec-
ognition by ChonB, intact tetrasaccharide substrates were
modeled into the active site of the enzyme using two different
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FIG. 6. Structure-based sequence alignment of the family 6 of polysaccharide lyases. Members of the PL-6 family are compared with
the secondary structures of P. heparinus chondroitin B lyase. Alpha helices and beta strands are represented as helices and arrows, respectively,
and beta turns are marked with TT. This sequence alignment was created using the following sequences from GenBankTM: P. heparinus ChonB
(AAC83384, residues 43-418), Pseudomonas sp. alginate lyase (BAA01182, residues 2-346), S. coelicolorA3(2) putative lyase (CAB61820, residues
70-408), and four open reading frames from M. degradans (ZP_00068043, residues 53-413; ZP_00068303, residues 112-478; ZP_00068304,
residues 39-428; ZP_00065540, residues 396-456). Dark shaded boxes enclose conserved positions, and light shaded boxes show positions with
homologous residues. Figure was prepared using the program ESPript (68).
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approaches. The models of the tetrasaccharide from both these
approaches revealed a significant deviation in the conformation
of the bound tetrasaccharide in the active site from the uniform
helical conformation (extended) of a free substrate to make
optimal contacts with the active site amino acids and impor-
tantly the calcium ion. The two molecular models constructed
here can also be viewed as two snapshots in the recognition of
the DS tetrasaccharide substrate at the ChonB active site. In
an early substrate-enzyme encounter complex, the dermatan
sulfate substrate would fold into the required constrained com-
pact conformation at the scissile glycosidic linkage, which is
facilitated by one of the several low energy conformations char-
acteristic to the iduronic acid. Final docking of the DS sub-
strate in the productive binding mode and with the correct
intermolecular contacts would then be accomplished at the cost
of deforming the low energy ring conformation of the IdoUA at
the +1 subsite into a higher energy one. It is quite plausible
that the introduction of conformational strain, both glycosidic
and endocyclic, around the substrate cleavage site in the sub-
strate-enzyme adduct would represent one of the mechanisms
by which ChonB achieves its catalytic efficiency in DS lysis.
Calculation of the helical parameters of the substrate high-
light its sharp bend by deviation from the uniform helical
conformation. Furthermore, the modeling studies also indicate
that the relatively rigid ring conformation of the glucuronic
acid (predominantly the 4 C1 form) in chondroitin sulfates is not
able to accommodate the highly constrained conformation of
the substrate in the active site. Thus, the topology and distri-
bution of basic amino acids of the chondroitinase B active site
and the Ca 2' ion coordination impose unique structural con-
straints in terms of sulfation pattern and conformation of the
substrate that can be satisfied only by an iduronic acid-con-
taining dermatan sulfate substrate.
Catalytic Machinery of ChonB and the Role of Ca2+--Al-
though the glycosyl hydrolases cleave glycosidic bonds through
an acid/base hydrolysis mechanism releasing a saturated oli-
gosaccharide, the polysaccharide lyases perform a 3-elimina-
tion reaction resulting in a 4,5-unsaturated product. This
mechanism consists of three steps: neutralization of the car-
boxyl group of the uronic acid, lowering the pKa of the H5
proton; abstraction of this proton by a Bronsted base; and
3-elimination of the substituent at 04 with concomitant forma-
tion of a C4-C5 double bond within the uronic acid at the
nonreducing end. This substituent is protonated either by a
Bronsted acid or by proton abstraction from a water molecule
(10). Three different mechanistic pathways are possible. In the
El-type reaction, the CP-X bond is cleaved before Ca-H, result-
ing in a carbocation intermediate. The Elcb pathway involves
a carbanion intermediate formed by a-carbon proton abstrac-
tion with subsequent leaving-group elimination. In the E2 re-
action the proton abstraction and leaving-group elimination
occur simultaneously (55).
The location of the Ca 2+ ion in the active site of the DSh
e
xa
co-crystal provided insight into the role of specific residues in
the active site of chondroitinase B. Asn-213, Glu-243, and Glu-
245 clearly are important for chelating the Ca 2+ ion, as indi-
cated by both the co-crystal structures and the site-directed
mutagenesis data (Fig. 3 and Table IV). These residues along
with the active site water molecules position the Ca 2+ ion for a
specific interaction with the C5 carboxyl group on the iduronic
acid in subsite +1. Therefore, the Ca2+ ion, not Lys-250 as
previously suggested (20), appears to neutralize the negative
charge on the carboxylate group, effectively lowering the pKa of
the C5 proton (Fig. 7). This is the requisite first step in the
p-elimination mechanism by which chondroitinase B degrades
DS. The calcium ligands, Asn-213, Glu-243, and Glu-245, are
conserved in the family PL-6 (Fig. 6), suggesting that all the
members of this family also display a calcium-dependent cata-
lytic machinery. Interestingly, calcium bound within the active
site of heparinase I (CB1) was proposed to play a similar role in
the degradation of its heparin substrate (24).
In retrospect, the discovery of the Ca 2+ ion in the co-crystal
structure of chondroitinase B should not have been entirely
surprising, given the requirement of the divalent cation in
other polysaccharide degrading lyases. In fact, polysaccharide
degrading enzymes from both the PL-1 and PL-10 families of
polysaccharide degrading enzymes have Ca2+ ions coordinated
by a substrate carboxylate group and an invariant, acidic
amino acid at the -1 and + 1 subsites (56). Interestingly, de-
spite the similar requirement of calcium for ChonB (PL-6 fam-
ily member) and the pectate lyases from the PL-1 and PL-10
families, the active sites of the different enzymes are not su-
perimposable, implying that the enzyme structure is influenced
more by the structure of the respective substrates than by the
overall protein fold. In addition, calcium is required for the
activity of heparinase I with a maximal activity observed at 10
mM calcium (25). The postulated Ca2+ coordination motifs in
heparinase I are loosely described by the EF hand motif,
whereas the calcium coordination in ChonB is more similar to
that seen in the PL-1 and PL-10 families (23, 23, 56). Regard-
less, the requirement of calcium for enzymatic activity is
emerging as a motif common for several members of the poly-
saccharide degrading families of enzymes.
The E-NH 3 moiety of Lys-250 is the only functional group
that is in the vicinity of the C5 proton of the iduronic acid in
subsite + 1 (Fig. 3B). Therefore, given the complete lack of
activity of the K250A mutant (20), this lysine likely acts as a
base in the abstraction of the C5 proton from the iduronate.
The theoretical pKa of the terminal amine of the lysine side
chain is 10.5, relatively high for the residue to be acting as a
general base. However, an arginine residue (theoretical pK, of
12.5) has been shown to act as a base in the p-elimination of
pectin substrates by members of the PL-1 and PL-10 pectate
lyase families (23, 56). Therefore, it is not unlikely that the
local microenvironment stabilizes the deprotonated form of
Lys-250, allowing it to abstract the C5 proton from the
iduronic acid.
Based on their position in the vicinity of the DS reaction
product, His-272 and Glu-333 were suggested as potential
Bronsted bases (15, 20). Their involvement in the catalysis
seems supported by the significant decrease of turnover ratio
resulting from their replacement by alanines. Nevertheless,
these substitutions do not completely abolish the activity, and
the product profiles of these mutants after 12 h of digestion are
identical to that of the wild-type ChonB (20). In the DShcxa
complex, His-272 and Glu-333 are both hydrogen-bonded to the
hydroxyl 03 of the L-iduronic acid at the + 1 subsite, but are far
from the C5 carbon atom (5.6 and 5.5 A, respectively) (Fig. 3B).
Although His-272 is almost invariant in the family PL-6, Glu-
333 is located in the loop (31-P32, which is highly divergent in
length and sequence in this family. Taken together, these bio-
chemical and structural data rule out a direct involvement of
His-272 and Glu-333 in the proton abstraction from C5 atom in
the family PL-6. However, the role of these residues in ChonB
seems to be related to proper substrate binding rather than
directly to catalysis.
Finally, the anomeric hydroxyl group 01 of the GalNac4S at
the -1 subsite is involved in a network of interactions that
include Arg-271 and Glu-333 (Fig. 3B). It is hydrogen-bonded to
the NH 2 (2.74 A) of Arg-271 and at a distance of 3.7 A from OE2
of Glu-333. The NH 2 of Arg-271 and OE2 of Glu-333 are also
hydrogen-bonded (3.0 A). In addition, the OE2 of Glu-333
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makes a hydrogen bond to 03 of L-iduronic acid in the +1
subsite, whereas the NE of Arg-271 is hydrogen-bonded to 05
of the +1 subsite GalNac4S. The guanidinium group of this
invariant arginine is sandwiched between the aromatic side
chains of Trp-298 and His-272. Based on the observed geome-
try, Arg-271 and Glu-333 could provide a relay system func-
tioning as a Bronsted acid, giving a proton to the oxygen atom
01 of GalNac4SB1 when the glycosidic bond is eliminated.
However, Glu-333 is not conserved throughout the family PL-6,
suggesting that an accessory function of this glutamate is lim-
ited to ChonB. Because of its invariance, Arg-271 is likely the
key residue in the protonation of the 0(1,4) linkage (Fig. 7). The
mutation R271A resulted in an insoluble protein (20), prevent-
ing the exact determination of the role of this residue in catal-
ysis. In the current study, two other less drastic substitutions
of Arg-271 to a lysine or glutamate led, as expected, to substan-
tially reduced activity. R271K is 10-fold less active than the
wild type enzyme, whereas R271E mutation results is complete
loss of activity (Table IV). These effects of mutations of Arg-271
on activity are in agreement with the postulated role of this
residue as a Bronsted acid during catalysis.
The bond cleavage order is difficult to predict based only on
the structural data. Recently, Rye and Withers (57) have ele-
gantly demonstrated that chondroitin AC lyase proceeds ac-
cording to a stepwise mechanism, with the deprotonation as a
rate-limiting step. However, this result is not directly applica-
ble to ChonB, because the catalytic machineries of these two
enzymes are unrelated. In the case of PellOAcm, the lack of a
Bronsted acid in the vicinity of the scissile glycosidic bond was
proposed as a sign that no negative charge occurs at this center,
ruling out the El-type reaction (56). This argument does not
apply here because of the presence of Arg-271 in a proximity to
the glycosidic bond.
Polycationic Character of ChonB May Play a Role in the in
Vivo Dissociation of Dermatan Sulfate Aggregates-The pres-
ence of a DS disaccharide bound to the external surface of
ChonB on the opposite side to the active site raises intriguing
questions concerning the potential function of this GAG-bind-
ing site. The electrostatic potential on this side of ChonB sur-
face is markedly positive and is characterized by an unusual
arginine stack (Arg-129, Arg-161, and Arg-199). The NE and
NH2 groups of Arg-129 are involved in a bidentate salt bridge
with Asp-163, the carboxylic group of this latter residue inter-
acting also with His-164 ND1. These residues form a sequence
pattern (R129, 161RXDH 1 64 ), which is conserved in five of the
seven members of the PL-6 family (Fig. 6), suggesting that this
carbohydrate-binding site may have a specific function in those
polysaccharide lyases. Such an alignment of arginine residues
was also found on the external surface of a p-helical L-carrag-
eenase (19). This enzyme degrades the L-carrageenan fibers
according to a highly processive mechanism (54). These crys-
talline fibers are made of double helices of sulfated galactans
aggregated through the chelation of Ca 2+ ions (58, 59). Prior to
the processive degradation of single L-carrageenan chain, this
p-helical hydrolase first dissociates the crystalline fibers. The
basic outer surface of L-carrageenase was proposed to act as a
polycation, which would displace the Ca 2+ counter-ions to bind
the sulfo groups of L-carrageenan, thus resulting in the disrup-
tion of the fibers (54). According to the polyelectrolyte theory, a
polycation indeed has a higher affinity for a polyanion than free
counter-cations (60). The binding of a DS oligosaccharide in the
vicinity of the arginine stack of ChonB is consistent with the
hypothesis that the noncatalytic basic surface of some P-helical
polysaccharide lyases could interact with polyanionic polysac-
charides. As in other (-helical enzymes (23, 53, 54, 61, 62), the
active site of ChonB can only accommodate a single polysac-
charide chain. Therefore, DS chains that are either auto-aggre-
gated through the chelation of cations (4, 63) or bound to basic
domains of extracellular matrix proteins (64-66) are not avail-
able as proper substrates for ChonB. We propose that, similarly
to L-carrageenases (54), the basic outer surface of ChonB may
disrupt these electrostatic interactions and liberate DS single
chains that would then be suitable substrates for this enzyme.
Conclusions-In summary, this study has combined crystal-
lographic structural data, enzyme kinetic analysis, and model-
ing to develop a more complete understanding of how chon-
droitinase B degrades DS. The crystal structures of DShe x a and
CStetra provide a more complete picture of the active site of the
enzyme including the identification of the + 1 and +2 subsites,
as well as the putative -4, -3, +3, and +4 subsites. Addition-
ally, the DShex a structure revealed for the first time the pres-
ence of a Ca 2+ ion coordinated by amino acids in the protein, as
well as by a carboxylate on the IdoUA in the substrate. Subse-
quent kinetic analysis and site-directed mutagenesis experi-
ments confirmed that calcium is essential for the activity of
chondroitinase B and that Glu-243, Glu-245, and Asn-213 are
required for the proper chelation of Ca 2+ ion in the active site.
The structure of an intact tetrasaccharide substrate within the
chondroitinase B active site was explored through two unique
modeling approaches, the results of which shed further light
onto the discrimination of DS versus CS substrates by chon-
droitinase B and the role of Ca 2 + in proper substrate binding
and catalysis. As such, this study represents a multifaceted
endeavor to understand the active site chemistry of chondroiti-
nase B, the only known enzyme that degrades DS as its
sole substrate.
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4.2.1 Introduction
In an effort to develop GAG-degrading enzymes as biochemical tools, we recently
cloned and recombinantly expressed chondroitinase ABC I, a broad substrate specificity
enzyme from Proteus vulgaris [1]. By constructing theoretical models of enzyme-
substrate complexes using the structure of cABC I [1], we investigated the putative active
site amino acids via site-directed mutagenesis. These preliminary studies into cABC I's
active site topology indicated potential differences in the processing of CS and DS
substrates by this enzyme. These putative differences were attributed to the different
orientations of the C-5 proton of the uronic acid relative to the cleavable glycosidic bond,
depending on the epimerization state [2, 3].
In these studies, we investigated in great detail the differences in processing of CS
and DS substrates by cABC I. Specifically, we examined the role of divalent cations,
such as Ca2 +, in catalysis. Previously, it has been observed that the divalent ion calcium is
required for the optimal activity of several polysaccharide-degrading enzymes. These
include heparinase I [4, 5] and chondroitinase B [6] from Pedobacter heparinus, and
pectate lyase C [7] from Erwinia chrysanthemi. The requirement for calcium might be
explained if binding between calcium and the enzyme facilitates substrate cleavage.
Alternatively, since it has been established that calcium interacts in a highly specific way
with heparin [8], it might be the case that the enzyme can only best act on a substrate
conformation enabled by calcium. It is possible that this latter premise is most important,
as the calcium-induced conformation of heparin might have an analog with regard to DS
(as both DS and heparin are composed of predominantly IdoA).
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In an effort to examine whether divalent ions play an important role in cABC I
activity, we undertook a series of experiments to determine whether cABC I binds
divalent ions and, if so, at which site(s) this interaction might take place, and how this
might affect enzyme activity and substrate processing. In this study, we indeed find that
cABC I binds calcium. Through fluorescence spectroscopy studies and the development
of site-directed mutants of the enzyme's putative calcium binding site, we characterize
cABC I's selective requirement of calcium for the optimal processing of one of its
substrates, DS.
4.2.2 Chondroitinase ABC I Activity Analysis
The role of Ca2+ in the catalytic activity of cABC I towards CS and DS substrates
was investigated in a systematic fashion. First, the effect of Ca2+ and other divalent metal
ions on the specific activity of the enzyme was measured. Second, the direct binding of
Ca2+ to the enzyme was investigated by titration with terbium, a calcium analog. Third,
the effects of Ca2+ on the chemical kinetics of CS and DS substrate processing were
measured. Finally, the molecular basis for the role of Ca2+ in substrate processing was
investigated in detail using theoretical enzyme-substrate complexes and site-directed
mutagenesis studies.
The effect of various divalent ions on the activity of cABC I against C6S and DS
substrates was assessed [Table 4.2.1]. With C6S as the substrate there was no apparent
change in enzyme activity upon addition of calcium, magnesium, or manganese. The
addition of zinc appeared to have an inhibitory effect, as reported previously [9, 10].
Interestingly, the activity of cABC I on DS increased dramatically in the presence of
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added calcium or magnesium, when compared to the control (1 mg/mL DS in 50 mM
Tris pH 8.0). Manganese and zinc had no appreciable effect on DS depolymerization.
Table 4.2.1. Specific activity of chondroitinase ABC I acting on chondroitin-6-
sulfate and dermatan sulfate in the presence of divalent ions.
Divalent ion'
Substrate: Chondroitin-6-sulfate
Tris pH 8
Ca2+
Mn2+
Mg2+
Zn2+
Substrate: Dermatan sulfate
Tris pH 8
Ca2+
Mn2+
Mg2+
Zn2+
Specific activity
(Units/mg protein)
169.7 + 9.7
158.2 + 10.5
129.3 + 6.2
200.7 + 17.4
19.1 3.2
8.9 + 3.3
231.3 + 8.2
12.8 ± 7.5
262.8 + 7.2
20.4 1.7
1 Divalent ions (chloride or sulfate salts) are added to the basic buffer of 50 mM Tris pH
8.0 (no additional salt) at a concentration of 10 mM. Specific activity is reported as the
mean of at least three experiments ± S.E.
In order to further understand the role of calcium in the selective enhancement of
cABC I activity towards DS, we first sought to evaluate the calcium concentration at
which maximal activity was observed. For these calcium titration experiments an
experimental arrangement based on the rate of product formation was employed and the
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Figure 4.2.1. Effects of Ca2+ on the cABC I-mediated processing of dermatan sulfate.
Calcium enhances the specific activity ofcABC I acting on dermatan sulfate as a
substrate. (A) Effect of calcium on the activity of cABC I cleaving DS in the absence of
any added sodium acetate. (B) Effect of calcium on the cABC I-mediated
depolymerization of DS in the presence of added sodium acetate (25 mM, solid line; 50
mM, long dashed line; 100 mM, short dashed line).
concentration of added CaCl2 was varied from 0 -40 mM. The data clearly indicated that
maximum activity was obtained at -10 mM CaC12 [Figure 4.2.1A].
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It is important to note that our initial experiments with added calcium were done
in the absence of any additional salt in the buffer; therefore, we next set out to ascertain
whether the enhancement observed for DS processing was dependent on the presence of
the divalent ions, or simply a byproduct of a salt effect. To this end, we performed a
comparison of the activity of the enzyme on DS in the presence of set quantities of
sodium acetate [2] over a range of calcium concentrations. Dermatan sulfate at a 1
mg/mL concentration was dissolved in 50 mM Tris pH 8.0 buffer containing 25 mM, 50
mM, or 100 mM sodium acetate. Using each of these as our starting solutions we
repeated the calcium titration analysis by adding various amounts of CaC12 (0 - 20 mM).
As illustrated in Figure 4.2.1B, the rate of enhancement observed upon the addition of 10
mM CaC12 still exceeds that observed when using the optimum salt concentration (100
mM sodium acetate). The results also indicate that the maximum enhancement observed
is constant at 10 mM calcium, irrespective of the sodium acetate content in the starting
buffer. These studies resolve the competing effects of salt and calcium on the cABC I-
mediated depolymerization of DS, and are an indication that the effect of calcium is
independent of a salt effect.
4.2.3 Interaction of Terbium with Chondroitinase ABC I
In order to address whether cABC I itself binds calcium, we studied the
interaction of Tb3+ with the recombinant enzyme in the absence of substrate. This
experimental design allows for the assessment of cABC I-terbium interactions
independently, that is, without the confounding factors associated with terbium-substrate
interactions. Tb3+ is a lanthanide analog of calcium often used to probe the nature of
protein interactions with divalent ions, including calcium [11]. In aqueous solution, Tb3+
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Figure 4.2.2. Biophysical characterization of cABC I interactions.
(A) Terbium binding to cABC I was investigated. Fluorescence intensity increases upon
titration of terbium to cABC I. Following addition of TbCl3, the solution was allowed to
come to equilibrium and the fluorescence at 545 nm was measured with an excitation
wavelength of 280 nm. The data is presented as relative fluorescence normalized
according to the peak measurement versus supplemented terbium. (B) Competition
experiments were performed to investigate whether calcium was capable of competing
for cABC I binding sites with terbium. The terbium-enzyme complex was titrated with
increasing amounts of calcium. The sample was incubated for 15 min. The fluorescence
at 545 nm was measured. Fluorescence intensity decreased with increased calcium
concentration. Relative fluorescence is presented in normalized form according to the
peak fluorescence measured.
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possesses an ionic radius that is very similar to that of calcium. Another beneficial
attribute of the protein-Tb3+ complex is that it is fluorescent. The increased charge
properties of terbium as compared to calcium additionally confer a relatively greater
affinity to calcium-binding sites for the lanthanide than for divalent calcium.
Upon titration of cABC I with terbium, an increase in fluorescence was observed
against both a direct excitation of the terbium adduct (488 nm) and at an excitation of the
proximal tyrosine sidechains which results in an energy transfer to the terbium adduct
(280 nm). Fluorescence intensity increased upon terbium titration to cABC I until a
terbium concentration of 8 mM [Figure 4.4.2A]. The fluorescence intensity plateaued at
this concentration and did not respond to further terbium addition.
Terbium often binds with greater affinity to a given site than does calcium.
Therefore, an excess of calcium is likely required in order to displace terbium from
binding sites within a terbium-enzyme complex. Such a competition between terbium and
calcium for position within the enzyme active site is useful for the purpose of inspecting
the specificity of binding interactions. In an attempt to occupy enzyme binding sites,
enzyme was pre-loaded with 6 mM terbium. Calcium was added to the terbium/enzyme
solution, and the fluorescence was measured. As shown in Figure 4.2.2B, the addition of
calcium does effectively compete with terbium to occupy cABC I binding positions.
These results indicate that the interaction of terbium with cABC I is specific, and that this
interaction substitutes for calcium binding to cABC I. These results are consistent with
previous experiments on heparinase I designed to establish terbium-enzyme interaction
and calcium specificity [5].
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4.2.4 Calcium Increases Dermatan Sulfate Processing by Chondroitinase ABC I
To further confirm the substrate-selective rate enhancement in the presence of
calcium, we undertook a kinetic analysis of cABC I processing on C6S and DS in the
presence and absence of 10 mM calcium chloride. The results are summarized in Table
4.2.2. With C6S as the substrate, the presence of 10 mM calcium had no effect on either
the Km or kcat of the enzyme. The presence of calcium, however, clearly had an effect on
the activity of cABC I when DS was the substrate. We observe an effective doubling of
the turnover (kat) from 17000 min-1 to 33000 min-' in the presence of calcium. The Km
was 1.4 4M in the absence of calcium and 2.9 LM in the presence of calcium. This
suggests that calcium is possibly involved in the binding and orientation of the dermatan
substrate in the active site. These phenomena provide an optimal conformation between
substrate and enzyme that facilitates more rapid processing. It further offers an additional
level of control regarding specificity, in that it can compromise the binding affinity of the
substrate for the enzyme.
In our previously derived theoretical models of the enzyme-substrate structural
complexes, we observed that in the case of C6S, both the C-5 proton and the glycosidic
oxygen in the cleavable linkage face the active site, whereas in the case of the DS
substrate, these atoms are oriented in opposite directions [3]. Based on these
observations, we had proposed that the DS substrate could potentially re-orient itself
through a slight rotation to facilitate both proton abstraction and protonation of the
leaving group by the catalytic amino acids. Given the differential effect of calcium in
enhancing DS processing, it is likely that calcium plays a role in establishing the proper
221
DS orientation by binding to both substrate and enzyme. It is in this element that the
differential processing of GAG substrates by cABC I manifests. These molecular aspects
sodium acetate pH 8.0 were investigated by further examining the enzyme-substrate
complexes derived from our previous study [3].
Table 4.2.2. Kinetic analysis of chondroitinase ABC I acting on chondroitin-6-
sulfate and dermatan sulfate in the presence of calcium. 1
Experiment Km kcat kcat/ Km
(WiM) (min') (pM - min)
Substrate: Chondroitin-6-sulfate
Buffer only 2  2.4 + 0.9 22000 + 1200 9100
Buffer + 10 mM CaC12  2.9 + 0.6 20000 + 5000 6900
Substrate: Dermatan sulfate
Buffer only 1.4 + 0.5 17000 + 1400 12000
Buffer + 10 mM CaCl 2  2.9 ± 0.5 33000 + 1800 11000
1 Values are the mean of at least three experiments + S.E.
2 Buffer is 50 mM Tris-HC1, 50mM
4.2.5 The Calcium Coordination Site
Divalent cations have historically been demonstrated to play a critical role in the
enzymatic depolymerization of IdoA-containing GAGs. In the case of heparinase I,
which predominantly cleaves GIcNS,6S-IdoA2S linkages in heparan sulfate GAGs, two
Ca2+ binding sites were identified, where one was implicated in substrate binding and the
other in the catalytic mechanism [4]. More recently, a crystal structure of cB (an enzyme
that cleaves DS as its sole substrate) with enzymatic degradation products revealed the
222
Figure 4.2.3. Role of Ca 2+ in processing of DS substrates by cABC I.
Shown on top is the stereo representation of the active site of cABC I with a docked
dermatan sulfate substrate {Prabhakar, 2005 #383}. Shown on bottom is the stereo view
of the potential reorientation of the DS substrate in the active site of cABC I. This
reorientation of the DS substrate, which is stabilized by Ca2+ binding, improves the
activity of cABC I towards DS. Based on the positioning of the oxygen atoms, the likely
location of the Ca2+ ion is indicated by a black dot. The carboxyl oxygens of Asp444 and
the IdoA in the +1 subsite are positioned to coordinate with the Ca2+ ion in the active site.
The CA trace is represented in green; the sidechains shown in the active are Lys, His and
Arg in blue; Tyr in purple; Asp and Glu in red; and Asn and Gln in cyan. The dermatan
substrate is colored gold where the carboxyl group of the IdoA in the +1 subsite is
colored differently (carbon atom in green and oxygen atoms in red) to highlight the
change in orientation of the DS substrate in the top schematic when compared to that in
the bottom schematic.
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presence of a Ca2+ ion in the active site [6]. This crystal structure demonstrated that the
conformational flexibility of IdoA enhanced the structural fit of the DS substrate into the
active site, and that the Ca2+ ion facilitated these interactions by coordinating both with
the active site amino acids as well as the carboxylate group of the IdoA in the substrate.
This provided a structural basis for the ability of cB to selectively cleave IdoA-containing
DS substrates in comparison with GlcA-containing CS substrates [6].
Since cABC I cleaves both CS and DS substrates, it provided an interesting
system to study the preferential effect of Ca2+ in processing these substrates. The crystal
structure of cABC I provided a unique framework to understand the potential differences
in the catalytic processing of GlcA-containing CS substrates and IdoA-containing DS
substrates by this enzyme. By docking tetrasaccharide CS and DS substrates into the
putative active site of cABC I, we obtained some preliminary structural insights into the
differences in the processing of these substrates [3]. Importantly, these differences were
attributed to the relative orientation of the C-5 proton of the uronic acid in the +1 subsite
and the oxygen atom in the cleavable glycosidic linkage. Whereas in GlcA-containing CS
substrates, both of these atoms were facing in the same direction towards the putative
active site residues, in the case of IdoA-containing DS substrates, they were facing in
opposite directions (one towards the active site and the other away from the active site).
Based on this observation, we proposed that the DS substrate must have the potential to
reorient itself during catalysis such that both the C-5 proton abstraction and the
protonation of the leaving anomeric oxygen atom (the glycosidic oxygen prior to
cleavage) would be accomplished at the catalytic site.
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Figure 4.2.4. Schematic of DS substrate reorientation stabilized by Ca2+ binding.
Shown on the right is a schematic of the DS substrate in the active site where the C-5
proton of the IdoA in the +1 subsite is positioned to be abstracted by His501. Shown on
the left is a schematic of the proposed reorientation of the DS substrate in the active site
where the glycosidic oxygen atom at the -1/+1 linkage is positioned to be protonated by
Tyr508 or Arg560. This orientation of the substrate is stabilized by Ca2+ coordination in
the active site. This appears to most likely involve the carboxyl oxygens of the IdoA in
the +1 subsite, Asp444, and the oxygen atom of either Tyr392 or Asn447, or both.
In this study, further investigations into the theoretical models of the enzyme-
substrate complexes revealed four aspartic acid residues-- Asp439, Asp442, Asp444, and
Asp490-- which could potentially be involved in Ca 2+ coordination. Among these
residues, Asp444 was the closest to the active site. Building on our earlier studies, we
sought to investigate if the processing of DS by cABC I would involve a reorientation of
the substrate which could be stabilized by interaction of Ca2+ with the substrate as well as
the enzyme in the active site. In our previous study, we docked the DS substrate into the
active site such that the C-5 proton of the IdoA in the +1 subsite was facing the active
site. Using a similar approach as outlined in our previous study [3], we docked the same
DS substrate in an orientation where the glycosidic oxygen atom of the cleavable linkage
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was facing the active site (Figure 4.2.3). In this orientation, the carboxylate group of the
IdoA in the +1 subsite faces the Asp444 residue, thus indicating the potential
coordination site for Ca2+ involving the oxygen atoms of Asp444 and those of the
carboxylate group of the IdoA in the substrate (Figure 4.2.4). Apart from the four oxygen
atoms of Asp444 and the IdoA, the oxygen atoms of Tyr392 and Asn447 are positioned
such that they could also be involved in interacting with the Ca 2+ ion. Furthermore, the
theoretical enzyme-substrate model also provides a plausible explanation for the selective
dependence of cABC I processing of DS substrate on the Ca 2+ ion concentration as
observed in the kinetic studies.
Figure 4.2.5. Active site topology of the cABC I active site.
A GAG (maroon) substrate is shown in the catalytic cleft of cABC I (backbone in green)
in close proximity to the active site residues (sequestered within circle) and several
aspartic acid residues. The residues Asp439, Asp442, Asp444, and Asp490 were
examined through mutagenesis studies in order to inspect their potential complicity
within a calcium coordination center.
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4.2.6 Calcium Coordination Mutagenesis Studies 
Site-directed mutagenesis studies were employed to further inspect the role 
calcium might play in the cABC I-mediated depolymerization of GAG substrates. Based 
on our model of the cABC I-derrnatan structural complex, four aspartic acid residues, 
Asp439, Asp442, Asp444, and Asp490 were chosen as potential players in the 
coordination of divalent ions (Figure 4.2.5). Tyr392 was hrther inspected, as our model 
suggested its oxygen atoms may interact with a calcium ion. These residues were each 
mutated to alanine independently. Circular dichroism spectra were created to establish 
that mutagenesis did not compromise the tertiary structure of the mutant proteins (Figure 
4.2.6). 
Our structural model of the enzyme-substrate complex suggests a direct role in 
calcium coordination for the Asp442 and Asp444 residues, according to proximity to the 
dermatan IdoA; Asp439 is more distant and is unlikely to play a central role in divalent 
ion coupling. Table 4.2.3 summarizes the activity of the cABC I mutants against C6S 
substrate in the absence and in the presence of 10 mM ca2+. Specific activity 
measurements of recombinant cABC I against C6S substrate did not show a dependence 
on calcium (Table 4.2.1). This result is consistent according to the kinetic parameters of 
the wildtype enzyme (Table 4.2.2), where both the K, and the turnover number are 
consistent with or without supplemented calcium. Kinetic analysis of the Asp439Ala 
mutant on C6S reveals reduced total activity when compared to wildtype enzyme, but 
does not present any calcium-mediated alteration in binding (K, of 1.5 pM in the absence 
of ca2+ and 1.7 pM in the presence of ca2+), turnover (kat of 3300 mid' versus 4200 
m i d ) ,  or catalytic efficiency (La$ K, of 2200 pM-' min-' versus 2400 pM-,' m i d ) .  The 
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Figure 4.2.6. CD spectra of cABC I and mutants.
The recombinant cABC I (closed circles) and the mutants Asp442Ala (open circles),
Asp439Ala (closed triangles), Asp444Ala (open triangles), and Asp490Ala (closed
squares) were examined via circular dichroism spectroscopy to inspect potential
alterations to protein structure following mutagenesis. The proteins were concentrated
and buffer-exchanged into 50 mM sodium phosphate buffer, pH 8.0. Proteins were
analyzed in a quartz cell with a 1 mm path length. All spectra were collected using a
protein concentration of 0.2 mg/ml in sodium phosphate, pH 8.0. CD spectra were
recorded between 195 and 280 nm with an average of five scans. The CD band intensities
are expressed as molar ellipticities, OM.
Asp439Ala mutant does react differentially to supplemented calcium in a DS-based
assay, with virtual doublings in Km and kcat on addition of Ca 2+, further excluding this
residue as a potential calcium coordination player (Table 4.2.4). Processing of C6S
substrate by the Asp442Ala and Asp490Ala mutants also did not result in altered kinetic
rates according to the inclusion of calcium, though both catalyzed the degradation of C6S
at far lower rates than wildtype (Tables 4.2.3 and 4.2.4). Asp444Ala had a very low
activity and thus establishing kinetic parameters was not possible. This is likely the result
of the proximity of this residue to the catalytic center (Figure 4.2.4), where perturbation
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Table 4.2.3. Chondroitin-6-Sulfate Kinetic Analysis of Mutants: Ca2+ Effects. a
Mutant ± 10 mM Ca2+  Km kcat kcat/ Km
AM min-' IM" min'
Asp439Ala - 1.5 ± 0.7 3300 ± 1300 2200
Asp439Ala + 1.7 ± 0.7 4000 ± 1100 2400
Asp442Ala - 4.0 + 0.9 400 ± 200 100
Asp442Ala + 4.5 ± 1.1 510 ± 240 110
Asp444Ala ± n.d. b n.d. n.d.
Asp490Ala - 17.7 ± 9.5 2100 ± 350 120
Asp490Ala + 14.5 ± 1.9 1800 ± 400 120
a Values are the mean of at least three experiments ± S.E.
b n.d., kinetic parameters not determined due to low activity of mutant.
of the active site microenvironment could substantially alter electrostatics or the binding
of substrate, even in a situation where calcium coordination is not necessarily required
(Figure 4.2.5).
As established earlier, processing of DS by cABC I proceeds in a calcium-
dependent manner (Table 4.2.2). Calcium is important for the optimal depolymerization
of DS, as seen with the mutants Asp442Ala and Asp444Ala. These residues are both
within coordination proximity to the cABC I active site and the IdoA carboxylate and are
inactive against DS, irrespective of the presence of divalent ions. The Asp490Ala mutant,
from which our enzyme-substrate structural model suggests an intermediate role in
calcium coordination, that is, greater than that mediated by Asp439 but less central than
Asp442 and Asp444, does show a kcat-dependent activity. The presence of calcium does
increase comparative turnover more than twofold for this mutant (klt in the absence of
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calcium is 280 min' and in the presence of calcium is 640 min'). The mutant Tyr392Ala,
positioned according to our enzyme-substrate structural complex as potentially involved
in calcium coordination, displayed a seven-fold greater activity in C6S (specific activity
of 84 units/mg) processing versus DS (specific activity of 12 units/mg) processing. This
ratio is important to note in the context of wildtype cABC I processing, in which DS
processing is far more comparable to C6S depolymerization in our activity screens (Table
4.2.1). These results suggest some role for Tyr392 in the strategy employed by cABC I to
cleave IdoA-containing GAGs.
Table 4.2.4. Dermatan Sulfate Kinetic Analysis of Mutants: Ca2+ Effects. a
Mutant + 10 mM Ca2+  Km kcat kat/ Km
gM min1' gM' min'
Asp439Ala - 1.7 ± 0.7 2300 + 90 1400
Asp439Ala + 2.8 ± 0.3 4500 + 340 1600
Asp442Ala + n.d .b n.d. n.d.
Asp444Ala + n.d. n.d. n.d.
Asp490Ala - 12 ± 4.0 280 + 90 19
Asp490Ala + 19 ± 7.2 640 + 80 34
a Values are the mean of at least three experiments ± S.E.b n.d., kinetic parameters not determined due to low activity of mutant.
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4.2.7 Perspectives
Given the broad range of substrates amenable to cleavage by cABC I, this system
presents both opportunities as well as challenges with respect to the molecular aspects of
substrate binding and catalysis. Although the structural fold of this enzyme is similar to
that of cAC, the substrate binding groove is wider and is composed of numerous basic
amino acids and tyrosines. Our initial biochemical characterization of cABC I enabled us
to confirm the critical amino acids among these various candidates [2]. Furthermore, the
theoretical enzyme-substrate complexes constructed in these studies provided preliminary
insights into the potential differences in the processing of CS and DS substrates by cABC
I [3].
Herein we build a case to clarify the phenomena by which cABC I possesses the
remarkable ability to cleave GAG substrates irrespective of uronic acid conformation.
Our results from this study suggest a calcium coordination strategy that cABC I employs
to optimally process DS substrates. We further suggest that this divalent ion
incorporation is not required for the cABC I-mediated depolymerization of chondroitin
substrates. These studies comprise the first evidence characterizing a dual-activity
scaffold for a broad substrate specificity glycosaminoglycan-degrading enzyme, where
catalysis of one class of substrates proceeds with a mechanism distinct from that used for
other substrates.
Titration with calcium clearly increases the efficiency of cABC I-mediated DS
degradation. Further biochemical and biophysical investigations confirm that cABC I
binds calcium. Several residues proximal to the catalytic site, specifically Asp442,
Asp444, and Tyr392, were shown to be critical to cABC I function against DS and are the
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most likely to be involved in calcium binding. It is challenging to conclusively determine
the role of these amino acids in the calcium-mediated processing of DS substrates. This is
primarily due to their proximity to the active site. Thus, the site-directed mutagenesis of
these amino acids (particularly the two aspartates) has an overall negative effect on the
catalytic activity of the enzyme. Nevertheless, based on our understanding of other GAG
lyases and the current studies, we suggest some scenarios for the molecular mechanism at
work during cABC I-mediated DS depolymerization.
In the context of the general fl-elimination mechanism postulated for the lyase-
based depolymerization of GAGs [12, 13] a cation (such as calcium) is poised to interact
with the carboxylate anion of the substrate. This in turn decreases the pKa of the carbon
acid to such a degree that the a-proton can be abstracted by a basic amino acid within the
active site of the enzyme.
A variety of enzymatic systems have been implicated to employ calcium-binding
processes for catalysis. Most notably, these include trypsin [14], chondroitinase B [6],
heparinase I [4, 5], and pectate lyase C [7]. Our studies on polysaccharide lyases,
specifically the bacterial chondroitinases and heparinases, clearly suggest some pivotal
role for calcium in the processing of polysaccharide substrates containing iduronate. The
ability of IdoA to adopt multiple ring conformations enhances the conformational
flexibility of IdoA-containing GAG oligosaccharides. In the case of cB, (which processes
DS as its sole substrate) the conformational 'flexibility' of IdoA has been implicated to
cause the substrate to bend into the active site, where it is involved in calcium
coordination along with the enzyme [6]. A structural comparison of cABC I from Proteus
vulgaris and cAC from Pedobacter heparinus indicates a similarity in overall architecture
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of the enzymes including the active site loci. This would tend to suggest that cABC I is
actually more appropriately suited to cleaving those substrates favored by cAC, that is,
CS. This is borne out by our earlier studies on cABC I which indicate that cABC I
processes CS substrates more favorably (from a kinetic standpoint) than DS substrates
[2]. Our modeling studies suggest that for CS substrates, the C-5 proton of the glucuronic
acid moiety is properly situated for facile abstraction by cABC I active site residues. In
the case of DS, this proton is situated far less favorably, distant from the relevant locus
within the active site, suggesting that the DS substrate needs to reorient to enable C-5
proton abstraction and protonation of the glycosidic oxygen by the same active site
residues.
Based on our results in this study, we propose that the reorientation of DS in the
active site is mediated by its ability to coordinate with calcium ion. Such coordination
would potentially involve the carboxyl group of iduronic acid and the amino acids in the
active site. Establishing the exact sequence of steps that bring about this transition state
(calcium coordination) complex involving the enzyme and the substrate is complex.
There are several scenarios by which calcium may enable GAG processing by
lyases. The requirement for calcium might be explained if binding between calcium and
the enzyme facilitates substrate cleavage. In this case, there are two basic possibilities.
First, calcium could bind the enzyme and induce a conformational change within the
enzyme itself. This would facilitate polysaccharide cleavage by altering the enzyme
active site microenvironment. In this case, the calcium coordination site need not
necessarily be proximal to the active site. Alternatively, calcium may bind to a
coordination site that is proximal to the active site. Here, calcium would play a direct role
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in substrate processing, with the interaction between calcium and the substrate
carboxylate enabling catalysis.
Yet another possibility is the formation of a DS-enzyme-calcium ternary complex,
in which the coordination motif and the active site are closely situated. Calcium may bind
the coordination site independently, or be brought in along with substrate. The
culminating event witnesses DS in the active site, with its iduronic C-5 proton
appropriately positioned for abstraction. Here, calcium does in fact lock the DS in the
'active' conformation. This scenario can be described as one in which calcium is not
playing a direct role in catalysis, but rather acts as an orienting agent. Our kinetic data on
cABC I processing dermatan sulfate in the presence and absence of added calcium would
tend to support this scenario. The increase in Km accompanied by an increase in kt
supports the idea that calcium reorients the DS substrate and locks it in an optimal
position for processing by the active site residues.
Our scrutinization of cABC I suggests that substrate processing follows a catalytic
model in which the substrate fit into the catalytic groove is critical. Dermatan substrates,
with their great degree of conformational flexibility, are aided into the 'active site-
acceptable' shape enabled by their interaction with calcium. From a structural standpoint,
this enzyme-substrate match allows easy access of the C-5 proton of the reactive carbon
from the iduronate moiety by the general base. Thus, the conformational fit facilitated by
calcium is the most important element within the catalytic strategy. In parallel, as calcium
does bind enzyme, it is further likely that calcium acts as a bridge between enzyme and
substrate.
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Recombinant GAG-degrading lyases are being developed for their potential
relevance to multiple systems. These include a variety of therapeutic indications [15-17]
and analytical applications [3, 18-22]. In the context of cABC I, the studies described in
this report are useful in a variety of ways. First, they more fully inform the technologist
of the mechanistic details of this tool, specifically with regard to an understanding of the
full spectrum of potential substrates. Additionally, they offer the possibility of divalent
triggers, where broad substrate specificity enzymes might be manipulated to have a
refined specificity, with temporal or spatial-sensitive tuning, to a controlled enzyme-
mediated reaction. This potentially could be used as one part of a strategy to deconvolute,
for example, the species present in a complex mixture of glycans within a biological
sample.
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Conclusions
The ability of chondroitinase ABC I to cleave polysaccharide substrates of either
the glucuronic acid or iduronic acid epimerization states has been examined. These
studies have established the role of calcium as a necessary cofactor in the chondroitinase
ABC I-mediated enzymatic activity against dermatan sulfate. These studies more fully
inform the technologist of the mechanistic details of this tool, specifically with regard to
an understanding of the full spectrum of potential substrates and products. Additionally,
they offer the possibility of divalent triggers, where broad substrate specificity enzymes
might be manipulated to have a refined specificity, with temporal or spatial-sensitive
tuning, to a controlled enzyme-mediated reaction. This potentially could be used as one
part of a strategy to deconvolute, for example, the species present in a complex mixture
of glycans within a biological sample.
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Chapter 5
Chondroitinase ABC II from Proteus Vulgaris
Summary
An important lyase that degrades chondroitin sulfate and dermatan sulfate,
chondroitinase ABC II, has been isolated and cloned from Proteus vulgaris. An efficient
system for the recombinant expression and purification of this enzyme is described. We
have characterized the recombinant chondroitinase ABC II biochemically. The reaction
conditions that provide the maximal enzyme activity have been determined. The enzyme's
substrate specificity and kinetic parameters have been assessed. Chondroitinase ABC II
cleaves chondroitin-6-sulfate (C6S), chondroitin-4-sulfate (C4S), and dermatan sulfate
(DS) to predominantly disaccharide products. The enzyme has a reduced ability to cleave
chondroitin and highly-sulfated chondroitin species (including chondroitins D and E).
The characterization of recombinant cABC II will be a critical element in the
compositional analysis of GalAG polymers important in biology. This work has been
submitted to the Journal of Biological Chemistry, and is included here with permission.
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5.1 Introduction
In efforts to extend our repertoire of tools to study complex polysaccharides, we
describe here the sub-cloning of chondroitinase ABC II from Proteus vulgaris and
discuss an efficient system for the recombinant expression and purification of this
enzyme. We have characterized the recombinant cABC II biochemically. The reaction
conditions that provide the maximal enzyme activity have been determined. The
enzyme's substrate specificity and kinetic parameters have been assessed. Chondroitinase
ABC II cleaves chondroitin-6-sulfate (C6S), chondroitin-4-sulfate (C4S), and dermatan
sulfate (DS) to predominantly disaccharide products (Figure 5.1). The enzyme has a
reduced ability to cleave chondroitin and highly-sulfated chondroitin species (including
chondroitins D and E). The characterization of recombinant cABC II will be a critical
element in the compositional analysis of GalAG polymers important in biology.
The depolymerization of GAGs can be achieved enzymatically by two classes of
proteins. In eukaryotes, the polysaccharide hydrolases (EC 3.2.1.-) act as either inverting
or retaining glycosidases. These include heparin hydrolase, keratanase, and hyaluronic
acid hydrolase. The lyases (EC 4.2.2.-) employ an elimination mechanism for GAG
cleavage [1, 2]. They fall into three general categories of mostly prokaryotic origin:
heparinases, chondroitinases, and hyaluronidases [3]. Many lyases have been purified and
utilized for industrial applications and they are thus more thoroughly characterized than
the hydrolases. Though much is known regarding the substrate specificity, product
compositions, and structures of some lyases, including chondroitinase AC (cAC) and
chondroitinase B (cB) from Pedobacter heparinus [4-8], far less is known about the
lyases from Proteus vulgaris. Recently, starting with a structural framework [9], our
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Figure 5.1. Composition of Chondroitin and Dermatan Sulfate Glycosaminoglycans.
One of four classes of glycosaminoglycans comprises a group of complex
polysaccharides known as chondroitin sulfate and dermatan sulfate. The basic building
block of these sugars consists of a disaccharide unit of uronic acid linked to a
hexosamine. Chondroitin and dermatan polymers differ from heparin sulfate GAGs in
that they contain galactosamine instead of glucosamine (hence, CS and DS are known as
galactosaminoglycans, GalAGs). Primary sulfation of GalAGs is often observed at the 4-
O and the 6-0 positions of the galactosamine. Rare sulfate occurs at the 2-0 and the 3-0
position of the uronic acid (X). In CS, the uronic acid moiety is glucuronic acid; in DS,
the uronic acid moiety contains iduronic acid.
group has established a recombinant cABC I, identified its active site, and investigated it
biochemically [10].
Chondroitinase ABC II from P. vulgaris degrades CS, DS, and hyaluronan
substrates via an eliminative cleavage reaction resulting in oligosaccharides with A4, 5-
unsaturated uronic acid residues at the non-reducing end. The existence of two broad
substrate specificity GaIAG-degrading lyases only became evident recently [11], and
most studies have been concerned with cABC I. In fact, the ability of the conventional
enzyme known as "chondroitinase ABC" to catalyze the complete depolymerization of
GalAG substrates to disaccharides is actually the result of the joint action of cABC I and
cABC II.
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Chondroitinase enzymes have been employed in attempts to promote functional
locomotor recovery following trauma to the central nervous system in a mouse model
[12, 13]. The application of cABC I at the site of brain injury is believed to prune CS
chains from proteoglycans localized to the glial scar. The absence of these CS chains,
inhibitory to axon regeneration, facilitates neural outgrowth and reconstruction of
damaged brain tissue. However, the use of these bacterial enzymes as therapeutics is
limited in several ways. First, the availability of pure, contaminant-free GalAG lyases is
largely lacking. Further, chondroitinase enzymes are often difficult to handle, due both to
thermal instability and spontaneous proteolysis, as reported by various groups [11, 14,
15]. The broad substrate specificity of cABC I results in the cleavage not only of CS
chains, but DS chains and hyaluronan. This non-specific action may be sub-optimal with
regard to spinal cord injury treatment. The production of contaminant-free, pure
chondroitinases and the further development of enzymes with well-characterized
alternative specificities will be required if this strategy is to be translated to the clinic.
In the current study, we report an efficient system for the Escherichia coli-
mediated expression and purification of chondroitinase ABC II. We further examine the
conditions that optimize the activity of the enzyme. The kinetic properties of the
recombinant enzyme and the major products of the degradation reactions were analyzed.
This work will facilitate the use of contaminant-free cABC II in a variety of
biotechnological applications-- for example, [1] to elucidate the fine structure of GalAGs
important in biology, and [2] to explore the efficacy of glycotherapeutic strategies to
reverse central nervous system deficit.
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5.2 The Chondroitinase ABC II Gene.
Two versions of the cABC II gene were cloned from P. vulgaris DNA: a full-
length version and a truncated version that corresponds to the mature form of the enzyme,
that is, without its putative leader sequence. These cABC II transcripts are approximately
3 kb in length--rather large, but still at an appropriate size to tolerate amplification via
standard polymerase chain reaction techniques. Following cloning into a TOPO vector,
the PCR product was subcloned into the pET28a expression vector. This facilitates E.
coli-mediated uptake of the transcript and ultimately, expression of the protein.
Chondroitinase ABC II was expressed in E. coli as described under the Materials and
Methods section. Purification over a charged Ni2+ resin was completed with the use of an
N-terminal His6 tag.
Previously, our group developed a recombinant cABC I [10]. Though we
undertook steps to prevent the generation of mutations in our clone, including the
minimization of cycling, the use of high fidelity PCR polymerases, and multiple
redundant reactions, we nonetheless observed several discrepancies between our cABC I
transcript and the sequence previously reported [9, 16]. These imperfections at the DNA
level of cABC I resulted in a recombinant protein that was virtually inactive against
GalAG substrates [10]. Aware of our previous difficulty with cABC I and the prospect of
an inactive recombinant cABC II, we unsuccessfully took additional measures (including
various high fidelity polymerases) to prevent corruption of the cABC II sequence. Our
cABC II PCR product ultimately included 5 sites of divergence from the sequence
reported by Ryan et al [16]. The codons of concern occupy positions 23 (our clone
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contains isoleucine instead of threonine), 247 (glycine instead of valine), 356 (arginine
instead of tryptophan), 389 (aspartic acid instead of asparagine), and 490 (histidine
instead of arginine). Unable to address the issue of these generated mutations at the PCR
stage, we alternatively used sequential site-directed mutagenesis to achieve the desired
DNA sequence.
Table 5.1. Purification of Recombinant Chondroitinase ABC II.
Fraction Protein yield Specific activity x-fold Purificationa(1 mg/ml C6S)
(mg) (Units / mg)
Crude lysate 165 5.5
Elution from Ni+2  55 10.3 1.9
column
Thrombin cleavage b 50 11.0 2.0
a The x-fold purification was determined relative to the specific activity measured for
crude lysate.
b Cleavage of the His 6 tag from the recombinant protein was confirmed by Western blot
analysis using an anti-histidine tag antibody (Amersham Biosciences). No detectable
difference in activity against GAG substrates was observed between the recombinant
cABC II and its His 6 tag-cleaved counterpart.
5.3 Recombinant Expression and Purification of Chondroitinase ABC II
Chondroitinase ABC II was expressed as a fusion protein with an N-terminal Hiss6
tag. Expression was induced in the log phase by addition of IPTG. Purification of cABC
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Figure 5.2. SDS/PAGE Analysis of the Purification of Chondroitinase ABC II.
Summary of protein expression and purification following expression in BL21 (DE3) as a
HiS6 N-terminal fusion protein. Lane 1, Invitrogen SeeBlue Plus2 pre-stained standard;
lane 2, cell pellet; lane 3, crude lysate; lane 4, empty; lane 5, recombinant cABC II.
cABC II migrates in close proximity to the 97 kDa standard band.
II generated in excess of 50 mg of protein per 500 ml of culture (Table 5.1). SDS/PAGE
analysis (Figure 5.2) confirmed the presence of highly pure cABC II at approximately
100 kDa, consistent with previously reported masses of the enzyme [11 ].
Expression of the full-length cABC II clone generated a protein largely present in
the insoluble fraction. The yield of soluble enzyme was greatly improved by the
engineered removal of the hydrophobic N-terminal signal sequence. We then turned our
attention to the truncated clones, both the original sequence and the transcript that
underwent our sequential mutagenesis resolution. Further preparation of the original
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Figure 5.3. Restoration of Recombinant Chondroitinase ABC I1 Activity. 
The original ( 0 )  expressed cABC I1 product had negligible activity against C6S substrate. 
Inspection of the genomic sequence of this clone revealed a series of point mutations at 
issue with previously reported sequences of cABC I1 purified from batch cultures of 
Proteus vulgaris. By implementing sequential mutagenesis steps, a clone was produced 
that, when expressed, provided cABC I1 (0)  that cleaved C6S at far greater rates. 
protein exposed an enzyme unable to effectively process GalAG substrates (Figure 5.3), 
as examined by tracking the absorbance (232 nm) of the double bond formed during the 
cleavage of GalAG substrates. Expression and purification of the manipulated gene 
generated a protein product with reinvigorated functionality as demonstrated by the 
observed cleavage of chondroitin-6-sulfate (Figure 5.3). 
5.4 Biochemical Conditions for Optimal Activity. 
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Figure 5.4. Chondroitinase ABC II Biochemical Reaction Conditions.
(A) Effect of reaction temperature. (B) pH profile in Tris buffer system. (C) pH profile in
sodium phosphate buffer system. For all panels: e, C6S; o, DS.
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We next sought to optimize reaction conditions for the cleavage of GalAG
polysaccharides by recombinant chondroitinase ABC II. To this end, we investigated
reaction properties so as to achieve maximal enzyme activity. These reaction parameters
included temperature, pH, ionic strength, and buffer system.
For C6S substrate, cABC II demonstrated maximal processing at 37*C, with a
greater than 50% decline in activity at 42*C (Figure 5.4). Chondroitinase ABC II
similarly acted on DS substrate maximally at 37"C, with a 50% drop at 42"C (Figure 5.4).
Activity against both substrates fell dramatically in excess of 45"C. For both C6S and DS
substrates, 37"C was chosen as the optimal temperature for biochemical experiments.
A Tris buffer system was chosen for biochemical experiments as it permitted
greater activity relative to phosphate buffer. The recombinant enzyme demonstrated
maximal activity at pH 8.0 for C6S. For DS, maximal activity occurred in the range from
pH 8.0 to 8.5. Chondroitinase ABC II processing of GalAG substrates is greatly curtailed
below pH 7.5 and above pH 8.8. For purposes of simplicity, pH 8.0 was taken as the
optimal pH for biochemical studies for both C6S and DS in a Tris buffer system.
For cABC I, ionic strength proved to be an important determinant in the
processing of GalAG substrates [10]. Chondroitinase ABC I required in excess of 50 mM
NaCl and 125 mM NaCI for the optimal processing of C6S and DS, respectively. Further,
chondroitinase ABC I was activated by addition of 50 to 100 mM sodium acetate in the
reaction buffer [10]. We explored the recombinant chondroitinase ABC II's requirements
for ionic strength with regard to GalAG cleavage. Our results indicate that NaCl
concentrations of approximately 100 mM NaCl reduce processing by 50% for both C6S
and DS substrates (Figure 5.5). Processing of C6S and DS is virtually eliminated in
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Figure 5.5. Salt Effects on Chondroitinase ABC II Processing.
(A) Sodium chloride titration. (B) Sodium acetate titration. For both panels: e, C6S; o,
DS.
excess of 250 mM NaC1. Additionally, we found that adding approximately 50 mM
sodium acetate for C6S and 100 mM sodium acetate for DS activates cABC II-mediated
processing. Depolymerization of GalAG substrate by cABC II is nearly completely
inhibited at 500 mM sodium acetate. Therefore, unlike cABC I, for cABC II the presence
of NaCl in the buffer actually decreases the activity.
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Table 5.2. Specific Activity of Recombinant Chondroitinase ABC II on
Glycosaminoglycan Substrates. a
Substrate
Chondroitin-6-sulfate
Chondroitin-4-sulfate
Dermatan sulfate
Chondroitin
Chondroitin sulfate D
Chondroitin sulfate E
Hyaluronan
Heparin/Heparan sulfate
Keratan sulfate
Specific activity
(milli-Units/mg protein)
29000
18000
17000
5400
4900
4900
n.d.
n.d.
n.d.
a Specific activity was determined by monitoring the increase in absorbance at 232 nm for
5 minutes. The initial rate of increase in A232 was determined for each substrate. The
enzyme activity in units (1 U = 1 iimole product formed / min.) was calculated from the
initial rate using E = 3800 M-1 for reaction products at pH 8.0.
5.5 Recombinant Chondroitinase ABC II-mediated Galactosaminoglycan Cleavage.
Having characterized a set of reaction conditions to optimize the cABC II-
mediated depolymerization of C6S and DS, we next assessed the specific activity of the
recombinant enzyme against a full panel of GAG substrates (Table 5.2). The results
suggest that cABC II is most proficient in degrading C6S, C4S, and DS substrates.
Chondroitin, chondroitin D, and chondroitin E were cleaved at lesser rates. We were
unable to detect reaction progression for hyaluronan, though this is most probably the
result of low cleavage rate and the use of a non-optimal pH for this substrate. As
expected, other GAG families, like heparin and heparan sulfate (which contain
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Table 5.3. Kinetic Analysis of Chondroitinase ABC II with Various Substrates. a
Substrate Km kcat kcat/ Km
gM min-  pM-1 min'
Chondroitin.-6-Sulfate 8.8 + 2.0 1400 ± 100 160
Dermatan Sulfate 19.2 ± 2.9 1200 ± 30 60
Chondroitin.-4-Sulfate 16.1 ± 4.2 1000 + 60 60
a Values are the mean of at least three experiments ± standard deviation.
glucosamine instead of galactosamine) were not processed by cABC II. Our analysis
further suggests that CS substrates are processed approximately ten-fold more efficiently
with cABC I[ (specific activity -300 units/mg protein) and DS substrates are processed
more than seven times more efficiently with cABC I (specific activity -120 units/mg)
than cABC II [10].
Kinetic parameters for recombinant cABC II acting on C6S, DS, and C4S are
summarized in Table 5.3. These measurements were obtained from the initial reaction
rates against each substrate using both Michaelis-Menten and Hanes analysis. The
turnover numbers for cABC II were experimentally determined to be 1400, 1200, and
1000 min- fbr C6S, DS, and C4S, respectively. The catalytic efficiency was highest
against C6S substrate (160 LM-' min-'), and comparable for DS and C4S (both 60 gM'
min').
Chondroitinase ABC II-mediated depolymerization of GalAG substrates was
further scrutinized with capillary electrophoresis. These studies allow for the
characterization of the final products of cABC II digestion following a 20 hour
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Figure 5.6: Product Profile Analysis of Recombinant Chondroitinase ABC II
Product profiles for cABC II acting on (A) C6S, (B) C4S and (C) DS (ADi4S = AUA-
GalNAc4S, ADi6S = AUA-GalNAc6S, ADi4S6S = AUA-GalNAc4S6S). Impurities in
commercial substrate preparations result in the ADi4S peak in electrophoretogram (A)
and the ADi6S peak in electrophoretogram (B).
exhaustive reaction at 37"C. Therefore these studies represent an end-point assay for
cABC II activity. For all substrates examined, the product profile contains an
overwhelming proportion of disaccharide products (Figure 5.6). For C6S, the dominant
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Figure 5.7. Comparative Processing by Chondroitinases ABC I and II.
Following exhaustive digestion with cABC I, DS is degraded to a mixture of products,
including disaccharides (see Figure 5.6 for label details) and a tetrasaccharide (Tetra) that
cABC I is unable to cleave further (A), despite the addition of supplementary enzyme and
longer digestion period. This tetrasaccharide can however be processed via cABC II-
mediated depolymerization (B).
product is a 6-O-sulfated disaccharide. For C4S, the major product is a 4-0-sulfated
disaccharide. With DS, a mixture of disaccharide products includes two mono-sulfated
species, the 4-O-sulfated DS disaccharide and the 6-O-sulfated DS disaccharide, and a
doubly-sulfated disaccharide, the 4-0-, 6-O-di-sulfated disaccharide. It should also be
noted that the amount of disaccharide released in each of these end-point assays is
considerably less (as measured by the double bonds generated i.e. A232 nm) when
compared with cABC I acting on each of these substrates. A possible explanation could
be that the enzyme (cABC II) acts more efficiently on the products generated by initial
cleavage of the substrate by cABC I. Alternatively, it is possible that since the enzyme
most likely acts exolytically on the substrate, it engages the substrate only at the non-
reducing end. While for shorter chains the substrate can bind in the active site effectively
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(thus allowing cleavage to take place), for longer saccharides this binding may be
energetically unfavorable due to entropy effects. Therefore the only disaccharide
products observed would represent those generated from the already small chains in the
mixture, after which the enzyme can no longer cleave any of the longer chains.
To address some of these issues we also looked into the action of cABC II on an
isolated tetrasaccharide from DS. A tetrasaccharide resistant to cleavage by cABC I was
previously examined and its composition was determined to be AUA-GalNAc4S-IdoA-
GalNAc4S by co-elution with a purified DS tetrasaccharide [10]. This tetrasaccharide
was placed in reaction with cABC II, which unlike cABC I, was able to degrade the
polymer further to disaccharides (Figure 5.7).
5.6 Chondroitinase ABC II Amongst the GalAG Depolymerizing Lyases
This report is the first to describe the expression of a stable, highly active,
contaminant-free recombinant chondroitinase ABC II from Proteus vulgaris. We further
examine this recombinant cABC II biochemically, including reaction conditions to
maximize enzyme efficacy, the product profile following digestion of GalAG substrates,
and kinetic analysis. Chondroitinase ABC I does cleave GalAG substrates at superior
rates to cABC II; however, depolymerization mediated by cABC II proceeds by a course
distinct from cABC I. Chondroitinase ABC I seems to prefer longer chain substrates and
cleaves in a predominantly endolytic fashion [10, 11]; cABC II, on the other hand,
degrades substrates to populations almost wholly represented by disaccharides. Thus,
recombinant cABC II most probably cleaves GalAG substrates by an exolytic mode of
action. This further suggests that cABC II has a preference for shorter chain rather than
longer chain substrates. Future studies will be directed at probing the action pattern [17,
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18] of cABC II: a characterization of its capacity to depolymerize linkages according to
position, sulfation pattern, chain length, and penultimate flanking residues.
A sequence alignment of cABC II against other chondroitinase enzymes (cABC I
from Proteus vulgaris, cAC I from Arthrobacter aurescens, and cAC II from Pedobacter
heparinus) and hyaluronate lyase from Streptococcus pneumoniae suggests that a
catalytic tetrad, crucial in enzyme activity, is conserved and at work in all of these
enzymes (Figure 5.8). The structures of various chondroitinases and hyaluronate lyase
have been previously determined [6, 9, 10, 19-21], and they each share similar structural
features with regard to the domain configurations that make up the proteins. Given the
sequence similarity evident with the conservation of residues and domain folds shared
among these enzymes, it would not be unreasonable to surmise that cABC II would also
share considerable structural homology. Crystallographic studies on cAC I
(predominantly exolytic) and cAC II (predominantly endolytic), both of which act on the
same substrates (C4S and C6S) via distinct mechanisms, have revealed that key structural
differences are reflective of the action pattern of the enzyme [19, 22]. While the active
site of cAC II resembles an open tunnel through which longer substrates can pass, in cAC
I, additional sequence insertions seem to close off one end of the substrate-binding site.
Structurally,, this limitation of access is consistent with the exolytic action pattern of this
enzyme. Therefore, it will be interesting to further study the structure of cABC II to see if
it also has similar structural constraints that define is capacity to process GalAG
substrates. An understanding of the structure and mechanism of action of cABC II would
therefore extend our understanding of precisely how these lyases function, and how
various structural features contribute to the depolymerization process. Further, the
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differential processing by which cABC I and cABC II (as well as cAC and cB) degrade
GalAG polymers will be valuable in their tandem use in technologies directed at
determining the fine structural elements of biologically relevant GalAGs [23]. These
enzymes may further be useful directly in strategies to interfere with GalAG function in
vivo, for example, in neural regeneration therapeutics.
cABC I 468 NLVNTFSHYITGALTQVPPGGKDGLRPDGTAWRHEGNYPGYSFPAFKNASQLIYLLRDTP
CABC II 422 QALAQLQSWLNKTILSSK-GVAGGFKSDGSIFHHSQHYPAYAKDAFGGLAPSVYALSDSP
CAC II 220 ----- YSYL---------------------QHGPQLQISSYGAVFITGVLKLANYVRDTP
cAC 1 228 -G----SFI---------------------QHSTTPYTGSYGVVLLTGLSKLFSLLGGTA
HA lyase 394 -----GSYI---------------------DHTNVAYTGAYGNVLIDGLSQLLPVIQKTK
CABC I 528 FSVGESGWNNLKKAMVSAWIYSNP--EVGLPLAGRHPFNSP----SLKSVAQGYYWLAMS
CABC II 481 FRLSTSAHERLKDVLLKMRIYTKET-QIPVVLSGRHPTGLH----KIGIAPFKWMALAGT
cAC II 254 YALSTEKLAIFSKYYRDSYLKAIRGSYMDFNVEGRGVSRPD----ILNKKAEKKRLLVAK
cAC 1 262 FEVSDPTRSIFFDAVEGSFAPVMINGAMADAVRGRSISREANTGYDLGASAIEAILLLAR
HA lyase 428 NPIDKDKMQTMYHWIDKSFAPLLVNGELMDMSRGRSISRANSEGHVAAVEVLRGIHRIAD
cABC I 626 NGGAFGIHR--WQDKMVTLKAYNTNVWSSEIYNKDNRYGRYQSHGVAQIVSNGSQLSQGY
CADC II 582 QRRASTQSP--QQSWLAIARGFSRYLVGNESYENNNRYGRYLQYGQLEIIP-ADLTQSGF
cAC II 344 WNGDYVQHL--RPAYSFNVRMVSKRTRRSESGNKENLLGRYLSDGATNIQLRGPEYYN--
cAC I 38 PAMDRTMHR--GPGWALSLALSSNRIAWYECGNGENNRGYHTGSGMTYFYTSDLGQYDDA
HA lyase 548 NKMDKTAMYNAEKGFGFGLSLFSSRTLNYEHMNKENKRGWYTSDGMFYLYNGDLSHYSDG
Figure 5.8. Analysis of the Chondroitinase ABC II Sequence.
ClustalW sequence alignment of chondroitin lyases and hyaluronate lyase show a
conserved tetrad of active site residues (highlighted in bold red) evident among this entire
group of GAG-degrading enzymes (cABC I and II, chondroitinase ABC I and II from
Proteus vulgaris, respectively; cAC II, chondroitinase AC from Pedobacter heparinus;
cAC I, chondroitinase AC from Arthrobacter aurescens; and HA lyase, hyaluronate lyase
from Streptococcus pneumoniae). Note that only the pertinent portions of the entire
sequences are shown.
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Conclusions
The current chapter provides the biochemical foundation with which to develop
chondroitinase ABC II both as a potential therapeutic (for example, in neural
regeneration strategies) and as a tool for the sequencing of complex polysaccharides. This
report is the first to achieve a system for the production ofcontaminant-free, highly pure
chondroitinase ABC II in large yield. The predominantly exolytic nature of
chondroitinase ABC II distinguishes it from its predominantly endolytic sibling,
chondroitinase ABC 1. This distinction thus provides an additional tool for the
technologist who wishes to manipulate with precise control the structure ofchondroitin
and dermatan polysaccharides. Future studies on the catalytic machinery of
chondroitinase ABC II will offer insights into the specific approaches to
glycosaminoglycan depolymerization by lyases generally.
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Chapter 6
Protein Engineering
Summary
The complex chemical topology ofchondroitinase ABC I and its broad substrate
specificity provide serious impediments to elucidating the enzyme's mode of action.
Especially puzzling is the enzyme's ability to degrade such a broad range ofsubstrates.
Chondroitinase ABC I can process substrates containing either uronic acid epimer. This
necessitates the ability to abstract the C-5 proton from either uronic acid configuration,
that is, from either side of the sugar ring. This may imply the existence of "redundant"
sets of catalytic machinery uniquely configured to discriminate between related
substrates with highly specific chemical patterns. Chondroitinase ABC I is also capable
of degrading hyaluronan, so that the enzyme 's catalytic range spans both galactosamine-
and glucosamine-containing polysaccharides. These circumstances entreat the possibility
of engineering enzymes with novel substrate specificities or action patterns by
modulating the enzyme's determinants ofspecificity. Here, we take the structural context
established for cABC I several steps further and design enzymes with refined specificity.
By engineering such variants with diminished substrate promiscuity, we achieve a
greater understanding of the mechanism of action of GalAG-depolymerizing enzymes and
allow for a more rigorous use of GalAG-degrading strategies for potential medical
therapies. This work is in preparation for the Proceedings of the National Academy of
Sciences, and is included here with permission.
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6.1 Introduction
Recent reports describe a broad-substrate specificity enzyme from the bacterium
Proteus vulgaris, chondroitinase ABC I, that degrades CS, DS and hyaluronan substrates
[1, 2]. A crystal structure of this enzyme revealed very little sequence identity when
compared with a related enzyme, chondroitinase AC from Pedobacter heparinus, though
the residues important for catalysis in chondroitinase AC are conserved in chondroitinase
ABC I [3]. Our group has further expressed cABC I recombinantly and identified the
enzyme active site. Also, we have assessed the enzyme's ability to depolymerize a
variety of GAG substrates and probed the importance of specific catalytic residues
involved in GAG-processing [2, 4].
The complex chemical topology ofcABC I and its broad substrate specificity
provide serious impediments to elucidating the enzyme's mode of action. Especially
puzzling is the enzyme's ability to degrade substrates containing either uronic acid
epimer. This necessitates the ability to abstract the C-5 proton from either uronic acid
configuration, that is, from either side of the sugar ring. This may imply the existence of
"redundant" sets of catalytic machinery uniquely configured to discriminate between
related substrates with highly specific chemical patterns. Such a condition presents the
possibility of engineering enzymes with novel substrate specificities or action patterns by
modulating these determinants of specificity. One might imagine that enzymatic
machinery comprises units, often single amino acids and sometimes groups of residues,
which are responsible for specific aspects of catalysis. These include units that provide a
substrate recognition motif; a substrate binding pocket; substrate positioning machinery;
active site residues responsible for the different chemical steps within a catalytic
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mechanism; and substrate processing or release residues. Mutagenesis studies might be
employed to ablate or manipulate one or more of these roles, providing a mutant enzyme
with altered properties. Such a novel tool may provide an enzyme with an altered action
pattern, substrate specificity, kinetic rate, or other favorable property.
In this study, we take the structural context established for cABC I several steps
further and design enzymes with refined specificity. By engineering such variants with
diminished substrate promiscuity, we achieve a greater understanding of the mechanism
of action of GalAG-depolymerizing enzymes and allow for a more rigorous use of
GalAG-degrading strategies for potential medical therapies, such as neural regeneration
treatment following spinal cord injury [5]. In fact, it might be the case that a broad
substrate specificity enzyme comprises an imprecise 'sledgehammer' approach to this
treatment, where cleavage of a great variety of GAG moieties takes place, instead of a
precise approach to target only desired sequences. Thus, an engineered enzyme of a
desired specificity might provide a more effective treatment and improved outcome,
lowering systemic toxicity or collateral tissue damage through more precise action.
6.2 Active Site Topology
Chondroitinase ABC I [Figure 6.1] shares little sequence homology with
chondroitinase AC over the entire length of the protein. However, the residues that are
critical for catalysis in chondroitinase AC have analogues in chondroitinase ABC I. The
chondroitinase ABC I active site contains a number of basic residues. While some of
these have structural analogues in the chondroitinase AC and hylauronate lyase co-crystal
structures, there are numerous others that are unique to chondroitinase ABC I. The highly
basic nature of the active site is potentially involved in the accommodation of a wide
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Figure 6.1: Structural representation of chondroitinase ABC I.
Shown in full in blue is the catalytic tetrad of chondroitinase ABC I, comprising the
residues His501, Arg560, Tyr508, and Glu653. Shown on the opposite cleft are two
histidine residues, His388 and His389. The wide active site cleft of chondroitinase ABC I
provides enough space for a variety of substrates, and even provides room for a dermatan
sulfate substrate to properly position for each step of catalysis.
variety of substrates, including C4S, C6S, DS, and hyaluronan, which have different
charge distributions due to their differences in sulfation pattern. His561 and Asn564 are
positioned to interact with the 4-0 sulfate group of the GalNAc4S at the -1 subsite,
present in both C4S and DS. Furthermore, several additional basic amino acids, including
His388, His389, Arg395, Argl05, and Lys312 are located on the upper side of the
catalytic cleft towards the N-terminal f3-sheet domain. These basic amino acids could
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play a potential role in governing the specificity of chondroitinase ABC I towards 
different substrates. 
Arg560 is also worth consideration. The proximity of Arg560 to the C-5 atom and 
the glycosidic oxygen suggests that it may play a role in proton donation and/or 
stabilization of the carbanion intermediate following proton abstraction. It is more likely 
to play the latter role since proton donation can be compensated via neighboring water 
molecules. Also, the Tyr508 is better positioned to protonate the leaving group based on 
our model. Arg560 could potentially play an additional role in neutralizing the 
carboxylate of the IdoA in DS based on its proximity to this group in the modeled cABC 
I-dermatan structural complex. Our structural model of the cABC I-CS complex and the 
earlier crystal structure studies [3,6] suggest that Arg5OO is likely to neutralize the 
charge on the carboxylate group of GlcA in CS. However, our studies of the Arg500Ala 
mutant do not conclusively justify this role since this mutant retains its activity towards 
chondroitin and dermatan substrates [I]. 
The active site topology at play in the chondroitinase ABC I-mediated 
depolymerization of chondroitin sulfate and dermatan sulfate was exploited to create 
mutants with altered substrate specificity. First, a mutant was sought after that cleaves 
chondroitin-4-sulfate and chondroitin-6-sulfate, but not dermatan sulfate. Here, it would 
be necessary to effectively knockout the enzyme's ability to negotiate cleavage of 
iduronic acid-containing moieties. Second, a mutant was sought after that cleaves 
dermatan sulfate, but not any species of the glucuronic acid-containing chondroitin type. 
Our understanding of the active site topology led us to consider the residues His388 and 
Arg560 as potentially important in substrate differentiation processes. 
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Figure 6.2: Recombinant expression of chondroitinase ABC I mutants.
In (A), on the left is an SDS-PAGE of the His388Ala mutant protein: lane 1, cell pellet;
lane 2, crude lysate; lane 3, Invitrogen SeeBlue Plus2 pre-stained standard (97 kDa); lane
4, chondroitinase ABC I His388Ala. On the right is an SDS-PAGE of the Arg560Lys
mutant: lane 1, Invitrogen SeeBlue Plus2 pre-stained standard (97 kDa); lane 2, cell
pellet; lane 3, crude lysate; and lane 4, the chondroitinase ABC I Arg560Lys mutant.
Circular dichroism studies are shown in (B). The recombinant chondroitinase ABC I
(pink) and the mutants His388Ala (blue and Arg560Lys (yellow) were concentrated and
buffer-exchanged into 50 mM sodium phosphate buffer, pH 8.0. Proteins were analyzed
in a quartz cell with a 1 mm path length. All spectra were collected using a protein
concentration of 0.2 mg/ml in sodium phosphate, pH 7.0.
6.3 Mutagenesis and Protein Expression
Site-directed mutagenesis studies were employed to introduce mutations at
specific positions within the chondroitinase ABC I sequence that were believed to be
important in the enzyme's ability to distinguish between chondroitin and dermatan
substrates. First, a transcript was created that replaced histidine at the 388 position with
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Figure 6.3. Product profiles of the His388Ala mutant. 
The chondroitinase ABC I His388Ala mutant acting on (A) C6S and (B) DS. 
alanine (His388+Ala). Next, a transcript was created that replaced arginine at the 560 
position with lysine (Arg56O+Lys). These were then recombinantly expressed in E.coli 
as fusion proteins incorporating a hexa-histidine tag. SDS-PAGE analysis [Figure 6.21 
revealed bands for each mutant at -1 10 kDa, in close agreement with previously reported 
masses of chondroitinase ABC I [4,7, 81. Circular dichroism spectroscopy was used to 
assess the overall secondary structure of the proteins. The resulting spectra displayed a
high a-helix and f3-sheet content [Figure 6.2]. These results are in close agreement with
the CD spectra for wildtype chondroitinase ABC I, suggesting that there are no gross
structural anomalies introduced through mutagenesis of these residues.
6.4 Substrate Specificity Assessments
The activity of the His388Ala mutant was analyzed in an end-point assay by
capillary electrophoresis, following a digestion of 18 h in duration at 370C. An exhaustive
digest of chondroitin-6-sulfate with His388Ala resulted in a complete product profile,
that is, similar to wildtype behavior. The product profile shows predominantly
disaccharide and some tetrasaccharide products [Figure 6.3]. The predominant product of
His388Ala-mediated digestion of C6S substrate was AUA-GalNAc6S, where AUA
represents A4,5 unsaturated uronic acid and GalNAc is N-acetylgalactosamine sulfated at
the 6-O-position. In the case of dermatan sulfate, the His388Ala mutant was unable to
cleaves the substrate, as evidenced by the complete lack of peaks in the capillary
electrophoretic investigation [Figure 6.3].
The activity of the Arg560Lys mutant was similarly inspected for activity against
chondroitin-6-sulfate and dermatan sulfate. Following an exhaustive digest, Arg560Lys
was shown to be completely inactive against chondroitin-6-sulfate [Figure 6.4].
Arg560Lys was, on the other hand, able to mediate the depolymerization of dermatan
sulfate substrate [Figure 6.4]. Here, the final products of digestion are a mixture
disaccharides and tetrasaccharides. These include the tetrasaccharide AUA-GalNAc4S-
IdoA-GalNAc4S (determination based on co-elution with a previously isolated pure
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Figure 6.4. Product profiles of the Arg560Lys mutant.
The chondroitinase ABC I Arg560Lys mutant acting on (A) C6S and (B) DS.
dermatan tetrasaccharide having the same structure), and the disaccharides ADi4S,
ADi6S, and ADi4S6S.
The activity of the His388Ala mutant and the Arg560Lys mutant, as assessed by
kinetic assay, are summarized in Table 6.1. His388Ala catalyzed the depolymerization of
chondroitin.-6-sulfate and chondroitin-4-sulfate. Dermatan sulfate cleavage was not
detectable in the kinetic assay. His388Ala had a Km of 10.0 ýM against chondroitin-6-t t l  i  t  i ti  ti  
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Table 6.1. Kinetics Analysis: Mutagenesis Studies.
Enzyme Substrate Km [ItM] keat [min-1]
His388Ala Chondroitin-6-sulfate 10.0 ± 3.5 1802.4 ± 11.2
His388Ala Chondroitin-4-sulfate 6.8 453.6
Arg560Lys Dermatan sulfate 24.5 ± 14.7 26.8 ± 0.2
Results are the means ± S.D. for at least three experiment, except in the case of
His388Ala with chondroitin-4-sulfate as the substrate, where the prohibitive cost of the
substrate allowed only one run.
sulfate and a kcat of 1802.4 min1 . With chondroitin-4-sulfate as the substrate, His388Ala
had a Km of 6.8 gM and a kat of 453.4 min'. For both substrates, the efficiency of
enzyme action is lower than for wildtype enzyme (wildtype catalytic efficiency against
chondroitin-6-sulfate is 31000 pM I' min- versus 180 LpM' min1' for His388Ala and
wildtype catalytic efficiency against chondroitin-4-sulfate is 35000 PM-1 min-' versus
66.4 NM-1 min 1 for His388Ala) [1]. The mutant enzyme nonetheless catalyzes the
depolymerization of chondroitin, but not dermatan, substrates.
Arg560Lys was unable to mediate the degradation of chondroitin-6-sulfate or
chondroitin-4-sulfate, as assessed by kinetic experiment [Table 6.1]. Against dermatan
sulfate, Arg560Lys had a Km of 24.5 pM and a kat of 26.8 min'. Wildtype
chondroitinase ABC I is far more catalytically efficient, with ket/Km of 11000 pM-' min'
versus a catalytic efficiency of 1.1 pM-' min-' for Arg560Lys.
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6.5 Modulating the Determinant of Specificity
The examples of mutant enzymes presented here demonstrate a strategy to alter
the attributes of GAG lyases for use in a variety of applications [9-13]. For example, the
use of chondroitinase ABC I in neural regeneration therapies for spinal cord injury,
though promising, have been associated with systemic toxicity and death.[5, 14, 15]. This
may in part be due to the non-specific nature of lyase activity of wildtype chondroitinase
ABC I. A less extreme version of the lyase that specifically targets the inhibitory (to
neural regeneration) chondroitin moieties would likely cause less systemic injury and
improved patient outcome.
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Conclusions
Detailed structural information regarding chondroitinase ABC I-substrate
complexes has not been available due to difficulties in crystallographic studies. Our
studies on the structure and biochemical topology of the enzyme were employed to
develop proteins with engineered attributes. Two example proteins were created: a
mutant of chondroitinase ABC I that cleaves both chondroitin-4-sulfate and chondroitin-
6-sulfate but not dermatan sulfate, and another mutant that cleaves dermatan sulfate but
not glucuronic acid-containing chondroitin species. Other mutants with altered substrate
specificity have been created but are not described here. These include mutants that
selectively cleave chondroitin-6-sulfate only; a variant that cleaves chondroitin-4-sulfate
(an activity that has not been found in nature); and a mutant of chondroitinase B which
provides an altered product profile. These mutants, and others that may in the future be
designed, represent a spectrum of enzyme activities against glycan species which may be
employed in a number of biotechnology applications.
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Thesis Summary and Future Work
The work described here is an integral part of a larger multidisciplinary strategy
to develop and integrate technologies associated with complex polysaccharides important
in disease processes. A central goal is to ultimately develop novel therapeutic approaches
to alleviate suffering from disease and promote overall human health.
For decades, biomedical scientists have been primarily concerned with
intracellular events at the genetic and protein levels. Recently, a wealth of new
information has revealed that the extracellular environment exerts tremendous influence
in both normal and aberrant pathophysiology. Thus, we are concerned with a third class
of important biomolecules that occur extracellularly, the glycans. To this end, this work is
geared toward the development and extension of a variety of technological platforms that
could advance our understanding of human health and disease. By coupling engineering
and computational approaches, we have sought to elucidate complex biomedical
phenomena.
Within the fields of molecular biology and enzymology lie important avenues
leading towards the analysis of glycan properties and function. Much like restriction
enzymes selectively cleave DNA at specific sites, a variety of enzymes in nature degrade
complex carbohydrates for the purposes of providing organisms nutrition and entry into
host cells. Using molecular biology and biochemical techniques, we seek to harness and
engineer these activities and systematically probe the importance of glycan components.
Many of these enzymes themselves could hold therapeutic value, either in their natural
form or through their manipulation using protein engineering strategies.
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Analytical chemistry platforms provide complementary information on various
aspects of glycan structure. However, the relative paucity of available glycan material,
the inability of investigators to amplify glycans, the high-negative charge of glycans, and
their chemical heterogeneity all serve to stymie glycan analysis. Our efforts serve to
ameliorate this situation through the development of a variety of platforms that make
available intricate information regarding the nature of glycans.
In this work we describe the cloning and recombinant expression of
chondroitinase ABC I, a glycosaminoglycan-degrading lyase from Proteus vulgaris that
acts across a variety of polysaccharides and has been elusive to many investigators. We
next probed the roles of specific amino acids in the catalytic degradation of
glycosaminoglycan substrates by chondroitinase ABC I. Through various experimental
inquiries we have probed the three-dimensional nature of biomolecules that dynamically
interact with glycans. These efforts included studies of the conformational geometry of
glycans; X-ray crystallographic investigations; and computational models of glycan-
protein interactions. Our modeling studies coupled with systematic biochemical
experimentation offered an intricate characterization of the active site topology of
chondroitinase ABC I. We further established the existence of chondroitinase ABC I's
dual substrate scaffold, where the catalytic machinery of the enzyme differentially
processes substrates according to glycosaminoglycan class using a calcium ion
coordination strategy. We further established a recombinant chondroitinase ABC II from
Proteus vulgaris, and analyzed this enzyme biochemically. Chondroitinase ABC II
differs from chondroitinase ABC I according to action pattern, and indeed it has become
evident that the enzymatic action of both lyases is required to degrade long-chain
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polysaccharides completely to disaccharides. These efforts, in addition to our ongoing
studies of chondroitinase AC and chondroitinase B from Pedobacter heparinus,
constitute a complementary collection of enzymes (and engineered variants) which are
powerful tools to deconvolute the complex functional information encoded by
chondroitin sulfate and dermatan sulfate chemical structure.
Oligosaccharide chains of nervous system origin influence a wide array of
biological processes. Through these same processes, glycans play an essential role in
neural development. Perhaps the most provocative evidence for the key role of complex
polysaccharides in neural development are recent findings demonstrating that these
sugars are critical in cytokinesis and morphogenesis during the early embryonic stages of
the nematode, Caenorhabditis elegans. Futhermore, glycans have also been implicated as
a major deterrent to the regeneration of axons following traumatic injury to the brain and
spinal cord. Such injuries typically result in paralysis, and the chances for recovery for
spinal cord injury patients are infinitesimally small. Our future work includes exploring
various glycan-based strategies geared toward alleviating these conditions.
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Appendix I
Chapter 4, Part 2: Methods
Materials
Porcine intestinal mucosa DS (average MW 35,000 g/mol) and shark cartilage
chondroitin-6-sulfate (C6S, average MW 50,000 g/mol) were purchased from Sigma.
Oligonucleotides were purchased from Invitrogen. The QuikChange Site-Directed
Mutagenesis Kit was purchased from Stratagene. The QIAprep Spin Miniprep Kit was
purchased from Qiagen. Protein concentration was measured using the Bio-Rad
Laboratories Bradford assay kit. Chelex resin was purchased from Bio-Rad. TbCl3 was
purchased friom Aldrich. All other materials are from common sources or are as noted
below.
Site-directed Mutagenesis of Chondroitinase ABC I
The development of recombinant cABC I and the methods used to produce cABC
I mutants are previously described [1]. The primer sequences for each of the mutants are
listed below. The Asp439Ala mutant primers have the sequences 5'- GAT ATG AAA
GTA AGT GCT GCT AGC TCT GAT CTA G-3' and 5'- C TAG ATC AGA GCT AGC
AGC ACT TAC TTT CAT ATC-3'. The Asp442Ala mutant primers have the sequences
5'- GT GCT GAT AGC TCT GCT CTA GAT TAT TTC AAT ACC-3' and 5'- GGT
ATT GAA ATA ATC TAG AGC AGA GCT ATC AGC AC-3'. The Asp444Ala mutant
primers have the sequences 5'- AGC TCT GAT CTA GCT TAT TTC AAT ACC TTA
TCT CGC C-3' and 5'- G GCG AGA TAA GGT ATT GAA ATA AGC TAG ATC AGA
GCT-3'. The Asp490Ala mutant primers have the sequences 5'- CCG GGT GGT AAA
GCT GGT TTA CGC CCT-3' and 5'- AGG GCG TAA ACC AGC TTT ACC ACC
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CGG-3'. The Tyr392Ala mutant primers have the sequences 5'- CC CAT CAC TGG
GGA TTC AGT TCT CGT TGG TGG-3' and 5'- CCA CCA ACG AGA ACT GAA
TCC CCA GTG ATG GG-3'. Plasmids were prepared using a miniprep kit and each
clone was sequenced to confirm the incorporation of the desired mutation.
Protein Expression and Purification
Recombinant cABC I and the site-directed mutants were expressed and purified
as previously described [2]. Protein purity was assessed by SDS-polyacrylamide gel
electrophoresis analysis using precast Invitrogen NuPAGE 12% Bis-Tris gels, the XCell
SureLock Mini-Cell and Simply Blue SafeStain. Protein content was assessed by
standard methods using a Bradford assay kit with bovine serum albumin (Sigma) as a
standard. In order to ensure that there were no structural perturbations in the mutant
enzymes when compared to recombinant cABC I, a structural characterization was
undertaken using circular dichroism (CD). Recombinant proteins were concentrated and
buffer-exchanged into 50 mM sodium phosphate pH 7.5 using Centricon 10 filters
(Millipore). Protein content was assessed using the Bradford assay. CD spectra were
recorded at 25"C on an Aviv 202 CD spectrophotometer using Quartz cuvettes with an
optical path length of 0.1 cm. Scans were collected between 300 and 195 nm with a 1.0-
nm bandwidth and a scan rate of 1 nm/min. Three scans were averaged for each protein.
All spectra were collected using a protein concentration of 0.2 mg/ml. For melting
experiments, spectra were collected from 5"C to 80*C.
Fluorescence Spectrometry
For terbium titrations of cABC I, aliquots of a terbium stock solution in 10mM
MOPS and 0.1 M KC1, pH 7.0 were added to a solution containing 5 pLM cABC I. The
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concentration of the terbium solution was determined by EDTA titration in the presence
of a xylenol orange indicator [3]. To ensure accurate readings, all solutions (except the
terbium stock) were run through a chelating column (Chelex resin) to remove trace
contaminants. After terbium addition, the sample was mixed and allowed to come to
equilibrium for 15 min. Fluorescence measurements were recorded on a Cary Eclipse
fluorescence spectrophotometer. The geometry of fluorescence detection was 900. All
experiments employed a quartz cell with a 1.0-cm path length. The excitation wavelength
was either 488 nm (direct excitation of terbium) or 280 nm (excitation of proximal
tyrosine residues) and the emission wavelength was 545 nm. Experiments involving
divalent ion competition titrations of cABC I were also performed. To a solution of
cABC I and 6 mM terbium, a calcium solution was added. After addition, the solution
was mixed and allowed to stand for 15 min before being measured.
Competition Experiments
For these studies, C6S and DS were dissolved at a 1 mg/mL concentration in 50
mM Tris pHI 8.0 (no salt) containing a fixed concentration (10mM) of different divalent
ion salts (CaC12, MgSO 4, MnC12, and ZnC12). Recombinant cABC I (0.2 jig) was added
to each of these solutions and the activity of the enzyme was assessed based on the
change in absorbance at 232 nm (A232 / minute). These experiments were carried out on a
SpectraMax 190 (Molecular Devices) using a 96 well quartz plate as previously described
[1]. The temperature was set at 370C for these experiments and enzyme activity was
calculated based on the initial rate of product formation.
281
Docking Models
The docking of CS and DS substrates into the active site of cABC I was
performed as previously described [2]. The Viewer and Discover modules of InsightlI
(Release 2000.1; Accelrys, San Diego, CA) were used for the orientation of the substrate
and the energy minimization.
Chondroitinase ABC IActivity Assessments
A kinetic analysis of cABC I employed our semi-high throughput
spectrophotometric approach and is essentially as previously described [1]. Briefly, 1 tl
of 0.2 tg/tl cABC I was added to 249 jil of a solution containing DS or C6S in 50 mM
Tris-HC1, 50 mM sodium acetate, 10 mM calcium chloride pH 8.0. Each well contained
different substrate concentrations ranging from 0.1 to 5 mg/ml. Product formation was
monitored by measuring the absorbance at 232 nm every 2 seconds. To evaluate the
kinetic data, the initial reaction rate (vo) was first determined from the value of the slope
from the plot of product formation as a function of time. The values of Vmax and Km were
extracted from the slope and y-intercept of the Hanes plot generated by monitoring the
product formation. A molar absorptivity coefficient (s) for the product of the enzymatic
reaction of 3,800 M-'ncm' was used. The calculated value for the path length of the well
using 250 pl1 volume for the reaction was 0.904 cm. The analyses were performed in
triplicate.
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Chapter 5 Methods
Isolating Chondroitinase ABC IlIfrom Proteus vulgaris
Genomic DNA was isolated from cultures of P. vulgaris (ATCC # 6896) using a
DNeasy purification kit (Qiagen). Primers were designed based on the available sequence
of the gene for both the full-length and mature versions [4]. Forward primers were
designed so as to incorporate an Nde I restriction site; the reverse primer was designed to
incorporate BamHI and Xho I restriction sites. This allowed cloning into a pET-28a
vector (Novagen). The primers for cloning cABC II have the sequences: 5'-
CATATGCTAATAAAAAACCCTTTAGCCC-3' (forward primer for the full length
gene), 5'-CATATGTTACCCACTCTGTCTCATGAAGC-3' (forward primer for the
truncated gene), and 5'-GGATCCTCGAGTTACTTAACTAAATTAATAACAGTAGG-
3' (reverse primer). PCR was run using genomic DNA as template with an extension time
of 3 min. The PCR product was ligated into the pCR 4-TOPO vector using the TOPO TA
Cloning Kit (Invitrogen) and transformed into TOP10 E. coli cells. Plasmid DNA was
isolated and the cABC II gene was excised by exploiting the Nde I and Xho I restriction
sites. The excised gene was ligated into similarly digested pET28a. These ligation
products were transformed into DH5a E. coli cells. Plasmid DNA isolated from the
colonies was screened by restriction digestion for incorporation of the cABC II gene.
Sequencing was also undertaken to confirm incorporation of the gene. E. coli cells
[BL21(DE3)] were transformed with plasmid DNA for expression.
Protein Preparation
Recombinant cABC II was expressed in E. coli using an adapted version of a
previous approach [1, 5]. The pET28a expression system contains an inducible T7
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promoter, as well as an N-terminal 6x-histidine tag for facile purification. Cultures of
Luria-Bertani broth containing kanamycin were inoculated, induced with 1 mM
isopropyl-13-D-thiogalactopyranoside (IPTG) in mid-log phase (OD 600 - 0.8), and
incubated at room temperature overnight. Centrifugation was used to harvest the cells and
the supernatant was discarded. The cell pellet was kept on ice and re-suspended in 50
mM Tris, 250 mM NaCl, 10 mM imidazole, pH 7.9 (binding buffer), and then lysed by
sonication. Soluble protein was collected by centrifugation at 15,000g for 15 min at 4"C.
The soluble lysate was sequentially filtered through a 0.8 pm and then a 0.45 gm
membrane. A 5 ml Hi-Trap Metal Chelate column (Pharmacia-Biotech) was prepared by
charging with 200 mM NiSO4 and treatment with binding buffer. The protein was loaded
onto the column, washed with a buffer containing 100 mM Tris, 250 mM NaCl and 50
mM imidazole and eluted into a similar buffer with increased imidazole (250 mM). The
6x-histidine tag was removed using the Thrombin Capture Kit (Novagen) as previously
described [6]. The presence and purity of the proteins was assessed by standard methods
using SDS-polyacrylamide gel electrophoresis. Protein concentration was measured using
the Bradford assay (Bio-Rad Laboratories) with bovine serum albumin (Sigma) as a
standard.
Mutagenesis Studies
The QuikChange Site-Directed mutagenesis Kit (Stratagene) was used with
plasmid DNA template to induce mutations in the cABC II clone. As previously
described [1], plasmid denaturation and annealing of custom-crafted complementary
oligonucleotide primers were used to introduce mutations. The primers designed as
follows (all primers are read in the 5'4 3' orientation): the 5' I23T primer had the
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sequence gaa ggt gaa tta ccc aat acc ctt acc act tc and 3' I23T primer had the sequence ga
agt ggt aag ggt att ggg taa ttc acc ttc; the 5' G247V primer had the sequence tgg gaa aaa
ttg gtg tta aca caa cac gct gat ggc and the 3' G247V primer had the sequence gcc atc agc
gtg ttg tgt taa cac caa ttt ttc cca; the 5' R356W primer had the sequence cc aga gaa ctt ttt
gat gca tgg ttt att ggc cgt c and the 3' R356W primer had the sequence g acg gcc aat aaa
cca tgc atc aaa aag ttc tct gg; the 5' D389N primer had the sequence gga cgt att ttt gaa aaa
aat aat gaa att gtt gat gca aat gtc and the 3' D389N primer had the sequence gac att tgc atc
aac aat ttc att att ttt ttc aaa aat acg tcc; and the 5' H490R primer had the sequence cgc tta
tct act tca gca cat gag cgt tta aaa gat g and the 3' H490R primer had the sequence c atc ttt
taa acg ctc atg tgc tga agt aga taa gcg. Extension of the primers in a PCR machine with
PfuTurbo DNA polymerase followed. The mutated plasmids were transformed into XL1-
Blue supercompetent cells. The plasmids were prepared using a Qiagen miniprep kit.
Each clone was sequenced to confirm the presence of the desired mutation. Plasmid DNA
was used to transform BL21(DE3) E. coli.
Product Composition Analysis
To investigate the composition of the final products of cABC II digestion,
capillary electrophoresis (CE) was performed as previously described [7]. Substrates
included C6S from shark cartilage (Sigma), DS from porcine intestinal mucosa (Sigma),
and C4S from sturgeon notochord (Seikagaku). Exhaustive overnight digestions of
substrate by cABC II analyzed using a Hewlett Packard 3D CE instrument with an
extended path-length cell. A voltage of 30 kV was applied using reverse polarity.
Oligosaccharides were injected into the capillary using hydrodynamic pressure. They
were detected using an ultraviolet detector set to 232 nm.
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Characterization of Chondroitinase ABC IIActivity
Substrates (C6S and DS) were dissolved at 1 mg/ml concentration in various
buffers in order to determine the relative effects of pH, temperature, ionic strength, and
sodium acetate concentration on enzyme activity, as previously described [1].
Chondroitin from shark cartilage (Seikagaku), hyaluronan from human umbilical cord
(Sigma), heparin (Celsus), heparan sulfate (Celsus), and keratan sulfate (Sigma) were
also used in these studies. For activity experiments, 2 pC of enzyme was placed in 248 Rl
of 50 mM Tris/HCl pH 8.0 and reacted with 1 mg/ml substrate at 37"C (0.25 mg/ml for
hyaluronan). Product formation was monitored as an increase in absorbance at 232 nm as
a function of time in a SpectraMax 190 (Molecular Devices) 96-well quartz format. For
kinetic assays, 1 pl of enzyme (0.2-1.0 glg/pl) was added to 249 gl of a solution
containing a GalAG substrate. Substrate concentration ranged from 0.1 to 5 mg/ml.
Product formation was monitored by measuring the absorbance at 232 nm every 2 s.
Kinetic parameters were determined using the initial rate of product formation and
calculated as previously described based on Michaelis-Menten and Hanes techniques [1].
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Chapter 6 Methods
Mutagenesis Studies and Recombinant Expression
The QuikChange Site-Directed mutagenesis Kit (Stratagene) was used with
plasmid DNA template to induce mutations in the cABC II clone. As previously
described [1], plasmid denaturation and annealing of custom-crafted complementary
oligonucleotide primers were used to introduce mutations. Primer design was
implemented using standard procedures. Extension of the primers in a PCR machine with
PfuTurbo DNA polymerase followed. The mutated plasmids were transformed into XL1-
Blue supercompetent cells. The plasmids were prepared using a Qiagen miniprep kit.
Each clone was sequenced to confirm the presence of the desired mutation. Plasmid DNA
was used to transform BL21(DE3) E. coli.
Recombinant cABC I mutants were expressed in E. coli using an adapted version
of a previous approach [1, 5]. The pET28a expression system and an N-terminal 6x-
histidine tag were employed. Cultures of Luria-Bertani broth containing kanamycin were
inoculated, induced with 1 mM isopropyl-13-D-thiogalactopyranoside (IPTG) in mid-log
phase (OD 600 - 0.8), and incubated at room temperature overnight. Centrifugation was
used to harvest the cells and the supernatant was discarded. The cell pellet was kept on
ice and re-suspended in 50 mM Tris, 250 mM NaCI, 10 mM imidazole, pH 7.9 (binding
buffer), and then lysed by sonication. Soluble protein was collected by centrifugation at
15,000g for 15 min at 4°C. The soluble lysate was sequentially filtered through a 0.8 gm
and then a 0.45 gm membrane. A 5 ml Hi-Trap Metal Chelate column (Pharmacia-
Biotech) was prepared by charging with 200 mM NiSO 4 and treatment with binding
buffer. The protein was loaded onto the column, washed with a buffer containing 100
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mM Tris, 250 mM NaCi and 50 mM imidazole and eluted into a similar buffer with
increased imidazole (250 mM). The presence and purity of the proteins was assessed by
standard methods using SDS-polyacrylamide gel electrophoresis.
Product Composition Analysis and Kinetics Measurements
Mutant proteins were assessed as described earlier. End-product profiles
following an overnight digestion of enzyme with substrate at 370C were characterized by
capillary electrophoresis. Kinetic parameters were established using standard Michaelis-
Menten theory by tracking the absorbance at 232 nm of the double bond formed by the
lytic degradation of substrate, as previously described.
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Appendix II
Abbreviations
AUA
ATIII
cAC
cABC
cB
cC
CD
CE
CNS
CS
CSGAG
C4S
C6S
DS
ECM
ESI
FGF(R)
GalAG
GAG
Gal
GalNAc
uronic acid with an unsaturated 4, 5 double bond
antithrombin III
chondroitinase AC
chondroitinase ABC
chondroitinase B
chondroitinase C
circular dichroism
capillary electrophoresis
central nervous system
chondroitin sulfate
chondroitin family glycosaminoglycan
chondroitin-4-sulfate
chondroitin-6-sulfate
dermatan sulfate
extracellular matrix
electrospray ionization
fibroblast growth factor (receptor)
galactosaminoglycan
glycosaminoglycan
galactose
N-acetyl galactosamine
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GlcA
HA
HCII
HGF/SF
HPLC
HS
HSGAG
HSV
IdoA
keat
KGF
Km
KS
LDL
LMWH
MALDI-MS
MPS
NMR
PAGE
PDGF
PEN
PG
PTP
glucuronic acid
hyaluronic acid
heparin cofactor II
hepatocyte growth factor/scatter factor
high pressure liquid chromatography
heparan sulfate
heparin/heparan sulfate glycosaminoglycans
herpes simplex virus
iduronic acid
catalytic constant
keratinocyte growth factor
the Michaelis constant
keratan sulfate
low density lipoprotein
low molecular weight heparin
matrix-assisted laser desorption ionization mass spectrometry
mucopolysaccharidosis
nuclear magnetic resonance
polyacrylamide gel electrophoresis
platelet-derived growth factor
property encoded nomenclature
proteoglycan
protein tyrosine phosphatase
292
SCI spinal cord injury
SNA-MS surface non-covalent association mass spectrometry
ST sulfotransferase
TGF-P transforming growth factor- p
VEGF vascular endothelial growth factor
Vmax maximal velocity of an enzymatic reaction
Xyl xylose
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